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I. Abstract 
Cancer cells adapt their metabolism to simultaneously fulfil the requirements of 
energy production and biomass generation necessary to sustain high proliferation 
rates. This deregulated energy metabolism and the proteins responsible therefor 
provide a potential new route of targeting cancer that has not been thoroughly 
explored. 3-Phosphoglycerate dehydrogenase (PHGDH), which takes 3-
phosphoglycerate (3-PG) out of the glycolytic pathway and into serine production, 
has been reported as potential target in certain breast cancer forms and melanoma. 
There is no known inhibitor of PHGDH to date to fully validate the target. 
Inhibition of PHGDH was explored in breast cancer and melanoma cell lines using 
siRNA and shRNA interference techniques. Greater knockdown was achieved by 
siRNA resulting in better growth inhibition than when using shRNA expressing cell 
lines. 
The substrate-binding pocket was investigated with substrate analogues and 
substrate-containing compounds. NAD+-binding was found to be stabilised by 
coordinated binding of substrates. The catalytic subunits of human PHGDH were 
crystallised and revealed a flexible lid domain that moves in response to substrate 
binding. 
The NAD+-fragment adenosine 5’-diphosphoribose (ADPR) was shown to be a 
moderate inhibitor of the enzymatic activity of PHGDH and was used for assay 
validation. Cofactor analogues with different substituents around the pyridine ring 
were equally suitable to promote the oxidation of 3-PG. 
A fragment screen was performed using differential scanning fluorimetry and hits 
were subsequently validated by competition isothermal titration calorimetry. To 
investigate the fragments in crystals of human PHGDH, a truncated form of PHGDH 
(construct 93) was engineered by limited proteolysis. Soaking of fragments into 
crystals of 93 confirmed binding of seven fragments. Structure-activity relationship 
studies were initiated around the confirmed hits. 
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Chapter 1. Introduction 
Despite a strong research effort, cancer is still among the leading causes of disease 
worldwide with an estimate of 14.1 million new cancer cases arising in 2012 [1]. In 
the UK alone, 331,500 people were diagnosed with cancer in 2011, with breast, lung, 
prostate and bowel cancer accounting for the largest part of the cancer burden [2]. 
Taking into account increasing population numbers as well as increased life 
expectancy, the burden of cancer as an age-related diseases, is predicted to 
increase to 23.6 million new cases each year by 2030 globally [1]. 
A major problem for the treatment of cancer is the complexity of the disease as 
illustrated by the large variety of cancer types and their genomic heterogeneity. 
Recent genetic analysis of over 1 million tumour samples identified over 2 million 
coding mutations, over 10,000 fusion mutations and more than 60 million gene 
expression variants [3]. Against such a multifaceted background, usage of the 
genetic information available on tumours to design tumour-specific drugs seems a 
challenging task. In addition, malignant cells develop from normal human cells and, 
as such, retain a very close similarity to healthy cells, which renders them difficult to 
target without harming healthy cells. In an attempt to find common features in the 
multistep process of tumorigenesis, a set of six hallmarks of cancer was presented by 
Hanahan and Weinberg. These include the ability to resist apoptosis, promote 
angiogenesis, overcome anti-growth signals, sustain growth signalling, activate 
tissue invasion and metastasis and limitless proliferation [4]. This set of capabilities 
acquired by cells during tumour development was recently expanded to include two 
emerging hallmarks: the power to evade immunological destruction and to adapt their 
energy metabolism [5]. Deregulated energy metabolism is thereby strongly related to 
the increased proliferation of cancer cells, which necessitates an adjustment of the 
cells’ energy metabolism so as to be able to fuel the increased demands of cell 
growth and division. 
 
1.1 Cancer cell metabolism 
Metabolism can be simply described as the sum of biochemical processes in a living 
organism involved in the generation or consumption of energy. The principal 
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metabolic pathways comprise intermediates, which are essential for energy 
homeostasis and synthesis of macromolecules, such as carbohydrates, fatty acids 
and amino acids. The core metabolic pathways can be divided into three major 
categories: processes for construction or synthesis of macromolecules (anabolism), 
processes for degradation of molecules to release energy (catabolism) and 
processes to eliminate toxic waste products (waste disposal) [6]. 
All cells have to carry out metabolic processes to generate energy so as to be able to 
execute important functions of cell maintenance, such as creation of concentration 
gradients, dynamic processes of the cytoskeleton, DNA repair, transcription and 
translation, protein turnover and vesicular trafficking [7]. Normal cells have complex 
signalling and sensing pathways to regulate nutrient uptake from the environment, 
and initiate the necessary metabolic pathways so that, under normal conditions, no 
uncontrolled nutrient uptake is observed in the absence of stimulation by growth 
factors [8]. Cancer cells seem to be able to overcome this dependency on growth 
signals. They are able to constitutively take up and metabolise nutrients, particularly 
glucose and glutamine, to assist cell survival and drive cell growth [6]. For fast 
proliferating cells, such as cancer cells, the main metabolic tasks are in balancing the 
need for sufficient energy production with fulfilling the additional anabolic demands of 
producing sufficient amounts of building blocks for the development of daughter cells. 
1.1.1 Glucose metabolism 
A major source of cellular energy and biomass is glucose, which is taken up from the 
environment through glucose transporter proteins (GLUT). In many cancers certain 
glucose transporter isoforms are upregulated and this can be mediated through 
activation of oncogenes such as c-Myc [9]. 
In the presence of oxygen, most cells metabolise glucose to pyruvate through 
glycolysis followed by the complete oxidation of pyruvate to carbon dioxide in the 
tricarboxylic acid (TCA) cycle (Figure 1.1). Through the steps of glycolysis, the six 
carbon sugar, glucose, is oxidized and split resulting in two molecules of pyruvate. In 
the subsequent processes of oxidative phosphorylation through the TCA cycle two 
adenosine 5’-triphosphate (ATP) molecules, one guanosine 5’-triphosphate (GTP) as 
well as nicotinamide adenine dinucleotide (NADH) and flavine adenine dinucleotide 
(FADH2), are generated. The subsequent use of NADH and FADH2 in the respiratory 
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chain in the mitochondria increases the ATP production per glucose molecule up to 
36 molecules. Under anaerobic conditions, however, normal cells will switch to an 
alternative fermentation process and reductively metabolise pyruvate to lactate. This 
process of anaerobic glycolysis is far less efficient with regards to ATP production 
than the oxidative phosphorylation in the mitochondria as it only generates 2 
molecules of ATP per glucose. 
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Figure 1.1 - Schematic representation of glycolysis and the subsequent TCA cycle.  
Glucose, after being transported into the cell, is cleaved into two three-carbon fragments 
(glyceraldehyde 3-phosphate and dihydroxyacetone phosphate). In this first part of glycolysis two 
molecules of ATP are consumed. Glyceraldehyde 3-phosphate is then further metabolised to pyruvate 
which results in the generation of two molecules of ATP. As the latter steps of the pathway are 
performed twice per glucose molecule, glycolysis results in an overall generation of two molecules of 
ATP. 
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1.1.2 The Warburg effect 
In the 1920s, Otto Warburg discovered that even in the presence of saturating 
amounts of oxygen, cancer cells seem to metabolise glucose mainly through 
fermentation, resulting in increased lactate production and reduced generation of 
ATP (Figure 1.2) [10, 11]. 
 
Figure 1.2 – Schematic representation of the Warburg effect 
Differentiated, healthy tissue (A) metabolises glucose depending on the cellular oxygen level, so that 
in the presence of sufficient oxygen large quantities of ATP are generated through the TCA cycle 
(oxidative phosphorylation). Only if oxygen levels drop, the majority of glucose will be metabolised to 
lactate which is excreted from the cells to allow further lactate production, thus sustaining a minimum 
level of ATP production (anaerobic glycolysis). (B) Tumorigenic cells metabolise the majority of 
glucose to lactate independently of intracellular oxygen levels (Warburg effect or aerobic glycolysis). 
Picture adapted from Vander Heiden et al., 2009 [8]. 
This apparently paradoxical phenomenon of aerobic glycolysis, named the “Warburg 
effect” after its discoverer, has since been demonstrated in many different tumour 
types [12]. Warburg initially thought that the observed decrease in oxidative 
phosphorylation was a consequence of defects in mitochondrial respiration resulting 
in compromised aerobic respiration and subsequent reliance on glycolytic 
metabolism [11]. However, subsequent evidence emerged to suggest that respiration 
is generally not impaired in cancer cells [13, 14]. How this metabolic rearrangement 
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is triggered, and if it is a prerequisite of tumour initiation, has still to be elucidated. 
However, further investigations have shown the importance of genetic as well as 
environmental factors in contributing to the Warburg effect. Among the genetic 
alterations reported are deregulation of transcription factors, such as c-Myc and 
hypoxia-inducible transcription factor (HIF-1α), that increase the expression of 
proteins that permit or mediate glycolysis, such as the GLUT1 transporter and the 
glycolytic enzyme hexokinase, as well as lactate dehydrogenase A (LDH-A) which 
converts pyruvate to lactate and is therefore a key enzyme in maintaining glycolysis 
[15]. These genetic alterations are closely related to changes in the tumour 
microenvironment where certain regions of the tumour are characterised by hypoxia 
and acidosis. Hypoxia refers to low oxygen levels often found in solid tumours due to 
irregular vasculature, that in turn results in poor blood flow and consequent 
upregulation of HIF-1α, which further regulates the expression of genes that mediate 
various metabolic processes (Figure 1.3). Acidosis can also be regarded as a 
consequence of hypoxia, since increased aerobic glycolysis increases the amount of 
intracellular lactate so that more lactate is transported out of the cells. Lactate export 
occurs through monocarboxylate transporters (MCT1-4). MCTs are symporters that 
facilitate the transport of lactate together with protons out of the cell and thus acidify 
the surrounding extracellular tissue (Figure 1.3) [16]. 
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Figure 1.3 – Summary of hypoxia-regulated genes. 
Under hypoxic conditions HIF-1α is stabilised and protected from degradation through oncogenic 
signalling pathways. After translocation into the nucleus, HIF-1α interacts with transcription factors 
(TF) to initiate transcription of hypoxia-regulated genes (HRE), such as LDH-A. Increased LDH-A 
activity results in increased lactate production. Lactate is subsequently excreted from the cell along a 
proton gradient via the MCT symporter. Picture adapted from [17]. 
However, despite increased understanding of the Warburg effect and its mechanisms 
of regulation, it is still unclear why cancer cells perform aerobic glycolysis against the 
background of this metabolic pathway being inferior to oxidative phosphorylation in 
terms of energy generation. One proposed explanation is that fermentation allows 
production of ATP at a faster rate (albeit lower efficiency) so that the overall ATP 
generation rate is higher than with oxidative phosphorylation [18]. However, ATP can 
also be generated from sources other than glucose, such as fatty acids, and a 
summary of data from measurements of oxidative and glycolytic ATP production in 
different cell lines and tissues showed that glycolysis only accounted for an average 
of 17 % of total ATP production, making this a rather unlikely explanation [14]. 
Another hypothesis is based on the increase in lactate production, which, through 
subsequent lactate transport out of the cells results in the aforementioned acidic 
microenvironment, which causes apoptosis in normal cells while sparing the hypoxia-
adapted cancer cells [19]. A third hypothesis proposes that the increased amount of 
glycolytic intermediates generated through up-regulated glycolysis provides the main 
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selective advantage underlying the Warburg effect. Sufficient amounts of glycolytic 
intermediates are necessary to fuel biosynthesis: for example, glucose-6-phosphate, 
fructose-6-phosphate and glyceraldehyde-3-phosphate all feed into nucleotide 
synthesis, while 3-phosphoglycerate (3-PG) is a precursor for amino acids and 
nucleobases [7]. 
Another consequence of the Warburg effect is that fewer glucose-derived metabolites 
enter the TCA cycle, which results in cancer cells being more reliant on alternative 
substrates that can be fed into the TCA cycle, such as glutamine [20]. 
1.1.3 Glutamine metabolism 
Glutamine is the most abundant amino acid in mammals with plasma concentrations 
of 0.6-0.9 mmol/L and it is used as a major source of nitrogen for the transamination 
reactions required for the synthesis of amino acids and nucleotides [21, 22]. After 
entering into the cytosol, glutamine donates nitrogen to purines and pyrimidines via 
transamination and is thereby converted into glutamate. Glutamate can then donate 
its remaining amino group to α-keto acids to form non-essential amino acids and α-
ketoglutarate, which can be transported into the mitochondria (Figure 1.4) [23]. The 
conversion of glutamine to α-ketoglutarate can also take place directly in the 
mitochondria. α-Ketoglutarate then enters into the TCA cycle, thereby mediating the 
carbon-donor function of glutamine [23]. In addition, glutamine plays an essential role 
in the suppression of oxidative stress through carbon and nitrogen donation for the 
synthesis of glutathione, a crucial intracellular antioxidant (Figure 1.4) [24]. 
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Figure 1.4 – Glutamine metabolism. 
Glutamine is imported into the cell via transporters, such as the SLC1A5 and then either directly 
further metabolised to glutamate and α-ketoglutarate (α-KG) or imported into the mitochondria to be 
there metabolised to α-KG. Picture adapted from [22]. 
Recently, additional evidence was presented that underlines the importance of 
glutamine metabolism in cancer cells. The majority of sporadic clear-cell renal 
carcinomas (RCC) harbour loss-of-function mutations in the von Hippel-Lindau (VHL) 
tumour suppressor gene resulting in hyperactivation of the transcription factors 
hypoxia inducible factor 1α and 2α (HIF-1α/ HIF-2α) [25]. Loss of VHL was found to 
be associated with cells performing reductive carboxylation from glutamine to support 
citrate and lipid synthesis even at normal oxygen levels [26]. The observation that 
glutamine deprivation with glutaminase inhibitors, inhibiting the enzyme that 
catalyses the first step in glutamine metabolism, was preferentially cytotoxic to VHL-
deficient cells, supports the idea of developing cancer therapeutics to target 
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glutamine metabolism [25]. However, depletion of glutamine in growing tumours also 
occurs naturally, due to increased glutamine catabolism [24]. Research undertaken 
to reveal the signalling pathways activated in response to glutamine deprivation 
showed that low glutamine levels triggered an increase in reactive oxygen species 
(ROS) levels, followed by a signalling cascade that leads to the activation of p53 and 
the induction of pro-survival p53 target genes such as Cdkn1a and Gadd45a [24]. 
Furthermore p53-deficient HCT116 cells seemed more sensitive to glutamine 
deprivation than p53-wild type controls, so that triggering glutamine metabolism in 
p53-deficient tumours could also be a valuable approach in cancer therapy [24]. 
1.1.4 Amino acid metabolism 
Amino acids play important roles in synthesis of other biomolecules as well as in cell 
signalling. As such, highly proliferating cells, such as cancer cells, require higher 
amounts of amino acids and thus have to alter their amino acid management to meet 
these demands. There are generally four mechanisms by which cells obtain amino 
acids: de novo biosynthesis; dietary uptake of exogenous amino acids from the 
circulation through transporters; dietary uptake by macropinocytosis; and recycling of 
amino acids by autophagy [27]. Essential amino acids have to be taken up from the 
diet as they can not be synthesised de novo. In order to regulate how much of each 
amino acid is currently required by the cell, cellular sensing mechanisms are likely to 
be involved. These have been shown to exist at least for leucine and arginine [28, 
29]. In this context, mammalian target of rapamycin complex 1 (mTORC1), a master 
regulator of cell growth in cancer cells, has been shown to be activated by amino 
acids, in particular arginine and leucine, through promotion of the translocation of the 
complex to the lysosomal surface [30]. The mTORC1 pathway is one of the most 
frequently mutated signalling pathways in cancer with significant effects on tumour 
progression, and several mTOR inhibitors are under investigation for therapeutic use 
in different cancer types [31]. 
Apart from the implications of L-glutamine metabolism, other amino acids that are not 
themselves essential can play important roles as intermediary metabolites, including 
L-serine. L-serine, and in particular its de novo synthesis pathway, have been shown 
to be upregulated in a subset of tumours [32]. 
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1.2 L-Serine metabolism 
L-serine belongs to the family of non-essential amino acids, as it can be synthesised 
de novo. However, it has been shown that under certain conditions, at least in cell 
culture, some of the non-essential amino acids become important for optimal cellular 
growth. In particular, L-serine was required to support the clonogenic survival of 
HeLa cells at very low densities [33]. L-Serine plays an important role in cell 
proliferation, as it is the main source of one-carbon units for the synthesis of purine 
nucleotides and the pyrimidine nucleotide deoxythymidine monophosphate (Figure 
1.5) [34]. In this pathway, serine is converted to glycine by serine hydroxymethyl-
transferase (SHMT), which transfers one CH2-unit of serine onto tetrahydrofolate 
(THF). The thereby-formed methylene-THF is a key intermediate for thymidylate 
synthesis and an indirect carbon source through other THF cofactors for purine 
synthesis. The glycine obtained in this SHMT-catalysed reaction is both a carbon and 
nitrogen source in the purine synthesis, and an important neurotransmitter [35]. 
In addition to glycine, serine metabolic pathways also provide the precursors for the 
synthesis of other amino acids such as cysteine and taurine as well as D-serine, a 
neuromodulator in the brain [36]. Other biomolecules derived from L-serine are 
sphingosine and phosphatidylserine, which both form part of the phospholipid bi-
layers that form cell membranes. Phosphatidylserine plays a particularly important 
role in the plasma membranes in the brain where it contributes to the activation of 
signalling pathways [36, 37]. Inborn serine-deficiency disorders, caused by defects in 
de novo L-serine biosynthesis, are associated with major neurological symptoms, 
further emphasising the importance of L-serine synthesis [38]. Under these 
conditions the de novo synthesis of L-serine is insufficient to fulfil the cellular 
demands, so that L-serine, can be classified as a conditionally essential amino acid 
[36]. 
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Figure 1.5 – Importance of L-serine in the biosynthesis of other biomolecules. 
Schematic representation of how L-serine is linked to the synthesis of various biomolecules. 
1.3 L-Serine biosynthesis 
There are four potential sources of L-serine: (i) uptake through the diet, (ii) de novo 
synthesis from the glycolytic metabolite 3-phosphoglycerate (3-PG), (iii) 
interconversion with glycine and (iv) degradation of proteins and phospholipids [36]. 
The contribution of each pathway to L-serine homeostasis in humans remains to be 
fully elucidated. A study on humans after 24 hours of fasting revealed protein 
breakdown as a minor L-serine source, contributing 20 % of total L-serine. In this 
study, the major contribution was from L-serine synthesis, with 27 % and 53 % 
derived from glycine and 3-PG respectively [39]. L-Serine homeostasis is likely to 
vary between the different organs as well as depending on the development stage 
[36]. As the transfer of L-serine across the blood-brain barrier is very low, most of the 
L-serine in the brain has to be derived from synthesis rather than through dietary 
uptake [40]. Investigations of L-serine biosynthesis in rat kidneys showed a 
prevalence of L-serine synthesis from 3-PG over the conversion of glycine [41]. In 
contrast, the majority of L-serine in foetal lamb liver was found to derive from glycine 
with the flux through SHMT accounting for over 50 % of L-serine production [42]. 
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1.3.1 Glycine degradation and SHMT 
SHMT catalyses the reversible conversion of L-serine to glycine through transfer of a 
CH2-group from L-serine onto THF to form 5,10-methylene THF (Figure 1.6). In 
humans two SHMT genes are known (SHMT1 and SHMT2) encoding for the 
cytoplasmic (cSHMT) and mitochondrial (mSHMT) isozymes. Mutagenesis studies in 
Chinese hamster ovary cells showed that cells lacking mSHMT were unable to 
synthesize glycine indicating that cSHMT functions could not compensate for the loss 
of mSHMT [43]. Thus mSHMT accounts for the generation of the majority of one-
carbon groups resulting in the formation of formate that can then be transported into 
the cytosol to be used in nucleotide synthesis [44]. cSHMT on the other hand 
functions as a metabolic switch in the cytosol to regulate the supply of one-carbon 
units for folate synthesis and methylation of homocysteine to methionine. Through 
the subsequent adenylation of methionine, S-adenosylmethionine (SAM) is 
generated. SAM is a cofactor for the methylation of many biomolecules, such as DNA 
and RNA [45]. 
Glycine degradation is also catalysed by glycine decarboxylase (GLDC), which in 
humans is part of a multienzyme complex that couples the decarboxylation of glycine 
with the synthesis of 5,10-methylene THF [46]. 5,10-methylene THF can then in turn 
function as a substrate of SHMT for the synthesis of L-serine. 
 
Figure 1.6 – SHMT in the regulation of serine, glycine and folate metabolism. Picture adapted 
from Fu et al. [44]. 
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1.3.2 The phosphorylated L-serine biosynthesis pathway and PHGDH 
For de novo serine biosynthesis two pathways were originally proposed: the 
‘phosphorylated pathway’, which uses the glycolytic intermediate 3-PG as a 
substrate, and the ‘non-phosphorylated pathway’, which involves D-glycerate and 
hydroxypyruvate. However, the non-phosphorylated pathway was later shown to 
preferentially participate in serine catabolism, in which L-serine is used for the 
synthesis of pyruvate to fuel gluconeogenesis. This does not occur in the 
phosphorylated pathway as the final dephosphorylation step is irreversible [36, 47]. 
Since the role of the non-phosphorylated pathway is primarily in L-serine 
degradation, the phosphorylated pathway has now been recognised as the primary 
route of L-serine synthesis [48, 49]. 
In the phosphorylated pathway, 3-phosphoglycerate dehydrogenase (PHGDH) 
catalyses the first step, at which glycolytic flux is diverted into the serine synthesis 
pathway (Figure 1.7). In this step 3-PG is oxidized to 3-phosphohydroxypyruvate 
(PHP) using NAD+ as a cofactor. NAD+ is concomitantly reduced to NADH as part of 
the reaction [50]. PHP is then metabolised to 3-phosphoserine by the enzyme 3-
phosphoserine aminotransferase (PSAT). For this reaction glutamate is used as a 
nitrogen donor, releasing α-ketoglutarate as a by-product. The final conversion of 
phosphoserine to serine is catalysed by 3-phosphoserine phosphatase (PSPH) [51]. 
The dephosphorylation of phosphoserine is irreversible, and explains the propagation 
of the reaction cascade to serine production despite the fact that the two preceding 
reaction steps in the serine synthesis cascade are reversible. The enzymes of the 
phosphorylated L-serine synthesis pathway are found in many organs and tissues 
with particular prevalence in kidney, testis, spleen and brain. Lower activity of these 
enzymes is seen in heart and skeletal muscle [32]. Studies on the enzymatic activity 
of PHGDH and PSPH in rat liver show an influence of the protein content in the diet, 
with both enzymes exhibiting low activity in a high protein diet, as well as hormonal 
factors, such as glucagon and corticosteroids [32]. 
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Figure 1.7 – Phosphorylated L-serine synthesis pathway 
1.3.3 Clinical relevance of L-serine 
The importance of L-serine in the cell is highlighted by the effect of modulating serine 
levels on disease development. An example are the serine deficiency disorders, a 
group of neurometabolic disorders that arise due to defects in L-serine biosynthesis 
[52]. Although serine deficiency disorders can be caused by defects in all three 
enzymes involved in L-serine synthesis, most patients diagnosed with this disease to 
date have a defect in PHGDH [52]. So far this defect is known to be caused by one of 
two identified mutations in PHGDH: a V490M or V425M substitution [53]. Patients 
were reported to suffer from congenital microcephaly, severe psychomotor 
retardation and intractable seizures, which can be partly treated through oral 
administration of high doses of L-serine and glycine [40]. 
There is increasing evidence for the involvement of enzymes necessary for L-serine 
synthesis or metabolism in tumorigenesis. For example, GLDC has been identified as 
a metabolic oncogene, with overexpression of GLDC in primary cells causing cell 
transformation [46]. On the other hand an increased supply of glycine through 
elevated mSHMT levels and activity have been reported in colon carcinoma and 
neuroblastoma [35, 54]. Interestingly high levels of mSHMT correlated strongly with 
high PHGDH levels in human neuroblastoma patient samples indicating that mSHMT 
could be one of the major utilizer of the increasing amounts of L-serine synthesised 
via the phosphorylated pathway [54]. Elevated levels of PSAT1 and PHGDH have 
also been reported in different tumour types, such as PSAT1 and PHGDH 
upregulation in hepatocellular carcinoma [55] and colon carcinoma [35], respectively. 
In this context, both enzymes have been proposed as potential targets in cancer 
therapy with the work presented herein focusing on PHGDH as a target. 
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1.4 PHGDH 
1.4.1 Structure 
3-Phosphoglycerate dehydrogenase (PHGDH) is ubiquitously found in all organisms 
although existing in at least three different basic structural forms, referred to as type 
I, II and III (Figure 1.8) [56]. These forms do not appear to be strictly organism 
specific as certain bacteria and lower eukaryotes, such as yeast and Neurospora, 
have a structurally similar PHGDH to the Escherichia coli enzyme, while mammalian 
PHGDH shows structural homology with the enzyme from the pathogenic bacterium 
Mycobacterium tuberculosis [56]. 
 
Figure 1.8 – Basic domain structure of PHGDH (adapted from Grant, 2012). 
The figure shows the basic domain structure found within the three enzyme types of PHGDH coloured 
by domain. Additional amino acids at the N-terminus are not explicitly shown as variations in length 
and composition of this part of the protein depend on the species (indicated by **). Two forms of the 
type III enzyme exist depending on whether lysine (type K) or histidine (type H) is present at the active 
site[57]. 
All three types of PHGDH contain two common domains, the substrate-binding 
domain and the nucleotide-binding domain, both of which are necessary for substrate 
binding and catalysis [57]. The substrate-binding domain starts at the amino terminus 
of the polypeptide chain, and is then interrupted by the entire nucleotide-binding 
domain before being completed. Type III enzymes are composed of only these two 
domains, however, a variant of type III exists where the catalytic histidine residue is 
replaced by a lysine (type K). The group of type II enzymes contain an additional 
regulatory ACT domain at the C-terminus, which was reported to function as a 
binding site for serine in feedback inhibited enzymes, such as E. coli PHGDH. This 
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ACT domain was first discovered in E. coli and is composed of approximately 60-70 
amino acids forming a βαββαβ structure [58]. Later, the ACT domain was recognized 
as a recurring motif that is mainly found in metabolic enzymes and transcriptional 
regulators involved in amino acid metabolism [59]. The ACT domain is also found in 
mammalian type I PHGDH, however the mammalian enzyme is no longer sensitive to 
serine due to mutations of key serine-binding residues [57]. Type I enzymes also 
contain an additional structural domain between the ACT domain and the substrate-
binding domain, the allosteric substrate binding (ASB) domain. The first ASB domain 
was observed in the structure of M. tuberculosis PHGDH and was shown to comprise 
150 amino acid residues that form an αβααββ motif [60]. In the type I enzymes from 
rat and M. tuberculosis, the ASB domain was found to constitute another serine 
binding site, being able to bind the substrate and induce substrate inhibition [61, 62]. 
Rat and human PHGDH share a high sequence homology of 94 % (Figure 1.9) [63]. 
Two mRNA transcripts of human PHGDH have been identified with the larger 2.1 kb 
transcript being the dominant transcript with high expression levels in prostate, testis, 
ovary, brain, liver, kidney, and pancreas. The 710 bp transcript, although also 
detected at low levels in most tissues where the larger transcript was expressed, is 
the main transcript in heart and the exclusive one in skeletal muscle [63]. 
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Figure 1.9 – Sequence alignment of human, rat and M. tuberculosis PHGDH. 
Sequence alignment was performed in UniProt [64] and amino acids involved in nucleotide-binding are 
highlighted in green. 
To date there has not been a published analysis of the structure of human PHGDH, 
although the structure of a truncated form (aa 3-314, sPHGDH) with malate and 
NAD+ bound to the active site has been solved (PDB 2G76) (Figure 1.10). This 
truncated form lacks the regulatory ACT and ASB domains, thus comprising only the 
substrate and nucleotide-binding sites, and is present as a homodimer in the crystal 
asymmetric unit. 
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Figure 1.10 - Crystal structure of the truncated version of human sPHGDH (aa 3-314) and 
interactions of malate with sPHGDH 
(A) Ribbon diagram of human PHGDH with two molecules present in the asymmetric unit (coloured by 
chain). The α-helices are shown as helical bands and the β-sheets are displayed as arrows with the tip 
pointing towards the C-terminus. For both chains the bound malate and NAD
+
 molecules are shown by 
atom type with the carbons in green. (B) Amino acids of PHGDH involved in malate-binding. Black 
dashed lines represent H-bonds and salt bridges. 
Crystallisation of human sPHGDH was performed in 0.1 M MMT buffer, which is 
composed of a 1:2:2 mixture of DL-malic acid: MES monohydrate: Tris base. As a 
result of the high DL-malate concentration in the buffer, binding of D-malate to the 
active site of the protein could be observed. In the crystal, malate, a substrate 
analogue of 3-PG, was shown to be favourably aligned for the catalytic reaction, 
including the formation of a salt bridge between the carboxylic group of malate and 
Arg235 of the enzyme (Figure 1.10 B) [57]. 
Despite the availability of the structure of the catalytic subunits of human PHGDH, 
the structure of full-length enzyme has not been solved to date. In fact, no atomic 
structure of any mammalian PHGDH is known, although purification of rat PHGDH 
indicated that the protein formed a tetramer on size exclusion chromatography [62]. 
M. tuberculosis PHGDH is thus the closest homologue for which the full-length 
structure has been solved. PHGDH from M. tuberculosis was shown to crystallise as 
a tetramer with the catalytic domains adopting the same orientation in all four 
subunits, whereas the regulatory domains adopt differing conformations (Figure 1.11) 
[60]. The catalytic subunit of PHGDH could not adopt the tetrameric form, most 
probably because it lacks the regulatory domains. 
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Figure 1.11 – Structure of active M. tuberculosis PHGDH tetramer 
(A) The structure of M. tuberculosis PHGDH (PDB 1YGY) is coloured according to its different 
domains with the cofactor-binding domains in magenta, the substrate-binding domains in blue, the 
ASB domain in red and the ACT domain in green. The black square highlights one of the four 
subunits, which form the active enzyme. (B) Scheme of the arrangement of the different domains in 
each subunit. The arrows indicate the direction of the amino acid sequence starting with the N-
terminus from the substrate-binding domain (Pictures adapted from Grant et al. [57]). 
1.4.2 Catalytic mechanism 
Under physiological conditions, the PHGDH-catalysed reaction proceeds in the 
direction of the oxidation of 3-PG because the final, irreversible step in L-serine 
biosynthesis draws the reaction in the direction of PHP synthesis. However, in vitro 
PHGDH activity has mainly been assessed by following reduction of PHP, since that 
reaction is readily promoted by exploiting the high affinity of PHGDH for NADH (Km of 
human PHGDH for NADH is 20 μM) [57].  
As the PHGDH-catalysed reaction uses both a substrate and a cofactor, different 
orders of binding of both ligands to the enzyme are possible. Although E. coli and M. 
tuberculosis PHGDH function both function via an ordered Bi-Bi mechanism, their 
respective orders of ligand binding are not consistent, with the substrate binding first 
to M. tuberculosis PHGDH, but the co-factor binding first to that of E. coli [57]. The 
catalytic mechanism for human PHGDH remains to be elucidated. 
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E. coli PHGDH, which belongs to the class of type II enzymes, can catalyse α-
ketoglutarate (α-KG) reduction to D-2-hydroxyglutaric acid (D-2HG), whereas rat and 
M. tuberculosis PHGDH were reported not to catalyse the reaction with α-KG as 
substrate [57]. This led to the wider hypothesis that mammalian PHGDHs in general 
might not be able to use α-KG as a substrate. However, more recent literature 
reports that human PHGDH makes a significant contribution to the production of D-
2HG in cells through reduction of α-KG (Figure 1.12). Fan and colleagues showed 
that knockdown of PHGDH reduced cellular D-2HG levels by 50 % in the breast 
cancer cell line MDA-MB-468 and overexpression of PHGDH in MDA-MB-231 cells 
yielded a two-fold increase in intracellular D-2HG levels [65]. In addition, 
oxaloacetate was shown to function as a substrate for recombinant purified human 
PHGDH yielding D-malate, which is in agreement with the reported co-crystal 
structure of the catalytic subunit of PHGDH with D-malate bound to its active site 
(PDB 2G76) [65]. 
 
Figure 1.12 – Reactions catalysed by human PHGDH 
Among the chemical structures of substrates and products, common sub-structures are coloured in 
black and differences are highlighted in blue. 
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1.4.3 PHGDH and cancer 
With increasing evidence of altered metabolic pathways in cancer cells, the 
importance of understanding how cancer cells adapt their metabolic processes to 
drive the macromolecular biosynthesis necessary for proliferation and rapid cell 
growth becomes apparent. Early research pointed towards the relevance of the 
serine synthesis pathway in cancer, with work from Snell and colleagues reporting 
significantly enhanced PHGDH activity in rat hepatomas [66, 67]. PHGDH activity 
was increased in slow- and fast-growing hepatomas, and was therefore concluded to 
be relevant for tumour initiation and progression, although the increase in activity in 
fast-growing hepatomas of 50-75-fold was most striking [66]. Subsequent 
investigation of PHGDH activity in human colon carcinoma revealed a 10-fold 
increase compared to normal human colon mucosa, and, although only a small 
cohort of four patients was investigated, the importance of PHGDH activity in human 
neoplasia was shown [35]. The work described so far compared the enzymatic 
activity of PHGDH in healthy and tumorous tissue without investigation of any genetic 
alterations. It was not until 20 years later that a pooled analysis of somatic copy 
number alterations revealed PHGDH, the gene encoding for PHGDH, as a frequently 
amplified gene across 3131 cancer samples [68]. The PHGDH gene is located on 
chromosome 1p12, a region that displays repeated copy number gain in 16 % of the 
cancers assessed [69]. Among the cancers examined for PHGDH gain, the most 
common tumour type was melanoma, with 40 % frequency in PHGDH amplification 
[69]. Moreover, analysis of 106 human tumour samples by correlating protein levels 
with mRNA expression revealed that high PHGDH expression was associated with 
certain breast cancer subsets such as triple-negative breast cancer and basal 
subtypes [69]. Previous studies had already shown a correlation between high 
PHGDH mRNA levels and poor five-year survival in ER-negative basal breast 
cancers [70, 71]. This was confirmed by a study showing that 70 % of ER-negative 
breast tumours had increased levels of PHGDH mRNA and protein [72]. Examination 
of a panel of breast cancer cell lines revealed that PHGDH protein levels were also 
elevated in two ER-negative cell lines lacking the PHGDH copy number gain [72]. 
This indicates that, in addition to genomic amplifications of PHGDH, other 
mechanisms must exist to increase PHGDH protein levels. 
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Consistent with these genetic data, it was found that shRNA mediated knockdown of 
PHGDH in melanoma cell lines with PHGDH copy number gain resulted in decreased 
proliferation compared to the non-amplified cell lines [69]. Similar experiments using 
RNAi-mediated suppression of PHGDH in different cell lines also found decreased 
cell proliferation only in cells with elevated PHGDH expression, both with and without 
PHGDH amplification [72]. Importantly, PHGDH suppression was also shown to 
affect the growth of established mammary tumours in mice. When mice bearing 
MDA-MB-468 tumours with either a doxycycline-inducible PHGDH or off-target (GFP) 
shRNA were treated with doxycycline there was a remarkable and significant 
suppression of tumour growth in the PHGDH knockdown but not the off-target control 
[72]. Another study on cervical adenocarcinoma samples revealed high PHGDH 
expression in this cancer type [73]. Consistent with the earlier knockdown 
experiments, PHGDH knockdown in HeLa cells significantly inhibited cell proliferation 
and halted tumour progression in vivo and was additionally shown to potentiate the 
effects of cisplatin in both cells and xenografts [73]. Another strong indication of the 
importance of PHGDH in tumorigenesis was provided by Possemato and colleagues 
who showed that ectopic expression of PHGDH in non-tumorigenic MCF-10A cells 
induced phenotypic alterations. Among these alterations were an abnormal large 
nuclear morphology, failure to orient in a uniform fashion adjacent to the basal acinar 
membrane and enhanced proliferation [72]. 
Interestingly, PHGDH suppression with shRNA resulted in reduced proliferation of 
cells containing the PHGDH amplification even when growing in media with 
additional serine or cell-permeable methyl-serine-ester [72]. This finding suggests 
that the PHGDH-mediated serine synthesis pathway promotes cell proliferation 
independently of serine synthesis. Recently, human PHGDH was shown to catalyse 
the NADH-dependent reduction of α-ketoglutarate (αKG) to 2-hydroxyglutarate (2-
HG) [65]. The oncometabolite 2-HG is a competitive inhibitor of α-KG-requiring 
enzymes and, as such, blocks the activity of for example DNA and histone 
demethylases [74]. Previously, increased 2-HG production was associated with the 
expression of mutant isocitrate dehydrogenase (IDH), however it has now been 
detected in human breast cancers with wild-type IDH [75]. Another proposed 
mechanism for the reduction in growth of certain tumours after PHGDH knockdown is 
through increased redox stress as PHGDH catalyses the oxidation of 3-PG in 
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combination with reduction of NAD+ to NADH, thus affecting the NAD+/NADH ratio 
and the cellular redox status [76]. In glioma cells, PHGDH was also found to have a 
crucial non-metabolic role through stabilising FOXM1, which is an oncogenic 
transcription regulator of for example cell cycle proteins, at the protein level [77]. 
1.5 Targeting cancer cell metabolism 
As outlined previously, metabolic pathways could represent attractive therapeutic 
targets in cancer therapy due to the fact that cancer cell metabolism is altered in 
certain aspects compared to the metabolism of normal cells by virtue of the demands 
of highly proliferating malignant cells (Figure 1.13). Nevertheless, this strategy 
generates the challenges of achieving a therapeutic window and developing non-
invasive methods for patient stratification, as not all tumours rely on the same 
metabolic pathways. 
 
Figure 1.13 - Core metabolic pathways and potential metabolic targets in cancer 
Metabolic enzymes which are under preclinical investigation are highlighted in red. Targets in early 
and more advanced clinical trials are highlighted in blue and green, respectively. (Figure adapted from 
[78, 79]). 
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In the late 1940’s successful targeting of cancer cell metabolism was already 
achieved using the antifolate drug aminopterin to induce remission in children with 
acute lymphoblastic leukaemia [80]. Today antifolate drugs, such as the dihydrofolate 
reductase (DHFR) inhibitor methotrexate, are effectively used in the treatment of 
various cancers [81]. Anti-folate drugs were a starting point for the development of 
other metabolite analogues as anticancer agents that interfere with nucleotide 
synthesis, such as 5-fluorouracil, hydroxyurea or gemcitabine. In addition, there are a 
variety of drugs for the treatment of other metabolic diseases already on the market. 
Such drugs can now be reassessed for their therapeutic effect in cancer patients 
(Table 1.1). For example, the hexokinase II inhibitor metformin, which is on the 
market for the treatment of diabetes II, is now being assessed in several clinical trials 
for cancer therapy [82]. 
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Compound Target 
Tumour / 
cancer cell type 
Clinical 
stages 
Glycolysis    
2-Deoxyglucose 
Glucose transporter, 
Hexokinase 2 
Prostate cancer 
Phase I 
(terminated) 
Silybin/silibinin Glucose transporter Prostate cancer Phase I/II 
Gossypol/AT-
101 
Lactate dehydrogenase 
A 
Multiple cancers Phase I/II 
Nucleic acid synthesis   
Methotrexate 
Folate metabolism 
(DHFR) 
Multiple cancers 
Approved 
agent 
5-Fluorouracil Thymidine synthesis Multiple cancers 
Approved 
agent 
Hydroxyurea 
Deoxynucleotide 
synthesis 
Multiple cancers 
Approved 
agent 
Gemcitabine Nucleotide incorporation Multiple cancers 
Approved 
agent 
Amino acid metabolism   
L-Asparaginase Asparagine 
Acute 
lymphoblastic 
leukaemia 
Approved 
agent 
Arginine 
deaminase 
Arginine Multiple cancers Phase II 
NAD metabolism   
FK866/APO866 
Nicotinamide phospho-
ribosyltransferase 
Cutaneous T-cell 
lymphoma, B-cell 
chronic 
lymphocytic 
leukemia, 
melanoma 
Phase II 
Table 1.1 - Therapeutic compounds that target metabolic enzymes with potential for use in 
cancer therapy (adapted from [21, 81]). 
Based on the increased understanding of the Warburg effect and the importance of 
glucose metabolism for cancer cells, silybin, an inhibitor of glucose transporters was 
developed and is currently in clinical studies [83]. 2-deoxyglucose, by contrast, was 
established as a molecule that is able to enter cells via the glucose transporters but 
cannot be metabolised beyond 2-deoxyglucose-6-phosphate and therefore 
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accumulates, thus inhibiting glucose catabolism [21]. Despite concerns that the 
toxicity of 2-deoxyglucose (especially brain toxicity) might be a limiting issue in the 
use of this drug, a completed phase I clinical study reported a dose of 45 mg/kg as 
recommended for follow-up phase II trials [84]. 
Although clinical trials have significantly added to the understanding of cancer 
metabolism, not all compounds showed clinical benefit and often treatment outcomes 
were most efficacious in combination with radiation and/or chemotherapy [79]. 
However, increased benefit of anti-metabolic drugs is expected with a better 
understanding of patient stratification for this class of chemotherapeutics. 
1.6 Targeting strategies for NAD+-requiring enzymes 
Although the multitude of NAD+-requiring enzymes mirrors their importance in 
biochemical processes, it also represents a challenge when it comes to selective 
targeting of specific NAD+-requiring enzymes. In particular, the idea of targeting the 
NAD+-binding pocket seems an irrational approach as protein structural motifs that 
bind NAD+/NADH are often very similar among related enzymes. In the case of 
dehydrogenases, a frequently-observed structural motif is the Rossmann fold, a 
βαβαβ subunit which provides a basic frame for binding nucleotides in general and 
coenzymes in particular [85]. With this strong structural homology among coenzyme 
binding pockets of NAD+ requiring enzymes, it has been assumed that selectively 
targeting these enzymes with NAD+-competitive therapeutics would be challenging 
and therefore rather lead to general toxicity [86]. Contradicting this hypothesis, the 
number of NAD+ or nicotinamide analogues, which have been found to target certain 
NAD+-utilising enzymes with high specificity, is increasing. 
1.6.1 Analogues of NAD+ 
An early example of selective inhibition of an NAD+-requiring enzyme was reported 
for horse liver alcohol dehydrogenase in 1993 [87]. It was found that of two isosteric 
analogues of NAD+, one a C-nucleotide of nicotinamide (C-NAD) and the other 
picolinamide (C-PAD), C-NAD was an extremely potent inhibitor of alcohol 
dehydrogenase (Ki = 1.1 nM). In this study, C-PAD was found to be 20000 fold less 
potent (Ki = 20 µM) (Figure 1.14) [87]. Crystallographic analysis revealed, that in the 
C-NAD complex, the nitrogen of the pyridine ring replaced the alcohol as the fourth 
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coordination ligand to the active site zinc atom whereas such a zinc-nitrogen 
interaction is not observed in the complex with C-PAD [88]. 
 
Figure 1.14 - Isosteric analogues of NAD: C-NAD and C-PAD. 
Another example of selective inhibition of an NAD+-requiring enzyme has been 
described for inosine monophosphate dehydrogenase (IMPDH), a key enzyme in the 
de novo GTP synthesis pathway [89]. IMPDH is selectively inhibited by the oncolytic 
C-nucleoside tiazofurin, which is metabolically activated by phosphorylation to give 
the 5’-monophosphate followed by conversion to the NAD analogue thiazole-4-
carboxamide adenine dinucleotide (Figure 1.15) [89]. Tiazofurin was tested in phase I 
and II clinical studies and found to induce complete haematological remission in 
patients with acute nonlymphocytic leukaemia or chronic myelogenous leukemia in 
blast crisis [90]. In addition, another inhibitor of IMPDH has been identified: 
mycophenolic acid. Mycophenolic acid inhibits IMPDH with a Ki of 7 nM (for the type 
2 isoform of IMPDH) by mimicking the interaction of the nicotinamide mononucleotide 
moiety of NAD with the enzyme [86]. To date mycophenolic acid appears to be 
specific for IMPDH as no other NAD+-requiring enzymes have been reported to be 
targets and the compound is used clinically as an immunosuppressant [86]. 
 
Figure 1.15 - Structures of IMPDH inhibitors, Tiazofurin and Mycophenolic acid. 
Tiazofurin is metabolised intracellularly to thiazole-4-carboxamide adenine dinucleotide (TAD). 
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1.6.2 Nicotinamide analogues 
The feasibility of targeting NAD+-requiring enzymes was also demonstrated by 
poly(ADP-ribose) polymerase (PARP) inhibitors, which are based on the nicotinamide 
moiety of NAD+. PARP-1 and 2 were shown to have a significant role in the 
recognition and repair of DNA damage, thus fulfilling a fundamental role in the 
maintenance of genomic stability. PARP inhibitors, originally designed to chemo- and 
radiosensitise by inhibiting repair of the DNA damage inflicted, have subsequently 
been shown to have remarkable activity in tumours with defective homologous 
recombination DNA repair. 
Based on the structure of nicotinamide, a naturally-occurring PARP inhibitor, the first 
generation of PARP inhibitors were benzamides and 3-substituted benzamides, 
which are structural analogues of nicotinamide with the nitrogen in the aromatic ring 
being substituted by a carbon (Figure 1.16). Although these inhibitors had a 
somewhat higher potency, being 10-20 fold more potent than nicotinamide, they still 
lacked specificity and potency [91]. 
 
Figure 1.16 - First generation of PARP inhibitors. 
A second generation of PARP inhibitors was developed in the 1990s when Banasik 
and colleagues used an “analogue by catalogue” approach to screen a panel of 170 
compounds for their inhibitory effect against PARP-1. They found more potent 
inhibitors (4-amino-1,8-naphthalimide, 6(5H)- and 2-nitro-6(5H)-phenanthridinone 
and 1,5-dihydroxyisoquinoline) with IC50 values approximately two orders of 
magnitude lower than 3-aminobenzamide (Figure 1.17) [92]. Other groups have used 
structure activity relationships (SAR) to drive their drug discovery programmes. For 
example, Suto et al. performed further work on the dihydroisoquinolinone core 
leading to the compound PD128763, which has an IC50 value 50-fold lower than 3-
aminobenzamide [93]. In parallel, two other structural classes, imidazole and 
benzoxazole carboxamides, were identified as potent PARP-1 inhibitors (Figure 1.17) 
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[94]. In these compounds the imidazole nitrogen functions as an intramolecular 
acceptor of the amide hydrogen giving rise to PARP inhibitors with IC50 values in the 
nM range [91]. 
 
 
Figure 1.17 - Second generation of PARP inhibitors. 
Built on these findings, further PARP-1/2 inhibitors have been developed using both 
SAR and structure-based drug design, and several are currently undergoing clinical 
trials. Among the most advanced compounds in clinical studies are AG014699 
(Rucaparib), Veliparib and Olaparib, which was licenced for the treatment of ovarian 
cancer in 2015 (Figure 1.18) [95]. 
 
Figure 1.18 - Potent PARP inhibitors in clinical trials. 
1.6.3 Bisubstrate analogue inhibitors 
One strategy to increase potency and specificity in enzyme inhibition is to target 
more than one subpocket of the enzyme using so-called bisubstrate or multisubstrate 
analogue inhibitors. A high degree of specificity is expected from these compounds 
as they combine features of two substrates (e.g. substrate and coenzyme) required 
by the target enzyme and should therefore not target enzymes that only use one of 
these substrates [96]. In addition, bisubstrate analogue inhibitors should also be 
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favourable from a thermodynamic point of view; as such a compound has the 
theoretical potential to have a binding free energy equal to the sum of the binding 
energies of both substrates [96], with a possible further contribution from reduced 
entropy. To date, this concept has mainly been used to design structural probes to 
elucidate enzymatic mechanism as in the case of isocitrate dehydrogenase. In this 
approach, bisubstrate inhibitors for isocitrate dehydrogenase were obtained by 
covalently linking 2-oxoglutarate with NAD+ and NADP+. These were shown to be 
able to distinguish between the two isoforms of pig heart mitochondrial isocitrate 
dehydrogenase where one isoform is known to use NAD+ as coenzyme and the other 
NADP+ (Figure 1.19) [97]. 
 
Figure 1.19 - Structure of bisubstrate inhibitor for isocitrate dehydrogenase. 
The nicotinamide portion is represented in red and the oxoglutarate moiety in blue. 
The concept of bisubstrate inhibitors has also led to potent therapeutic compounds, 
such as Mupirocin, a femtomolar inhibitor of bacterial isoleucyl-tRNA synthetase 
widely used as a topical antibiotic [98]. 
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1.7 Aims and Objectives 
Increasing evidence for particular differences in the metabolism of cancer cells 
compared to normal cells are reported, indicating the importance of metabolic targets 
in cancer. However, to date antimetabolites are mostly targeted at the nucleic acid 
metabolism. A potential novel area for therapeutic targeting is represented by 
upregulated anaerobic glycolysis in cancer cells. In this context, PHGDH, which 
utilises the glycolytic metabolite 3-PG, has been proposed as a potential target in 
cancer therapy. PHGDH, a member of the NAD+-requiring dehydrogenase family, 
might be difficult to specifically target due to similarities within its protein family. 
However, other protein targets have been shown to overcome specificity issues as 
seen with inhibitors of the NAD+-consuming PARPs and also dehydrogenase 
inhibitors. In the particular case of dehydrogenases, specific inhibition was shown to 
improve using bi-substrate mimics. 
The main aims of the investigations reported here were: 
1. To further explore PHGDH as a target in different cancer types and validate the 
target through knockdown experiments. 
2. To design potential PHGDH inhibitors based on a bisubstrate approach through 
investigation of the substrate-binding site. 
3. To investigate the cofactor-binding site of PHGDH with NAD+ analogues. 
4. To develop site-directed mutants of PHGDH to reduce binding affinity for the 
cofactor. 
5. To screen for PHGDH inhibitors based on a fragment library and develop a FBDD 
cascade for PHGDH. 
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Chapter 2. Materials and Methods 
2.1 Chemicals and Reagents 
All chemicals listed in the biological materials and methods section were of analytical 
grade and obtained from Sigma Aldrich, St. Louis, MO, USA, unless otherwise 
stated. Chemicals used for compound synthesis are described in chapter 9. 
2.2 Purification buffers 
Extraction buffer I 50 mM NaH2PO4, pH 8, 10 mM Imidazole, 300 mM NaCl, 2 mM 
DTT or 0.5 mM TCEP, 0.01 mg/mL DNase, 0.05 mg/mL RNase, 
0.25 mg/mL Lysozyme, 5 mM MgCl2, 1 EDTA-free complete
TM 
protease inhibitor tablet (Roche, Basel, Switzerland)/ 50 mL 
Extraction buffer II 50 mM NaH2PO4, pH 8, 25 mM Imidazole, 150 mM NaCl, 10 % 
(v/v) glycerol, 0.01 mg/mL DNase, 0.05 mg/mL RNase, 0.25 
mg/mL Lysozyme, 5 mM MgCl2, 1 EDTA-free complete
TM 
protease inhibitor tablet (Roche, Basel, Switzerland)/ 50 mL 
Binding buffer I 50 mM NaH2PO4, pH 8, 10 mM Imidazole, 300 mM NaCl, 2 mM 
DTT or 0.5 mM TCEP 
Binding buffer II 50 mM NaH2PO4, pH 8, 25 mM Imidazole, 150 mM NaCl, 10 % 
(v/v) glycerol 
Elution buffer I 50 mM NaH2PO4, pH 8, 250 mM Imidazole, 300 mM NaCl, 2 mM 
DTT or 0.5 mM TCEP 
Elution buffer II 50 mM NaH2PO4, pH 8, 800 mM Imidazole, 150 mM NaCl, 10 % 
(v/v) glycerol 
SEC buffer 25 mM HEPES, pH 7.5, 100 mM NaCl, 2 mM DTT or 0.5 mM 
TCEP 
Low salt buffer 20 mM Tris, pH 8, 40 mM NaCl, 2 mM DTT or 0.5 mM TCEP 
High salt buffer 20 mM Tris, pH 8, 40 mM NaCl, 2 mM DTT or 0.5 mM TCEP 
2.3 Transformation of competent cells 
Transformation, which is the process of introducing foreign DNA into a host cell, was 
performed using the two chemically competent E. coli strains DH5α (Life 
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Technologies, Carlsbad, CA, USA) and Rosetta (DE3) (Merck, Darmstadt, Germany). 
The DH5α strain was used for the production of high quality DNA for sequencing and 
Rosetta (DE3) was used as an expression strain for large-scale protein production. 
For the transformation, 1 μL purified plasmid DNA (approximately 20 ng/μL) was 
added to 20-50 μL competent cells and incubated on ice for 5 – 30 minutes. Cells 
underwent heat shock for 30 seconds at 42 °C, followed by incubation on ice for 15-
30 min. After addition of 80 – 180 μL of prewarmed LB or SOC media (Sigma Aldrich, 
St Louis, MO, USA) the cells were incubated at 37 °C for 1 h while shaking at 250 
rpm. 25 – 80 μL of cells were plated onto LB agar plates containing 50 μg/mL 
kanamycin. Plates were incubated for 18 h at 37 °C and single colonies used to 
inoculate aliquots of 5 mL LB medium containing 50 μg/mL kanamycin. These 
cultures were used to prepare glycerol stocks (15 % (v/v) glycerol) as well as to 
prepare vector DNA stocks (for DH5α only). 
2.4 DNA sequencing 
Plasmid DNA was extracted from the 5 mL overnight culture using a Spin Miniprep 
Kit (Qiagen, Venlo, Netherlands) according to the manufacturer’s instructions. The 
integrity of all DNA constructs was verified by DNA sequencing. DNA sequencing 
was carried out by Source Bioscience (Nottingham, UK) in forward and reverse 
directions using universal T7 primers. 
2.5 Protein expression 
2.5.1 PHGDH, sPHGDH and site-directed mutants thereof 
The pNIC28-Bsa4 plasmids containing the human PHGDH cDNA encoding for the 
full-length enzyme (aa 1-533) as well as a truncated version (sPHGDH, aa 3-314) 
were kindly donated by Wyatt Yue (SGC Oxford, Oxford, UK). Both plasmids are 
fused with an N-terminal His6-tag and a Tobacco Etch Virus (TEV) protease 
recognition site (Figure 2.1). For large-scale protein production, the proteins were 
expressed in E. coli Rosetta (DE3) grown in TB medium (Sigma Aldrich, St. Louis, 
MO, USA) containing 50 µg/mL kanamycin. 
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Figure 2.1, pNIC28-Bsa4 vector map and amino acid sequence of PHGDH. 
(A) pNIC28-Bsa4 vector map highlighting the T7 promoter and terminator regions as well as different 
restriction sites. The plasmid contains a kanamycin resistance gene (kanR) and a SacB gene allowing 
for antibiotic selection and negative selection on 5 % sucrose, respectively. Picture adapted from 
vector information sheet provided by SGC Oxford [99]. (B) Amino acid sequence of PHGDH with His6-
tag and TEV cleavage site highlighted in red and blue, respectively. Amino acid sequence of sPHGDH 
is highlighted in bold. 
Glycerol stocks were used to inoculate 5 mL aliquots of TB medium containing 50 
µg/mL kanamycin. Starter cultures were grown overnight at 37 °C and 1 mL of the 
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overnight culture used to inoculate 1 L TB medium containing 50 µg/mL kanamycin. 1 
L cultures were grown at 37 °C with shaking (200 rpm) until an optical density at λ = 
600 nm (OD600) of 0.8 was reached. Then, the temperature was lowered to 25 °C and 
cells further incubated for one hour to allow for the temperature to equilibrate. Protein 
expression was induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG) 
to a final concentration of 0.5 mM. Cells were grown overnight before harvesting by 
centrifugation at 4000 rpm, 4 °C for 15 minutes (Beckman Avanti J-26, JLA 8.100 
rotor). Cell pellets were stored at -80 °C until further use. 
2.5.2 TEV protease 
E. coli Rosetta (DE3) cells containing the pRK793 plasmid with cDNA encoding for 
TEV protease fused with an N-terminal His6-tag were kindly donated by Vincent Rao 
(Newcastle University, Newcastle-upon-Tyne, UK). For large-scale protein 
production, a starter culture was prepared in 5 mL LB medium containing 100 µg/mL 
ampicillin and 30 µg/mL chloramphenicol. Cells were grown at 37 °C overnight and 
used to inoculate 1 L LB medium containing 100 µg/mL ampicillin and 30 µg/mL 
chloramphenicol. Large-scale bacterial growth was performed at 37 °C with shaking 
(200 rpm) until an OD600 of > 0.5 was reached. The temperature was lowered to 25 
°C and cells further incubated for 30 minutes to allow for the temperature to 
equilibrate. Protein expression was induced with IPTG at a final concentration of 1 
mM, and cells incubated for another 16 hours. Cells were harvested by centrifugation 
at 4000 rpm, 4 °C for 15 minutes (Beckman Avanti J-26, JLA 8.100 rotor), and cell 
pellets stored at -80 °C until further use. 
2.6 Protein purification 
2.6.1 General procedure for PHGDH, sPHGDH and site-directed mutants 
thereof, and construct 93 
Cell pellets were resuspended in extraction buffer I and the cells lysed by sonication 
on ice for 3.5 min (intervals of 20 sec sonication and 40 sec rest). The lysate was 
cleared by centrifugation (20000 rpm, 4 °C, 1 h, Beckman Avanti J-26, JA 25.50 
rotor) and the supernatant filtered through 0.45 µm serum acrodiscs (Sartorius AG, 
Göttingen, Germany) before applying to a HisTrap Ni-Sepharose column (GE 
Healthcare, Little Chalfont, UK) equilibrated in binding buffer I. Protein was eluted 
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with a linear 10 column volume (cv) gradient up to a maximum concentration of 
imidazole of 250 mM (elution buffer II). To remove the His6-tag from the protein, His6-
tagged TEV protease was added at a mass ratio of 1:25 protease: protein and the 
sample incubated at 4 °C overnight. The sample was applied to a gravity flow column 
containing Ni-Sepharose beads (GE Healthcare, Little Chalfont, UK) and the protein 
samples collected from the flow-through, leaving uncleaved protein and tagged TEV 
protease bound to the column. The protein was concentrated using Vivaspin 
concentrators with 10 – 30 kDa molecular weight cut-off (VivaProducts, Littleton, MA, 
USA). The concentrated protein fraction was further purified by size exclusion 
chromatography on a SuperdexTM 75 26/60 gel filtration column (GE Healthcare, 
Little Chalfont, UK) in SEC buffer. The protein containing fractions were combined, 
concentrated and buffer exchanged into low salt buffer using a PD-10 column (GE 
Healthcare, Little Chalfont, UK). The protein was further purified by anion exchange 
chromatography using a linear gradient up to 1 M NaCl (high salt buffer). The 
fractions were analysed by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) and those containing the protein of interest were 
pooled and concentrated to about 15 mg/mL. Protein concentration was determined 
using the extinction coefficients and calculated molecular mass as determined by 
ProtParam [100]. 
2.6.2 General procedure for TEV protease 
Cell pellets were resuspended in extraction buffer II and the cells lysed by sonication 
on ice for 3.5 min (intervals of 20 sec sonication and 40 sec rest). The lysate was 
cleared by centrifugation at 20000 rpm, 4 °C for 1 h (Beckman Avanti J-26, JA 25.50 
rotor) and the supernatant filtered through 0.45 µm serum acrodiscs (Sartorius AG, 
Göttingen, Germany) before applying to a HisTrap Ni-Sepharose column (GE 
Healthcare, Little Chalfont, UK) equilibrated in binding buffer II. Protein was eluted 
with a linear 20 cv gradient up to a maximum concentration of imidazole of 800 mM 
using binding and elution buffer II. Fractions containing TEV protease were 
determined according to the UV trace (280 nm) and SDS-PAGE. DTT was added to 
TEV protease-containing fractions to a final concentration of 1 mM. Fractions were 
pooled and the concentration determined using a Nanodrop 2000 (Thermo Fisher 
Scientific, Waltham, MA, USA) in combination with the specific extinction coefficient, 
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31970 M-1cm-1, and the molecular weight, 28617 Da, as calculated by ProtParam 
[100]. The TEV protease was stored in aliquots at -80 °C. 
2.7 SDS-PAGE 
SDS-PAGE is a technique to separate proteins according to their molecular weight 
by loading the proteins onto a gel and apply an electric field. SDS is an anionic 
detergent, which linearizes the proteins and gives them a negative charge. The 
linearized proteins move through the gel along the electric field according to their size 
with smaller proteins moving faster towards the anode compared to larger proteins. 
Protein samples were mixed in a 3:1 ratio with RunBlue LDS Sample buffer 
(Expedeon, San Diego, CA, USA) and denatured through heating at 95 °C for 5 
minutes. Samples are loaded onto SDS Precast gels (Expedeon, San Diego, CA, 
USA) with at least one well being loaded with PageRuler prestained protein ladder 
(Thermo Fisher Scientific, Waltham, MA, USA) to allow for approximate localisation 
of the protein bands by weight. Gels were run in RunBlue RAPID Running buffer 
(Expedeon, San Diego, CA, USA) at 150 V for 60 minutes. Protein bands were 
visualised by staining the gel with the Coomassie-based gel stain InstantBlue 
(Expedeon, San Diego, CA, USA). 
2.8 In vitro PHGDH activity assay 
The enzymatic activity of PHGDH or its catalytic domain (sPHGDH) was measured in 
the direction of 3-PG oxidation to PHP by coupling with a resazurin reduction reaction 
to allow fluorescence detection (Figure 2.2). The red fluorescent product, resorufin 
can be detected by monitoring emission at 580 nm upon excitation at 540 nm. 
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Figure 2.2 - Scheme of the reaction catalysed by PHGDH. 
PHGDH converts 3-PG to PHP with concomitant reduction of the cofactor NAD+ to NADH. The 
reaction is coupled to a second enzymatic reaction in which diaphorase catalyses the conversion of 
resazurin to resorufin and concomitantly regenerates NAD+ by oxidation of NADH. The red fluorescent 
dye, resorufin, is measured by monitoring the emission at 580 nm upon excitation at 540 nm. 
The assay mixture contained 18 mM BIS TRIS propane, pH 7.5, 1.7 mM EDTA, pH 
7.5, 10 μM Triton X-100, 3.3 mM glutathione, 140 μM 3-PG (Santa Cruz 
Biotechnology, Dallas, Texas, USA), 25 μM NAD+ and 75 nM purified human PHGDH 
or sPHGDH. The assay was performed in black 96-well plates (Sterilin Ltd, Gwent, 
UK) in 150 μL total volume of which 25 μL was the NAD+ recycling mixture containing 
the diaphorase and resazurin (Amplite Fluorimetric assay buffer, Stratech Scientific 
Ltd., Suffolk, UK). The fluorescence was measured on an Omega Platereader (BMG 
Labtech, Ortenberg, Germany) over 40 – 50 minutes. Analysis was performed in 
GraphPad Prism by determining the initial velocity from the slope of increase in 
fluorescence over time. The initial velocity was corrected for baseline increase in 
fluorescence in the absence of protein. 
2.9 Differential scanning fluorimetry 
Differential scanning fluorimetry is used to monitor protein unfolding with increasing 
temperature and in the presence of a fluorescent dye, e.g. Sypro Orange (Figure 
2.3). 
The assay allows for the quantification of protein stability by derivation of the 
protein’s melting temperature (Tm), which is the temperature at which half of the 
protein is unfolded. In the presence of a bound ligand, the protein stability and 
 
540 nm 
 
580 nm 
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therefore the Tm is increased due to the contribution of free energy of binding from 
the ligand. 
 
Figure 2.3 - Typical fluorescence emission curve for thermally induced protein unfolding in the 
presence of a fluorescent dye. 
Protein and dye are mixed and excited at 490 nm and emission detected at 600 nm when using 
SYPRO orange as fluorescent dye. As the temperature is increased the protein unfolds and exposes 
hydrophobic patches to which the dye binds resulting in increased fluorescence emission. After all the 
protein has unfolded, the observed fluorescence decreases due to protein aggregation and 
dissociation of the dye from the protein. (Picture adapted from [101].) 
Unless otherwise stated the assay mixture contained 25 mM HEPES, pH 7.5, 100 
mM NaCl, 0.5 mM TCEP, 10 x Sypro Orange (Thermo Fisher Scientific, Waltham, 
MA, USA), 2 % DMSO and 15 µM protein. The final assay volume was 15 µL (384-
well plate) or 20 µL (96-well plate). The heat denaturation curves were recorded 
using an RT-PCR instrument (ViiA7, Applied Biosystems, Warrington, UK). The 
temperature was increased by 3 °C/min starting at 25 °C up to 95 °C and the 
fluorescence of Sypro Orange measured with excitation and emission wavelengths of 
470 and 570 nm, respectively. Analysis was performed using the Boltzmann equation 
in GraphPad Prism. 
2.10 Isothermal titration calorimetry 
Isothermal titration calorimetry measures enthalpy changes arising from interactions 
between molecules, e.g. protein-ligand or protein-protein binding, through 
 41 
comparison of the temperature in a reaction cell to that of a reference cell. In addition 
to changes in enthalpy (ΔH) other thermodynamic parameters of the binding reaction 
can be obtained, such as the equilibrium constant (Ka), changes in entropy (ΔS) and 
the stoichiometry of the interaction (n). 
For the determination of the thermodynamic parameters the calorimetric data is fitted 
by nonlinear least squares curve fitting using the Wiseman isotherm (Equation 2.1) 
[102].  
𝑑𝑄
𝑑[𝑋]𝑡
= ∆𝐻°𝑉0 [
1
2
+
1 − 𝑋𝑅 − 𝑟
2√(1 + 𝑋𝑅 + 𝑟)2 − 4𝑋𝑅
]  𝑤𝑖𝑡ℎ 𝑟 =
1
𝐾𝑎[𝑀]𝑡
 
Equation 2.1 - Wiseman isotherm for ligand – receptor binding at 1:1 stoichiometry. 
Abbreviations: X = Ligand, M = Receptor, [M]t = total receptor concentration, dQ/d[X]t = change in 
heat/ moles of ligand added, ΔH = change in enthalpy, V0 = effective volume of calorimetric cell, XR = 
[X]t/[M]t = ratio of ligand to receptor concentration, Ka = binding constant. 
With the Wiseman isotherm, changes in enthalpy (ΔH), the binding constant and the 
stoichiometry of the reaction can be determined. To obtain the enthropic contribution 
to the binding, the experimental data is combined with the Gibbs-Helmholtz equation 
(Equation 2.2). 
∆𝐺 = −𝑅𝑇𝑙𝑛𝐾𝑎 = ∆𝐻 − 𝑇∆𝑆 
Equation 2.2 – Gibbs-Helmholtz equation. 
Abbreviations: G = Gibbs free energy, T = temperature, R = ideal gas constant, Ka = binding constant, 
H = enthalpy, S = entropy 
The relation of the measured equilibrium binding constant Ka and the total receptor 
concentration, which also defines the shape of the binding isotherm, is summarised 
in the Wiseman c-parameter (Equation 2.3). 
𝑐 = 𝑛[𝑀]𝑡𝐾𝑎 
Equation 2.3 – Equation for the Wiseman c-parameter. 
Abbreviations: n = number of binding sites per receptor, [M]t = total receptor concentration, Ka = 
binding constant. 
ITC experiments were performed at 25 °C in 25 mM HEPES, pH 7.5, 100 mM NaCl, 
0.5 mM TCEP with the protein in the sample cell and the ligand in the syringe using a 
 42 
MicroCal iTC200 (GE Healthcare, Little Chalfont, UK). In general, 1 x 0.5 μL, followed 
by 17 x 2 μL injections of ligand into the protein with 120 seconds spacing between 
the injections were conducted. Data was corrected for the heat of dilution by 
subtracting ligand: buffer titration heats. All thermodynamic parameters of the 
reaction were determined following peak integration and best-fit of data to the one-
site binding model using the ORIGIN software, version 7.0. 
2.11 Fluorescence polarisation assay 
In a fluorescence polarisation experiment, the amount of polarised light emitted from 
a fluorophore (e.g. NADH), which itself is excited with polarised light, is measured. 
The degree of polarisation of the fluorophore is related to its rotation such that for a 
small fluorophore, which is rapidly rotating most of the emitted light is not polarised. 
When the rotation of the fluorophore is hindered through binding to a larger and 
therefore more slowly tumbling molecule such as a protein, the amount of polarised 
light is increased. When an inhibitor binds to the same binding site on the protein as 
the fluorophore, the fluorophore is displaced resulting in a decrease in the amount of 
polarised light. 
Fluorescence polarisation assays were carried out in black 96 well microplates 
(Sterilin Ltd, Gwent, UK) with a final assay volume of 60 μL per well. The assay 
mixture contained 40 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 mM TCEP or 2 mM 
DTT, 1 μM NADH and 2 μM PHGDH or sPHGDH. Compounds were screened at 0.5 
and 1 mM in 5 % (v/v) DMSO by adding the compounds at a ratio of 1:3 to the assay 
mixture from appropriate stock solutions in 15 % (v/v) DMSO. Samples were 
incubated for 30 min at RT and fluorescence polarisation was measured using a 
PHERAstar FS plate reader (BMG Labtech, Ortenberg, Germany) with an FP filter 
module (λex = 340 nm and λem = 440 nm). % Inhibition was calculated using NADH 
only in FP buffer as positive control (100 % inhibition) and NADH plus protein in FP 
buffer as negative control (0 % inhibition) (Equation 2.4).  
 43 
% 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =  (
𝐹𝑃𝑐− − 𝐹𝑃𝑠𝑎𝑚𝑝𝑙𝑒
𝐹𝑃𝑐− − 𝐹𝑃𝑐+
) ×  100 
Equation 2.4 – Calculation of % protein inhibition. 
FP stands for fluorescence polarisation signal of positive (c+) and negative (c-) control. 
The robustness of the assay was evaluated by determining the Z’-factor which is 
defined as the ratio of the separation band to the signal dynamic range of the assay 
(Equation 2.5) [103]. 
𝑍′ =  1 −  
(3𝜎𝑐+ + 3𝜎𝑐−)
|𝜇𝑐+ − 𝜇𝑐−|
 
Equation 2.5 – Calculation of Z’-factor.  
Standard deviation (σ) of positive (c+) and negative (c-) control, mean values (μ) from positive (c+) and negative 
(c-) control. 
2.12 Crystallography 
Initial sitting drop vapour diffusion crystallisation trials were set up against 
commercially available sparse matrix screens: Index (Hampton Research, Aliso 
Viejo, CA, USA), JCSG+, Structure, Proplex and Morpheus (all from Molecular 
Dimensions, Newmarket, Suffolk, UK) in 96-well MRC crystallisation plates 
(Molecular Dimensions, Newmarket, Suffolk, UK). Plates were set up using a 
Mosquito LCP liquid handler (TTP Labtech, Melbourn, UK) with two drops of 300 nL 
protein (15 mg/mL) mixed with 300 or 600 nL precipitant and a shared reservoir 
solution of 70 µL precipitant. Crystal trials were stored at 4 or 20 °C. 
Deep-well blocks of optimisation screens were prepared using a Biomek (Beckman 
Coulter, Brea, CA, USA) and drops pipetted as described above. The precipitant was 
optimised by varying the buffer pH as well as the concentrations of the different 
chemicals in the condition (salt, PEG). 
2.13 Data collection and analysis 
Crystals, for which datasets were collected and presented in this work, were grown in 
a variety of conditions (Table 2.1). 
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Name Protein construct Ligand Growth condition 
sPHGDH 01 aa 3-314 NAD+, α-ketoglutarate 0.1 M BIS-TRIS, pH 6.5, 0.2 M NH4Ac, 27 % (w/v) PEG3350 
sPHGDH 02 aa 3-314 NAD
+, L-tartrate 0.1 M TRIS, pH 8.5, 0.2 M MgCl2 hexahydrate, 20 % (w/v) 
PEG3350 
sPHGDH 03 aa 3-314 ADPR 0.1 M BIS-TRIS, pH 6, 0.3 M NH4Ac, 23 % (w/v) PEG3350 
sPHGDH 04 aa 3-314 TAD 0.1 M BIS-TRIS, pH 6, 21 % (w/v) PEG3350 
sPHGDH 05 aa 3-314 AMP 0.1 M Sodium HEPES/ MOPS buffer, pH 7.5, 0.12 M 
monosaccharides, 30 % (w/v) PEG550-MME and PEG20K 
sPHGDH 06 aa 3-314 1:1000 chymotrypsin 0.1 M HEPES, pH 7.5, 0.02 M MgCl2, hexahydrate, 22 % (w/v) 
Poly(acrylic acid sodium salt) 5,100 
sPHGDH 07 aa 3-314 1:1000 chymotrypsin, 
fragment E 
0.2 M Sodium formate, 20 % (w/v) PEG3350 
93-10 aa 93-298 NAD+ 0.1 M TRIS, pH 8, 0.2 M NH4Cl, 20 % PEG6000 
93 aa 93-298 apo-protein for 
soaking experiments 
0.1 M PCTP buffer, pH 7, 22-28 % PEG1500 
Table 2.1 – Crystal growth conditions 
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Crystals were harvested using CryoLoops (Hampton Research, Aliso Viejo, CA, 
USA) matched in size to the crystal and cryo-protected in reservoir solution 
supplemented with 20 % (w/v) PEG400 or ethylene glycol before being flash 
cooled in liquid nitrogen. For crystals grown in the presence of ligand or used for 
ligand soaking the cryo-condition additionally contained the ligand at the 
concentration stated in the relevant section. 
Data were processed using xia2, an automated combination of XDS [104], 
XSCALE [104] and programs from the CCP4 suite [105] and used for molecular 
replacement with PHASER [106] as implemented within CCP4i2 suite [105], 
using the published structure of human PHGDH (PDB 2G76) as search model. 
The structure was refined using cycles of manual correction in COOT [107] 
followed by refinement with Refmac5 [108] within CCP4i2 [105]. Models were 
validated using the validation available in COOT [107], e.g. checking for 
geometry and Ramachandran outliers, and MolProbity [109]. Figures were 
produced using CCP4mg [110]. 
2.14 Statistics 
Statistical analyses were performed in GraphPad Prism (version 6) using the 
appropriate analysis parameters. * = < 0.1, ** = < 0.01, *** = < 0.001, **** = < 
0.0001 and ns = not significant. 
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Chapter 3. Target validation 
3.1 Introduction 
The drug discovery pipeline is a complex process with huge costs estimated to 
amount to be over $ 1 billion for the development of a launched drug [111]. The 
development process of a drug can be broken down into the four stages of target 
selection, hit discovery, candidate identification and subsequent clinical trials with 
the candidate compound (Figure 3.1) [112]. 
 
Figure 3.1 – Drug discovery pipeline. Picture adapted from [112]. 
Historically, phenotypic screenings have been performed, in which compounds 
are assessed in cellular models to identify compounds that modify the behaviour 
of the cell in the desired way, followed by identification of the molecular target. 
However, these days target-based drug discovery is more frequently undertaken. 
A target-based drug discovery program may be initiated following the 
identification of a novel molecular target. Most often this target is upregulated or 
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activated, driving the disease process, and downregulation or inhibition of the 
target causes a phenotypic change indicating amelioration of the disease. Target 
validation is a critical milestone in the drug discovery cascade. Its importance is 
emphasised by the main reasons for candidate drug failure in clinical trials, which 
are insufficient safety, or the drug simply does not work; both are often a 
consequence of poor target validation early on [113]. Difficulties in reproducing 
published target validation experiments are an additional well-known obstacle. A 
recent analysis by Bayer® on their in-house target identification and validation 
projects showed that only in 35 % of cases could literature findings be fully or 
partially repeated [114]. 
Previous studies have shown the overexpression of PHGDH in certain melanoma 
and breast cancer cell lines as well as the dependence on PHGDH expression for 
cell growth in these cell lines and xenograft models [69, 72]. A follow up study on 
breast cancer as a target reproduced growth inhibition effects in in vitro models 
following PHGDH knockdown, but failed to be translated into in vivo efficacy 
[115]. As a possible explanation for the differences seen in the in vivo studies, the 
stage of the tumour was proposed as an important characteristic, such that 
PHGDH inhibition might only be a beneficial treatment at early stages of tumour 
development [115]. However, recent literature further supports a role for PHGDH 
in cancer, including one in cervical cancer with positive in vivo data, but also the 
potential of using PHGDH expression levels as prognostic marker [73, 116]. 
To a large extent, literature data points towards PHGDH as being a putative 
oncogene associated with progression in several tumour types. Its role as a 
therapeutic target is supported by several cell-based studies, but to date the in 
vivo data are somewhat contradictory. 
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3.2 Aims of the project 
The aims of these investigations were: Firstly, to determine PHGDH expression 
in a panel of cell lines including as far as possible cell lines that had been used in 
the published literature studies [72, 115]. PHGDH expression levels in the various 
cell lines were also analysed in regards to their p53 status, as PHGDH has been 
reported to be a target of p53 regulation [117]. In addition, expression of other 
proteins, i.e. c-Myc and PARP, was investigated to see if a correlation with 
PHGDH expression could be identified. Secondly, PHGDH knockdown 
experiments using siRNA or stable, transduced shRNA cell lines were performed 
to investigate if the reported target validation could be repeated by looking at the 
effect of PHGDH knockdown on cell growth. 
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3.3 Materials and Methods 
All chemicals listed in the biological materials and methods section were of 
analytical grade and obtained from Sigma Aldrich, St. Louis, MO, USA, unless 
otherwise stated. 
3.3.1 Cell culture 
All tissue culture plasticware was obtained from Corning (Corning, NY, USA). Cell 
culture reagents were purchased from Invitrogen Life Technologies (Carlsbad, 
CA, USA) unless otherwise stated. Cell culture work was performed in class II 
microbiological safety cabinets (BioMAT2, Medical Air Technology, Manchester, 
UK) using aseptic techniques. 
Breast cancer cell lines MDA-MB-231, MDA-MB-468 and Hs578T as well as the 
highly transfectable HEK293T cells were obtained from the American Type 
Culture Collection (Manassas, VA, USA). The three breast cancer cell lines are 
triple-negative (ER-, PR- and HER2-). MDA-MB-468 has amplified PHGDH 
whereas Hs578T and MDA-MB-231 have no PHGDH amplification [72, 118]. 
Melanoma cell lines SK-MEL-28, containing a PHGDH amplification [119] and its 
BRAF-mutant clone were provided by Dr Penny Lovat (Newcastle University, 
Newcastle-upon-Tyne, UK). All cells were cultured in Roswell Park Memorial 
Institute (RPMI) 1640 medium supplemented with 10 % fetal bovine serum (FBS). 
Except for HEK293T cells, cell media was further supplemented with penicillin 
(100 U/mL) and streptomycin (1.0 mg/mL). Cell lines were maintained at 
exponential growth at 37 °C in a humidified atmosphere of 5 % CO2 and 95 % air. 
All cells were confirmed to be mycoplasma free by regular testing (MycoAlert 
mycoplasma detection kit, Lonza, Basel, Switzerland). Flasks of exponentially 
growing cells of a variety of cancer cell lines for protein expression analysis were 
generously donated by researchers in the NICR. 
3.3.2 Preparation of cell lysates for SDS-PAGE and Western blotting 
After removal of media, the cells were washed with ice-cold PBS and covered 
with a thin layer of Trypsin/EDTA (0.05 % trypsin and 0.02 % EDTA in PBS). 
Cells were left until they detached and then resuspended in media. The cell 
suspension was transferred into Eppendorf tubes and centrifuged at 500 x g for 5 
minutes at 4 °C. The supernatant was discarded and the cell pellet resuspended 
in an approximately equivalent volume of Phosphosafe extraction reagent (EMD 
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Millipore, Billerica, MA, USA). The cells were extracted for 10 min at RT, then 
further broken up by sonication for 8 seconds at 6 mHz using a Soniprep 150 
Plus (MSE, London, UK). Cell debris was pelleted by centrifugation at 16000 x g 
for 5 minutes at 4 °C. The supernatant was transferred into a fresh tube and 
stored at -20 °C until further analysis by SDS-PAGE and Western blotting. The 
protein content in supernatants was measured using a Pierce BCA Protein Assay 
(Thermo Fisher Scientific, Waltham, MA, USA). 
3.3.3 SDS-PAGE 
SDS-PAGE was performed according to section 2.7 with the difference that 
protein lysates were loaded onto Criterion TGX Precast 7.5 % gels (BIO-RAD, 
Hercules, CA, USA) and the gel run at 100 V for 90 minutes. 
3.3.4 Western blotting 
After separation by SDS-PAGE proteins are transferred onto a membrane, which 
allows for detection of specific proteins through binding of specific antibodies. 
Those specific antibodies are themselves recognised by secondary antibodies 
conjugated to horseradish peroxidase (HRP). HRP catalyses the oxidation of 
luminol to 3-aminophthalate resulting in the emission of light and this signal can 
be further amplified and detected. 
Protein transfer onto HybondTM-C Extra nitrocellulose membrane (Amersham 
Bioscience, GE Healthcare, Little Chalfont, UK) was performed at 100 V for 60 
minutes in TRIS-Glycine transfer buffer (Thermo Fisher Scientific, Waltham, MA, 
USA). At this point the membrane was stained for total protein content using 
Ponceau S stain (see section 3.3.5) After Ponceau S staining, the membrane 
was blocked in 5 % milk or 5 % BSA in TRIS-buffered saline with 0.1 % Tween-
20 (TBS-T) followed by incubating with primary antibody (Table 3.1) in 5 % milk 
or 1 % BSA in TBS-T at 4 °C overnight. Following incubation with primary 
antibodies, the membrane was washed twice in TBS-T before incubation with 
HRP-conjugated secondary antibody (Table 3.1) in 5 % milk or 1 % BSA in TBS-
T for one hour at RT. Unbound secondary antibody was removed by washing the 
membrane twice in TBS-T. Proteins were detected by enhanced 
chemiluminescence using Amersham ECL Western blotting detection reagent 
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(GE Healthcare, Little Chalfont, UK) and visualised and analysed in a FujiFilm 
LAS-3000 (Fujifilm, Minato, Tokyo, Japan). 
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Protein 
Molecular weight of 
detected proteins (kDa) 
Antibody 
Type 
Clone Isotype Supplier Cat No. Dilution 
Primary Antibodies        
PHGDH 57 kDa Polyclonal -  Sigma Aldrich HPA021241 1:1000 
c-Myc 
57 kDa (predicted: 49 
kDa) 
Monoclonal Y69 IgG Abcam Ab32072 1:500 
PARP 
114 kDa PARP-1 
holoenzyme 
85 kDa apoptosis-related 
fragment 
50/62/74 kDa necrosis-
related fragments 
Monoclonal C2-10 IgG1 Trevigen 4338-MC-50 1:2000 
GAPDH (loading 
control) 
37 kDa Polyclonal - IgG 
Santa Cruz 
Biotechnology Inc. 
Sc-25778 1:1000 
Secondary Antibodies       
Goat Anti-Mouse IgG, 
HRP conjugate 
- Polyclonal - IgG Dako P 0447 1:1000 
Goat Anti-Rabbit IgG, 
HRP conjugate 
- Polyclonal - IgG Dako P 0448 1:2000 
Table 3.1 – Primary and secondary antibodies used in this study. 
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3.3.5 Ponceau S staining 
Ponceau S staining solution was used to reversibly visualise the total amount of 
protein on the Western blot membrane. 
After protein transfer, the membrane was stained for 5 minutes with 0.1 % (w/v) 
Ponceau S in 5 % acetic acid. After washing the membrane twice for 5 minutes with 
distilled water to remove any non-specific background staining, a picture of the 
membrane was taken. The total amount of protein per lane was quantified by 
integrating the stained area using the FujiFilm LAS-3000 (Fujifilm, Minato, Tokyo, 
Japan). Ponceau S stain was removed by washing the membrane twice for 5 minutes 
in TBS-T. Subsequently, the membrane could be used for blocking and 
immunological detection of desired proteins. 
3.3.6 Transient siRNA knockdown 
Small interfering RNA (siRNA) was used for transient silencing of protein coding 
genes by binding to target mRNA, which was subsequently targeted for cleavage and 
degradation. 
Transient siRNA-mediated knockdown of PHGDH was achieved in cells using 5 nM 
ON-TARGET plus PHGDH siRNA (ON-TARGETplus, 009518, Dharmacon, 
Lafayette, CO, USA) by either using individual siRNAs or a pool of four individual 
siRNAs (Table 3.2), with each siRNA at 1.25 nM. Scrambled (sc) siRNA (as a pool of 
four different sc siRNAs) was used in parallel as negative control (Table 3.2). siRNA 
was transfected into 2 x 105 cells/well of a 6-well plate using lipofectamine RNAiMax 
reagent (Invitrogen, Life Technologies, Thermo Fisher Scientific, Waltham, 
Massachusetts, USA) in OptiMEM medium (Life Technologies, Thermo Fisher 
Scientific, Waltham, Massachusetts, USA). Cells were allowed to grow for 24 – 240 
hours in antibiotic-free medium before being analysed or used for further 
experiments. 
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siRNA Target sequence Company details 
PHGDH 05 GGAAAUUGCUGUUCAGUUC Dharmacon, Lafayette,CO, USA 
PHGDH 06 CGACAGGCUUGCUGAAUGA Dharmacon, Lafayette,CO, USA 
PHGDH 07 GACCCUUGCUGCCGGAAAGA Dharmacon, Lafayette,CO, USA 
PHGDH 08 UGAACUUGGUGAACGCUAA Dharmacon, Lafayette,CO, USA 
sc siRNA 
(pool of 4) 
UGGUUUACAUGUCGACUAA, 
UGGUUUACAUGUUGUGUGA, 
UGGUUUACAUGUUUUCUGA, 
UGGUUUACAUGUUUUCCUA 
Dharmacon, Lafayette,CO, USA 
Table 3.2 - Sequences of siRNAs targeting PHGDH and control scrambled siRNA (sc siRNA). 
3.3.7 Development of inducible shRNA-containing cell lines 
Short hairpin RNA (shRNA) is used for long-term knockdown of the target mRNA by 
endogenous expression of shRNA. As the shRNA sequence is integrated into the 
host genome and therefore continuously synthesised, the knockdown of the target 
protein is expected to last longer compared to siRNA treatment of cells. To be able to 
integrate the shRNA into the host genome, the sequence is incorporated into a 
lentiviral vector, which is then transduced into the host. Once integrated into the host 
genome, the shRNA is transcribed by RNA polymerases to yield an RNA sequence 
that is incorporated into the RNA-induced silencing complex (RISC) and directs the 
RISC to the target mRNA sequence to allow for its degradation. 
In the following experiments, the pTRIPZ inducible shRNA vector (Figure 3.2) was 
used. In the pTRIPZ vector, the gene for the shRNA is under the control of TRE 
promoter, which also drives the expression of the TurboRFP reporter and thus allows 
observation of expression from the TRE promoter and, ergo, expression of the 
shRNA DNA through detection of red fluorescence. 
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Vector element Utility 
TRE Tetracycline-inducible promoter 
tRFP 
TurboRFP reporter for visual tracking of transduction and shRNA 
expression 
shRNA MicorRNA-adapted shRNA (based on miR-30) for gene knockdown 
UBC 
Human ubiquitin C promoter for constitutive expression of rtTA3 and 
puromycin resistance genes 
rtTA3 
Reverse tetracycline-transactivator 3 for tetracycline-dependent 
induction of the TRE promoter 
Puro
R
 
Puromycin resistance permits antibiotic selective pressure and 
propagation of stable integrants 
IRES 
Internal ribosomal entry site allows expression of rtTA3 and puromycin 
resistance genes in a single transcript 
5’ LTR 5’ long terminal repeat 
3’ SIN LTR 3’ self-inactivating long terminal repeat for increased lentivirus safety 
Ψ 
Psi packaging sequence allows viral genome packaging using lentiviral 
packaging systems 
RRE 
Rev response element enhances titer by increasing packaging efficiency 
of full-length viral genomes 
WPRE 
Woodchuck hepatitis posttranscriptional regulatory element enhances 
transgene expression in the target cells 
Amp
R
 Ampicillin resistance  
pUC ori Origin of replication for propagation in E. coli 
SV40 ori Origin for replication in mammalian cells 
Figure 3.2 - Schematic vector map of the pTRIPZ inducible lentiviral shRNA vector including 
description of components 
(Picture adapted from suppliers’ technical manual: 
http://dharmacon.gelifesciences.com/shrna/tripz-lentiviral-shrna-controls/?Parent=12884902171 
#ProductStrip-2) 
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3.3.8 Plasmid preparation 
To prepare the plasmid DNA of the pTRIPZ expression vector, 5 mL Luria Bertani 
(LB) medium containing 100 µg/mL ampicillin were inoculated with the respective 
glycerol stocks of the pTRIPZ-inducible shRNA E. coli clones (Table 3.3) and grown 
at 37 °C for 8 hours. The starter inoculum was then diluted 1:500 into a larger culture 
volume of 200 mL LB medium supplemented with 100 µg/mL ampicillin and grown at 
37 °C for 18 hours. Bacterial cells were harvested by centrifugation at 6000 x g for 15 
minutes at 4 °C. The plasmid DNA was purified from the cell pellet using the 
EndoFree Plasmid Maxi Kit (Qiagen, Venlo, Netherlands) according to the 
manufacturer’s instructions. The final DNA content was measured using a Nanodrop 
(Thermo Fisher Scientific, Waltham, MA, USA) and aliquots stored at -20 °C until 
further use. 
Abbreviation Name Mature antisense sequence 
B03 V2THS_91260 TAGAAGTGGAACTGGAAGG 
B04 V2THS_91258 TGCTGTACTACAGGGTCAG 
B05 V3THS_327719 CATTCAGCAAGCCTGTCGT 
B08 V3THS_327721 CTGACACCAGTGAAGTCTG 
Non-targeting 
control (NTC) 
- CTTACTCTCGCCCAAGCGAGAG 
Table 3.3 - Mature antisense sequences of shRNA produced from TRIPZ inducible shRNA 
clones. 
shRNA clones were from Dharmacon, Lafayette, CO, USA. The NTC was kindly provided by Dr 
Natalia Martinez-Soria, Newcastle University, UK. 
3.3.9 Virus particle preparation 
For virus particle preparation, 2 x 106 HEK293T cells were seeded into a 75 cm2 
tissue culture flask and left to attach and grow. After 24 hours the medium was 
removed from the cells and replaced with fresh medium supplemented with 
packaging mixture. The packaging mixture was prepared twenty minutes prior to 
usage and contained 2.25 µg pMD2.G envelope plasmid (plasmid # 12259, Addgene, 
Cambridge, MA, USA), 6.75 µg psPA2X packaging plasmid (plasmid #12260, 
Addgene, Cambridge, MA, USA), 9 µg pTRIPZ expression plasmid for PHGDH 
(Dharmacon, Lafayette, CO, USA) or pTRIPZ non-silencing control (Dharmacon, 
Lafayette, CO, USA), 54 µL LT1 transfection reagent (MirusBio, Madison, WI, USA) 
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and 1 mL OptiMEM medium. Viral supernatants were collected after 72 hours, 
centrifuged at 1000 x g for 5 minutes at RT and filtered through a 0.45 µm filter to 
remove any cells. The supernatant was then ultracentrifuged at 119 944 x g for 2 
hours at 4 °C. The supernatant was decanted, the virus pellet resuspended in 1 mL 
basal medium, and 100 μL aliquots were stored at -80 °C. 
3.3.10 Assessment of puromycin sensitivity 
The pTRIPZ vectors transduced into mammalian cells contain a puromycin 
resistance gene. Administration of the antibiotic will therefore allow selection for cells 
that have been successfully transduced with the pTRIPZ vector, hence generating 
stable transfected cell lines. In order to avoid killing any transfected cells at the 
beginning of the selection process, the lowest amount of puromycin required to kill all 
non-transfected cells had to be established. 
5 x 104 cells were seeded per well of a 24-well plate. After 24 hours medium was 
exchanged for fresh medium containing varying concentrations of puromycin (0, 0.1, 
0.25, 0.5, 1, 2, 3, 5 µg/mL). Following 72 hours incubation, cells were fixed by 
addition of 0.1 mL ice-cold Carnoy’s fixative (3 parts methanol and 1 part acetic acid) 
and left at 4 °C for 1 hour. Plates were then washed several times with water and left 
to dry. Cells were stained with 0.4 mL 0.4 % SRB solution (0.4 % Sulforhodamine B 
dissolved in 1 % acetic acid) for 30 minutes. Unbound dye was washed off with 1 % 
acetic acid and plates left to dry. SRB was solubilised in 0.4 mL 10 mM Tris (pH 10.5) 
and absorbance of the coloured solution measured at 570 nm. 
3.3.11 Transduction of target cells 
The day before transduction 2 x 105 cells/well were seeded into a 6-well plate. The 
next day medium was removed from the cells and the cells were treated with different 
amounts (10 and 50 µL) of virus stocks (target sequences B03 and B04, and non-
silencing control) in serum-free RPMI 1640 medium in a total volume of 1 mL. After 8 
hours of incubation at 37 °C, 1 mL of full RPMI 1640 medium (containing 10 % FBS, 
penicillin and streptomycin) was added to the cells. At 48 hours post-transduction, 
the medium was removed from the cells and replaced with 2 mL full medium 
containing 1 µg/mL puromycin. Every 2-3 days, medium was replaced with freshly 
prepared selective medium (medium containing 1 µg/mL puromycin) to continue 
selection for transduced cells. 
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3.3.12 TRIzol RNA extraction 
TRIzol, a monophasic solution containing phenol and guanidine isothiocyanate, is 
used to lyse cells and dissolve cell components without compromising the integrity of 
the RNA, thus allowing the extraction of RNA from cell samples. 
Cells were removed from the plastic surface using trypsin-EDTA (0.05 % trypsin and 
0.02 % EDTA in PBS) and centrifuged for 5 min at 500 x g at 4 °C. The supernatant 
was removed and the cell pellet mixed vigorously with 500 µL TRIzol. After 
incubating for 5 min at RT, 100 µL chloroform was added and the mixture incubated 
for a further 5 min. To separate the aqueous and organic layer the sample was spun 
at 12000 x g for 15 min at 4 °C. The aqueous layer was transferred into a fresh tube 
and mixed with 250 µL isopropanol. The samples were incubated at RT for 10 min to 
allow for complete RNA precipitation before centrifugation at 12000 x g for 10 min at 
4 °C. The supernatant was removed from the RNA pellet and the pellet washed by 
adding 1 mL 75 % ethanol. The sample was spun for 5 min at 7500 x g at 4 °C and 
the supernatant removed and discarded. The remaining pellet was air dried and then 
resuspended in 20 µL diethylpyrocarbonate-treated (DEPC) water and stored at -20 
°C until required. 
3.3.13 Two step quantitative reverse transcription polymerase chain reaction 
(qRT-PCR) 
Step one: Reverse Transcription Reaction 
In order to be able to analyse the RNA content in cell samples via qRT-PCR, the 
RNA must first be transcribed into complementary DNA by the Moloney murine 
leukemia virus reverse transcriptase (M-MLV-RT). 
For the reverse transcription reaction, 1-2 µg RNA in DEPC water was incubated at 
65 °C for 5 min to disrupt the RNA secondary structure, followed by 2 min incubation 
at 37 °C. The RNA was mixed with M-MLV RT buffer (Promega, Fitchburg, WI, USA), 
M-MLV reverse transcriptase (Promega, Fitchburg, WI, USA) at a final concentration 
of 3 units/µL, dNTP mix (Promega, Fitchburg, WI, USA) at a final concentration of 0.4 
mM and Oligo(dT)15 primer (Promega, Fitchburg, WI, USA) at a final concentration 
of 2.5 µM. The mixture was incubated at 37 °C for one hour, followed by 5 min 
incubation at 95 °C to inactivate the reverse transcriptase.  
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Step two: real-time qPCR 
Quantitative, real-time PCR allows for the detection and quantification of cDNA levels 
as the reaction progresses. As the cDNA is amplified a fluorescent probe (e.g. SYBR 
green) present in the reaction mix, binds to the synthesised double-stranded DNA 
and emits fluorescence. 
Real-time qPCR was performed with 0.5-0.75 µg cDNA in a final volume of 10 µL 
using PHGDH, GAPDH or β2-microglobulin (β2m) -specific primers (Table 3.4). A 
serial dilution standard of a control cDNA sample (treated with scrambled siRNA) was 
used to determine the linear regression. RT-qPCR was performed with 7900 Real-
Time PCR system (Applied Biosystems, Waltham, MA, USA) following the cycling 
profile below (Figure 3.3). Reaction was run in the presence of Platinum® SYBR® 
Green qPCR SuperMix-UDG (Thermo Fisher Scientific, Waltham, MA, USA), and 
analysed through correction for GAPDH transcription level. 
Gene Orientation Abbreviation Primer Sequence (5’-3’) 
PHGDH 
Forward RT1F CACGACAGGCTTGCTGAATGA 
Reverse RT1R CTTCCGTAAACACGTCCAGTG 
GAPDH 
Forward fGAPDH CGACCACTTTGTCAAGCTCA 
Reverse rGAPDH GGGTCTTACTCCTTGGAGGC 
β2m 
Forward Pb2mF GAGGCTATCCAGCGTACTCCA 
Reverse Pb2mR CGGCAGGCATACTCATCTTTT 
Table 3.4 - Primers for real-time qPCR 
 
 
Figure 3.3 - Thermal cycling profile of real-time qPCR 
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3.3.14 Clonogenic survival assays 
Clonogenic survival assays were used to determine the ability of cells to proliferate 
and form colonies. Cells are seeded at very low density and left to undergo > 5 
division cycles so that colonies comprising > 30 cells are obtained and can be 
observed by eye.  
Method 1: siRNA treated cells 
Cells were treated with siRNA as described in section 3.3.6 and incubated for 48 
hours. Cells were then harvested through addition of trypsin-EDTA (0.05 % trypsin 
and 0.02 % EDTA in PBS) and seeded at specific densities in 2 mL final volume of 
full medium into 6-well plates. Cells were left to replicate for 10-16 days until colony 
formation was observed. Following colony formation, medium was removed from the 
cells and the cells were fixed by addition of 1 mL Carnoy’s fixative (methanol: acetic 
acid, 3:1, v:v), and incubation for 10 minutes at RT. Carnoy’s fixative was removed 
from the cells and the plates left to dry. Cells were stained with 1 % crystal violet 
solution in 10 % aqueous ethanol for 20 minutes. Crystal violet was removed, 
residual stain washed away with water and the plates allowed to dry. Colonies were 
then counted by eye and the cloning efficiency calculated (Equation 3.1). 
𝐶𝑙𝑜𝑛𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑐𝑜𝑢𝑛𝑡𝑒𝑑
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
 ×  100 % 
Equation 3.1 – Calculation of cloning efficiency. 
Method 2: shRNA treated cells 
Cells were treated with medium with and without 1 μg/mL doxycycline for 72 hours; 
medium was replaced with fresh medium with and without doxycycline every 24 
hours. Cells were harvested using trypsin-EDTA (0.05 % trypsin and 0.02 % EDTA in 
PBS) and seeded at specific densities in 2 mL final volume of medium with or without 
doxycycline. Cells were left to replicate for 10-16 days until colony formation was 
observed and subsequent visualisation and analysis were performed as described for 
method 1. 
3.3.15 Growth inhibition assay 
Growth inhibition assays were performed to investigate cellular proliferation over a 
fixed period of time, typically 7-10 days. For the quantification of cells, cells were 
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stained with a coloured dye, such as sulforhodamine B (SRB) for staining of protein 
or 4’,6’-diamidino-2-phenylindole (DAPI) for staining of DNA. 
Exponentially growing cells were cultured for three days in media with or without 
1 μg/mL doxycycline by replacing media with fresh media (with or without 
doxycycline) every 24 hours. Cells were then counted and a fixed number of cells 
seeded into wells of a 96-well plate in media with or without 1 μg/mL doxycycline. 
Cells were allowed to grow for up to seven days with one plate being fixed every 24 
hours. Cells were fixed by adding 25 μL of Carnoy’s fixative and incubated for 10 min 
at RT. Carnoy’s fixative was removed and remaining traces washed away with water. 
Plates were dried and stored at 4 °C until required. To measure the amount of cells 
per well, cell protein content was determined by staining with 0.4 % SRB in 1 % 
acetic acid which bound under these mild acidic conditions to basic amino acid 
residues. The stain was removed after 30 minutes and plates washed four times by 
submersion in 1 % acetic acid solution. After the plates had dried, the SRB dye was 
solubilised in 10 mM Tris, pH 10.5 (100 μL/well) and absorbance measured at 570 
nm on a PHERAstar FS platereader (BMG Labtech, Ortenberg, Germany). 
3.3.16 Live-cell imaging 
Cells were treated with siRNA as described in section 3.3.6 and incubated for 48 
hours. Cells were then harvested through addition of trypsin-EDTA and seeded at 
specific densities in 2 mL final volume of full medium into 6-well plates. Cells were 
imaged using the IncuCyte Zoom HD system (Essen bioscience, Ann Arbor, MI, 
USA) by capturing pictures of 16 separate regions per well every 6 hours. During the 
live-cell image, cultures were permanently kept in a 37 °C incubator. 
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3.4 Results 
Julia Reber, a summer project student working under my supervision, performed part 
of the work with the melanoma cell lines (section 3.4.3). 
3.4.1 PHGDH expression varies in a panel of cancer cell lines 
To confirm differences in PHGDH expression reported for melanoma and breast 
cancer cell lines [69, 72] and to investigate PHGDH expression beyond the reported 
cell lines, a panel of cancer cell lines was assessed by SDS-PAGE and Western 
blotting Due to the variety of cancer cell lines being assessed it was found that levels 
of so-called house-keeping proteins, such as GAPDH, vinculin or Histone H1 varied 
between the cell lines (Figure 3.4). To overcome this, each sample was normalised to 
the total protein content of the sample as visualised and determined by PonceauS 
staining (Figure 3.4). 
 
Figure 3.4 - Comparison of expression levels of different “house-keeping” proteins with total 
protein content per sample 
Cells were harvested and 40 ng of protein lysate loaded per well and analysed by SDS-PAGE and 
Western blotting. (A) Representative blots of GAPDH, histone H1 and vinculin expression measured 
by chemiluminescence using the Fuji. (B) Total protein content on Western blot visualised by Ponceau 
S staining. 
Due to the large number of cell lines being assessed multiple experiments had to be 
performed, therefore protein expression levels in K562 cell lysates were used as an 
internal normalisation standard. In this context, the measurement of inter- as well as 
intra-assay variability was important to correct for the reliability of the measured 
protein expression. The intra-assay coefficient of variation (CV) was found to be 
reasonably low at 6.0 % for the PHGDH/Ponceau S ratio. As expected, the inter-
assay CV was higher with a PHGDH/Ponceau S ratio at 28.9 % after normalisation to 
the respective standard sample, but found to be in a reasonable range for Western 
blot experiments. 
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The observed PHGDH expression levels varied from almost no expression to 6-fold 
higher expression compared to K562 cells (Figure 3.5). For some cell lines, a large 
difference in expression levels was observed in cell lysates harvested from different 
passages of the cell culture. Analysis of PHGDH protein expression according to the 
cancer types the cell lines were derived from showed that breast cancer and 
melanoma were upon the cancer types with the highest PHGDH expression levels 
(Figure 3.5 C). However, no cancer type was associated with significantly higher 
overall PHGDH expression compared to the other cancer type. 
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Figure 3.5 - PHGDH expression in a panel of cancer cell lines 
Cells were harvested, lysed and the proteins separated by gel electrophoresis. Proteins were detected 
using Western blotting and quantified by chemiluminescence using the Fuji. Bands were normalised to 
total protein content visualised by PonceauS staining and quantified in relation to protein expression in 
K562 as the chosen standard cell line. (A) One representative blot showing PHGDH expression in 16 
different cell lines. (B) PHGDH expression in all cell lines assessed relative to PHGDH expression in 
K562 control samples. Protein expression levels were assessed in one sample (grey circles) or if 
available in two or more samples (black squares). (C) PHGDH levels, normalised to PHGDH protein 
level in K562 cells, were group according to their tissue of origin. 
In melanoma cell lines, wt p53 has been shown to regulate PHGDH mRNA and 
protein levels where activation of p53 through Nutlin-3 treatment resulted in 
decreased PHGDH mRNA and protein levels. With this regulation mechanism in 
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mind we investigated the PHGDH protein expression levels in context of the p53 
status in the various cell lines. Overall the p53 mutant cell lines showed higher 
PHGDH protein levels (p = 0.023) compared to cell lines with wt p53 (Figure 3.6 A). 
As the investigated cell line panel spans cancers of different origins, the p53 status 
was also taken into account in the individual cancer types, but no significant 
difference in PHGDH expression according to the p53 status could be detected 
(Figure 3.6 B). 
 
Figure 3.6 – Analysis of PHGDH protein expression in context of the cell lines’ p53 status 
PHGDH protein levels were determined as described before and normalised to PHGDH expression in 
K562 cells as reference. p53 status of the different cell lines was determined from IARC TP53 
database, version R17, November 2013 [120]. For the following cell lines the p53 status was 
determined from the cited literature: D425 [121], D283 [122], T778 [123], Hs578T [124], OCI-LY18 
[125], Pfeiffer [126]. Cell lines for which the p53 status was not known are excluded from the analysis. 
(A) PHGDH expression grouped according to the cell lines’ p53 status. Data was analysed in 
GraphPad Prism using a paired t.test. p = 0.023. (B) Separation of PHGDH expression according to 
cancer type and p53 status. Only cancer types with at least one cell line per p53 status were included. 
3.4.2 PHGDH expression correlates negatively with c-Myc 
Alongside PHGDH expression levels, expression levels of c-Myc were investigated in 
the reported cell lines. As outlined earlier c-Myc is implicated in the regulation of 
many metabolic pathways, such as glutamine, glucose and nucleotide metabolism, 
and was recently shown to positively regulate mRNA expression of proteins involved 
in serine synthesis, such as PHGDH [127, 128]. As the band for c-Myc runs at 57 
kDa, the same molecular weight as PHGDH, lysates were split and run on two gels to 
allow for detection of both proteins (Figure 3.7 A). A variety of c-Myc expression 
levels were detected within the panel of cell lines with very high levels in the 
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medulloblastoma cell lines D425 and D283 and in the ovarian cancer cell line MDAH-
2774. D425 contain a c-Myc gene amplification and re-arrangement of one allele was 
found in D283, both factors reported to increase c-Myc expression substantially in 
those cell lines [129]. In order to investigate if the expression levels of c-Myc and 
PHGDH were correlated, a Spearman correlation analysis was performed using the 
expression levels of cell lines that were assessed at least twice. Intriguingly, a 
negative correlation (Spearman r = -0.4716, p = 0.0014) was determined where high 
c-Myc levels were observed in cells with low PHGDH expression (Figure 3.7 C). 
Despite the relatively high correlation coefficient, analysis of the correlation blot by 
eye rather indicates an unordered distribution of both protein levels (Figure 3.7 D). 
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Figure 3.7 – c-Myc expression in a panel of cancer cell lines 
Cells were harvested, lysed and proteins separated by gel electrophoresis. Proteins were detected 
using Western blotting and quantitated by chemiluminescence using the Fuji. Bands were normalised 
to total protein content visualised by PonceauS staining and quantified in relation to protein expression 
in K562 as the chosen standard cell line. (A) One representative blot showing c-Myc and PHGDH 
expression in 16 different cell lines. (B) c-Myc expression in all cell lines assessed relative to c-Myc 
expression in K562 control sample. Protein expression levels were assessed in one sample (grey 
circles) or if available in two or more samples (black squares). (C) Spearman correlation analysis of c-
Myc and PHGDH expression levels in 43 different cancer cell lines was performed in GraphPad Prism. 
The red line indicates the correlation line (r = -0.4716). 
In addition to c-Myc and PHGDH, protein levels of poly(ADP-ribose) polymerase 1 
(PARP1) were also investigated. PARP1 catalyses the transfer of the ADP-ribosyl 
moiety of NAD+ onto various target proteins, a post-translational modification called 
PARylation. PARP1 plays important roles in different cellular processes, such as 
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DNA repair, genomic stability, cell death signalling and cellular metabolism [130]. In 
the context of cellular metabolism, PARP1 activation by DNA damage depletes NAD+ 
levels, this affecting the glycolytic pathway, which uses NAD+ as a key cofactor [131]. 
Since PHGDH is a NAD+-requiring enzyme linked to glycolysis, a possible correlation 
of PARP and PHGDH expression levels was investigated. 
Among the cell lines investigated, a range of PARP1 expression levels was observed 
(Figure 3.8 A and B). However, there was no significant correlation (p = 0.0805) seen 
between PHGDH and PARP1 protein levels in these cell lines (Figure 3.8 C). 
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Figure 3.8 – PARP1 expression in a panel of cancer cell lines 
Cells were harvested, lysed and proteins separated by gel electrophoresis. Proteins were detected 
using Western blotting and quantitated by chemiluminescence. Bands were normalised to total protein 
content visualised by PonceauS staining, and quantified in relation to protein expression in K562 cells. 
(A) One representative blot showing PARP expression in 12 different cell lines. (B) PARP expression 
in all cell lines assessed relative to PARP expression in K562 control sample. Protein expression 
levels were assessed in one sample (grey circles) or if available in two or more samples (black 
squares). (C) Spearman correlation analysis of PARP and PHGDH expression levels in 43 different 
cancer cell lines was performed in GraphPad Prism. The red line indicates the correlation line (r = -
0.2693). 
3.4.3 siRNA-mediated knockdown of PHGDH 
In order to validate PHGDH as a potential target, siRNA-mediated knockdown was 
performed in breast cancer cell lines. Based on the literature, three breast cancer cell 
lines were chosen: MDA-MB-231 (non-amplified PHGDH), MDA-MB-468 (amplified 
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PHGDH) and Hs578T (non-amplified PHGDH, but with high expression) [72]. The 
effects on cell growth after PHGDH knockdown were expected in the PHGDH 
amplified or highly expressing cell lines. 
Optimisation of the protocol for siRNA-mediated knockdown of PHGDH was 
performed in Hs578T cells. Hs578T cells were treated with four different siRNAs 
(siRNA 5-8) or scrambled siRNA (sc siRNA) at a final concentration of 10 nM for 72 
hours. PHGDH mRNA and protein expression levels were determined every 24 hours 
by RT-PCR and Western blotting, respectively. Although PHGDH mRNA levels were 
successfully decreased by more than 90 % after 24 hours of siRNA treatment, a 
decrease in protein levels was only seen after 48 hours, indicating a protein half-life 
between 24 and 48 hours (Figure 3.9). After 72 hours of siRNA treatment, 30 % of 
protein remained (Figure 3.9 C). 
 
Figure 3.9 – siRNA-mediated PHGDH knockdown in Hs578T cells 
Cells were seeded into wells of a 6-well plate at a density of 2 x 10
5
 cells/well and treated with 5 nM 
on-target or scrambled siRNA or medium only control. Cells were harvested and lysed or RNA isolated 
after 24, 48 and 72 hours. Proteins were separated by gel electrophoresis and detected using Western 
blotting before visualisation by chemiluminescence. (A) Relative mRNA expression levels as detected 
by RT-PCR using GAPDH as reference gene and normalised to respective media control. (B) Western 
blots showing PHGDH and GAPDH protein levels. (C) Quantification of PHGDH protein levels 
detected by Western blotting and normalised to total protein content of the sample and to the media 
control. 
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Further initial experiments, different concentrations of siRNA were investigated to see 
if the maximum possible knockdown of PHGDH was achieved with 10 nM siRNA, as 
well as to investigate if a lower siRNA concentration would result in the same level of 
knockdown and thereby minimise possible off-target effects of the siRNA. In addition 
to individual on-target siRNAs, a pool of all four siRNAs was used as they were of 
similar potency and this allowed the use of smaller amounts of each individual 
siRNA, thus further minimising potential off-target effects. As 24 hours had been 
shown not to be a sufficient time of knockdown to see a reduction in protein levels, 
only 48 and 72 hours were investigated. The experiment confirmed that 5 nM of 
individual siRNA as well as the pool of four individual siRNAs was sufficient to induce 
the same level of knockdown as seen with 10 or 20 nM (Figure 3.10). Although 
PHGDH protein expression was already reduced by 50 % after 48 hours of siRNA 
treatment, a further reduction was seen after 72 hours (Figure 3.10). 
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Figure 3.10 – siRNA-mediated knockdown of PHGDH in Hs578T with different concentrations of 
siRNA. 
Cells were seeded into wells of a 6-well plate at a density of 2 x 10
5
 cells/well and treated with 5, 10 or 
20 nM individual siRNA05, siRNA08, a pool of four individual siRNAs or scrambled siRNA. Cells were 
harvested and lysed or RNA isolated after 48 (i) and 72 (ii) hours. Proteins were separated by gel 
electrophoresis and detected using Western blotting before visualisation by chemiluminescence. (A) 
Relative mRNA expression levels as detected by RT-PCR using GAPDH as reference gene and 
normalised to respective scrambled siRNA control. (B) Western blots showing PHGDH and GAPDH 
protein levels. (C) Quantification of PHGDH protein levels detected by Western blotting and 
normalisation to total protein content of the sample and to the media control. 
The experimental conditions established (5 nM pool siRNA, ≥ 72 h) were then used 
to assess the effect of PHGDH knockdown in all three breast cancer cell lines. mRNA 
levels were significantly reduced in all three cell lines over 120 hours resulting in 
PHGDH mRNA levels below 10 % (Figure 3.11 A). The reduction in mRNA levels 
was directly translated into PHGDH protein levels, which were also significantly 
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reduced in Hs578T and MDA-MB-468 cells over 120 hours, whereas the reduction in 
PHGDH levels in MDA-MB-231 was only about 50 %, however, this result is likely to 
be also due to the low PHGDH protein content in this cell line, which was difficult to 
detect by Western blotting (Figure 3.11 B and C). 
 
Figure 3.11 – siRNA-mediated knockdown of PHGDH in breast cancer cell lines 
Cells were seeded into wells of a 6-well plate at a density of 2 x 10
5
 cells/well and treated with 5 nM 
siRNA (pool of four individual siRNAs) or scrambled siRNA. Cells were harvested and lysed or RNA 
isolated after 72, 96 or 120 hours. Proteins were separated by gel electrophoresis and detected using 
Western blotting before visualisation by chemiluminescence. (A) Relative mRNA expression levels as 
detected by RT-PCR using GAPDH as reference gene and normalised to respective scrambled siRNA 
control. (B) Western blots showing PHGDH and GAPDH protein levels. (C) Quantification of PHGDH 
protein levels detected by Western blotting and normalisation to total protein content of the sample 
and to the scrambled siRNA control. 
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To determine whether PHGDH knockdown had an effect on cell survival, the three 
breast cancer cell lines were treated with 5 nM siRNA for 48 hours and assessed for 
colony formation. In general, scrambled and mock controls had only minor impact on 
cell survival, with the exception of mock treatment of MDA-MB-468 (Figure 3.12 B). 
Comparison of the siRNA-treated cells with the respective scrambled controls 
showed that as expected, cell growth of MDA-MB-231 was not impaired and the 
growth of MDA-MB-468 cells was significantly reduced by about 47 % (Figure 3.12 
A). In contrast to literature findings, the growth of Hs578T cells was not affected by 
PHGDH knockdown, indicating that a PHGDH amplification has to be present so that 
knockdown induces a growth inhibiting effect. 
 
Figure 3.12 – Sensitivity of breast cancer cell lines to PHGDH knockdown 
Hs578T, MDA-MB-231 and MDA-MB-468 cells were seeded at 2x10
5
 cells/well in a 6-well plate and 
treated with 5 nM on-target or scrambled siRNA, lipofectamine (mock control) or medium only (NT 
control). After 48 hours, cells were reseeded in fresh medium at low density and grown for 14 days to 
allow colony formation. Colonies (> 30 cells) were fixed using Carnoy’s fixative, stained with 0.4 % 
crystal violet and counted. The plating efficiency was calculated and normalised to (A) scrambled 
control or (B) NT control. Graphs represent averages and SD of three independent experiments with 
three intra-assay replicates. Significant reduction of cell growth compared to control sample was 
determined by paired t-test; ** p = 0.0022. 
In addition, live cell imaging was used to measure cell proliferation in the three breast 
cancer cell lines over 7 days following 48 h of siRNA knockdown. In agreement with 
colony formation assays, knockdown of PHGDH in MDA-MB-468 cells had an effect 
on cell growth compared to not-treated (NT) cells or control treatment (sc siRNA or 
mock) (Figure 3.13B). MDA-MB-231 were overall unaffected in their growth by 
PHGDH knockdown whereas data for Hs578T cells was inconclusive as sc siRNA, 
and to a larger extent, mock treatment impaired cell growth (Figure 3.13 A and C). 
However, maximum confluency achieved after 7 days was low for all cell lines, so 
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that either seeding out more cells or observing the cells for longer would have 
obtained a better read-out. 
 
Figure 3.13 – Analysis of cell confluence using live cell imaging. 
Hs578T (A), MDA-MB-468 (B) and MDA-MB-231 (C) cells were seeded at 2x10
5
 cells/well in a 6-well 
plate and treated with 5 nM on-target or scrambled siRNA. After 48 h cells were reseeded and lower 
density and grown at 37 °C over 7 days and imaged every 6 hours. Cell confluence analysis was 
performed using the IncuCyte analysis software. Data shows one representative experiment. 
PHGDH knockdown had also been shown to impair cell growth in melanoma cell 
lines with PHGDH copy number gain. Therefore the melanoma cell lines SK-Mel28, 
which contains a PHGDH amplification, and a BRAF-mutant cell line with low 
PHGDH protein expression were investigated. Cell lines were treated with 5 nM 
siRNA for 48 hours and reseeded to allow analysis of subconfluent cell samples for 
longer times after initial siRNA treatment. PHGDH protein levels were still 
significantly reduced after 168 h and 240 h in SK-Mel28 and BRaf-mutant cells, 
respectively (Figure 3.14 A and B). This was in agreement with reduced mRNA levels 
with the exception of the 120 h time-point in BRaf-mutant cells, which might be due to 
an experimental error in the RT-PCR as later timepoints showed significantly reduced 
mRNA levels in this cell line (Figure 3.14 C). 
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Figure 3.14 - siRNA-mediated knockdown of PHGDH in SK-Mel28 and BRaf-mutant cell line 
Cells were seeded into wells of a 6-well plate at a density of 2 x 10
5
 cells/well and treated with 5 nM of 
a pool of four on-target siRNAs, scrambled siRNA or lipofectamine only control (mock, m) or not-
treated (NT). Cells were harvested after 48 hours, reseeded at lower density and grown for different 
times. At indicated timepoints cells were lysed or RNA isolated. Proteins were separated by gel 
electrophoresis and detected using Western blotting before visualisation by chemiluminescence. (A) 
Relative mRNA expression levels as detected by RT-PCR using (i) GAPDH or (ii) β2-microglobulin as 
reference gene and normalised to respective NT control. (B) Western blots showing PHGDH and 
GAPDH protein levels in (i) BRaf-mutant cells and (ii) SK-Mel28. (C) Quantification of PHGDH protein 
levels detected by Western blotting and normalisation to total protein content of the sample and to the 
NT control. 
Both cell lines were investigated in clonogenic survival assays following PHGDH 
knockdown. Although cell proliferation was slightly reduced in both cell lines 
compared to medium only control, the reduction was not significant when compared 
to cells treated with scrambled siRNA (Figure 3.15). 
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Figure 3.15 – Sensitivity of melanoma cell lines to PHGDH knockdown 
BRaf-mutant and SK-Mel28 cells were seeded at 2x10
5
 cells/well into a 6-well plate and treated with 5 
nM on-target or scrambled siRNA, lipofectamine (mock control) or medium only (NT control). After 48 
hours cells were reseeded in fresh medium at low density and grown for 14 days for colony formation. 
Colonies (> 30 cells) were fixed using Carnoy’s fixative, stained with 0.4 % crystal violet and counted. 
The plating efficiency was calculated and normalised to (A) NT control (B) scrambled control. Graphs 
represent averages and SD of three independent experiments with three intra-assay replicates. 
3.4.4 Development of stable cell lines with tetracycline-inducible shRNA 
expression 
The reduction in cell growth in MDA-MB-468 cells after siRNA-mediated knockdown, 
though significant, was less prominent than reported in the literature when using 
shRNA, whereas no effect at all was seen in Hs578T [72]. siRNA is typically used for 
short-term knockdown of target molecules, whereas shRNA-mediated knockdown 
can be performed for longer times [132]. With PHGDH being a relatively stable 
protein, this difference in the duration of knockdown was suspected to have an 
influence on the growth inhibition studies. Although siRNA and shRNA both direct 
mRNA cleavage and degradation by binding to their complementary mRNA strand, 
the delivery mechanism of the double-stranded RNA into the cells is different. siRNA 
is brought into the cells with the help of a delivery system, such as lipofectamine, 
whereas the DNA encoding the shRNA is integrated into the cell genome with the 
help of lentviral vectors. 
E. coli cells containing the pTRIPZ expression vector with the DNA sequence of the 
respective shRNA were amplified and the plasmid DNA extracted. The obtained 
plasmid DNA, together with the packaging psPA2X vector and the pMD2.G envelope 
plasmid, were used to transfect HEK293 cells from which the final virus particles 
could be extracted. The breast cancer cell lines Hs578T, MDA-MB-468 and MDA-
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MB-231 were transduced with 10 and 50 μL of two on-target virus stocks or the non-
target control virus. After 48 hours, puromycin selection of the transduced cells was 
started using medium containing 1 μg/mL puromycin, as this was the lowest dose of 
puromycin found to kill 100 % of non-transduced cells (Figure 3.16). 
 
Figure 3.16 - Puromycin kill curves for different breast cancer cell lines. 
Untransduced MDA-MB-468, MDA-MB-231 and Hs578T cells were treated with increasing amounts of 
puromycin (0-5 µg/mL) and left under puromycin selection for 72 hours. 1 µg/mL was found to be a 
sufficient amount of puromycin to kill all non-transduced cells within 72 hours in all three cell lines. 
In order to test if the cell lines had been efficiently transduced, each newly generated 
shRNA-expressing cell line was seeded into 6-well plates in medium with or without 
0.5 or 1 μg/mL doxycycline for 72 hours. Doxycycline binds to the tetracycline-
inducible TRE promoter and thus activates the expression of red-fluorescent protein 
and shRNA, so that efficiency of transduction can be observed using a fluorescent 
microscope. All three cell lines transduced with both amounts of virus stock (10 and 
50 μL) showing efficient transduction (Figure 3.17). 
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Figure 3.17 - RFP expression in transduced MDA-MB-468 following exposure to doxycycline. 
MDA-MB-468 cells were transduced with 10 µL shB03 virus and left to grow for 24 hours. Addition of 
doxycycline (1 µg/mL) to the medium resulted in RFP and shRNA expression with RFP expression 
being measured after 72 hours. 
All shRNA-containing cell lines were assessed for the effectiveness of PHGDH 
knockdown following 72 hours of doxycycline treatment at 0, 0.5 or 1 μg/mL through 
analysis of mRNA and protein levels. Analysis of the mRNA levels showed overall 
good reduction of PHGDH mRNA levels after doxycycline treatment in all three 
breast cancer cell lines transduced with on-target shRNA. In Hs578T and MDA-MB-
231 the knockdown in the on-target cell lines (B03 and B04) was of similar level 
independent of the amount of virus (10 or 50 μL) used for transduction, whereas in 
the respective cell lines of MDA-MB-468, the cells transduced with higher amounts of 
virus had better knockdown results at least after treatment with 0.5 μg/mL 
doxycycline (Figure 3.18). Analysis of the protein levels in the different cell lines 
showed that, as expected, the NTC-shRNA had no effect on PHGDH levels, whereas 
cell lines containing the plasmid for the two on-target shRNAs (B03 and B04) showed 
a reduction in PHGDH protein levels after doxycycline treatment (Figure 3.19). 
However, PHGDH protein levels were only reduced about 50-60 % with no significant 
increase in the cell lines transduced with more virus particles (50 μL). Overall, in cells 
treated with 1 μg/mL doxycycline the PHGDH levels were slightly lower compared to 
0.5 μg/mL doxycycline treatment. 
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Figure 3.18 – mRNA levels in shRNA-expressing breast cancer cell lines after doxycycline 
treatment. 
Cells were seeded into wells of a 6-well plate at a density of 2 x 10
5
 cells/well and treated with 0 (No 
Dox), 0.5 (0.5 Dox) or 1 (1 Dox) μg/mL doxycycline for 72 hours with fresh medium applied every 24 
hours. Cells were harvested, lysed and mRNA levels determined by RT-PCR in (A) Hs578T, (B) MDA-
MB-468 and (C) MDA-MB-231. mRNA levels of PHGDH were normalised to mRNA levels of β2m and 
expressed relative to the No Dox treatment of the respective NTC-50 cell line. 
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Figure 3.19 – PHGDH protein levels in shRNA-expressing breast cancer cell lines after 
doxycycline treatment. 
Cells were seeded into wells of a 6-well plate at a density of 2 x 10
5
 cells/well and treated with 0 (-), 
0.5 (+) or 1 (++) μg/mL doxycycline for 72 hours with fresh medium applied every 24 hours. Cells were 
harvested, lysed and proteins were separated by gel electrophoresis and detected using Western 
blotting before visualisation by chemiluminescence. Western blots showing PHGDH and GAPDH 
protein levels as well as quantification of protein levels in (A) Hs578T, (B) MDA-MB-468 and (C) MDA-
MB-231. 
Since transduction with 50 μL virus did not significantly improve the knockdown of 
PHGDH compared to 10 μL virus, cells transduced with the lower amount of virus 
were taken forward in order to minimise the likelihood of integration of multiple 
lentiviral vector copies per cell. 
The effect of PHGDH knockdown was assessed in the transduced cell lines in colony 
formation assays. Cells were maintained in medium with (1 μg/mL) or without 
doxycycline for 72 hours with fresh medium applied every 24 hours. Cells were then 
seeded at low density in medium with or without doxycycline and left to proliferate for 
14 days. Comparison of the doxycycline-treated cell lines compared to the non-
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treated counterparts showed that treatment with doxycycline increased cell 
proliferation independently of which shRNA was expressed. 
 
Figure 3.20 - Sensitivity of breast cancer cell lines to PHGDH knockdown assessed by colony 
formation. 
Hs578T, MDA-MB-231 and MDA-MB-468 cells stably transduced with on-target (B03 and B04) or 
control (NTC) shRNA were split into two flasks with one being treated with 1 μg/mL doxycycline. After 
72 hours of doxycycline treatment, the cells were reseeded in fresh medium (+/- doxycycline) at low 
density and grown for 14 days for colony formation. Colonies (> 30 cells) were fixed using Carnoy’s 
fixative, stained with 0.4 % crystal violet and counted. The plating efficiency was calculated and 
normalised to the respective non-treated cell sample. Data represent mean and error of two 
independent experiments with three intra-assay replicates. 
In addition to colony formation assays, growth inhibition assays were performed to 
investigate the effect of PHGDH knockdown on cell proliferation over a shorter period 
of time (7 days) with a daily read-out. No effect was seen on cell growth in any of the 
transduced cell lines after doxycycline treatment (Figure 3.21). 
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Figure 3.21 - Sensitivity of breast cancer cell lines to PHGDH knockdown assessed by SRB 
growth assay. 
(A) MDA-MB-468, (B) Hs578T and (C) MDA-MB-231 cells stably transduced with on-target (B03 and 
B04) or control (NTC) shRNA were split into two flasks with one being treated with 1 μg/mL 
doxycycline. After 72 hours of doxycycline treatment, the cells were reseeded in fresh medium (+/- 
doxycycline) into wells of a 96-well plate with 1 x 10
4
 cells (MDA-MB-231) or 2.5 x 10
4
 cells/well (MDA-
MB-468, Hs578T) at low density and grown for 7 days. Every 24 hours, one plate per cell line was 
fixed using Carnoy’s fixative, stained with 0.4 % SRB before being solubilised and SRB absorbance 
measured. Data represent mean and error of two independent experiments with six intra-assay 
replicates. 
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3.5 Discussion 
PHGDH has been validated by previous studies as a potential target in breast cancer 
and melanoma cell lines [69, 72]. Thorough target validation is a critical step in the 
drug discovery process and disagreement with literature findings is not uncommon. 
Therefore the work described in this chapter focused on repeating the published 
target validation as well as exploring PHGDH expression levels in a wider set of 
cancer cell lines. 
PHGDH expression was investigated in a panel of 65 cancer cell lines, in order to 
extend the set of potential tumours that would benefit from PHGDH inhibitors beyond 
breast cancer and melanoma. The different cell lines investigated included cancers 
from about 15 different organs, which made it difficult to find a housekeeping protein 
to use for normalisation of protein levels in all cell lines. Variations in protein and 
mRNA levels of the preferentially used housekeeping genes, such as GAPDH or β-
actin, have been reported with very high differences seen between different organs 
as well as between tumorigenic and healthy tissues [133, 134]. Therefore, to exclude 
introduction of variations resulting from changes in housekeeping proteins, the 
protein levels were normalised to the total amount of protein per lane detected by 
Ponceau S staining and quantified by densitometry. PHGDH protein levels were 
compared to PHGDH expression in K562 as reference cell line. Among the cell lines 
with 3.5-6-fold higher PHGDH expression compared to K562, there were, as 
expected, breast cancer (MDA-MB-468, MDA-MB-453 and TD47) and melanoma 
(CHL-1, A375) cell lines, but also a gastric cancer cell line (SNU1), a 
medulloblastoma cell line (DAOY) and the choriocarcinoma cell line JEG-3, which is 
the only one reported to have a PHGDH amplification [3]. In contrast to published 
data, T47D cells were shown to express high amounts of PHGDH [115]. However, 
with only one sample analysed for this cell line together with an inter-assay CV of 
about 29 % additional repeats would be necessary to set T47D in the right context. 
To date, no implication of PHGDH in gastric or uterine cancers has been reported or 
investigated. However, recent studies observed elevated PHGDH expression levels 
in astrocytic tumours with PHGDH inhibition resulting in reduced proliferation in 
glioma cells [77]. Hence, further investigations into other cancer types might expand 
the potential usage of PHGDH inhibitors. 
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Interestingly, PHGDH expression was correlated with c-Myc expression. c-Myc has 
been shown to positively regulate enzymes of the serine synthesis pathway through 
their mRNA expression under nutrient deprivation conditions [127]. Surprisingly, in 
this study c-Myc and PHGDH protein levels correlated negatively with a Spearman 
correlation coefficient of -0.47. However, the cell lines analysed were cultured in 
complete medium and therefore it would be interesting to see if different protein 
expression levels could be detected under nutrient deprivation. In addition, some of 
the cell lines reported herein have only been tested once, so that more repeats would 
be necessary to strengthen the findings. 
Besides c-Myc, PARP1 protein levels were also explored with PARP1 being among 
the major NAD+-consuming enzymes and thus regulating cellular NAD+ levels, which 
in turn has implications for glycolytic enzymes using NAD+ as a major cofactor. In the 
cell lines investigated, a variety of PARP1 expression levels was detected, which, 
however, did not correlate with PHGDH expression levels. 
To validate the reported effects on cell proliferation following PHGDH knockdown, 
siRNA-mediated knockdown of PHGDH in three breast cancer cell lines was 
investigated. MDA-MB-231 which have very low PHGDH expression, Hs578T that do 
not contain a PHGDH amplification, but were found to have high PHGDH protein 
expression, and MDA-MB-468, which have a genomic amplification of PHGDH [72]. 
Optimisation, performed in Hs578T cells showed that 5 nM of a pool of four individual 
siRNAs resulted in about 90 % reduction in mRNA levels and ≥ 80 % reduction in 
protein levels. Similar effects on mRNA levels after PHGDH knockdown were 
achieved in MDA-MB-231 and MDA-MB-468 cells resulting in good reduction of 
protein levels in MDA-MB-468 cells. To determine the effect on cell growth, 
clonogenic survival after siRNA treatment was investigated. The survival rate was 
significantly reduced to about 50 % in MDA-MB-468 cells, which is in agreement with 
reported data of 57 % growth inhibition after seven days using clonogenic survival 
assays [115]. However, the original study from Possemato and colleagues reported a 
much more prominent reduction in cell growth of MDA-MB-468 cells of 80-90 % [72]. 
Interestingly, knockdown of PHGDH in Hs578T cells did not affect cell growth, which 
is in contrast to literature data reporting a similar reduction in cell growth as seen with 
PHGDH amplified MDA-MB-468 [72]. Live cell imaging experiments, the second 
technique used to assess cell growth, similar cell growth was observed in cells with 
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and without PHGDH knockdown in MDA-MB-231 cells, whereas knockdown impaired 
cell growth in MDA-MB-468 cells. In Hs578T cells, the mock control showed a 
stronger effect on cell growth compared to siRNA treated cells indicating off-target 
effects. Live cell imaging analysis is based on the quality of the pictures of the cells, 
and, although being able to distinguish between cells and plastic surface, the 
software only analyses cell confluence and therefore does not distinguish between 
larger cell numbers and enlarged cells, which might be a drawback when using this 
technique. 
Likewise, successful PHGDH knockdown resulting in a reduction of at least 80 % at 
the protein level had no significant effect on cell growth in the melanoma cell line SK-
Mel28 and a BRaf-mutant cell line, despite SK-Mel28 being reported as being 
dependent on PHGDH expression [69]. Experiments represented in the literature had 
been performed with stably transduced shRNA-expressing cell lines, which allow 
more precise manipulation and longer knockdown of the target gene, and might be a 
reason for differences seen compared to this study where transient siRNA-mediated 
knockdown was performed. On the other hand, despite siRNA-mediated knockdown 
being of a transient nature, analysis of PHGDH levels over 240 h in BRaf-mutant 
cells showed that siRNA-mediated knockdown was able to reduce PHGDH levels 
over this extended period. 
For a better comparison with literature experiments, stably transduced Hs578T, 
MDA-MB-468 and MDA-MB-231 cell lines were produced. It was chosen to take the 
whole transduced and puromycin-selected cell populations forward, compared to 
picking individual clones, in order to account for cell heterogeneity. By keeping the 
transduced cell lines all the time in puromycin-containing medium, a constant 
selective pressure was imposed on the cells, so that cells lacking the transduced 
vector, because of unsuccessful transduction or cell leakage, should not survive. 
Transduction was successfully performed in all three breast cancer cell lines as seen 
through expression of the red-fluorescent protein (RFP) and reduced PHGDH mRNA 
levels. However, PHGDH protein levels after 3 days of doxycycline treatment of 
transduced cell lines compared to protein levels after 3 days in siRNA-treated cells 
showed that the knockdown was less effective in the stably transduced cell lines with 
about 50 % reduction in PHGDH compared to 80-90 % when using siRNA. 
Insufficient knockdown may be the reason why no effect on cell growth, either 
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determined by colony formation or in a growth inhibition assay based on the 
measurement of cellular protein content (SRB assay), was detected in all three 
breast cancer cell lines. Despite stable knockdown of PHGDH in cells transduced 
with two different on-target shPHGDH constructs, Chen and colleagues reported 
differential effects on growth inhibition in the same cell line depending on which 
shPHGDH construct was expressed as determined by monitoring cellular ATP 
content [115]. However, one has to bear in mind that measurement of the ATP 
content is an indirect read-out of cell proliferation as through ATP it measures active 
cell metabolism and, despite being frequently used, has been shown to be less 
reliable for cell enumeration compared to SRB assay or colony formation assays 
[135]. 
This study has extended the range of cell lines revealing various protein expression 
levels of PHGDH and showing that cancer types other than breast cancer and 
melanoma are worth further investigation and might be targetable with PHGDH 
inhibitors. Attempts to reproduce literature evidence for dependence of cell 
proliferation on PHGDH were partly successful as a significant effect was seen after 
siRNA knockdown in the breast cancer cell line MDA-MB-468 and no effect in the 
control MDA-MB-231 cells. However, reported growth inhibition after PHGDH 
knockdown in Hs578T cells or the melanoma cell line SK-Mel28 could not be 
reproduced. From the siRNA and shRNA-mediated knockdown experiments, it was 
found that the level of knockdown of PHGDH was crucial to affect cell growth and 
that 50 % PHGDH reduction at protein level was insufficient to affect cell growth. 
Furthermore, the performed experiments showed that the assay format used to 
assess cellular growth was critical. 
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Chapter 4. Investigating the substrate-binding pocket 
4.1 Introduction 
Among the most remarkable characteristics of enzymes is their specificity in regards 
to the substrate used as well as the reaction catalysed. The degree of specificity can 
vary from absolute specificity, where the enzyme will only catalyse a reaction for one 
specific substrate, which is the expected case for PHGDH, to relatively broad 
specificity where the enzyme catalyses a reaction on a group of substrates. For 
example, lipases hydrolyse ester bonds in a variety of triglycerides [136]. To inhibit 
an enzyme through interaction with the substrate-binding site, it is necessary to 
understand which structural features of the enzyme define its substrate specificity 
and also how to avoid off-target effects on other proteins. It is especially critical to 
consider potential effects on other members of the same protein family as a high 
degree of similarity in sequence and/or tertiary structure is often observed within a 
protein family. 
Dehydrogenases belong to the family of oxidoreductases, which accounts for about 
23 % of the enzymes currently targeted with FDA-approved drugs [137]. 
Dehydrogenases catalyse redox reactions in which the substrate is oxidised through 
the transfer of a hydride ion (H-) onto a cofactor such as NAD(P)+ or FAD (Flavin 
adenine dinucleotide). For this transfer reaction to take place, the nicotinamide 
moiety of the cofactor and the substrate have to be in close proximity (Figure 4.1). 
There are many NAD+-requiring dehydrogenases and the binding site for NAD+ is 
very similar among them [85]. Specificity rather derives from the substrate-binding 
site, making this site more interesting for the design of specific inhibitors. The 
substrate-binding site of dehydrogenases is often a hydrophilic pocket preferentially 
accommodating molecules that are charged at physiological pH, such as acids. 
Mimicry of an acid functional group is, however, not ideal for a drug due to limited 
passive diffusion of charged species across biological membranes as well as 
undesirable metabolic effects and toxicity in in vivo studies [138].  
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Figure 4.1 – Substrate-binding sites of human NAD
+
-requiring dehydrogenases. 
Substrate binding site of (A) PHGDH with D-malate bound to the substrate-binding site (PDB 2G76) 
and (B) lactate dehydrogenase with D-lactate bound (PDB 4QO8). The protein surface around the 
substrate-binding site is coloured by electrostatic potential: red is negatively charged and blue is 
positively charged. Ligands are coloured by atom type with green = carbon, red = oxygen and blue = 
nitrogen. 
Despite these drawbacks, carboxylic acid functionalities are found in a large number 
(>450) of approved drugs [138]. In addition, for another dehydrogenase, lactate 
dehydrogenase A (LDHA), recent examples of inhibitors of the human enzyme all 
contained an ionisable, acidic functional group, which was found to be important to 
sustain the inhibitory activity [139]. To overcome problems of limited trans-cellular 
absorption, ester prodrugs, which mask the acidic function, have been developed 
[140, 141]. Esterification improves the lipophilicity of the compound and allows better 
transfer across the cell membrane and is often reversible in the cell by hydrolysis of 
the ester to the active acidic acid. However, development of ester prodrugs with a 
suitable level of ester stability and desired pharmacokinetic parameters can be 
difficult [141]. 
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4.2 Aims and Objectives 
The overall aim of this chapter was to investigate the substrate-binding pocket of 
PHGDH and to identify compounds that could potentially target this site. As a starting 
point, fragments containing the substrate analogue malate were investigated, as a 
crystal structure of a truncated form of human PHGDH (sPHGDH) with D-malate 
bound to the substrate-binding site was known (PDB 2G76). In addition, a wider 
range of substrate analogues was probed as potential binding partners for PHGDH. 
A further objective was the crystallisation of sPHGDH in the presence of substrate 
analogues or potential substrate-binding site-directed inhibitors. 
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4.3 Materials and Methods 
All chemicals listed in the materials and methods section were of analytical grade 
and obtained from Sigma Aldrich, St. Louis, MO, USA, unless otherwise stated. 
4.3.1 Buffers 
All buffers were as described in section 2.2 apart from the following: 
Affinity binding buffer 50 mM NaH2PO4, pH 8, 300 mM NaCl, 10 mM Imidazole, 
2 mM DTT 
Affinity wash buffer 50 mM NaH2PO4, pH 8, 300 mM NaCl, 50 mM Imidazole, 
2 mM DTT 
Affinity elution buffer 50 mM NaH2PO4, pH 8, 300 mM NaCl, 250 mM 
Imidazole, 2 mM DTT 
4.3.2 Differential scanning fluorimetry 
Differential scanning fluorimetry assays were run as described in section 2.9. The 
assay contained 25 mM HEPES, pH 7.5 with 1 x Sypro Orange, 1 μM PHGDH and 
200 μM ligand. All ligands were prepared fresh prior to the assay by dissolving in 25 
mM HEPES, pH 7.5 and the pH of the solution was adjusted to about 7.5. 
Concentrations of stocks of cofactors NAD+ and NADH in 25 mM HEPES, pH 7.5, 
were determined using the Beer-Lambert law (Equation 4.1) by measuring the 
absorbance at 260 and 340 nm respectively and using the specific extinction 
coefficients of 18 000 M-1cm-1 and 6 220 M-1cm-1 for NAD+ and NADH respectively. 
𝐴 =  𝜀 ×  𝑐 ×  𝑑 
Equation 4.1 – Beer-Lambert law 
A = absorbance, ε = extinction coefficient (M
-1
 cm
-1
), c = concentration of solution (M), d = length of solution the 
light passes through (cm) (generally 1 cm cuvette). 
4.3.3 Fluorescence polarisation assay 
Fluorescence polarisation assays were carried out as described in section 2.11. 
Briefly, the assay mixture contained 40 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 mM 
TCEP or 2 mM DTT, 1 μM NADH and 2 μM PHGDH or sPHGDH. Adenosine 5’-
diphosphoribose (ADPR) was dissolved in 40 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 
mM TCEP or 2 mM DTT and screened at a concentration range from 0.5 and 1 mM. 
The reaction mixture with ADPR was incubated for 30 min at RT and fluorescence 
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polarisation was measured using a PHERAstar FS platereader (BMG Labtech, 
Ortenberg, Germany) with an FP filter module (λex = 340 nm and λem = 440 nm). 
4.3.4 Protein purification 
Full length PHGDH (aa 1-533) and its truncated version sPHGDH (aa 3-314) were 
expressed in E. coli Rosetta(DE3) cells and purified according to section 2.6.1 except 
that for initial purification the affinity purification step was performed by gravity-flow 
chromatography using Ni-NTA agarose beads (QIAGEN, Limburg, Netherlands). The 
gravity-flow column was equilibrated with affinity binding buffer prior to application of 
clarified protein lysate. Non-specifically bound protein was removed by washing the 
column with 10 column volumes (cv) of affinity binding buffer, followed by 10 cv of 
affinity wash buffer. The desired protein was eluted with 5 cv affinity elution buffer. 
Fractions were analysed by SDS-PAGE, concentrated using centrifuge concentrators 
with 10 kDa or 30 kDa molecular weight cut-off membranes for sPHGDH and 
PHGDH respectively. Purification was continued by size exclusion and anion 
exchange chromatography as described in section 2.6.1. Both proteins were 
concentrated to 10 – 15 mg/mL and either used directly or flash frozen in liquid 
nitrogen and stored at -80 °C. 
4.3.5 Crystallography 
Initial screening of sPHGDH against sparse matrix screens and crystal optimisation 
followed the protocols described in section 2.12. For co-crystallisation, sPHGDH was 
mixed with ligands and incubated at 4 °C overnight before setting up sitting-drop 
vapour diffusion crystal trials. Crystals for which datasets were collected were 
analysed as described in section 2.13.   
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4.4 Results 
4.4.1 Investigation of malate-containing inhibitors 
The co-crystal structure of sPHGDH with NAD+ was available in the public domain 
(PDB 2G76) and showed NAD+ as well as D-malate bound to the active site with D-
malate sitting in the substrate-binding site (Figure 4.2 A). Incorporation of D-malate 
into the sPHGDH-NAD+ crystals was an unintended consequence of the presence of 
10 mM malate in the crystallisation buffer, which contained 0.1 M MMT buffer. MMT 
buffer is a mixture of DL-malate, MES and TRIS (1:2:2 ratio). D-Malate is a structural 
analogue of 3-phosphoglycerate (Figure 4.2 B) and is presumed to bind in a similar 
manner to the substrate-binding site as the bona fide substrate. 
 
Figure 4.2 - Detail of the active site of sPHGDH (PDB 2G76) with bound NAD
+
 and D-malate. 
Ribbon diagram of the active site of one molecule of sPHGDH shown in blue with bound NAD
+
 and D-
malate coloured by atom type as in Figure 4.1. The distance between the amide oxygen of NAD
+
 and 
the hydroxyl group of D-malate was measured as 2.7 Å and is indicated with a yellow line. The 
substrate surface is coloured by electrostatic potential: red is negatively charged and blue is positively 
charged. 
With D-malate known to bind to PHGDH, the first set of potential inhibitors to be 
investigated comprised malate-containing fragments. To generate a bisubstrate 
inhibitor, a malate moiety (mimicking D-3-Phosphoglycerate) should ideally be linked 
to an aromatic group (mimicking the nicotinamide moiety of NAD+). A search among 
commercially available compounds identified a small library of seven malate-
containing fragments (Figure 4.3). Only one of these fragments, 1,2,3-
butanetricarboxylic acid (7), did not contain an aromatic group, but rather an aliphatic 
side-chain with a carboxylic group that could potentially be used for further 
derivatisation. For the remaining compounds (1-6), the linker between malate and the 
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aromatic ring varied from zero to three atoms. The distance between the hydroxyl 
group of malate and the oxygen of the amide group in nicotinamide was measured to 
be 2.7 Å. The malate-containing fragments with different linker lengths therefore 
provide the possibility to experimentally determine the best length (Figure 4.2). 
 
Figure 4.3 - Structures of investigated malate-containing fragments. 
The malate moiety of each fragment is highlighted in blue. 
These malate-containing compounds were screened in a fluorescence polarisation 
assay with NADH as fluorophore. The principle of the fluorescence polarisation assay 
exploits the finite lifetime of a fluorophore’s excited state.  When excited with 
polarized light, the short rotational correlation time of a rapidly tumbling fluorophore 
allows it to adopt a random orientation during the lifetime of the excited state, and 
therefore emit depolarized light. Upon binding to a larger molecule, e.g. a protein, the 
fluorophore will tumble more slowly so that light it emits remains. If an inhibitor binds 
to the binding site of the fluorophore, a decrease in polarised light can be measured 
as the fluorophore is released once again into solution (Figure 4.4). NADH has a 
fluorescence emission peak at 440 nm after excitation at 340 nm and has been 
successfully used as fluorophore in fluorescence polarisation experiments [142]. 
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Figure 4.4 – Principle of fluorescence polarisation assay. 
(A) After excitation of a fluorophore (e.g. NADH) in buffer solution, no polarised light can be detected 
as the small fluorophore is tumbling fast. It is not until the rotational correlation time of the fluorophore 
is increased by binding to a larger molecule, e.g. protein, that polarised light can be measured. (B) 
Addition of an inhibitor to the fluorophore-protein mixture replaces the fluorophore at its binding site on 
the protein, so that an increase in depolarised light is detected. 
A fluorescence polarisation (FP) assay protocol was established using 1 μM NADH in 
40 mM HEPES, pH 7.5 with 0.05 % BSA added to account for nonspecific protein 
binding. The direct binding curves of sPHGDH or PHGDH into 1 μM NADH gave a KD 
for NADH of 2.0 ± 0.3 μM and 2.4 ± 0.5 μM for PHGDH and sPHGDH, respectively 
(Figure 4.5 A). Titration of NADH into buffer showed that up to 1 μM NADH the 
fluorescence polarisation was constant (Figure 4.5 B). 
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Figure 4.5 – Protein and fluorophore titration curves for FP Assay 
FP (λex/λem= 340/440 nm) was measured with increasing concentrations (20-40 000 nM) of sPHGDH 
or PHGDH (A) in the presence of 1 μM NADH. (B) Titration of increasing concentrations of NADH 
(0.05-100 μM) into buffer only (+/- BSA). 
To validate the assay the cofactor analogue ADPR was used. ADPR is structurally 
identical to NAD+ but lacks the nicotinamide moiety (Figure 4.6 C). With the addition 
of increasing concentrations of ADPR, a decrease in polarised light was observed 
due to NADH displacement by ADPR. The data were transformed into % 
displacement of NADH on PHGDH and sPHGDH, and IC50 values of 282 ± 1 μM and 
137 ± 1 μM were obtained, respectively. These are the concentrations of ADPR at 
which 50 % of NADH was displaced from the respective protein. However, although a 
displacement of NADH was observed with increasing concentrations of ADPR, a 
general increase in fluorescence was also seen indicating interference of ADPR with 
the fluorescence of NADH and therefore rendering the calculated IC50 values less 
reliable. Moreover, the Z-score, which is the number of standard deviations from the 
mean, was found to vary for the different runs of the experiments, ranging from -0.3 
to 0.9. In addition, NAD+ was also investigated for its potential to displace NADH at 
the binding pocket and was found to be a much weaker binder compared to ADPR, 
being only able to displace about 35 % NADH at the maximum NAD+ concentration 
of 1 mM (Figure 4.6 B). 
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Figure 4.6 – Displacement of NADH by ADPR (A) and NAD
+
 (B) in fluorescence polarisation 
assay. 
Fluorescence polarisation of NADH was measured in the presence of increasing concentrations of 
ADPR (A) or NAD
+
 (B). For each compound two independent measurements were performed with two 
replicates per measurement. Data were fit by non-linear regression using GraphPad Prism. (C) 
Chemical structure of ADPR. 
The malate-containing fragment library (Figure 4.3) was tested in the fluorescence 
polarisation assay at 0.5 mM and 1 mM compound concentrations. Two fragments 
decreased fluorescence polarisation remarkably, namely 3-indole-DL-aspartic acid 
(3) and diethyl 2-[(4-aminobenzyl) amino] succinate (6). 3-Indole-DL-aspartic acid at 
1 mM exhibited the strongest response with 55 % and 40 % displacement of NADH 
from PHGDH and sPHGDH respectively, as well as showing a concentration 
dependent response when comparing displacement of NADH from PHGDH and 
sPHGDH at 0.5 mM and 1 mM compound concentration. 
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Figure 4.7 – Inhibition of sPHGDH (A) and PHGDH (B) with malate-containing fragments. 
All malate-containing fragments (for structures see Figure 4.3) were tested in two independent 
fluorescence polarisation experiments in duplicate. % Inhibition of PHGDH and sPHGDH through the 
addition of fragments was calculated by using a sample containing only NADH as 100 % displacement 
control and a sample containing NADH and protein as 0 % displacement reference. Significant 
inhibition of sPHGDH or PHGDH was determined in GraphPad Prism using two-way ANOVA with ns = 
not significant, ** = p = 0.008, **** = p < 0.0001. 
4.4.2 Synthesis and evaluation of 3-Indole-DL-aspartic acid analogues 
Of the malate-containing fragments investigated, 3-indole-DL-aspartic acid showed 
the most promising effect in the FP assay. As the purchased 3-Indole-DL-aspartic 
acid was a mixture of the respective enantiomers, it was important to investigate 
whether one of the enantiomers was a more active component than the other. 
Therefore synthesis of the separate enantiomers was attempted. 
Initially, the reaction of 3-indoleacetyl chloride with the aspartic acid was investigated 
following described procedures (Scheme 4.1) [143, 144]. Although 3-indoleacetyl 
chloride was synthesised, the subsequent coupling reaction did not work, when using 
either aqueous conditions in the presence of NaOH (Schotten-Baumann conditions), 
or pyridine as solvent with catalytic properties. 
 
Scheme 4.1 – Reagents and conditions: (i) PCl5, Et2O, 0 °C to RT, 1 h, 68 %; (ii) NaOH, Et2O, 0 °C to 
RT, 2 h; (iii) pyridine/ THF, DMAP, 0 °C to RT, 8 h. 
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As an alternative synthetic route, the active nitrophenylester of indoleacetic acid was 
prepared. Although not such a good leaving group as chloride, active esters are 
expected to react cleanly with amines under mild conditions [145, 146]. Under these 
conditions 3-indole-D-aspartic acid (9) and 3-indole-L-aspartic acid (10) were 
obtained in high yields of 51 % and 95 %, respectively (Table 4.1). 
In addition to generating the resolved enantiomers of the hit compound, synthesis of 
a small library of analogues was undertaken. Because 3-indole-DL-aspartic acid had 
been shown to bind to PHGDH and sPHGDH in only a single biochemical assay 
format, only a small library of analogues was prepared. With the synthetic route in 
place using 3-indoleacetic acid as starting material, other heterocycles than indole, 
namely isoxazole and benzothiophene with an acetic acid functional group in the 
respective 3-positions were used as starting materials. While the synthesis of the 
active nitrophenol ester gave good yields (46-91 %), the following amide coupling did 
not work very well for other heterocycles than indole (yields 8–15 %) and would have 
required further optimisation. 
 
 Step 1 Step 2a Step 2b 
X1 = NH, X2 = C 55 % 51 % (10) 95 % (9) 
X1 = O, X2 = N 46 % 8 % (13) 11 % (12) 
X1 = S, X2 = C 91 % 13 % (16) 15 % (15) 
 
Table 4.1 – Summary of yields for the two step synthesis of enantiopure indole-3-aspartic acid 
and analogues. 
Reagents and conditions: (i) DCC, EtOAc, 0 °C to RT, 90 min; (ii) L-aspartic acid (step 2a) or D-
aspartic acid (step 2b), tetramethylguanidine, aq. MeOH, RT, 48 h. The number of the synthesised 
compounds is given in brackets. 
Comparison of the enantiopure 3-indole-aspartic acids showed a significantly higher 
displacement of NADH from sPHGDH with 3-indole-L-aspartic acid (10) compared to 
the D-enantiomer (9) at both concentrations of compound investigated. This effect 
was less statistically significant for the displacement of NADH from PHGDH at 0.5 
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mM compound concentration alone and was not significant at 1 mM (Figure 4.8). 
Interestingly, all heterocyclic analogues investigated were less potent than the 
compounds containing the indole moiety, but still exhibited a dose-dependent NADH 
displacement from sPHGDH or PHGDH when comparing the displacement of NADH 
at 0.5 and 1 mM compound concentration. 
 
Figure 4.8 - Inhibition of sPHGDH (A) and PHGDH (B) with 3-indole-DL-aspartic acid and 
analogues thereof. 
3-Indole-DL-aspartic acid and its analogues were tested in a fluorescence polarisation experiment in 
duplicate. % Inhibition of PHGDH and sPHGDH through the addition of fragments is calculated by 
using a sample containing only NADH as 100 % inhibition control and a sample containing NADH and 
protein as 0 % inhibition reference. Statistic analysis was performed in GraphPad Prism using two-way 
ANOVA; * = p = 0.02, *** = p = 0.0002, **** = p < 0.0001, ns = non significant. 
4.4.3 Investigating additional substrate analogues 
In addition to malate, other substrate analogues were investigated that were similar 
in size to 3-phosphoglycerate (3-PG) as well as containing the 2-hydroxypropanoic 
acid moiety (Figure 4.9 A). Unfortunately, the other physiological binding partner of 
PHGDH, 3-phosphohydroxypyruvate (PHP) was not commercially available, so that 
only structural analogues thereof could be investigated (Figure 4.9 B). Binding of 
these analogues was assessed using a differential scanning fluorimetry assay. This 
technique monitors protein unfolding through the use of a fluorescent dye that 
specifically binds to unfolded protein. Based on the fluorescence signal a so-called 
melting temperature (Tm) of the protein can be defined, which is the temperature at 
which half of the protein is unfolded. DSF also allows investigating ligand binding to 
the protein as a bound ligand contributes to the total Gibb’s free energy of protein 
unfolding and thus results in an increased Tm (see also section 2.9) [101, 147]. 
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Figure 4.9 – Structures of the substrate 3-phosphoglycerate (A) and the product 3-
phosphohydroxypyruvate (B) and their analogues. 
For 3-phosphoglycerate and its analogues, the common 2-hydroxypropanoic acid moiety is highlighted 
in green. For 3-phosphohydroxypyruvate and its analogues, the 2-oxopropanoic acid moieties are 
coloured in blue. 
Of the substrate and analogues tested in the DSF assay, only 3-phosphoglycerate 
(3-PG) and α-ketoglutarate induced a shift in the melting temperature of PHGDH 
greater than or equal to 0.5 °C, and only the natural substrate 3-PG resulted in a 
statistically significant increase in the Tm of PHGDH of 2.5 ± 0.6 °C (Figure 4.10). 
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Figure 4.10 – Change in Tm of PHGDH upon addition of substrate and analogues. 
Thermal denaturation of 1 µM PHGDH in the presence of 0.2 mM substrate analogues. Graphs 
represent mean and standard deviation of three independent experiments with two replicates per 
experiment. Statistical analysis was performed in GraphPad Prism (two way ANOVA). **** = p < 
0.0001. 
Due to the close proximity of the substrate and cofactor-binding sites, the presence 
of cofactor might be necessary for optimal substrate binding. Testing of NAD+ in 
combination with substrate and analogues showed that a significant increase in 
binding was seen with 3-PG as well as DL-malate (Figure 4.11). As expected, NAD+ 
alone had only a weak effect on the stability of PHGDH with an increase in Tm of 0.9 
± 0.7 °C. The combined addition of NAD+ and 3-PG resulted in an increase in Tm of 
4.5 ± 0.7 °C compared to the buffer control. This might be due to a synergistic effect 
of the two compounds rather than an additive effect, which would have only resulted 
in an increase of 3.4 ± 0.9 °C. A synergistic effect was also observed for the 
combination of NAD+ and DL-malate, leading to an increase in the Tm of PHGDH of 
2.2 ± 0.7 °C, whereas DL-malate alone did not affect the Tm of PHGDH at all 
indicating undetectable binding of DL-malate in the absence of NAD+. 
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Figure 4.11 – Change in Tm of PHGDH through the addition of substrate (analogues) and NAD
+
. 
Thermal denaturation of 1 µM PHGDH in the presence of 0.2 mM NAD
+
 alone and in combination with 
0.2 mM substrate analogues, was measured. Graphs represent mean and standard deviation of three 
independent experiments with two replicates per experiment. Statistical analysis was performed in 
GraphPad Prism (two way ANOVA). Blue lines indicate statistically significant differences of NAD
+
 
compared to NAD
+
 and substrate whereas red lines show statistical significant variations between 
substrate alone and the respective substrate plus NAD
+
 combination. ** = p = 0.0026, **** = p < 
0.0001. 
A similar experiment was performed using the substrate analogues in combination 
with the cofactor NADH. NADH has a much higher affinity for PHGDH than NAD+ 
resulting in a Tm shift of 9.3 ± 0.5 °C. All substrate and analogues investigated failed 
to stabilise PHGDH further in the presence of NADH (Figure 4.12). The observed 
destabilising effect of the substrate analogues was not significant and the decrease 
in Tm compared to NADH alone ranged from 0.4-1.1 °C. 
 
Figure 4.12 – Change in Tm of PHGDH through the addition of substrate (analogues) and NADH. 
Thermal denaturation of 1 µM PHGDH in the presence of 0.2 mM NADH alone and in combination 
with 0.2 mM substrate analogues was measured. Graphs represent mean and standard deviation of 
three independent experiments with two replicates per experiment. Statistical analysis was performed 
in GraphPad Prism (two way ANOVA). 
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4.4.4 Crystallisation of sPHGDH 
Crystallisation conditions for PHGDH that would allow for co-crystallisation of the 
protein with ligands of interest such as the substrate analogues were sought in order 
to improve molecular understanding of substrate analogue binding. 
As the structure of a truncated form of PHGDH (sPHGDH, aa 3-314) co-crystallised 
with D-malate and NAD+ was available in the public domain (PDB 2G76), this 
construct was chosen for crystallisation (Figure 4.13). 
 
Figure 4.13 – Sequence of PHGDH and sPHGDH. 
(A) Amino acid sequence of PHGDH with sequence of sPHGDH highlighted in green. (B) Secondary 
structure elements of sPHGDH are shown above the amino acid sequence with β-strands indicated by 
yellow arrows, β-bridges by khaki triangles, α-helices by red lines and turns by purple lines. The 
binding sites for NAD
+
 and D-malate are marked with yellow and blue circles, respectively. Picture was 
taken from the RCSB protein databank (PDB 2G76). 
 109 
The plasmid DNA used for transformation of competent E. coli Rosetta (DE3) cells 
contained human sPHGDH incorporated into the pNIC28-Bsa4 vector and was kindly 
donated by Wyatt Yue (SGC Oxford, Oxford, UK). sPHGDH was overexpressed with 
an N-terminal His6-tag and purified using Ni-affinity chromatography and size 
exclusion chromatography (SEC) as well as an additional anion exchange 
chromatography step to increase purity of the protein (Figure 4.14). The large-scale 
production of sPHGDH gave very good protein yields of 30 mg/L culture. 
 
Figure 4.14 – Purification of sPHGDH. 
Human sPHGDH was purified from E. coli Rosetta (DE3) cells. (A) After cell lysis, sPHGDH was 
purified by Ni-affinity chromatography, followed by (B) size exclusion chromatography (Superdex 75 
26/60) and (C) anion exchange chromatography. A representative purification is shown with the UV 
traces of the respective purification steps together with the analysis of the obtained fractions by SDS-
PAGE. 
Initial crystallisation trials were aimed at reproducing the published crystallisation 
conditions (0.1 M MMT, pH 7.0, 30 % PEG1000, 5 mM NAD+) using a home-made 
screen around these conditions (optimisation screen 1). Sitting drop vapour diffusion 
crystallisation trials were set up with 15 mg/mL protein and 200 and 300 nL drop size 
at 1:1 and 1:2 protein: reservoir ratios, respectively, at 4 °C did not produce any 
crystals. Therefore a wider screen against commercially available sparse matrix 
conditions was performed with 15 mg/mL sPHGDH mixed with 5 mM NAD+. In 
(A) (B) (C) 
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parallel, trials were also set up with sPHGDH plus 5 mM ADPR, as ADPR had been 
shown to be a stronger binder to PHGDH compared to NAD+ in the FP assay (see 
section 4.4.1). Initial crystals were very small and formed in the presence of 5 mM 
ADPR and a crystallisation buffer comprising 0.1 M BIS TRIS, pH 5.5, 0.2 M 
ammonium acetate (NH4Ac), 25 % (w/v) PEG3350. An optimisation trial was 
designed around this condition with variations in the pH (5.5-7.0), the amount of 
PEG3350 (21 – 31 % (w/v)) and the concentration of NH4Ac (0.1-0.3 M) (optimisation 
screen 2) as well as exploring the temperature of the crystal trials (4 and 20 °C). Co-
crystallisation with ADPR and obtained crystal structures will be further discussed in 
section 5.4.1. 
4.4.5 Co-crystallisation of sPHGDH with substrate analogues 
Using the crystallisation conditions described above for sPHGDH, co-crystallisation of 
the protein with cofactor (NAD+) and substrate analogues, namely 3-PG, α-
ketoglutarate and L-tartrate, was attempted. Co-crystallisation in the presence of α-
ketoglutarate and L-tartrate gave protein crystals, although the diffraction pattern was 
generally of poor quality and a limited numbers of datasets were collected. 
For a co-crystal of sPHGDH with NAD+ and α-ketoglutarate grown in 0.1 M BIS-TRIS, 
pH 6.5, 0.2 M NH4Ac and 27 % (w/v) PEG3350, the structure (sPHGDH 01) could be 
solved using chain A of the published structure as a search model (PDB 2G76). 
However, as the initial Fo-Fc electron density indicated that only NAD+ was bound in 
the active site, the structure was not fully refined (Figure 4.15). Optimisation of the 
co-crystals of NAD+ and α-ketoglutarate was attempted using higher concentrations 
of α-ketoglutarate, as well as increasing concentrations of the substrate analogue in 
the cryo-protectant to avoid diffusion of the substrate out of the crystal during crystal 
harvesting. Although additional crystals were obtained, none of the crystals tested 
showed good quality diffraction, and no datasets were collected. 
  
 111 
 
Figure 4.15 - Co-crystallisation of sPHGDH with NAD
+
 and α-ketoglutarate (sPHGDH 01). 
(A) Data collection statistics for sPHGDH 01 (co-crystal with α-ketoglutarate and NAD
+
). The data 
were collected on a single crystal at 100 K on beamline I02, Diamond Light Source (DLS). The data 
were processed using xia2 (3daii-run). The statistics are presented as averages with values for the 
highest resolution shell in parentheses. (B) Active site of sPHGDH 01 with NAD
+
 bound. Protein 
secondary structure is shown in grey and NAD
+
 is coloured by atom. No electron density was 
observed for α-ketoglutarate (orange circle); 2Fo-Fc electron density map contoured at 0.37 
electrons/Ā
3
. 
In addition, several crystals of sPHGDH grown in the presence of NAD+ and L-
tartrate were obtained. Of the measurable crystals, only one crystal grown in 0.1 M 
Tris, pH 8.5, 0.2 M MgCl2 hexahydrate and 20 % (w/v) PEG 3350 showed evidence 
for bound L-tartrate. The dataset (sPHGDH 02) was collected to 2.24 Å resolution 
using synchrotron radiation (Figure 4.16). The measured crystal had the same 
symmetry (monoclinic, space group P 1 21 1) as the published structure (PDB 2G76). 
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Figure 4.16 – Data collection statistics for sPHGDH co-crystallised with substrate analogue L-
tartrate and NAD
+
 (sPHGDH 02). 
(A) Data collection statistics for sPHGDH 02 (co-crystal with L-tartrate and NAD
+
). The data were 
collected on a single crystal at 100 K on beamline I04-1, Diamond Light Source (DLS). The data were 
processed using xia2 (3daii-run). The statistics are presented as averages with values for the highest 
resolution shell in parentheses. (B) Active site of sPHGDH 02 with NAD
+
 bound. Protein secondary 
structure is shown in grey and NAD
+
 is coloured by atom. Electron density observed for L-tartrate is 
highlighted with an orange circle; 2Fo-Fc electron density map contoured at 0.34 electrons/Ā
3
. 
Molecular replacement was performed with PHASER [106] as part of the CCP4 suite 
[105] using the published structure (PDB 2G76) as a search model. The model was 
refined with Refmac5 [148] and validated using MolProbity [109] (Table 4.2). Early 
refinement maps indicated a significant structural change in the orientation of the 
sPHGDH lid domain that was beyond the radius of convergence of REFMAC. An 
iterative autobuild protocol using BUCCANEER and REFMAC was used to help to 
reinterpret the electron density and reveal the conformational change. 
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(A) Refinement  (B) Molprobity Parameters Value 
 
Rwork/Rfree 0.21/0.25 
 
Clashscore, all atoms 6.54a 
 Mean B-value 
(Å2) 
  Poor rotamers 2.75 % 
    All atoms 26  Ramachandran outliers 0.5 % 
    Protein 8  Ramachandran favoured 96.0 % 
    Water 36  No of Cβ deviations 
(> 0.25 Å) 
9 
    NAD+ 28  Molprobity Score 1.97b 
    L-Tartrate 33  Residues with bad bonds 19 
 No of atoms   Residues with bad angles 18 
    Protein 8809    
    Water 74    
    NAD+ 66    
    L-Tartrate 12    
 Rmsd     
    Bond lengths 
(Å) 
0.02    
    Angles (°) 2.21    
Table 4.2 – Refinement and validation statistics for the co-crystal structure of sPHGDH with 
NAD
+
 and L-tartrate. 
(A) Refinement statistics generated with Refmac5 as part of CCP4i2 suite. (B) Validation statistics 
generated by MolProbity web server. The clashscore
a
 was 98
th
 percentile and the MolProbity score
b
 
was 91
st
 percentile for a structure of 2.30 ± 0.25 Å. 
As expected from the published structure, two molecules were present in the 
asymmetric unit (ASU). However, while both molecules had NAD+ bound to the 
cofactor sites, L-tartrate was only present in one molecule. In the absence of L-
tartrate, the lid domain, which otherwise closes over the substrate-binding site had 
undergone rigid domain movement. In order to characterise the movement, the two 
molecules in the ASU were compared using the DynDom webserver [149, 150]. 
Three domains could be distinguished: a fixed core domain (aa 100-287), the mobile 
lid domain (aa 9-93 and aa 289-301) and a hinge domain (aa 94-99 and aa 302) 
(Figure 4.17A-B). Superposition of the two conformations with and without bound L-
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tartrate showed that the lid domain had rotated by 28.9° about an axis aligned along 
upon substrate binding (Figure 4.17 C). 
 
Figure 4.17 – Analysis of the domain movement in a co-crystal structure of sPHGDH with L-
tartrate and NAD
+
. 
The protein crystal structure was analysed using the DynDom web server. Sequence (A) and structure 
of sPHGDH chain A (B) with different domains highlighted: fixed domain in blue, mobile domain in 
orange, hinge domain in green. The cofactor NAD
+
 is shown as spheres coloured by atom type. (C) 
Superposition of the two molecules in the ASU with the structures containing L-tartrate and without L-
tartrate coloured in purple and grey respectively. NAD
+
 and L-tartrate are coloured by atom type and 
displayed as spheres. 
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A closer view of the substrate-binding site in both chains revealed distinct 
movements of the amino acids involved in L-tartrate binding that, in the absence of L-
tartrate, either move out of the binding site (Arg74, Arg53) or adopt alternate rotamer 
that orient away from the binding site (Gln291) (Figure 4.18). 
 
Figure 4.18 – Changes in substrate-binding site of sPHGDH observed on binding of L-tartrate 
(A) Chain A (light blue) with L-tartrate (green) and NAD
+
 (grey) bound to the active site superposed 
onto chain B (lilac) with only NAD
+
 (grey) bound to the active site. Movement of individual amino acids 
involved in L-tartrate binding indicated with orange arrows. (B) Chain A (light blue/ gold) with L-tartrate 
bound (dark purple) superposed onto chain A (grey) of sPHGDH with NAD
+
 and D-malate bound 
(cyan) (PDB 2G76). New hydrogen bonds are formed between the amino acids highlighted in gold and 
the additional OH-group of L-tartrate compared to binding of D-malate. 
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4.5 Discussion 
To date there are no known inhibitors of PHGDH, thus precluding full validation of 
PHGDH as a potential target in cancer therapy. Knowledge of the structure of 
PHGDH is also limited with only one crystal structure available for the first 300 amino 
acids comprising the cofactor and substrate-binding domain. Although human 
PHGDH contains regulatory domains of incompletely understood function, their 
structure is not yet known. Therefore inhibitors were investigated and designed to 
target the substrate-binding site. With the cofactor-binding site being similar within 
the family of dehydrogenases, inhibitors binding specifically to the substrate-binding 
site of PHGDH were sought so as to provide the specificity for on-target inhibition. 
In the crystal structure of sPHGDH (PDB 2G76), D-malate is bound to the substrate-
binding site. A small set of commercially available malate containing fragments with 
malate attached through different linkers to an aromatic ring or, in one case, a 
carboxylic acid was tested for binding to PHGDH. This approach of linking a 
substrate analogue to an aromatic ring and thereby targeting simultaneously the 
cofactor and substrate-binding sites had been successfully used for the development 
of inhibitors of human lactate dehydrogenase A as well as in a study on the 
specificity of mitochondrial isocitrate dehydrogenase isozymes [97, 140]. To test the 
potential of the malate-containing fragments library, the compounds were 
investigated for their ability to displace NADH from the cofactor-binding site using a 
fluorescence polarisation assay with NADH as fluorophore. Although FP assays with 
NADH as fluorophore have been reported in the literature, NADH is a relatively weak 
fluorophore compared to fluorescent dyes such as fluorescein or rhodamine [142], 
thus the assay read-outs were not very robust and often suffered from a low signal-
to-noise ratio. Despite these limitations, 3-indole-DL-aspartic acid (3) and diethyl 2-
[(4-aminobenzyl) amino] succinate (6) were shown to be able to displace NADH to a 
significant extent and in a concentration-dependent manner. Testing of the 
compounds in a second assay, the DSF assay, confirmed binding of compound 3 but 
not 6, thus compound 3 was taken forward for further investigation. 
With the commercial 3-indole-DL-aspartic acid being a racemic mixture, it was 
necessary to synthesise the enantiomers separately as to find out if there was a 
difference in activity between them. Although enantiomers have the same physical 
and chemical properties in an achiral environment, this can change in a chiral 
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environment such as that presented by biological macromolecules [151]. Testing the 
enantiopure 3-indole-aspartic acids revealed the L-enantiomer as a significantly more 
potent compound compared to its D-analogue. Accordingly, displacement of NADH 
seen with 3-indole-L-aspartic acid was also increased compared to the racemic 
mixture. As a synthetic route had been established for 3-indole-aspartic acids, 
benzisoxazole and benzothiophene analogues were synthesised and investigated. 
Although changing the indole moiety deteriorated the induced NADH displacement, 
the 3-benzisoxazole- and 3-benzothiophene aspartic acids still displaced NADH from 
sPHGDH and PHGDH in a concentration-dependent manner. 
In addition to malate, other substrate analogues of 3-PG and PHP were tested at 
0.2 mM in a DSF screen. Of the tested substrate-analogues, L-tartrate and α-
ketoglutarate (α-KG) stabilised PHGDH marginally, whereas the addition of the 
natural substrate 3-PG gave a significant increase in Tm. Tartrate has not been 
reported as a potential substrate for PHGDH. α-KG on the other hand can be used as 
a substrate by E. coli PHGDH, whereas human as well as rat and M. tuberculosis 
PHGDH have been reported not to share this trait [57]. A recent study, however, 
found human PHGDH to be able to catalyse the NADH-dependent reduction of α-KG 
to D-2-hydroxyglutarate, an oncometabolite associated with brain cancer and acute 
myeloid leukaemia [65]. 
Binding of substrate analogues was also investigated in combination with the 
cofactors, NAD+ or NADH, as possible interdependence of substrate and cofactor 
binding is suggested by the close proximity of their respective binding sites. In 
addition, the catalytic mechanism of human PHGDH is not yet known and could 
proceed by an ordered Bi Bi mechanism requiring the binding of cofactor prior to 
substrate binding or vice versa. Indeed, the combination of 3-PG and NAD+ 
increased the Tm significantly, and by more than the simple addition of the effects 
seen with the two compounds separately. The same was found to be true for DL-
malate where the presence of NAD+ appeared to be necessary for the substrate 
analogue to bind at all, whereas NAD+ was able to bind on its own. Based on these 
findings it is, however, difficult to definitely determine the reaction mechanism, as 
according to the data for DL-malate and NAD+, cofactor binding seems necessary to 
initiate binding of the substrate analogue, whereas the Tm shift seen with 3-PG alone 
does not support this hypothesis. The other tested substrate analogues did not show 
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synergistic behaviour in combination with NAD+. In the case of PHP analogues, 
where the reaction partner is NADH, NADH failed to enhance substrate binding. 
However, NADH itself binds very strongly to PHGDH, making it difficult to detect any 
additional and probably small changes in the Tm following substrate binding. 
Of the compounds investigated, DL-malate was found to be the most promising 
starting point for an inhibitor targeted to the substrate-binding site as supported by 
the published crystallographic data (PDB 2G76). Crystallisation of sPHGDH with 
additional compounds was attempted in order to provide a wider understanding of 
substrate and substrate analogue binding and provide additional start points for 
inhibitor design. Although the published crystallisation conditions could not be 
reproduced, crystals were obtained in 0.1 M BIS-TRIS buffer, pH 5-7, with different 
salts and in a range of concentrations of PEG3350. In general, the crystals grew as 
thin, stacked plates, making it difficult to obtain single crystals that would diffract well 
in all directions (i.e. isotropically). Optimisation did not result in better-diffracting 
crystals making it necessary to test many crystals before a measurable one was 
found. Co-crystals of substrate analogues and NAD+ were only obtained for α-KG 
and L-tartrate. However, in the case of α-KG, the substrate was not visible in the 
electron density. For L-tartrate the substrate was present in one molecule of the 
crystal dimer whereas the other molecule contained only NAD+. Comparison of the 
two molecules showed that in the presence of L-tartrate a movement of the lid 
domain towards a more closed substrate pocket had occurred. 
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Chapter 5. Investigating the cofactor binding pocket 
5.1 Introduction 
In addition to substrate, many enzymes require cofactors to assist catalysis, e.g. 
metal ions or coenzymes. Dehydrogenases usually require NAD+/NADH as a 
cofactor. The hydride-transfer reaction catalysed by dehydrogenases requires that 
the nicotinamide group of NAD+ be in close proximity to the hydrogen donor atom of 
the substrate. The substrate and coenzyme binding pockets are therefore adjacent. A 
common structural domain for nucleotide-binding proteins, the Rossmann fold, 
largely determines the structure of the coenzyme-binding site [152]. The Rossmann 
fold is among the most common structural motifs in proteins [153]. It is characterised 
by alternating β-strands and α-helices, and is found in dehydrogenases from different 
organisms (Figure 5.1). 
 
Figure 5.1 – Ribbon diagram illustration of different dehydrogenases. 
The Rossmann-fold is depicted with β-strands in blue and α-helices in red. Additional secondary 
structure elements are coloured in grey. Cofactor NAD
+
 is rendered as spheres and coloured by atom 
type. (A) Bacterial 3α-20β-hydroxysteroid dehydrogenase from Streptomyces exfoliatus (PDB 2HSD). 
(B) Truncated form of human 3-phosphoglycerate dehydrogenase (sPHGDH) (PDB 2G76). (C) Human 
class II alcohol dehydrogenase (PDB 3COS). 
Not only might the conservation of the nucleotide-binding regions become 
problematic for the development of specific inhibitors, but also the pocket itself can 
be challenging to target due to its hydrophilic nature. For example one component of 
the pocket is the diphosphate-binding site, which is ideally constructed to bind a 
highly charged unit such as the diphosphate linker. Mimicking the properties of the 
 121 
phosphate group with its tetrahedral geometry and dianionic charge at physiological 
pH is not trivial. 
NAD+-binding also involves various hydrogen bonds and van der Waals interactions 
with the protein, so that mimicking the complete interaction pattern with a drug-like 
molecule will be difficult (Figure 5.2). 
 
Figure 5.2 – Cofactor-binding site in PHGDH (PDB 2G76) 
Protein chains are coloured in grey. Amino acids involved in cofactor binding are highlighted in light 
blue with oxygen and nitrogen coloured in red and blue, respectively. Cofactor NAD
+
 is rendered as 
stick and balls and the different moieties coloured in cyan (adenine), pink (phosphate) and purple 
(nicotinamide). 
However, NAD+-requiring enzymes have been successfully targeted in the past 
through (parts of) the NAD+-binding pocket, which is the case for the sirtuin inhibitor 
Ex-527 that binds to the nicotinamide part of the NAD+-binding pocket and thus 
prevents the enzymatic reaction [154]. Another example was presented with the 
development of LDHA inhibitors that were shown to simultaneously target the 
adenine and nicotinamide subsites of the cofactor-binding pocket, but interestingly, 
did circumvent the phosphate-binding region [140]. 
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5.2 Aims and Objectives 
This chapter focuses on the investigation of the cofactor-binding site of PHGDH 
through separate examination of the different areas of this pocket in more detail. The 
investigated areas include: (1) the nicotinamide pocket where NAD+ analogues with 
modified nicotinamide moieties were evaluated, (2) the phosphate binding region for 
which the impact of variations in the size of the phosphate linker were analysed and 
(3) the adenine-binding subsite for which analogues of adenine were tested. 
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5.3 Materials and Methods 
All chemicals listed in the materials and methods section were of analytical grade 
and obtained from Sigma Aldrich, St. Louis, MO, USA, unless otherwise stated. 
5.3.1 Differential scanning fluorimetry 
DSF experiments were performed in 96 well plates according to section 2.9 with the 
following protein and SYPRO Orange concentrations. The assay contained 25 mM 
HEPES, pH 7.5 with 1 x Sypro Orange, 1 μM PHGDH and 200 μM ligand. All ligands 
were prepared fresh prior to the assay by dissolving in 25 mM HEPES, pH 7.5 and 
the pH of the solution was adjusted to about 7.5. The concentration of solutions 
containing NAD+ and analogues thereof was determined spectrophotometrically by 
measuring the absorbance at λ = 260 nm. From the absorbance the respective 
concentrations were calculated using the Beer-Lambert law as described in section 
4.3.2 with the specific extinction coefficients listed in Table 5.1, followed by dilution of 
the stocks to give the final assay concentration. 
Compound Extinction coefficient (ε) at λ = 
260 nm (M-1 cm-1) [Reference] 
Nicotinamide adenine dinucleotide (NAD+) 18,000 [155] 
Thionicotinamide adenine dinucleotide (TAD) 19,700 [156] 
Pyridinealdehyde adenine dinucleotide (PAD) 18,300 [157] 
Acetylpyridine adenine dinucleotide (APAD) 16,400 [157] 
Adenosine 5’-diphosphoribose (ADPR) 15,400 [158] 
Adenosine triphosphate (ATP) 15,400 [155] 
Adenosine diphosphate (ADP) 15,400 [155] 
Adenosine monophosphate (AMP) 15,300 [155] 
Table 5.1 – Specific extinction coefficients of NAD
+
, NAD
+
 analogues and fragments of NAD
+
. 
5.3.2 Isothermal titration calorimetry 
ITC experiments were performed as described in section 2.10. Briefly, PHGDH as 
well as ADPR were in 25 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 mM TCEP. 
Changes in enthalpy and entropy were measured at 25 °C using a MicroCal iTC200 
(GE Healthcare, Little Chalfont, UK). All thermodynamic parameters of the reaction 
were determined using the ORIGIN software package, version 7.0. 
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5.3.3 Enzyme activity assay 
In vitro enzymatic activity of PHGDH or sPHGDH was measured 
spectrophotometrically as described in section 2.8. The concentration range of NAD+ 
and TAD used was 0.1 – 200 μM and for APAD and PAD was 0.5 – 700 μM. 
5.3.4 Fluorescence polarisation assay 
Fluorescence polarisation assays were carried out as described in section 2.11. 
Briefly, the assay mixture contained 40 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 mM 
TCEP or 2 mM DTT, 1 μM NADH and 2 μM PHGDH or sPHGDH. AMP, ADP, ADPR 
and NAD+ were dissolved in 40 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 mM TCEP or 
2 mM DTT and screened at a maximum concentration of 3 mM for AMP and ADP 
and mM for ADPR and 2 mM for NAD+. The reaction mixture with compound was 
incubated for 30 min at RT and fluorescence polarisation was measured using a 
PHERAstar FS plate reader (BMG Labtech, Ortenberg, Germany) with a FP filter 
module (λex = 340 nm and λem = 440 nm). 
5.3.5 Crystallography 
Co-crystallisation of sPHGDH with NAD+ or its analogues (TAD, PAD, APAD) or 
fragments (AMP, ADP) was performed by screening against sparse matrix screens 
as well as optimisation screen I as described in section 2.12. Crystals for which 
datasets were collected were analysed as described in section 2.13. 
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5.4 Results 
5.4.1 ADPR as a moderate inhibitor of PHGDH 
In order to identify inhibitory hits of a possible drug target, it is necessary to develop 
biochemical and/ or biophysical assays of sufficient sensitivity. To validate those 
assays, one would ideally use a known and relatively potent inhibitor of the target.  
However, for PHGDH no such inhibitor has been reported to date. From the literature 
adenosine 5’-diphosphoribose (ADPR), a truncated analogue of NAD+ lacking the 
nicotinamide moiety is known to bind strongly to rabbit glyceraldehyde 
dehydrogenase and function as potent competitive inhibitor [159]. Therefore, ADPR 
was investigated in an optimised in vitro enzyme activity assay based on a protocol 
developed during a preceding project [160]. Optimisation included i) the addition of 
Triton-X-100 to the assay mixture to decrease any surface adsorption of the protein, 
ii) the change of buffering agent from TRIS to BIS TRIS propane, as this buffer 
system can be used over a wider pH range (6.3 to 9.5), and iii) the reduction of 3-PG 
concentration from 2.5 mM to 140 μM, which was determined as the Km of 3-PG 
under these reaction conditions. In the in vitro enzyme activity assay, ADPR was able 
to inhibit full-length PHGDH activity by 50 % at the maximum tested dose of 120 μM. 
In addition, ADPR also inhibited the activity of the truncated sPHGDH that contains 
only the substrate and cofactor-binding domains, by about 40 %, indicating that 
ADPR functions as a competitive inhibitor of the cofactor, which would be expected 
due to the structural homology of NAD+ and ADPR (Figure 5.3). 
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Figure 5.3 – Inhibition of PHGDH/sPHGDH activity with ADPR. 
Enzymatic activity of PHGDH or sPHGDH was measured in the presence of increasing concentrations 
of ADPR (0.5 – 120 μM). % Inhibition was calculated by comparison to control samples containing no 
inhibitor (0 % inhibition) and a control without enzyme (100 % inhibition). Graph represents mean and 
standard deviation of three independent experiments with two intra-assay repeats. Data were 
analysed using nonlinear regression (log(inhibitor) vs. response – variable slope) in GraphPad Prism. 
In addition, ADPR binding to PHGDH was investigated by ITC as well as in the DSF 
assay (Figure 5.4). ITC experiments were performed by titrating 1 mM ADPR into 
0.05 mM PHGDH. ADPR was found to be a moderately potent ligand of PHGDH with 
a KD of 40.0 ± 5.4 μM. Binding was mainly driven through changes in enthalpy (i.e. an 
exothermic reaction) with ΔH = -35.6 ± 14.1 kJ/mol with only a minor contribution 
from entropic factors, with a ΔS = -0.13 J/(mol x K). 
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Figure 5.4 – Binding of ADPR to PHGDH as investigated by ITC and DSF. 
(A) 1 mM ADPR was titrated into 0.05 mM PHGDH in 25 mM HEPES, pH 7.5, 100 mM NaCl and 0.5 
mM TCEP. Top panel: raw data for 1 x 0.5 µL, followed by 17 x 2 µL injections of 1 mM ADPR into the 
isothermal cell containing 0.05 mM PHGDH. Data were corrected for heat of ADPR dilution by 
subtracting the heats from ADPR to buffer titration. Bottom panel: integrated heats from the peaks in 
the top panel plotted against the molar ratio of ADPR to PHGDH. The line of best fit to the data was 
plotted as obtained by non-linear regression using the built-in one-site fit model of the ORIGIN 
software. (B) Data obtained from the one-site fit model in ORIGIN. Stoichiometry of the reaction (= 
number of binding sites, N), changes in entropy (ΔS) and enthalpy (ΔH) as well as the association 
constant (Ka) were determined. The binding constant (KD) was calculated by taking the reciprocal of 
Ka. (C) Thermal denaturation of 1 μM PHGDH in the presence of 0.2 mM ADPR in combination with 
0.2 mM substrate analogue. Graphs represent mean and standard deviation of at least two 
independent experiments with two replicates per experiment. Statistical analysis was performed in 
GraphPad Prism (two way ANOVA). **** = p < 0.0001, ** = p = 0.0022. 
Due to its structural similarity with NAD+, together with the finding that ADPR was 
able to inhibit not only full-length, but also sPHGDH activity, ADPR was assumed to 
bind to the cofactor-binding site in a similar manner as NAD+. In order to prove this, 
co-crystallisation of sPHGDH with ADPR was attempted. Initial crystal trials of 
sPHGDH in the presence of ADPR yielded crystalline hits from 0.1 M BIS TRIS, pH 
5.5, 0.2 M NH4Ac, 25 % (w/v) PEG3350 and this condition was used as start point for 
further optimisation (see section 4.4.4). From the optimisation, several crystals were 
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obtained, of which one diffracted sufficiently well to collect a dataset. This crystal was 
grown from 0.1 M BIS TRIS, pH 6, 0.3 M NH4Ac, 23 % (w/v) PEG3350, and a dataset 
(sPHGDH 03) was collected to 2.2 Å resolution using synchrotron radiation (Table 
5.2). 
 sPHGDH 03 
Wavelength (Å) 0.98 
Space Group P 1 
a, b, c (Å) 43.2, 59.5, 63.7 
α, β, γ (°) 89, 90, 80 
Resolution (Å) 58.6 - 2.16 (2.22 – 
2.16) 
I/σI 3.7 (1.9) 
Rmerge 0.02 (0.53) 
Completeness (%) 97.2 (95.3) 
Multiplicity 2.0 (1.9) 
 
Table 5.2 – Data collection statistics for sPHGDH co-crystallised with ADPR (sPHGDH03). 
Data were collected from a single crystal at 100 K on beamline I02, DLS. The data were processed 
using xia2 (3daii-run). The statistics are presented as averages with values for the highest resolution 
shell in parentheses. 
Analysis of the data showed that neither ADPR nor NAD+ completely satisfied the 
observed electron density in the cofactor-binding site. This was best illustrated by 
modelling NAD+ into the active site. The weighted electron density map from the 
subsequent refinement shows no evidence for the presence of the amide function 
(Figure 5.5 A). In addition, the nicotinamide moiety refines with much higher B-factors 
than the ADPR moiety, indicating either a large degree of flexibility or that this moiety 
is partly missing. A partial occupancy with some cofactor-binding sites containing 
ADPR and others NAD+ provides a good fit to the experimental data. 
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Figure 5.5 – Cofactor-binding site of crystal sPHGDH03 with NAD
+
 modelled into the active site. 
(A) Weighted electron density map from refinement (2Fo-Fc) contoured in blue at 0.39 electrons/Ā
3
. 
Position of the nicotinamide-moiety highlighted by an orange circle. (B) Detail of the cofactor-binding 
site with NAD
+
 coloured according to temperature factors with increasing temperature factors from 
pink to red. The protein surface was coloured by electrostatic potential. 
This interpretation of the electron density maps for crystal sPHGDH03 suggests that 
sPHGDH is likely to co-purify with its cofactors. This was supported from measured 
OD260/OD280 ratios of purified sPHGDH, which were around 0.8 whereas 0.57 is 
reported for pure protein. Treatment of sPHGDH with charcoal, which is known to 
adsorb nucleotides, resulted in a reduction of the OD260/OD280 ratio to 0.65 (see 
section 6.4.1). By contrast, full length PHGDH co-purified with NAD+ or NADH to a 
lesser extent  (if indeed at all) according to a measured OD260/OD280 ratios of 0.66. 
Measurements of binding affinities of NAD at both oxidation states (NAD+ and NADH) 
to full-length PHGDH by ITC, showed that especially NADH had a very high affinity 
for PHGDH with a KD of 0.22 μM, whereas the KD measured for NAD
+ was 2000-fold 
lower at 0.44 mM (Figure 5.6). 
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Figure 5.6 – Binding of NAD
+
 and NADH to PHGDH as investigated by ITC. 
(A) 0.5 mM NADH or (B) 5 mM NAD
+
 was titrated into 0.05 mM PHGDH in 25 mM HEPES, pH 7.5, 
100 mM NaCl and 0.5 mM TCEP. Top panel: raw data for 1 x 0.5 µL, followed by 17 x 2 µL injections 
of NADH or NAD
+
 into the isothermal cell containing 0.05 mM PHGDH. Data were corrected for heat of 
cofactor dilution by subtracting the heats from cofactor to buffer titration. Bottom panel: integrated 
heats from the peaks in the top panel plotted against the molar ratio of cofactor to PHGDH. The line of 
best fit to the data was plotted as obtained by non-linear regression using the built-in one-site fit model 
of the ORIGIN software. (B) Data obtained from the one-site fit model in ORIGIN. Stoichiometry of the 
reaction (= number of binding sites, N), changes in entropy (ΔS) and enthalpy (ΔH) as well as the 
association constant (Ka) were determined. Binding constant (KD) was calculated by taking the 
reciprocal of the Ka. 
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5.4.2 NAD+ analogues 
NAD+ analogues were used to study the effect of changes around the nicotinamide-
binding subsite on the enzymatic activity and stability of PHGDH and to understand 
what functional groups would be tolerated in this part of the cofactor-binding site. 
TAD, APAD and PAD were tested in the enzyme activity assay instead of NAD+ and 
all of them were found to allow the enzymatic reaction to proceed (Figure 5.7). In 
particular, TAD was very similar to NAD+ in terms of maximum velocity (Vmax) (10.0 
and 7.2 pmol/min for TAD and NAD+ respectively) and kcat (0.45 and 0.32 min
-1 for 
TAD and NAD+ respectively). In contrast, Vmax for APAD and PAD was higher than 
NAD+. APAD showed a 10-fold increase in kcat compared to NAD
+, whereas PAD 
showed a slightly reduced kcat. 
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Figure 5.7 – Enzyme kinetic data for PHGDH with various substrate analogues. 
In vitro PHGDH activity assay containing recombinant human PHGDH and increasing concentrations 
of NAD
+
 or TAD (A) or the NAD
+
 analogues PAD or APAD (B). The increase in fluorescence due to 
conversion of NAD
+
 to NADH was measured and initial velocity determined by linear regression. The 
initial velocity was plotted against cofactor/ cofactor analogue concentration and data fitted to a 
Michaelis-Menten model. All curve fitting was performed using GraphPad Prism. Data plotted 
represents mean and standard deviation of two independent experiments with two replicates per 
experiment. (C) Summary of calculated parameters of PHGDH activity. 
a
 R is used to denote the ADP-
ribose moiety. 
All cofactor analogues tested could replace NAD+ and sustain PHGDH activity. In 
order to compare their binding affinities with NAD+, a DSF assay was performed. All 
the cofactor analogues stabilised PHGDH less than NAD+, with APAD showing no 
increase in Tm, suggestive of a lack of binding (Figure 5.8). In combination with 3-PG, 
all analogues showed the same synergistic behaviour, increasing the Tm of PHGDH 
to the same extent as NAD+. This result is even more striking considering that the 
NAD+ analogues yielded only small increases in Tm of PHGDH when used on their 
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own. Intriguingly, for NAD+ analogues in combination with other substrate analogues, 
a significant change in Tm was only seen for PAD together with α-KG. 
 
Figure 5.8 – Change in Tm (ΔTm) of PHGDH upon addition of NAD
+
 analogues in combination 
with substrate/ substrate analogues. 
Thermal denaturation of 1 μM PHGDH in the presence of 0.2 mM NAD
+
 analogue in combination with 
0.2 mM substrate analogue. Graphs represent mean and standard deviation of at least two 
independent experiments with two replicates per experiment. Statistical analysis was performed in 
GraphPad Prism (two way ANOVA). **** = p < 0.0001. 
Co-crystallisation of sPHGDH with the cofactor-analogues was attempted by sitting 
drop vapour diffusion in 96-well plates. Optimisation trays around the published 
crystallisation conditions using MMT buffer (optimisation screen 1) and the in-house 
established conditions with BIS-TRIS buffer (optimisation screen 2) were set up with 
15 mg/mL sPHGDH and 5 mM cofactor analogue at RT and 4 °C. Crystals were 
obtained with the cofactor analogues TAD and APAD only in conditions of the 
optimisation screen 2. Three datasets of co-crystals of sPHGDH with TAD were 
collected and analysed and an example dataset (sPHGDH04) collected to 1.95 Å 
resolution using synchrotron radiation is shown (Figure 5.9). NAD+ and TAD differ 
only in the acetamide group that is a thioacetamide group in TAD. Although this 
means that the oxygen is changed for sulphur, the geometry of the respective 
adjacent carbon is trigonal in both molecules and due to the similar electronic 
configuration of oxygen and sulphur, sulphur is also able to form the same hydrogen 
bonds. Therefore from the electron density alone, it cannot be excluded that the 
active site of sPHGDH in the co-crystal with TAD is still partly occupied by NAD+. 
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Figure 5.9 – Data collection statistics for sPHGDH co-crystallised with cofactor analogue TAD 
(sPHGDH 04). 
(A) Data collection statistics for sPHGDH 04 (co-crystal with TAD). The data were collected on a single 
crystal at 100 K on beamline I04, Diamond Light Source (DLS). The data were processed, scaled and 
merged using xia2 (3daii-run), aimless, pointless and programs from the ccp4i2 suite. The statistics 
are presented as averages with values for the highest resolution shell in parentheses. (B) 
Superposition of the active site of sPHGDH 04 with TAD bound onto sPHGDH with NAD
+
 bound (PDB 
2G76). Protein secondary structure is shown in blue (sPHGDH 04) and gold (PDB 2G76) and TAD 
and NAD
+
 are coloured by atom. 
5.4.3 NAD+ fragments 
Phosphate groups are polar and negatively charged at physiological pH. The 
phosphate linker within the NAD+ cofactor is therefore able to contribute substantially 
to ligand binding to the protein, provided complementary positive charges are 
suitable presented in the cofactor-binding site. In order to further investigate the 
effect of the phosphate groups on binding of NAD+ to PHGDH, two cofactor 
fragments, namely ADP and AMP, as well as ATP, which has an additional 
phosphate group compared to NAD+, were tested in the DSF assay. The results from 
the DSF assay clearly show an increase in ability to stabilise the Tm of PHGDH with 
increasing number of phosphate groups, making ATP the strongest binding partner 
with an increase in Tm of 4.7 ± 0.9 °C (Figure 5.10 A). Addition of substrate 
analogues to the NAD+ fragments failed to further amplify the effect on the Tm of 
PHGDH. Direct comparison of NAD+ with ADP shows that whilst ADP, in contrast to 
NAD+, does not show a synergistic effect with any of the substrate analogues, ADP 
promotes a significantly larger increase in Tm of PHGDH than does NAD
+, and this 
effect is independent of the addition of substrate analogues (Figure 5.10 B). 
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Figure 5.10 – Change in Tm (ΔTm) of PHGDH through the addition of NAD
+
 fragments in 
combination with substrate (analogues). 
(A) Thermal denaturation of 1 μM PHGDH in the presence of 0.2 mM NAD
+
 fragment and in 
combination with 0.2 mM substrate analogue. (B) Comparison of changes in Tm of PHGDH in the 
presence of NAD
+
 or ADP. Graphs represent mean and standard deviation of at least two independent 
experiments with two replicates per experiment. Statistical analysis was performed in GraphPad Prism 
(two way ANOVA). * = p = 0.041, ** = p = 0.0003, **** = p < 0.0001. 
In addition to the binding studies by DSF, the NAD+ fragments were also investigated 
for their potential to displace NADH using the FP assay. Within the group of AMP, 
ADP and ADPR the potency for displacement of NADH from the protein increases 
with the size of the fragment (Figure 5.11 A-C). The difference between AMP, which 
results in 25 % displacement at the highest concentration of 3 mM, and ADP, which 
yields 70 % displacement at the same concentration, is particularly remarkable. The 
presence of the second phosphate group in ADP has a marked effect on potency. 
ADPR is the most active compound in this assay with EC50 values of 236.3 ± 1.1 μM 
(PHGDH) and 188.7 ± 1.1 μM (sPHGDH), whereas NAD+ shows a similar effect to 
ADP (Figure 5.11 C-D). 
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Figure 5.11 – Binding of NAD
+
 fragments to PHGDH and sPHGDH determined by FP. 
FP of NADH was measured with 1 μM NADH and 2 μM PHGDH or sPHGDH in the assay mixture in 
the presence of NAD
+
 and fragments thereof. The compounds were tested at increasing 
concentrations over the range of 8-3000 μM for AMP (A) and ADP (B), and over the range of 0.5-1000 
μM for ADPR (C), all three fragments of NAD
+
, as well as NAD
+
 itself over the range of 2-2000 μM (D). 
Previous crystallisation experiments showed that NAD+ was often present in the 
crystal structure to some extent, even when not specifically added to the 
crystallisation conditions, which indicated co-purification of the protein with its 
cofactor (section 5.4.1). Fragments of NAD+ (AMP and ADP) were shown to bind to 
sPHGDH and to be able to displace NADH (Figure 5.11A and B). Therefore co-
crystallisation of charcoal-treated sPHGDH with the NAD+ fragments AMP and ADP 
was hoped to yield crystals containing only the NAD+ fragments, thus leaving the 
nicotinamide pocket empty and accessible to inhibitors binding to this part of the 
active site. 
Co-crystallisation of sPHGDH with AMP and ADP was therefore attempted to assess 
the degree of displacement of pre-bound cofactor and thus the potential to use these 
crystals for soaking of small inhibitors intended to bind to the nicotinamide subsite of 
the cofactor-binding pocket and/or the substrate-binding pocket. In addition, prior to 
crystallisation, sPHGDH was treated with activated charcoal onto which nucleotides 
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are known to adsorb as an additional means to remove the co-purified cofactor (see 
section 6.4.1). 
Co-crystallisation of sPHGDH with 5 mM AMP resulted in a number of crystals, which 
grew from various conditions of both commercial sparse matrix screens as well as 
the optimisation screen II. A single dataset from one crystal grown in 0.1 M Sodium 
HEPES/ MOPS buffer, pH 7.5, 0.12 M monosaccharides, 30 % (w/v) PEG550-MME 
and PEG20K was obtained (sPHGDH 04) (Figure 5.12). Disappointingly, analysis of 
the data showed residual electron density for parts of nicotinamide and adjacent 
ribose (Figure 5.12). The same was found to be true for co-crystals of sPHGDH with 
ADP. 
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Figure 5.12 – Co-crystallisation of sPHGDH with AMP (sPHGDH 05) 
A) Data collection statistics for sPHGDH 05 (co-crystal with AMP). The data were collected on a single 
crystal at 100 K on beamline I04-1, Diamond. The data were processed, scaled and merged using 
xia2 (3daii-run), aimless, pointless and programs from the ccp4i2 suite. The statistics are presented as 
averages with values for the highest resolution shell in parentheses. (B) Active site of sPHGDH 05 
with AMP bound. Protein and AMP are coloured by atom. Additional electron density seen after AMP 
was built into the model indicating presence of NAD (red circle); electron density map (2Fo-Fc) shown 
as blue wire and the difference map (Fo-Fc) in red and green at contour levels of 0.29 electrons/Ā
3
. 
5.4.4 Exploring the adenine moiety 
Interactions in the adenine-binding pocket mainly occur through Ser211, which 
donates a hydrogen bond to the N-3 of the purine ring as well as accepting a 
hydrogen bond from the exocyclic amino-group (Figure 5.13A). A small pocket 
seemed available to accommodate a group at the 6-position of the purine ring. To 
investigate how well removal of the hydrogen-donor amino-group would be tolerated, 
nicotinamide hypoxanthine dinucleotide (NHD), which has a keto-group at the 6-
position of the purine ring, and guanosine 5’-diphosphate, which has the keto-group 
in the 6-position and an additional amino-group in the 2-position, were tested in the 
DSF assay (Figure 5.13 B and C). 
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Figure 5.13 – Structures of nucleobase analogues. 
(A) Detail of the cofactor-binding pocket of sPHGDH highlighting the interactions of the adenine moiety 
of NAD
+
. PHGDH backbone is shown in grey with protein surface shown according to its electrostatic 
potential. Structure of NAD
+
 is coloured by atom type. (B-C) Structures of the NAD
+
 analogue 
nicotinamide hypoxanthine dinucleotide (NHD) and (B) the ADP analogue, guanosine 5’-diphosphate 
(GDP). 
Results from NHD and GDP addition to PHGDH in the DSF assay were compared to 
effects seen with their respective natural ligand counterparts, NAD+ and ADP. In the 
DSF assay, GDP behaved very similarly to ADP, showing an identical increase in Tm 
of PHGDH of 2.2 ± 0.3 °C (Figure 5.14 A). As already observed for ADP, no 
additional increase in Tm was seen for GDP in combination with substrate/ substrate 
analogues. On the contrary, NHD was unable to stabilise PHGDH and did not assist 
malate binding in contrast to what was seen with NAD+. This indicates that 
exchanging the adenine moiety in NAD+ for hypoxanthine, which is equivalent to 
replacing the amine group in the 4-position with a ketone group and thereby losing 
the hydrogen bond donor attributes of the amine, is detrimental for binding to 
PHGDH (Figure 5.14 B). 
 
(B) 
 
(C) 
(A) 
Ser211 
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Figure 5.14 - Change in Tm (ΔTm) of PHGDH through the addition of nucleobase analogues in 
combination with substrate/ substrate analogues. 
Thermal denaturation of 1 μM PHGDH in the presence of 0.2 mM NAD
+
, NHD, ADP or GDP in 
combination with 0.2 mM substrate analogue. Graphs represent mean and standard deviation of at 
least two independent experiments with two replicates per experiment. Statistical analysis was 
performed in GraphPad Prism (two way ANOVA). *** = p < 0.001. 
During a previous study adenine analogues had been assessed for their potential to 
inhibit PHGDH activity using an in vitro enzyme activity assay (Figure 5.15). In this 
assay, which measures PHGDH activity in the physiological direction of 3-PG 
oxidation, compounds 14 and 15 were found to be moderate inhibitors of PHGDH, 
inhibiting its activity by about 50 % at the highest assessed concentration of 120 μM 
[160]. 
 
Figure 5.15 – Structures of available adenine analogues from the NICR compound library. 
All adenine analogues investigated contain an additional amino group at the 6-position together with 
modifications at the 1- (highlighted in blue) or 4-position (highlighted in red). 
To confirm their inhibitory effects, compounds 14 and 15 were re-assessed in the in 
vitro PHGDH activity assay using the optimised protocol (see section 5.4.1). Re-
testing confirmed the inhibitory potential of 14 and 15 as similar to the inhibition seen 
with the pan-dehydrogenase inhibitor ADPR (Figure 5.16A). From an extrapolation of 
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the sigmoidal dose-response fit, the IC50 values for 14 and 15 were determined as 
173.4 ± 1.2 μM and 276.5 ± 1.3 μM, respectively. Interestingly, and in contrast to 
ADPR, no inhibition was seen in the in vitro enzyme activity assay with truncated 
sPHGDH (Figure 5.16 B). 
 
Figure 5.16 – Inhibition of PHGDH (A) and sPHGDH (B) with compounds 14 and 15 compared to 
ADPR. 
Enzyme activity was measured in an in vitro activity assay using purified recombinant human proteins. 
Inhibitor concentrations ranged from 0.12 to 120 µM. Graphs represent averages and standard 
deviations of three independent experiments. Data were fitted to a dose-response model using 
GraphPad Prism. 
The lack of inhibitory activity against sPHGDH, which comprises the active site and 
misses any regulatory domains, suggest that these compounds may not in fact target 
the adenine pocket. To investigate this further the mode of inhibition of compounds 
14 and 15 was determined by kinetic studies and compared to that of ADPR. In the 
case of an NAD+- competitive inhibitor, the same maximum velocity (Vmax) should be 
achievable in the presence of the inhibitor as in the absence, with inhibition showing 
up as an apparently elevated Km in the presence of the inhibitor. A noncompetitive 
inhibitor, which binds outside the active site and induces some conformational 
change that inhibits enzymatic activity, results in a decreased Vmax (Figure 5.18 A). 
Equation 5.1, which describes noncompetitive binding, could be used to distinguish 
between competitive and noncompetitive inhibition by determining the parameter α. 
In the case where α >> 0, the equation can be simplified to that describing a 
competitive inhibitor, whereas for a noncompetitive inhibitor 0 < α < 1 (Equation 5.1). 
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Figure 5.17 – Schematic Michaelis-Menten curve showing the effect of competitive and 
noncompetitive inhibitors. 
(A)            (B) 
𝑣 =  
𝑣𝑚𝑎𝑥[𝑆]
[𝑆] (1 +
[𝐼]
𝛼𝐾𝑖
) + 𝐾𝑀 (1 +
[𝐼]
𝐾𝑖
)
    ;      𝑓𝑜𝑟 𝛼 ≫ 1:    𝑣 =
𝑣𝑚𝑎𝑥[𝑆]
1 + 𝐾𝑀 (1 +
[𝐼]
𝐾𝑖
)
 
Equation 5.1 – Equation relating initial velocity to substrate concentration in the presence of an 
inhibitor for noncompetitive (A) and competitive (B) inhibition [161]. 
Ki = dissociation constant of the Enzyme-Inhibitor complex 
αKi = dissociation constant of the enzyme-inhibitor-substrate complex 
Vmax = maximum velocity at infinite substrate concentration 
KM = Michaelis-Menten constant = substrate concentration yielding half of Vmax 
Variability in the activity of PHGDH was observed between different purification 
batches. The independent repeats for each inhibitor were therefore analysed 
separately and a representative experiment is shown (Figure 5.18). As anticipated, 
ADPR was shown to act as a competitive inhibitor (α = 18.5-31.4), whereas 
compounds 14 and 15 were noncompetitive inhibitors (α = 0.16 – 0.67 and 0.75 – 
1.36). 
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Figure 5.18 – Mode of inhibition for adenine analogues 14, 15 and ADPR. 
In vitro activity of recombinant human PHGDH in the presence of varying concentrations of cofactor 
NAD
+
 (0 – 150 μM) and constant substrate concentration (3-PG, 140 μM), and inhibitors 14 (A), 15 (B) 
or ADPR (C) (0 - 120 μM). Initial velocity was determined from the increase in fluorescence over time, 
and plotted against increasing concentrations of NAD
+
. The data were fitted to the mixed-model 
equation in GraphPad Prism. Representative graphs of three independent experiments for each 
inhibitor are shown. The initial velocity was calculated from two intra-assay repeats. 
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Inhibitor 
Vmax 
(pmol/min) 
KM (µM) Ki (µM) α 
Mode of 
inhibition 
No 
inhibitor 
7.2 ± 0.6 5.3 ± 3.5 - - - 
14 
6.7 ± 0.2 15.2 ± 2.2 146.1 ± 79.3 0.7 ± 0.4 
Non-
competitive 
23.5 ± 10.8 14.5 ± 1.9 1804 ± 6313 0.2 ± 0.6 
17.6 ± 1.2 14.4 ± 3.8 465.8 ± 1157 0.2 ± 0.5 
15 
30.0 ± 1.3 12.6 ± 2.1 149.3 ± 92.1 0.8 ± 0.6 
Non 
competitive 
24.1 ± 0.8 15.0 ± 2.1 120.3 ± 51.6 1.4 ± 0.7 
19.5 ± 0.7 14.0 ± 2.2 211.0 ± 143 1.0 ± 0.8 
ADPR 
31.4 ± 1.2 11.4 ± 2.1 33.3 ± 9.5 28.6 ± 30.8 
Competitive 26.4 ± 0.7 10.4 ± 1.3 48.4 ± 10.8 8.9 ± 3.9 
18.5 ± 0.4 10.4 ± 1.1 24.1 ± 3.9 15.4 ± 5.7 
Table 5.3 – Results of mixed-model inhibition fit in GraphPad Prism. 
Three independent experiments were conducted with two intra-assay repeats. The data were 
analysed by fitting to the mixed-model inhibition equation (Equation 5.1) in GraphPad Prism. The 
determined α value was used to distinguish between competitive and noncompetitive inhibition. 
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5.5 Discussion 
PHGDH belongs to the family of dehydrogenases, which catalyse redox reactions. 
Although different dehydrogenases catalyse reactions with a wide variety of 
substrates, most of them use NAD+ as a common cofactor. The binding of NAD+ is 
mediated by a conserved structural domain, the Rossmann fold, which suggests that 
specific inhibition of a dehydrogenase by targeting its NAD+-binding site will be 
challenging. Therefore work in this chapter was focused on gaining a better 
understanding of the cofactor-binding site of PHGDH as well as probing for small 
compounds that could provide a starting point for potent inhibitors. 
In the previous chapter, adenosine 5’-diphosphoribose (ADPR) was shown to be able 
to displace NADH from its binding site in an FP assay. Further characterisation of the 
interaction of PHGDH with ADPR using an in vitro enzymatic activity assay showed 
that ADPR was able to inhibit nearly 50 % of enzymatic activity at 120 μM not only of 
full-length PHGDH, but also using the truncated form sPHGDH. sPHGDH lacks the 
regulatory domains compared to full-length PHGDH, so that ADPR must bind to the 
catalytic domain and is expected to function as a competitive inhibitor of its structural 
analogue NAD+. Although ADPR is only a moderate inhibitor of PHGDH, it represents 
an important tool compound for validation of biochemical and biophysical assays. 
ADPR is, however, also likely to have a general affinity for NAD+-binding proteins and 
is a highly charged nucleotide analogue with difficulties to cross cell membranes. As 
such, it is not suitable as a chemical probe for target validation studies or for cell-
based assays. Co-crystallisation studies of ADPR with sPHGDH revealed partial 
occupancy of the active site with a mix of cofactor and ADPR indicating co-
purification of sPHGDH with bound cofactors. The pre-bound cofactor would make it 
challenging for weak inhibitors to bind to the active site of sPHGDH, and although 
partial removal of cofactor was achieved through charcoal treatment, this technique 
did not provide completely empty active sites (see section 6.4.1). 
The NAD+ analogues APAD, TAD and PAD are known to be able to replace NAD+ in 
reactions catalysed by a variety of enzymes [162, 163]. This was also found to be 
true for PHGDH. In particular, APAD showed a ten-fold higher kcat than NAD
+, which 
is likely due to its higher oxidation potential, which supports a faster reduction of 
APAD compared to NAD+ [164]. Interestingly, analysis of the binding affinities of the 
cofactor analogues by DSF showed that none of the analogues stabilised PHGDH to 
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the same extent as NAD+, and APAD, for example, did not stabilise PHGDH at all. 
However, all cofactor analogues were able to exert a stabilising effect in combination 
with 3-PG. This could be an indication that the catalytic reaction mechanism follows 
an ordered Bi Bi mechanism with substrate binding occurring before cofactor binding, 
as is the order of reaction found for PHGDH from M. tuberculosis [57]. In contrast, 
effective binding of DL-malate was only detected in the presence of NAD+ and to a 
weaker extent with NAD+ analogues, implying that in the absence of cofactor/ 
cofactor analogue, this substrate analogue was not able to bind to the enzyme. With 
the exception of α-ketoglutarate in combination with PAD, this effect was not 
observed with other substrate analogues. The significant increase in the Tm of 
PHGDH in the presence of PAD and α-KG, but not seen when combining one of the 
other cofactor/ cofactor analogues with α-KG is unlikely to be due to a difference in 
the electron distribution around the aromatic ring. The aldehyde, like the amide 
substituent on the aromatic ring, has an electron withdrawing inductive and 
resonance effect on the aromatic ring. Therefore it is more likely due to the difference 
in size with hydrogen replacing the NH2 group in PAD [165]. This would also explain 
why the effect is only seen with PAD and not with APAD and TAD with the latter 
having a methyl group or an NH2 group at the position of the hydrogen in the 
aldehyde group, respectively. Co-crystallisation of NAD+ analogues in combination 
with substrate analogues was attempted to validate this hypothesis. A crystal 
structure with TAD was obtained, however it was not clear whether TAD or 
NAD+/NADH was bound to the active site due to the co-purification of sPHGDH with 
cofactors. 
The phosphate-binding region in the cofactor-binding site is another challenging area 
of this pocket to target as phosphate groups are charged at physiological pH and in 
the case of PHGDH show multiple interactions with the protein. In addition to charge, 
the phosphate groups possess a difficult to mimic sp3 geometry, making them doubly 
difficult to replace with functional moieties typically found in bioavailable compounds. 
The NAD+ fragments AMP, ADP and ATP were investigated in the DSF assay and 
highlighted that the addition of beta and gamma phosphate groups to AMP 
potentiated binding affinity. No synergistic effect was seen in combination with 
substrate analogues, which was expected, as the NAD+ fragments do not contain the 
nicotinamide moiety, which is the part of cofactor that makes interactions with the 
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substrate. Interestingly, there was no additive effect with 3-PG (i.e. the Tm shift 
induced by 3-PG was of similar size as that of 3-PG together with AMP or ADP). The 
ability of AMP and ADP to displace NADH was also investigated in the FP assay. 
ADP was shown to displace NADH as effectively as NAD+ whereas ADPR is more 
effective in displacing NADH than NAD+ as well as ADP. Taking these findings 
together shows that in the absence of substrate, the nicotinamide moiety, although 
showing some specific interactions with the protein, makes a minimal contribution to 
the affinity for PHGDH. 
Finally, the adenine-binding subsite was investigated, as it is assumed to be a pocket 
that may readily be targeted by heterocycles other than adenine. To investigate the 
effect of the amine function in the 4-position on the purine ring, NAD+ was compared 
to NHD, which contains a keto group at the 4-position. NHD alone failed to stabilise 
PHGDH in the DSF assay, and was also unable to stabilise PHGDH in combination 
with DL-malate. This indicates that the interaction of the amine group with Ser211 of 
PHGDH makes an important contribution to binding affinity. 
In addition, some guanine analogues with bulky side chains at the 1- and 4- positions 
of the purine ring were investigated. Compounds containing a triisopropylsilyl function 
in the 4-position showed potency in the enzymatic activity assay. However, in 
contrast to ADPR, inhibition was only seen with PHGDH and not sPHGDH indicating 
that these compounds probably bound outside the active site. This was confirmed by 
investigating their mode of inhibition, which was non-competitive for NAD+. Although 
these compounds could inhibit PHGDH, their potency was probably driven by the 
somewhat un-drug-like triisopropylsilyl group, and together with the lack of 
information on their binding sites, they did not provide a good starting point for further 
optimisation. 
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Chapter 6. Site-directed mutants to investigate substrate- and 
cofactor-binding sites 
6.1 Introduction 
3-Phosphoglycerate dehydrogenase (PHGDH) was found to have a nanomolar 
affinity for its cofactor NADH, as described in chapter 5. This is in accordance with 
published data on other dehydrogenases where NADH binding is generally favoured 
over NAD+ binding represented in lower free energies of binding [166]. In general, the 
thermodynamics of dehydrogenase-catalysed reaction reveal larger negative 
enthalpy changes accompanied with small positive entropy changes in the direction 
of NADH oxidation [166]. This is in accordance with literature findings showing that 
the equilibrium of the PHGDH catalysed reaction lies far in the direction of 3-PG with 
over 95 % of substrate/ product in the form of 3-PG [57]. This means that the reaction 
catalysed by PHGDH occurs predominantly in the direction of reduction of 3-
phosphohydroxypyruvate (PHP) to 3-PG thereby oxidising NADH to NAD+. Under 
physiological conditions the reaction is forced in the direction of oxidation of 3-PG 
through consumption of the reaction product PHP in the subsequent transamination 
reaction (Figure 6.1). 
 
Figure 6.1 - Reaction catalysed by PHGDH. 
Under physiological conditions the equilibrium of the PHGDH-catalysed reaction lies far in the 
direction of 3-phosphohydroxypyruvate (PHP) consumption. Only when 3-phosphohydroxypyruvate is 
further modified by phosphoserine aminotransferase (PSAT) followed by dephosphorylation to yield L-
serine, will PHGDH catalyse the oxidation of 3-phosphoglycerate to compensate for the removal of 
PHP. 
Due to the high affinity of PHGDH for NAD+ and NADH, the artificially engineered 
truncated form sPHGDH always co-purified with its cofactors. This could be observed 
by measuring the OD260/OD280 ratio after purification, showing an elevated ratio of 
0.8-0.9, instead of 0.57 as could be expected for pure protein, indicating a 
contaminant that absorbs light at 260 nm [167]. In addition, the contamination 
observed spectrophotometrically was confirmed by analysis of the crystal structures 
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of different sPHGDH co-crystals with NAD+ fragments, such as AMP or ADP, which 
contained more or less prominent electron density for the cofactor in the respective 
binding pocket (Figure 6.2). Although neither the OD260/OD280 measurement nor the 
crystallographic data could give evidence whether NAD+ or its reduced form NADH is 
bound to the protein, the 2000-fold higher affinity of NADH compared to NAD+ for 
PHGDH suggests that sPHGDH co-purified with NADH. 
 
Figure 6.2 – Active site of sPHGDH with AMP 
Active site of sPHGDH with AMP modelled into the active site. Protein and AMP are coloured by 
element. Additional electron density seen after AMP was built into the model indicating presence of 
NAD; electron density map (2Fo-Fc) shown as blue wire and the difference map (Fo-Fc) in red and 
green at contour levels of 0.29 electrons/Ā
3
. 
To be able to search for potential inhibitors of PHGDH by targeting the cofactor- and 
substrate-binding sites, it is essential that these sites should be free and accessible. 
One possible strategy to remove the cofactor is through treatment of the protein with 
activated charcoal. This method was attempted and will be further explained in 
section 6.4.1. 
Another option to remove the cofactor could be through unfolding of the protein 
followed by extensive dialysis and refolding. However, in vitro protein refolding can 
be difficult to achieve due to the differences between authentic folding and folding in 
an extracellular environment. These differences include differences in pH, 
temperature, macromolecular crowding, and chaperoning through co-translational 
interactions with the ribosome and post-translational interaction with dedicated 
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cellular protein-folding systems. In addition, it can be challenging to find suitable 
buffer conditions to perform protein folding in vitro as the buffer composition, ionic 
strength and pH can all effect the hydrophobic and electrostatic forces acting on the 
protein. 
Against this background a novel approach was taken where key residues in the 
cofactor-binding pocket were mutated to prevent binding of the cofactors. A similar 
strategy of protein engineering of kinases is reported for the examination of biological 
signalling pathways [168]. As the binding pocket for NAD+/NADH is quite large, it 
should be possible to mutate amino acids at one end of the pocket, e.g. the adenine-
binding region, while leaving the other end, the nicotinamide-binding subsite, 
unchanged and vice versa (Figure 6.3). 
 
Figure 6.3 - Schematic representation of the mutation strategy 
Mutants were designed in order to prevent cofactor binding while retaining free, accessible space for 
the binding of small molecule inhibitors. 
(A) Mutation interfering with nicotinamide-binding subsite whilst the remaining part of the binding 
pocket (highlighted in orange) including the adenine-binding subsite is unchanged. (B) Opposite 
approach where the mutation is introduced at the adenine-binding subsite, whereas the nicotinamide-
binding subsite (highlighted in purple) stays unmodified. 
  
  
  
  
(A) (B) 
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6.2 Aims and Objectives 
In order to probe potential inhibitors for their binding to PHGDH, a variant of the 
protein with an empty and accessible cofactor-binding site was sought. Therefore two 
strategies were investigated, (i) removal of the bound cofactor from the purified 
protein through charcoal treatment, and (ii) prevention of cofactor binding to the 
protein through introduction of specific mutations. In the following sections an 
investigation of both approaches for their potential to yield a protein with free, 
accessible cofactor-binding site that can be used for structure-based drug design is 
described. 
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6.3 Materials and methods 
All chemicals listed in the materials and methods section were of analytical grade 
and obtained from Sigma Aldrich, St. Louis, MO, USA, unless otherwise stated. 
6.3.1 Charcoal treatment 
sPHGDH was mixed with 0.5 to 1.5 weight equivalents of activated charcoal and the 
mixture incubated under agitation for 30 to 120 minutes at room temperature (RT). 
Charcoal was removed through centrifugation at 16000 g, 10 min, 4 °C. Any 
remaining charcoal was removed by running the supernatant through a PD-10 
column (GE Healthcare, Little Chalfont, UK). The purity of the proteins was 
determined by measuring the OD260/OD280 ratio on a NanoDrop 2000 (Thermo Fisher 
Scientific, Waltham, MA, USA). 
6.3.2 Site-directed mutagenesis 
Point mutations were introduced by polymerase chain reaction (PCR) using the 
oligonucleotides outlined in Table 6.1. PCRs were performed with High-Fidelity 
Phusion DNA polymerase (New England Biolabs, Ipswich, MA, USA) using 20 ng 
purified sPHGDH DNA (see section 2.5.1), 1 μg of each primer, 0.5 mM dNTPs and 1 
x GC buffer (New England Biolabs, Ipswich, MA, USA) and run according to the 
thermal cycling profile in Figure 6.4. PCR product separation by size was performed 
by agarose gel electrophoresis and visualised by GelRed nucleic acid gel stain 
(Biotium, Hayward, CA, USA). Where the amplicon was detected, the remaining 
template was digested with DpnI (New England Biolabs, Ipswich, MA, US) for 1 h at 
37 °C, followed by transformation of the reaction mixture into E. coli DH5α cells. 
 
Figure 6.4 - Thermal profile of PCR reaction. 
The PCR was performed using a GeneAmp PCR System 2700 (Applied Biosystems, Waltham, 
MA,USA). The cycle of denaturation, primer annealing and extension was repeated 18 times. 
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Mutation Orientation Primer sequence (5’-3’) 
R154E Forward cttggcctgggcgagattgggagagagg 
 Reverse cctctctcccaatctcgcccaggccaag 
T206W Forward catcactgtgcactggcctctcctgccctcc 
 Reverse ggagggcaggagaggccagtgcacagtgatg 
T212W Forward cctctcctgccctcctggacaggcttgctgaatg 
 Reverse cattcagcaagcctgtccaggagggcaggagagg 
P175A/T206A/T212A Forward 
(1) tcatcactgtgcacgcgcctctcctgccctccgcgacaggcttgc 
(2) ctatagggtatgacgcgatcatttccccagagg 
 Reverse 
(1) gcaagcctgtcgcggagggcaggagaggcgcgtgcacagtg
atga 
(2) cctctggggaaatgatcgcgtcataccctatag 
D259N Forward gccggggctgcactgaatgtgtttacggaagagcc 
 Reverse ggctcttccgtaaacacattcagtgcagccccggc 
R235A/H282A Forward 
(1) gtggtgaactgtgccgcgggagggatcgtggacg 
(2) gtcatcagctgtcccgcgctgggtgccagcaccaagg 
 Reverse 
(1) cgtccacgatccctcccgcggcacagttcaccac 
(2) ccttggtgctggcacccagcgcgggacagctgatgac 
A285E Forward gtccccacctgggtgagagcaccaaggaggctc 
 Reverse gagcctccttggtgctctcacccaggtggggac 
 
Table 6.1 - Primer pairs for the generation of site-directed mutants of sPHGDH. 
Forward and Reverse primers are shown with the mutated positions underlined. All primers were 
manufactured by Eurofins Genomics (Ebersberg, Germany). 
 
Figure 6.5 – Amino acids mutated in sPHGDH. 
Amino acid sequence of sPHGDH with the amino acids mutated in the different site-directed mutants 
highlighted in red. 
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6.3.3 Transformation 
Transformation into competent E. coli DH5α subcloning efficiency cells (Life 
Technologies, Thermo Fisher Scientific, Waltham, MA, USA) was performed 
according to the manufacturer’s instructions. Briefly, 1 μL of DpnI-digested plasmid 
was added to 20 μL of competent cells and incubated on ice for 30 minutes. Cells 
underwent heat shock for 20 seconds at 42 °C, followed by cooling on ice for 2 
minutes. After addition of 180 μL pre-warmed medium, the cells were incubated at 37 
°C for 1 hour while shaking at 250 rpm, followed by plating on an LB/Agar plate 
containing 50 μg/mL kanamycin. Plates were incubated for 18 h at 37 °C and single 
colonies used to inoculate aliquots of 5 mL LB medium containing 50 μg/mL 
kanamycin. The cultures were grown under agitation at 200 rpm at 37 °C over night. 
DNA was isolated from the cells using the QIAprep Spin Miniprep Kit (Qiagen, Venlo, 
Netherlands) according to the manufacturer’s instructions. The mutations were 
confirmed by DNA sequencing (Source Bioscience, Nottingham, UK). The mutated 
DNA was used to transform the E. coli expression strain Rosetta (DE3) (Novagen, 
Darmstadt, Germany) grown in TB medium containing 50 μg/mL kanamycin. The 
transformation protocol followed was similar to the one described above with the 
exception of a 30 second heat shock at 42 °C. Glycerol stocks of the transformed 
cells in 15 % (v/v) glycerol were prepared from overnight cultures and stored at -80 
°C. 
6.3.4 Protein expression purification 
Large-scale protein expression was performed in E. coli Rosetta (DE3) cells in 2 L 
culture volume (see section 2.5.1). Site-directed mutants were purified as described 
in section 2.6.1 with a final yield of 10 – 20 mg depending on the mutant.  
6.3.5 Isothermal titration calorimetry (ITC) 
Isothermal titration calorimetry was performed as described in section 2.10. 50 μM 
protein was exchanged into ITC buffer (25 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 
mM TCEP) using a PD-10 desalting column (GE Healthcare, Little Chalfont, UK). 50 
μM wt sPHGDH or mutated protein or buffer alone was used as receptor in the cell 
and 0.2 – 0.5 mM NADH as ligand in the syringe. After an initial test injection of 
0.5 μL ligand, a further 17 injections of 2 μL every 120 seconds were performed. For 
data analysis, the heat of dilution effect of titrating ligand into buffer was subtracted 
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from the ligand to protein titration data. Data were analysed using the ORIGIN 
software. 
6.3.6 Differential scanning fluorimetry (DSF) 
DSF experiments were performed with 20 μM protein in 25 mM HEPES, pH 7.5, 100 
mM NaCl, 0.5 mM TCEP and 10 x SYPRO Orange. The assay was run in a total 
volume of 15 μL in a 384-well format according to the procedure in section 2.9. 
6.3.7 Enzyme activity assay 
The enzymatic activity of sPHGDH and its mutants was measured in the direction of 
3-phosphoglycerate oxidation according to the procedure in section 2.8. Each sample 
was run in duplicate in three independent experiments, and the percentage 
enzymatic activity of the mutants compared to wt sPHGDH was determined. 
6.3.8 Circular dichroism (CD) 
Circular dichroism (CD) is a spectroscopic technique used to study the secondary 
structure and conformation of chiral molecules, such as proteins. CD is the difference 
in absorption of left-handed and right-handed circularly polarised light, which occurs 
when chiral molecules interact with light. The characteristic CD spectra of proteins 
are defined through the amines of the polypeptide backbone resulting in distinct CD 
spectra for defined structural elements such as α-helices, which e.g. show negative 
bands at 222 nm and 208 nm and a positive band at 193 nm [169] . 
CD was performed on a JASCO J-810 spectropolarimeter (Japan Spectroscopic, 
Gross-Umstadt, Germany), recording 185-250 nm with a bandwidth of 0.2 nm and a 
scan speed of 20 nm/min. All measurements were performed with 0.5 mg/mL protein 
in 20 mM NaH2PO4, pH 8. Each measurement comprised the average of 10 repeated 
scans in a 0.02 cm path-length quartz cuvette and was subtracted from a blank 
measurement of buffer alone. The data was processed in CDSSTR software and 
secondary structure analysis performed on the DICHROWEB server with the 
CONTINLL algorithm and reference set 7 [170-172]. Data were plotted using 
GraphPad Prism. 
6.3.9 Crystallisation 
Crystallisation experiments were performed as described in section 4.3.5. Briefly, 
site-directed mutants were dialysed into low salt buffer composed of 25 mM HEPES, 
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pH 7.5, 100 mM NaCl and 0.5 mM TCEP. For co-crystallisation experiments, proteins 
were mixed with ligands to yield a final concentration of 5 mM ligand and 15 mg/mL 
protein and incubated at 4 °C overnight. Sitting drop vapour diffusion crystallisation 
trials using sparse matrix screens were performed in 96-well format at 4 and 20 °C. 
Trials contained drops with 0.3 + 0.3 μL and 0.3 + 0.6 μL protein and precipitant. 
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6.4 Results 
Part of the work presented in this chapter was performed by Sophie Bex and Nabila 
Aljufri, a summer project student and an M.Sc. student, working under my 
supervision. 
6.4.1 Charcoal treatment 
The literature contains various examples in which the adsorption properties of purine 
and pyrimidine derivatives on charcoal were used for the isolation of nucleotides from 
biological samples, the purification of nucleotide derivatives and the removal of 
diphosphopyridine dinucleotide from glyceraldehyde 3-phosphate [173-175]. On the 
basis of these data, purified sPHGDH was incubated with different amounts of 
activated charcoal for a maximum of 2 hours at RT. After removal of the charcoal, the 
absorbance of the samples at 280 nm and the OD260/OD280 ratio were used to 
monitor the protein concentration and purity, respectively. The measurements 
showed that not only cofactors adsorbed on the charcoal, but also protein, resulting 
in a reduced protein concentration. This was especially evident in samples treated 
with 1 or 1.5 weight equivalents of activated charcoal, which resulted in 
approximately 45 % and 70 % of protein loss, respectively, compared to 
approximately 25 % protein loss when treated with 0.5 weight equivalent of charcoal 
(Table 6.2). In addition, the highest purity achieved was an OD260/OD280 ratio of 0.65-
0.7, which is still higher than the ratio of 0.57 reported for pure protein, indicating that 
some cofactor is still bound. Incubation for longer than 30 minutes did not increase 
the purity of the protein. For further experiments with charcoal-treated sPHGDH, the 
protein was treated with 0.5 weight equivalent of activated charcoal for 30 minutes at 
room temperature as these conditions yielded protein with the highest degree of 
purity achieved without losing too much protein by its adsorption on charcoal. 
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 Untreated 0.25 eq. charcoal 0.5 eq. charcoal 
Time 
[protein] 
(mg/mL) 
OD260/OD280 
[protein] 
(mg/mL) 
OD260/OD280 
[protein] 
(mg/mL) 
OD260/OD280 
0 min 15.0 0.90 15.0 0.90 15.0 0.90 
30 min 15.0 0.89 12.1 0.65 11.2 0.69 
60 min 15.2 0.89 11.4 0.69 10.6 0.69 
120 
min 
15.4 0.89 11.3 0.7 10.2 0.7 
 
 1 eq. charcoal 1.5 eq. charcoal 
Time 
[protein] 
(mg/mL) 
OD260/OD280 
[protein] 
(mg/mL) 
OD260/OD280 
0 min 15.0 0.90 15.0 0.90 
30 min 8.6 0.69 5.0 0.67 
60 min 7.7 1.04 3.9 0.66 
120 min 4.4 1.21 2.7 0.73 
Table 6.2 - Removal of cofactor through charcoal treatment. 
15 mg/mL sPHGDH was mixed with different amounts of charcoal (0.25, 0.5, 1.0 and 1.5 weight 
equivalent to sPHGDH) for a maximum of 120 minutes at rt. Samples were taken after 30, 60 and 120 
minutes, charcoal removed by centrifugation (10 min, 4 °C, 16000 g) and protein concentration and 
purity measured using a NanoDrop 2000. 
NADH binding to untreated and charcoal-treated sPHGDH was explored by ITC. 
When titrating 0.5 mM NADH in the syringe into 0.05 mM wt sPHGDH in the cell, the 
binding site was saturated too quickly to obtain a complete, sigmoidal binding curve. 
Therefore the concentration of NADH in the syringe was reduced to 0.2 mM in the 
titration experiment (Figure 6.6 A). However, after charcoal-treatment a full binding 
curve was obtained using 0.5 mM NADH giving a first indication that more cofactor 
binding sites were now empty and accessible (Figure 6.6 B). This was also reflected 
by the calculated stoichiometry (n) rising from 0.3 to 0.8 for non-treated and charcoal-
treated sPHGDH respectively. Analysis of the different protein batches by DSF 
showed that charcoal-treated sPHGDH had a significant lower Tm of 46.0 ± 0.1 °C 
compared to non-treated protein with a Tm of 47.8 ± 0.1 °C, whereas addition of 1 
mM NADH resulted in an increase in Tm compared to that observed for non-treated 
protein, indicating that the higher Tm of non-treated sPHGDH was probably due to 
some pre-bound ligand (Figure 6.6 C). Despite the success in removing the cofactor 
from the protein to a certain extent through charcoal treatment, it was not clear what 
proportion of binding sites would still be occupied after charcoal-treatment. In 
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addition, a variation in efficiency of cofactor removal from experiment to experiment 
was found. Due to these disadvantages a more robust technique was sought. 
 
Figure 6.6 - Comparison of NADH binding to charcoal-treated and non-treated wt sPHGDH. 
Calorimetric isothermal titration of (A) 0.05 mM non-treated wt sPHGDH with 0.2 mM NADH and (B) 
0.05 mM charcoal-treated wt sPHGDH with 0.5 mM NADH. The upper panel shows the raw data for 1 
x 0.5 μL, followed by 17 x 2 μL injections of NADH into the 0.05 mM protein. Data was corrected for 
the heat of NADH dilution by subtracting NADH to buffer titration heats. Bottom panel: integrated heats 
of from the raw data peaks in the top panel plotted against the molar ratio of NADH to protein. Shown 
is the line of best-fit data as obtained by a one-site fit model using the ORIGIN software. (C) Values of 
generated by one-site fit model. (D) and (E) DSF profiles of sPHGDH and charcoal-treated sPHGDH 
alone (D) or in the presence of 1 mM NADH (E). 
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6.4.2 Design, expression and purification of site-directed mutants 
The cofactor-binding pocket is rather large, with NAD+ or NADH maintaining many 
interactions with the surrounding amino acids (Figure 6.7). Therefore two mutation 
strategies were pursued to abrogate cofactor binding; (i) mutation of amino acid 
residues directly involved in binding the cofactor through hydrogen bonds or 
hydrophobic interactions into residues that would not be able to maintain those 
interactions and (ii) mutation of small amino acids around the cofactor-binding pocket 
into the bulky amino acid tryptophan so as to potentially occupy part of the pocket 
(Table 6.3, Figure 6.8). The mutants were designed based on prior investigation of 
the likely conformation in COOT [107]. 
 
Figure 6.7 – Interactions of NAD
+
 with sPHGDH 
All interactions between NAD
+
 (grey shape) and sPHGDH are shown with the amino acids targeted for 
mutation highlighted with blue circles. In addition amino acids that are not involved in direct binding of 
NAD
+
, but were mutated in some of the site-directed mutants are depicted as well (red circles). Colour 
legend: black dashed lines – hydrogen bonds, salt bridges; green solid lines – hydrophobic 
interactions; green dashed lines – Pi-Pi, Pi-cation interactions. 
 
 
 
 
 
Pro175 
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Site-
directed 
mutant 
Category 
Mutated 
residues 
Mutated to Concept 
R154E A Arg154 Glu 
Mutation of key binding 
residue involved in H-
bonding 
T206W A Thr206 Trp 
Filling up adenine-binding 
subsite 
T212W A Thr212 Trp 
Filling up adenine-binding 
subsite 
P175A/T206
A/T212A 
A 
Pro175, 
Thr206, 
Thr212 
3 x Ala 
Mutation of key binding 
residue involved in H-
bonding and hydrophobic 
interactions (Pro175) 
D259N N Asp259 Asn 
Mutating key binding 
residue involved in H-
bonding 
R235A/H282
A 
N 
Arg235, 
His282 
2 x Ala 
Mutation of key binding 
residue involved in H-
bonding 
A285E N Ala285 Glu 
Mutation of key binding 
residue 
 
Table 6.3 - Summary of designed mutants. 
The mutants are divided into two categories depending on whether the adenine-binding subsite (A) or 
nicotinamide-binding subsite (N) was mutated. 
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Figure 6.8 - Illustration of adenine-subsite (A) and nicotinamide-subsite (B) mutants. 
Wild-type sPHGDH structures are shown on the left hand sides with key amino acids highlighted in orange. The right hand side pictures present models of the 
site-directed mutants assuming the side chains of mutated amino acids occupy the most likely conformation according to COOT [107] (mutated amino acids 
highlighted in green). 
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The mutants were generated by site-directed mutagenesis using specifically 
designed primers for each mutation. After transformation into competent E. coli DH5α 
cells, DNA was isolated and verified by sequencing. For large-scale expression, 
plasmid DNA was used to transform E. coli strain Rosetta (DE3). The general 
purification scheme for the mutants comprised an initial Ni-affinity chromatography 
step followed by cleavage of the His6-tag with TEV protease, size exclusion 
chromatography and finally anion exchange chromatography to increase the purity of 
the protein. As an example, purification of mutant A285E is illustrated in Figure 6.9. 
As the mutations introduce only minor changes, the purification of the various 
mutants was very similar to wt sPHGDH with yields of about 10 mg/L bacterial 
culture. Initial determination of the purity of the mutants by measuring the 
OD260/OD280 ratio indicated that all proteins showed a remarkably lower ratio of 0.6-
0.7, which is in the range of the purity seen for sPHGDH after charcoal treatment. 
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Figure 6.9 - Typical purification result for mutants of sPHGDH illustrated using mutant A285E. 
sPHGDH mutants were purified from E. coli Rosetta (DE3) cells. A representative purification is shown 
with the UV traces of the different purification steps (upper panel) together with the analysis of the 
obtained fractions (red numbers) by SDS-PAGE and subsequent staining with a Coomassie-based 
stain. (A) First purification step by immobilised metal affinity chromatography (IMAC) using a HisTrap 
Ni-Sepharose column. Protein was eluted with a linear gradient up to a maximum concentration of 250 
mM imidazole. There was a single peak in the UV trace comprising mainly the desired protein as 
determined by SDS-PAGE analysis. (B) Size exclusion chromatography of affinity-purified protein after 
TEV cleavage, using a Superdex
TM
 75 26/60 gel filtration column equilibrated in 25 mM HEPES, pH 
7.5, 100 mM NaCl and 0.5 mM TCEP. A major peak of the desired protein was obtained, which often 
contained some impurities of high molecular weight as found by SDS-PAGE. (C) Additional anion 
exchange purification step with the intention to improve protein purity; bound protein was eluted with a 
non-linear salt gradient. 
6.4.3 Site-directed mutants fold properly but have altered secondary structure 
To assess the proper folding of the engineered mutants they were investigated by 
differential scanning fluorimetry (DSF). All site-directed mutants exhibited the 
expected DSF profile for properly folded proteins with a gradually increasing content 
of unfolded protein as the temperature increased (Figure 6.10). However, there was 
some variation in the intrinsic fluorescence of the mutants, which ranged from 4 x 105 
to 1.3 x 106 FU, as well as in the maximum fluorescence observed reflecting the 
differences in amino acid composition and possible structural differences. 
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Figure 6.10 - DSF profiles of site-directed mutants. 
Mutants are mixed with the fluorescent dye Sypro Orange and excited at 470 nm. Fluorescence 
emission was measured at 570 nm. 
Compared to wt sPHGDH, the introduced mutations affected the protein stability to 
various degrees as shown by DSF when comparing the normalised datasets (Figure 
6.11). Three of the adenine-subsite mutants, namely T206W, T212W and the triple 
mutant P175A/T206A/T212A, had a significantly lower Tm than the wt sPHGDH, with 
P175A/T206A/T212A displaying the largest reduction in stability of 7.3 °C. This 
decrease in Tm could actually represent the absence of bound cofactor as well as 
missing intramolecular interactions within the protein. Point mutations around the 
nicotinamide-binding subsite had less influence on protein stability. Remarkably for 
mutant D259N an increase in Tm of 1.3 °C was detected.  
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Figure 6.11 - Comparison of DSF curves for wt and site-directed mutants of sPHGDH. 
Graphs showing the normalised fluorescence measurements of adenine-subsite mutants (A) and 
nicotinamide-subsite mutants (B) compared to wt sPHGDH under conditions of increasing 
temperature. The melting temperatures are calculated from three independent experiments with four 
replicates per experiment. 
In addition to measurement of thermal stability, an initial investigation of the mutant 
structures was performed using circular dichroism (CD). CD is a spectroscopic 
technique that measures the differences in absorption of left-handed and right-
handed circularly polarised light after the light has passed through a chiral molecule 
[176]. In the case of proteins the chromophoric groups are the backbone amide 
groups, which are oriented towards each other in a manner that depends on the 
position of the polypeptide backbone. As a consequence, the different structural 
elements seen in proteins, such as α-helixes or β-sheets, display distinct CD spectra 
(Figure 6.12). Although CD measurements cannot give structural information for 
specific residues within the protein, as may be obtained from X-ray crystallographic 
or NMR spectroscopic measurements, it allows for investigation of the secondary 
structure in aqueous buffer using a small amount of protein. As the structure of wild 
type sPHGDH was known, CD measurements were used as a reference to assess 
the effects of the point mutations on the protein’s overall secondary structures. 
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Figure 6.12 - Characteristic far UV CD spectra for different secondary structure elements. 
Typical spectra associated with α-helix (blue line), β-sheet (green line) and unordered protein (orange 
line) in the far UV region (165-250 nm) are depicted (adapted from [176]). 
Overall, the CD measurements show that all introduced mutations altered the 
secondary structure of the protein (Figure 6.13A and B). In order to quantify these 
changes, the data were further analysed using the DICHROWEB web server with the 
CONTINLL algorithm and reference set 7 [170-172]. The analysis showed that all 
mutants had an increase in unordered protein fraction of at least 26 % mainly at the 
expense of helicity (Figure 6.13). Most of the mutants also showed prominent 
reduction in the proportion of β-sheets and turns with only the nicotinamide-subsite 
mutant R235A/H282A and the adenine-subsite mutant P175A/T206A/T212A having 
a higher content of β-sheets. This decrease in secondary structure could result from 
the non-binding of the cofactor leading to a less ordered protein structure. 
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Figure 6.13 - Structural changes adopted from introduction of point mutations in sPHGDH as 
measured by circular dichroism. 
Graph of wavelength blotted against molar elipticity of 0.5 mg/mL adenine-subsite (A) or nicotinamide-
subsite mutant (B) in 20 mM NaH2PO4, pH 8 at 20 °C. (C) Per cent changes in secondary structure 
elements through introduction of mutations compared to wt sPHGDH. CD data analysis was 
performed using the CONTINLL algorithm (reference set 7) on dichroweb [170-172]. 
6.4.4 Evaluation of NADH binding by ITC, DSF and enzymatic activity 
In order to investigate whether the site-directed mutants had abrogated cofactor 
binding and if so to what extent, binding experiments were performed with NADH as 
ligand. As NADH was found to bind much more tightly to PHGDH or its truncated 
form, sPHGDH, than NAD+, NADH binding was easier to monitor in all of the 
biophysical experiments performed. Firstly, NADH binding was investigated by DSF 
by measuring the melting temperature (Tm) of the protein alone and in the presence 
of 1 mM NADH. According to the DSF data, all mutations reduced NADH binding, but 
to different extents (Figure 6.14). The adenine-subsite mutations 
P175A/T206A/T212A, T206W and T212W abrogated NADH binding completely 
whilst the mutant R154E retained some affinity for NADH, displaying a ΔTm of 0.8 ± 
0.4 °C. In contrast, the nicotinamide-subsite mutants all retained some ability to bind 
NADH with the strongest binding seen with mutant A285E with ΔTm of 3.3 ± 0.6 °C. 
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However, this was still a two-fold lower ΔTm value than was found with wt sPHGDH. 
Considering that the Tm value calculated for NADH binding to wt sPHGDH is an 
underestimate due to co-purification of the protein with cofactor, the abrogation of 
NADH binding seen with mutant A285E is significant. 
 
Figure 6.14 - NADH binding to wt and site-directed mutants of sPHGDH investigated by DSF. 
Thermal denaturation of (A) adenine- and (B) nicotinamide-subsite mutants as well as (C) wt sPHGDH 
was monitored in the presence and absence of 1 mM NADH.  
 170 
In order to collect more information on the nature of NADH binding, ITC experiments 
were performed by titrating 0.5 mM NADH into 0.05 mM site-directed mutant. ITC 
data confirmed the results of the DSF experiments with the adenine-subsite mutants 
T206W, T212W and P175A/T206A/T212A completely lacking affinity for NADH and 
reduced binding seen with the remaining mutants (Figure 6.15). Of the mutants still 
able to bind NADH, only A285E showed the expected binding stoichiometry (n) of 
about 1, whereas for the other mutants n was between 0.2 and 0.4. Against this 
background, the determined association constant (Ka) is only accurate for A285E, 
while for the other mutants an overestimate was calculated with the actual Ka being 
much weaker. However, even the mutant with the strongest remaining NADH affinity, 
A285E, had a 5-fold lower binding constant (KD) compared to charcoal-treated 
sPHGDH (Table 6.4). 
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Figure 6.15 - Measurement of NADH binding to PHGDH mutants by isothermal titration 
calorimetry. 
0.5 mM NADH was titrated into 0.05 mM protein in 25 mM HEPES, pH 7.5, 100 mM NaCl and 0.5 mM 
TCEP. Top panel: raw data for 1 x 0.5 µL, followed by 17 x 2 µL injections of 0.5 mM NADH into the 
isothermal cell containing 0.05 mM protein. Data were corrected for heat of NADH dilution by 
subtracting the heats from NADH to buffer titration. Bottom panel: integrated heats from the peaks in 
the top panel plotted against the molar ratio of NADH to protein. The line of best fit to the data was 
plotted as obtained by non-linear regression using a one-site fit model using the ORIGIN software.  
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R154E D259N R235A/H282A A285E 
charc. 
sPHGDH 
N (# of sites) 
0.41 ± 0.03 0.22 ± 0.02 0.34 ± 0.05 0.99 ± 0.01 0.83 ± 0.01 
K
a
 (M
-1
) 
1.00E6 ± 
1.57E4 
1.40E5 ± 
1.28E4 
7.90E4 ± 
1.50E4 
4.99E5 ± 
5.73E4 
4.40E6 ± 
9.50E5 
K
D 
(µM) 1.00 ± 0.02 7.12 ± 0.65 12.66 ± 2.40 2.00 ± 0.23 0.23 ± 0.05 
ΔH (kJ/mol) -45.6 ± 4.5 -67.4 ± 5.4 -68.3 ± 11.3 -38.7 ± 0.6 -66.2 ± 0.9 
ΔS (J/(mol x 
K) 
-0.21 -0.47 -0.49 -0.08 -0.35 
Table 6.4 - Thermodynamic parameters obtained from ITC experiments for binding of NADH to 
sPHGDH wt and mutants. 
Data was analysed using the one-site fit model in ORIGIN. Stoichiometry of the reaction (= number of 
binding sites, N), changes in entropy (ΔS) and enthalpy (ΔH) as well as the association constant (Ka) 
were determined. Binding constant (KD) was calculated by taking the reciprocal of the Ka. As no 
binding of NADH to mutants T206W, T212W and P175A/T206A/T212A was detected, no parameters 
could be calculated. 
Not all of the mutants lost cofactor binding completely, as determined by DSF and 
ITC. For those mutants that were still able to bind to cofactor it was not clear how the 
binding occurred. It is possible that whilst the mutations prevented binding to the 
mutated part of the pocket, the cofactor, in this case NADH, retained binding to the 
other end of the binding pocket. For example, the nicotinamide-subsite mutants might 
still allow the adenosine moiety of NADH to bind to its cognate pocket while 
preventing binding to the nicotinamide-binding region. Taking into account that the 
cofactor-binding site in sPHGDH is quite open to the solvent, such partial-binding 
seems feasible. However, if the binding of cofactor to the mutants occurred in a 
different orientation or was hindered, the catalytic activity of the proteins should be 
impaired. The mutants and wt sPHGDH were therefore tested in an enzyme activity 
assay measuring the oxidation of 3-phosphoglycerate and simultaneous reduction of 
NAD+. All mutants, irrespective of their ability to bind NADH, were inactive in the 
assay. This indicates that even in the cases in which NADH binding could still be 
measured, namely all nicotinamide-subsite mutants and the adenine-subsite mutant 
R154E, the binding must occur in such a way that the catalytic reaction can no longer 
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be performed or that the structure around the active site of the protein is less ordered 
and unable to form productive interactions with cofactor and substrate. In alignment 
with the design strategy of the mutations to inhibit binding at the different sub pockets 
(adenine- or nicotinamide-subsite) whilst maintaining integrity of the remaining 
pocket, the NADH-binding studies carried out so far could indicate that the measured 
NADH-binding is due to part of NADH still being able to bind to the unmutated 
subsites, e.g. the adenine moiety of NADH likely binds to the unmutated adenine-
subsite of nicotinamide-subsite mutant D259N. To prove this hypothesis the protein 
crystal structures of the mutants were investigated. 
 
Figure 6.16 - Site-directed mutants are unable to catalyse the oxidation of 3-phosphoglycerate. 
Site-directed mutants were run alongside wt sPHGDH in an enzymatic activity assay measuring 
protein activity based on NAD
+
 reduction. Each protein was run in duplicate in three independent 
experiments. 
6.4.5 Crystallisation 
In addition to the overall 2D structural characterisation of the mutants, thermal 
stability measurements and the demonstrated abrogation of NADH binding, the 
determination of the structure, e.g. through X-ray crystallography, will allow a detailed 
analysis of the effects of the mutations on the cofactor-binding site as well as the 
overall protein structure. 
All purified mutants were screened against several sparse matrix screens at 4 °C and 
20 °C with only R154E crystallising in some of the conditions tested. R154E 
crystallised in different morphologies, but mainly as plates similar to crystals obtained 
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from wt sPHGDH (Figure 6.17 A-C). The crystals were tested using synchrotron 
radiation and were found to give very smeary diffraction in one direction of the two 
test shots separated by a rotation of 90 °. This smeary diffraction pattern in one 
direction is indicative of multiple layers of plates growing on top of each other. The 
same behaviour had been seen with crystals from wt sPHGDH, and could not be 
improved upon optimisation of the growth conditions. In view of successful co-
crystallisation of wt sPHGDH in the presence of cofactor and substrate analogues 
(chapters 5 and 6), the co-crystallisation of R154E with nicotinamide mononucleotide 
(NMN) alone and in the presence of tartrate was attempted. NMN is a truncated 
version of NAD+, lacking the adenine moiety and one phosphate group. As R154E 
had been designed as an adenine-site mutant, NMN ought to still be able to bind to 
R154E. Although more cubic crystals of R154E were obtained under these 
conditions, the diffraction was still smeary and a structure was not obtained (Figure 
6.17 D-E). 
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Figure 6.17 - Crystallisation attempt of R154E. 
(A) and (B) Apo-crystals of R154E obtained in 0.1 M Bis-Tris propane pH 6.5, 0.2 M sodium nitrate, 20 
% (w/v) PEG 3350 (PACT screen) and 0.1 M Bis-Tris pH 5.5, 0.2 M ammonium sulfate, 25 % (w/v) 
PEG 3350 (JCSG+ screen) respectively. (C) Diffraction pattern of an apo-crystal of R154E using 
synchrotron radiation (D) Co-crystal of R154E with 5 mM nicotinamide mononucleotide (NMN) in 0.8 M 
succinic acid pH 7.0 (JCSG+ screen) (E) (i) Diffraction pattern of R154E co-crystallised with NMN 
using synchrotron radiation. (ii) Closer view of the diffraction pattern in the black rectangle of (i). 
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6.5 Discussion 
PHGDH as well as sPHGDH were found to co-purify with cofactor bound to the active 
site, which limits their utility in searching for potential PHGDH inhibitors targeting the 
cofactor/substrate-binding pockets. Therefore the focus of the experiments described 
in this chapter was to remove the cofactor from the protein and thus make the 
binding site accessible. Two strategies were pursued: (i) to remove the cofactor after 
protein purification through treatment with charcoal and (ii) to mutate the cofactor-
binding pocket and thus prevent binding in the first place. 
Treatment with activated charcoal was shown to remove cofactor from the protein, 
however this was accompanied by loss of protein, which was likely to be also 
absorbed onto the charcoal to a certain extent. According to the minimum 
OD260/OD280 ratio of 0.65 measured after charcoal treatment, completely pure protein 
(OD260/OD280 = 0.57) was never obtained. In addition, due to the nature of the 
experiment, batch-to-batch variability in the amount of cofactor that was removed 
from the protein added a further variability to subsequent experiments. ITC could 
have been used to determine the amount of free binding sites per charcoal-treated 
protein batch so as to take this into account for further experiments, but would have 
added a further time-consuming step to the purification process and would measured 
rather than solved the issue. In addition, although charcoal treatment of proteins is 
reported to successfully remove cofactors from proteins, the treatment was also 
shown to reduce the specific activity of the treated protein, raising the possibility that 
charcoal treatment might have led to partial inactivation of the protein [173]. 
Accordingly, a site-directed mutagenesis strategy was attempted, based on the idea 
that mutating the cofactor-binding site at one end would prevent binding of such large 
molecules as the cofactors, but at the same time retain a smaller pocket that would 
be targetable by low molecular weight inhibitors. Protein engineering approaches 
have been successfully used in the past in particular with kinases to modulate the 
ATP-binding site in order to bind a specific compound, such as an inhibitor or an 
analogue of ATP [168, 177].  In the case of protein kinase engineering, specific 
ligands and cofactors were designed in parallel that would only interact with the 
mutant protein. In contrast, the strategy presented herein was attempted in order to 
find mutants that would differ from wt protein in respect of cofactor binding, but at the 
same time allow identification of inhibitors that ultimately should target wt PHGDH. 
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The designed mutants were successful in reducing NADH binding, in some cases to 
zero. With no measurable enzymatic activity in any of the mutants, one could 
speculate that even in cases where cofactors were still able to bind, their binding 
mode must have changed so that the hydride-transfer reaction could no longer take 
place. As the hydride-transfer reaction likely requires very precise alignment of 
cofactor and substrate, even a small disturbance to the binding pocket may interfere 
with enzyme activity without completely preventing binding. The structural analysis of 
the site-directed mutants by DSF and CD suggested that the mutations had 
introduced changes in the 2D structure. In particular, a reduced α-helical content 
compared to wt sPHGDH was observed which could be indicative for changes of the 
cofactor binding region which is composed of the conserved Rossmann fold, an 
alternation of β-sheets and α-helices. Such a loss in ordered structure of the catalytic 
side on the protein could have abrogated enzymatic activity too. However, despite 
those structural alterations, binding studies by DSF and ITC showed that some of the 
mutants had retained the ability to bind NADH. This would suggest that some of the 
introduced mutations only induced minor changes around the binding site allowing it 
to still accommodate NADH albeit in a different orientation. Another possibility could 
be that only a fraction of the cofactor, such as the adenine or nicotinamide moiety, is 
able to bind to the respective unmutated binding subsite, placing the rest of the 
molecule outside the binding pocket. Given that the cofactor-binding site of the 
truncated sPHGDH is open to solvent, it would be possible to accommodate the 
cofactor in such a manner. However, the measured OD260/OD280 ratios of all mutants 
showed that co-purification of the mutants with cofactor was less of an issue as the 
cofactor was not present in the binding pocket irrespective of the measured affinity of 
the mutant for NADH and at least to the same extent as after treatment of sPHGDH 
with charcoal. Comparison of the different mutants against each other shows that 
replacement of an amino acid with tryptophan, which contains a bulky side chain, 
results in complete abrogation of cofactor binding, but also led to a large increase in 
structural disorder. Replacement of amino acids involved in hydrogen bonding 
resulted in a broader spectrum of reduced NADH binding and less impact on 
structural integrity, as might be expected for substitutions that selectively remove 
specific interactions with the ligand. 
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However, without precise knowledge of the mutants’ structures, it is not known how 
well the binding site is preserved. Crystallisation attempts so far have proven 
challenging as the only crystals obtained were with mutant R154E and these grew in 
layers of multiple plates, which precluded analysis. Crystallisation of sPHGDH had 
also previously been shown to result in the formation of layers of plates (Chapter 4). 
Introduction of the site-directed mutations increased the amount of unordered protein 
regions as monitored by CD and DSF and this will further interfere with crystallisation 
as well as enzymatic activity. According to the CD data, the portion of unordered 
structure was increased in all mutants by 26-50 % compared to wt sPHGDH, with 
triple mutant P175A/T206A/T212A retaining most structural order. However, in this 
case the amount of disordered structure is unlikely to predict the protein’s tendency 
to crystallise as no knowledge is gained on which regions of the protein are more or 
less disordered. For the crystallisation, time limitations prevented an investigation of 
additional optimisation strategies such as crystal seeding, testing further additives or 
optimisation of the protein buffer conditions. 
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Chapter 7. Fragment-based drug design 
7.1 Introduction 
In recent years, fragment-based drug design (FBDD) has emerged as a valuable 
technique for the discovery of new molecules that modulate biological functions. 
Pioneering work in the field has been done by Jencks, who provided the basic 
concept for FBDD. Jencks described the binding energy of a molecule-protein 
interaction as a function of the binding energies arising from the molecule dissected 
into its individual components or fragments [178]. Further studies on the inhibition of 
HMG-CoA reductase showed that inhibitors could also be seen as linked fragments 
binding to different sites of the enzyme’s binding pocket [179]. The essential task of 
FBDD lies in identifying these fragments and building on them to obtain high-affinity 
binders of the target of interest. In general, fragments are considered to comply with 
an adapted form of Lipinski’s rules, the so-called “rule of three”, which specifies a 
molecular weight of less than 300 Da, a calculated logP below three, and a maximum 
of three hydrogen bond donors and acceptors [180]. 
FBDD has certain advantages over the otherwise often-used high throughput 
screening (HTS) of large libraries of molecules. In FBDD a significantly lower number 
of compounds compared to HTS are screened while still sampling an equivalent or 
even larger chemical space. Even by constraining the molecular weight of ligands 
used in HTS to 300-500 Da, there are still 1060-10200 potential molecules to be 
screened whereas there are only 107 possible fragment-like molecules with up to 
eleven atoms of C, N, O and F that comply with the rule of three [180]. There is also 
no need to screen such large libraries as in HTS to obtain hits as, due to the lower 
complexity of the fragments, the likelihood of binding to the target is increased [181]. 
Another consequence of the small size of fragments is that for a fragment found to 
bind to the target, the proportion of atoms involved in target binding is larger than in 
the case of bigger molecules, therefore fragments can be considered as more 
efficient binders with high binding energy per unit molecular mass often referred to as 
high ligand efficiency (LE) [181]. The physicochemical properties of molecules to be 
developed into drugs are very important, and compounds with higher molecular 
weight and higher lipophilicity have been shown to be more likely to fail during clinical 
development than smaller and less lipophilic compounds [182]. Whereas fragments 
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with a molecular weight of below 300 Da are well within the margins of size for a 
drug-like molecule, HTS libraries are likely to include compounds that are not suitable 
for further development into drugs in terms of size and physicochemical properties. In 
addition, the small-sized fragments have more scope to include further optimisation 
of physicochemical properties into the potency improvement process. 
Development of potent inhibitors, or binders to the target, can be started once one (or 
more) fragment(s) binding to the target have been identified as a starting point. In 
principle, there are three approaches to increase binding affinity and specificity of 
fragments for the target: (1) Growing the fragment to increase target interaction 
through additional functionalities, (2) in the case where several fragments binding to 
different sites of the target pocket have been identified, increased potency can be 
achieved by linking the fragments, and (3) if chemically distinct fragments have been 
found their key functionalities can be combined in one molecule through “fragment 
merging” (Figure 7.1). 
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Figure 7.1 - Illustration of the basic strategies to increase fragment potency. 
(A) Example of fragment growing starting from 7-azaindole (IC50 > 200 µM) with low affinity and 
potency to finally give the highly potent and selective B-Raf kinase (VE600 mutant) inhibitor zelboraf 
(IC50 = 0.031 µM) [183]. (B) Linking of two fragments binding to the cofactor binding site of lactate 
dehydrogenase A. Fragment 1 (KD = 280 µM) binds to the nicotinamide/substrate-binding site whereas 
fragment 2 (KD = 770 µM) binds to the adenine-binding site of the cofactor/substrate binding pocket. 
The linked fragment has a 1000-fold increase in binding affinity (KD = 0.13 µM) over the individual 
fragments [140]. (C) Fragment merging strategy illustrated in the search of inhibitors for CYP121 by 
fragment 1 (KD = 1600 µM) and fragment 2 (KD = 400 µM) whose merging leads to the significantly 
more potent fragment (KD = 28 µM) [184]. 
Despite the advantages of FBDD, there are also challenges with this approach. Most 
difficulties arise from the fact that, due to the small size and low complexity of 
fragments, they are most likely to exhibit only weak affinity for the target. It can 
therefore be difficult to develop a suitable assay, so as to unambiguously detect hits 
and follow them up. Thus FBDD often relies at some point on knowing the structure 
of the target through e.g. X-ray crystallography or nuclear magnetic resonance 
(NMR). Evaluation of the fragment can then be performed in the context of this 
(A) Fragment growing 
(B) Fragment linking 
(C) Fragment merging 
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structural information (co-crystallisation, modelling). A proposed screening cascade 
for finding and evaluating fragments is shown in Figure 7.2. 
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Figure 7.2 - Schematic representation of a typical fragment screening cascade. 
Full-length protein or fragments thereof have to be produced in sufficient amounts for binding assays 
and crystallisation. A fragment library consisting of 300-1000 fragments that comply with the rule of 
three is screened directly by crystallography and/or using a biophysical method such as differential 
scanning fluorimetry. The primary screen has to be high-throughput and suitable for the detection of 
weak binders. In the case where crystallography is not used as the primary screen, hits from the 
primary assay are structurally characterised by soaking into protein crystals and/or co-crystallising with 
the target protein. In addition, hits are also confirmed using a second binding assay, which, in the case 
of isothermal titration calorimetry, also gives information on the thermodynamic and kinetic parameters 
of fragment binding. Structural and biophysical information gained on the fragment hits is used to 
guide medicinal chemistry to improve the potency and physicochemical properties of the initial hits. 
(Figure adapted from [185])  
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7.2 Aims and objectives 
Prompted by the difficulties in finding inhibitors based on a rational substrate- and 
cofactor-mimic approach as outlined in previous chapters (chapter 4 and 5), a more 
general approach to hit finding was taken by screening a fragment library. The 
following objectives were formulated: 
(1) Screening of fragment library against human PHGDH using a high throughput 
assay. 
(2) Optimisation of the crystallisation of human PHGDH to allow for co-crystallisation 
with fragments or fragment soaking into empty crystals. 
(3) Development of a secondary assay to validate the initial fragment hits. 
(4) Optimisation of fragment hits based on crystal structures. 
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7.3 Materials and Methods 
7.3.1 Differential scanning fluorimetry (DSF) 
The DSF assay was used for screening of the fragment library and was performed 
according to the procedure described in section 2.9. Briefly, 150 nL of 100 mM 
compound in 100 % DMSO were dispensed in duplicate into 384-well plates using 
the Echo® liquid handler (Labcyte, Sunnyvale, CA, USA). 150 nL of 100 mM NADH 
was dissolved in assay buffer (25 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 mM TCEP) 
and used as positive control. Reference wells contained 150 nL DMSO (reference for 
fragment containing wells) or 150 nL buffer only (reference for NADH containing 
wells). The final assay mixture contained 25 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 
mM TCEP, 10 x Sypro Orange (Thermo Fisher Scientific, Waltham, MA, USA), 3 % 
(v/v) DMSO, 15 µM full-length PHGDH and 1 mM compound in a final assay volume 
of 15 µL. Measurement and analysis of the heat denaturation curves was performed 
as described in section 2.9. 
7.3.2 Isothermal titration calorimetry (ITC) competition experiments 
For ITC competition experiments, sPHGDH was treated with charcoal as described in 
section 6.3.1 to remove as much co-purified cofactor as possible. To take into 
account batch-to-batch variability due to charcoal treatment, a reference titration of 
0.5 mM NADH into 0.5 mM sPHGDH was performed for each charcoal-treated 
sPHGDH aliquot on the day of the competition experiments. For the competition 
experiments, sPHGDH at a final concentration of 0.05 mM was mixed with 100 mM 
fragment in 100 % (v/v) DMSO to yield a final fragment concentration of 5 mM (5 % 
(v/v) DMSO). NADH dissolved in ITC assay buffer was also mixed with 100 mM 
fragment in 100 % (v/v) DMSO to yield a final ligand mixture of 0.5 mM NADH, 5 mM 
fragment and 5 % (v/v) DMSO. The NADH-fragment mixture was used as titrant, and 
the sPHGDH-fragment mix was placed in the sample cell. ITC experiments were then 
performed at 25 °C in 25 mM HEPES, pH 7.5, 100 mM NaCl, 0.5 mM TCEP using 
the injection pattern described in section 2.10 on a MicroCal iTC200 (GE Healthcare, 
Little Chalfont, UK). All thermodynamic parameters of the reaction were determined 
using the ORIGIN software, version 7.0. Ka and ΔH for the fragments were calculated 
using Equation 7.1 and Equation 7.5 with the respective error propagation (Equation 
7.2 and Equation 7.6) [186]. 
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𝐾𝑥 = (
𝐾1
𝐾𝑎𝑝𝑝
− 1) ×
1
𝐿𝑥,𝑡𝑜𝑡
 
Equation 7.1 – Calculation of Ka for fragment x (Kx) 
K1 =binding constant determined in direct ITC control experiment with high affinity ligand (NADH) (M
-1
) 
Kapp = binding constant calculated in the presence of fragment x in displacement ITC (M
-1
) 
Lx,tot = total ligand concentration of fragment x (M) 
∆𝐾𝑥 = |
𝑐
𝐾𝑎𝑝𝑝
| × ∆𝐾1 + |
−𝑐𝐾1
(𝐾𝑎𝑝𝑝)
2| × ∆𝐾𝑎𝑝𝑝 
Equation 7.2 – Error propagation for the calculation of Kx 
ΔK1 = error for K1, calculated by Origin software 
ΔKapp = error for Kapp, calculated by Origin software 
𝐾𝐷,𝑥 =
1
𝐾𝑥
= 𝐾𝑥
−1 
Equation 7.3 – Calculation of KD 
∆𝐾𝐷,𝑥 = |
𝜕𝐾𝐷,𝑥
𝜕𝐾𝑥
| × ∆𝐾𝑥 = |
−1
𝐾𝑥
2| × ∆𝐾𝑥 
Equation 7.4 – Error propagation for the calculation of KD 
𝛥𝐻𝑥 = (𝛥𝐻1 − 𝛥𝐻𝑎𝑝𝑝) × (1 +
1
𝐾𝑥 × 𝐿𝑥,𝑡𝑜𝑡
) 
Equation 7.5 – Calculation of ΔHx for the fragment x 
Kx = binding constant for fragment determined in displacement ITC (see Equation 7.1) (M
-1
) 
ΔH1 = change in enthalpy for high affinity ligand (NADH) as determined in direct ITC control 
experiment 
ΔHapp = change in enthalpy in the presence of fragment x in displacement ITC 
𝛥𝛥𝐻𝑥 = |1 +
1
𝐾𝑥 × 𝐿𝑥,𝑡𝑜𝑡
| × ∆𝛥𝐻1 + |−1 −
1
𝐾𝑥 × 𝐿𝑥,𝑡𝑜𝑡
| × 𝛥𝛥𝐻𝑎𝑝𝑝 + |
𝛥𝐻𝑎𝑝𝑝 − 𝛥𝐻1
𝐾𝑥
2 × 𝑐
| × 𝛥𝐾𝑥 
Equation 7.6 – Error propagation for the calculation of ΔHx for the fragment x 
ΔΔH1 = error in ΔH1, calculated by Origin software 
ΔΔHapp = error in ΔHapp, calculated by Origin software 
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7.3.3 Limited proteolysis 
Limited proteolysis uses proteases with defined cleavage sites to digest proteins into 
smaller, more stable fragments that are expected to have a higher probability of 
crystallising. Limited proteolysis can be performed in situ by using the protein-
protease mixture directly in crystal trials, or the digested fragments can be analysed, 
re-cloned and purified prior to crystallisation. 
For in situ proteolysis 54 mg/mL sPHGDH was mixed with protease in a molar ratio of 
1:100 or 1:1000 and incubated at rt for 10 minutes. The mixture was used in 
homemade crystallisation trials in a 1:1 and 1:2 protein:reservoir ratio using sodium 
citrate or MMT buffer over a range of pH in combination with different PEGs (400 – 
1000) as the reservoir. 
To determine if stable fragments were produced by proteolysis, 100 µg sPHGDH or 
PHGDH were mixed with different proteases at a molar ratio of 1:100 and 1:1000. 
Proteolysis was performed for one hour at RT or 37 °C before the reaction mixture 
was separated by SDS-PAGE. Characterisation of stable protein fragments was 
performed by LC-MS using the liquid protein and protease mixture prior to gel 
electrophoresis (Mass Spectrometry Facility, University of Leeds, Leeds, UK). 
7.3.4 Cloning of new PHGDH fragments 
Following on from the determination of new stable PHGDH fragments by limited 
proteolysis and subsequent LC-MS analysis, constructs corresponding to those 
fragments were obtained through removal of N- and C-terminal amino acids by 
deletion mutagenesis. 
Mutagenesis of sPHGDH (aa 3-314) was performed in two rounds of PCR with the 
first round generating the N-terminal and the second round the C-terminal truncation 
(Figure 7.4). For the generation of the N-terminal truncations the NcoI restriction site 
was kept in the reverse primer, whereas the forward primer contained the NcoI 
restriction site followed by an alanine and the bases corresponding to the desired N-
terminal amino acids of the new N-terminus (Table 7.1). The purified DNA obtained 
after the first round of PCR, followed by DpnI and NcoI digestion and ligation, was 
used for the second round of PCR. For removal of the C-terminal bases 5’-
phosphorylated primers were used. In this case, the reverse primers determined the 
C-terminal truncation of the sequence, whereas a common forward primer for all 
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three constructs was used containing a stop codon followed by the LIC cloning site of 
the pNIC-28-BsaI vector. By performing two rounds of PCR mutagenesis, the need 
for subcloning into empty pNIC-28-BsaI vector was avoided. The PHGDH fragments 
generated were constructs 93 (aa 93-298), 92-2 (aa 92-299) and 92-3 (aa 92-301) 
(Figure 7.3). 
1st round of PCR 
Final 
construct 
name 
Construct 
after PCR 
Template 
DNA 
Direction Primer Sequence (5’  3’) 
93 aa 93-314 sPHGDH Forward GCCTGAGCCCATGGCTTTGGTT
ATGAACACCCCC 
92-2 and 
92-3 
aa 92-314 sPHGDH Forward GCCTGAGCCCATGGCTATCTTG
GTTATGAACACCCCC 
93, 92-2 
and 92-3 
aa x-314 sPHGDH Reverse GAGCACTTTCCGCAGATTTGCC
ATGGATTGGAAGTA 
2nd round of PCR 
93, 92-2 
and 92-3 
- - Forward Phos-TGACAGTAAAGGTGGAT 
ACGGATCCG 
93 aa 93-298 aa 93-314 Reverse Phos-AATTTCCTCCCCACAGCG 
GCTCTGAGCCTCC 
92-2 aa 92-299 aa 92-314 Reverse Phos-AGCAATTTCCTCCCCACA 
GCGGCTCTGAGC  
92-3 aa 92-301 aa 92-314 Reverse Phos-CTGAACAGCAATTTCCT 
CCCCACAGCGGCTCTGAGCC 
 
Table 7.1 – Primers used for PCR mutagenesis to generate new PHGDH fragments 
Primers for 1
st
 round of PCR: NcoI restriction site is underlined with the codon for the starting alanine 
highlighted in blue, followed by the codon for the first amino acid of the new PHGDH fragments 
highlighted in yellow. 
Primers for 2
nd
 round of PCR: Stop codon highlighted in bold; codon for the respective final amino acid 
residue is highlighted in pink; Phos = phosphorylated residue. 
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Figure 7.3 – Amino acid sequences of sPHGDH and shorter fragments. 
Scheme representation of the amino acid sequence of PHGDH with the lid domain, hinge region and 
core domain underlined in orange, green and blue, respectively. The green square highlights the 
sequences of the shorter fragments 93, 92-2 and 92-3. Amino acids involved in substrate and cofactor 
binding, according to the crystal structure (PDB 2G76), are highlighted in red and magenta, 
respectively. 
The PCR reactions followed the method and thermal profile described in section 
6.3.2, except using sPHGDH DNA or DNA generated after the 1st round of PCR as 
template DNA. DpnI as well as DpnI and NcoI double digests were performed for 1 h 
at 37 °C, followed by ligation with T4 DNA ligase (New England Biolabs, Ipswich, MA, 
USA). Ligation was achieved using 17 μL of the PCR restriction digested PCR 
reaction, 2 μL ligation buffer and 1 μL T4 DNA ligase for 2 hours at RT. 
Transformation of E. coli DH5α, DNA purification and sequencing was performed as 
described in sections 2.3. 
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Figure 7.4 – Scheme of PCR-based mutagenesis method to generate PHGDH fragments. 
7.3.5 Expression and purification 
PHGDH fragments 93, 92-2 and 92-3 were transformed in to E. coli Rosetta (DE3) 
cells and clones selected on LB Agar containing 50 μg/mL kanamycin for 18 h at 37 
°C. Single colonies were picked and used to inoculate aliquots of 5 mL LB medium 
containing 50 μg/mL kanamycin. From these cultures, glycerol stocks (15 % (v/v) 
glycerol) were prepared and stored at - 80 °C. 
Glycerol stocks were taken to inoculate starter cultures for large-scale growth and 
expression of PHGDH fragments as described in sections 2.5.1. 
7.3.6 Crystallisation of PHGDH fragment 93 
Initial sitting drop vapour diffusion crystallisation trials were set up against 
commercially available sparse matrix screens as described in section 2.12 and stored 
at 4 or 20 °C. After first crystals were obtained, the growth conditions were optimised 
by screening different buffer systems in combination with different precipitant 
concentrations, and resulted in 0.1 M PCTP buffer, pH 7 and 23-28 % (w/v) PEG 
1500 as the best growth conditions at 20 °C. Deep-well blocks of the optimised 
condition were prepared using a Biomek (Beckman Coulter, Brea, CA, USA) and 
drops pipetted as described in section 2.12. 
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7.3.7 Soaking of compounds into crystals of 93 
For soaking experiments, compounds were dissolved at 80 mM in soaking buffer 
which was a mixture of the reservoir buffer (25 % PEG 1500, 0.1 M PCTB pH 7) and 
the gel filtration buffer used for the protein purification (25 mM HEPES, pH 7, 100 
mM NaCl, 0.5 mM TCEP) at a 3:2 ratio supplemented with 20 % (v/v) DMSO. 
Crystals were transferred into drops containing the dissolved compounds, and 
soaked at 20 °C for 24 hours. Crystals were harvested using CryoLoops (Hampton 
Research, Aliso Viejo, CA, USA) matched in size to the crystal and cryo-protected in 
soaking buffer containing 80 mM compound and supplemented with 15 % (w/v) 
PEG400 before being flash cooled in liquid nitrogen. 
Crystals were measured and data collected either at the Diamond Light Source 
(DLS) synchrotron or on an in-house Rigaku Micromax 007 (2005) fitted with an R-
Axis IV++ image plate detector. Data analysis was performed as described in section 
2.13 using a truncated model of sPHGDH for molecular replacement until a high-
resolution structure of 93 was obtained and could be used as a model for subsequent 
analysis. 
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7.4 Results 
7.4.1 Fragment screening using DSF 
The fragment library used within this study was kindly provided by CRT Cambridge 
and was a selection of compounds following the rule of three further selected on 
solution behaviour and suitability for NMR fragment screening. 
The fragment library was screened at 1 mM compound concentration against full-
length PHGDH in a DSF assay in two independent experiments. Hits were 
determined based on an average Z-score ≥ 1, which is equivalent to a change in Tm 
of PHGDH in the presence of compound of ≥ one standard deviation greater than the 
mean. For the Z-score calculation, the control wells were excluded. Using this cutoff, 
42 out of 661 compounds were classified as hits, which is equivalent to a hit rate of 
6.4 % (Figure 7.5A). The two independent screening runs performed correlated with 
a Pearson correlation coefficient of 0.36 (r2 = 0.13) (Figure 7.5B). 
 
Figure 7.5 – Results of fragment screening using DSF. 
(A) Thermal denaturation profiles of 10 µM PHGDH in the presence of 1 mM fragment (3 % (v/v) 
DMSO) were measured. Graph shows the mean of two independent experiments with two replicates 
per experiment. The average Z-score was calculated, and fragments with a Z-score ≥ 1 defined as hits 
(highlighted in blue). (B) Pearson correlation graph of the two independent DSF screens with the 
Pearson r = 0.36 and r
2
 = 0.13, p < 0.0001. 
From the 42 initial hits, 15 were commercially available and were purchased (Table 
7.2). All purchased fragments were re-evaluated in the DSF screen and interestingly 
only seven were able to increase the Tm of PHGDH at all, indicating that the DSF 
screens are prone to false positive results. 
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ID Name Structure Z scorea ΔTm
a 
(°C) 
ΔTm
b (°C) 
A 2-Ethyl-4-
methylimidazole  
1.0 ± 1.0 2.0 ± 2.1 -0.1 ± 0.2 
B 1-Methyl-3-
phenyl-1H-
pyrazol-5-amine 
 
1.0 ± 0.4 2.2 ± 0.8 -0.2 ± 0.2 
C 5-Fluoro-4-
hydroxy 
quinazoline 
 
1.0 ± 0.8 2.4 ± 1.1 0.2 ± 0.3 
D 3-Chloro-4-
fluorobenzamide 
 
1.0 ± 0.8 2.3 ± 1.0 -0.1 ± 0.2 
E 7-Methyl-1H-
indole 
 
1.1 ± 0.7 2.4 ± 1.2 0.2 ± 0.2 
F [3-(6-
methylpyrazin-2-
yl)oxyphenyl] 
methanol 
 
1.2 ± 0.9 1.8 ± 1.7 -0.3 ± 0.2 
G 6-Hydroxy-2,3-
dihydrobenzo[b] 
furan-3-one 
 
1.5 ± 0.4 1.7 ± 0.6 0.4 ± 0.4 
H 5-Amino-1-
methyl-1H-indole 
 
1.8 ± 1.4 2.0 ± 1.2 1.2 ± 0.4 
I 3-(1,3-oxazol-5-
yl)aniline 
 
1.0 ± 0.9 1.4 ± 0.6 -0.8 ± 0.3 
J 3-(6-
Methylpyrazin-2-
yl)oxyaniline  
1.1 ± 0.6 1.7 ± 0.7 -0.6 ± 0.6 
K 1-Benzylimidazole 
 
1.1 ± 0.2 1.3 ± 0.9 -0.6 ± 0.4 
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ID Name Structure Z scorea ΔTm
b (°C) ΔTm
c (°C) 
L 2,4.Dihydroxy 
pyridine 
 
1.4 ± 0.2 0.8 ± 0.1 0.3 ± 0.1 
M 5-Fluoro-2-
methylbenzoic 
acid 
 
1.1 ± 0.2 1.4 ± 0.5 0.4 ± 0.3 
N N-(3-chloro-4-
methoxyphenyl) 
acetamide  
1.2 ± 0.3 1.3 ± 0.2 -0.2 ± 0.4 
O 3-Hydroxy 
benzisoxazole 
 
1.4 ± 0.7 2.5 ± 0.7 0.2 ± 0.3 
 
Table 7.2 – Repurchased fragment hits from DSF screening. 
a
 = Average Z score of primary fragment screens by DSF; 
b 
= average ΔTm of primary fragment 
screens by DSF; 
c
 = average ΔTm of purchased fragments. Data represent average and standard 
deviation of two independent experiments with two intra-assay repeats. 
7.4.2 Validation of hits by ITC competition assay 
To validate the initial hits from the DSF screen, an orthogonal assay was needed, 
ideally with a non- fluorescent read-out to avoid repeating false positives that 
interfere with the fluorescence signal rather than binding to PHGDH. In this regard, 
isothermal titration calorimetry (ITC) is a valuable technique that measures the heat 
energy changes associated with a molecular interaction, and allows determination of 
the enthalpic and entropic contributions to the interaction as described in section 
2.10. Wiseman c-parameters in a range from 10 ≤ c ≤ 500 are thought to define a 
suitable range of binding constants that can be reliably determined by ITC [102]. For 
a one-site binding model, the binding constant is determined from the inflection point 
of the sigmoidal binding curve. As c approaches zero the shape of the binding curve 
approaches a horizontal line, thus complicating an error-free determination of the 
binding constant (Figure 7.6). 
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Figure 7.6 – Variations in the ITC titration curve in relation to the c-parameter. 
Figure adapted from [102]. 
In cases where the binding affinity of the ligand for the receptor is very low (i.e. the 
experiment has a low c value), and an ideal c value cannot be achieved through 
increasing receptor/ ligand concentrations due to limited receptor and/or ligand 
solubility, displacement experiments can provide a solution. In these experiments, a 
high affinity ligand must be available that binds to the same binding site as the ligand 
under investigation. As the high affinity ligand competes for the binding site, it will 
bind more slowly, hindered by the low affinity ligand, resulting in a different shape of 
the binding curve due to differences in the thermodynamic parameters of the 
reaction. ITC displacement experiments have been mainly used to deconvolute the 
contribution of individual fragments of a natural, high affinity ligand to receptor 
binding [186-188], but is finding increasing application in fragment-based drug design 
[189, 190]. 
PHGDH was shown to bind to NADH with very high affinity, with a KD of 0.22 μM as 
determined by direct ITC (section 6.4.1), so that NADH was a suitable high-affinity 
ligand for ITC competition experiments. For these experiments, human sPHGDH was 
used rather than full-length PHGDH as sPHGDH could be produced in higher yields, 
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and as ITC competition experiment would only allow the characterisation of ligands 
that compete for the cofactor-binding site, the regulatory domains of the protein were 
not required. As noted earlier (section 6.3.1), sPHGDH was found to co-purify with 
cofactor, so the protein was treated with charcoal to remove bound cofactor prior to 
the ITC experiments (see section 6.3.1 and 6.4.1). In order to be able to analyse the 
competition experiments, the binding thermodynamics of NADH to sPHGDH were 
characterised. Each set of experiments performed with a particular batch of charcoal-
treated protein was compared to an NADH titration into the same batch of sPHGDH 
to account for variability in the efficiency of cofactor removal through charcoal 
treatment. 
For the ITC competition experiment itself the NADH titration was repeated with the 
low-affinity ligand (e.g. fragment) added to sPHGDH in the calorimetric cell, as well 
as to the NADH, to avoid interference from any additional effects of ligand dilution. In 
order to validate the experimental set up, ADPR, which has a KD for PHGDH of 40 
μM as determined by direct ITC, was used at different concentrations in combination 
with 0.5 mM NADH (Figure 7.7). 
 
Figure 7.7 – ITC competition experiment with ADPR at different concentrations 
0.5 mM NAD
+
 mixed with different concentrations of ADPR (0-1 mM) was titrated into 0.05 mM 
PHGDH mixed with different concentration of ADPR (0-1 mM) in 25 mM HEPES, pH 7.5, 100 mM 
NaCl, 0.5 mM TCEP and 5 % (v/v) DMSO. Data were analysed by non-linear regression using the 
built-in one-site fit model of the ORIGIN software. Data showing the heat generated per mole of 
injected ligand against the molar ratio of receptor to ligand was plotted in GraphPad prism.  
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[ADPR] (mM) 0 0.01 0.05 0.1 1 
Ka1 (μM
-1) 3.74 ± 0.30 2.45 ± 0.29 2.38 ± 0.17 1.85 ± 0.13 0.68 ± 0.12 
Ka2 (μM
-1) - 0.05 ± 0.03 0.01 ± 0.004 0.01 ± 0.003 0.005 ± 0.001 
KD (mM) - 0.02 ± 0.01 0.09 ± 0.04 0.10 ± 0.03 0.22 ± 0.07 
ΔH1 (kJ/mol) -1.63E4     
ΔH2 (kJ/mol)  -4.84E6 -7.59E6 -1.20E7 -1.13E7 
Table 7.3 – ITC displacement experiment with ADPR 
The affinity constant Ka1 was determined from the one-site fit model of the ORIGIN software as an 
analysis of a direct titration and used to calculate the actual affinity constant of ADPR Ka2 in each 
competition titration experiment. The dissociation constant (KD) was obtained from the reciprocal of 
Ka2. ΔH1 refers to the chance in enthalpy measured in the titration experiment and ΔH2 was calculated 
therefrom. 
The ITC competition experiment with ADPR showed that the technique could be 
used to measure the binding of low-affinity fragments to sPHGDH, and the 
repurchased fragments A-O were thus evaluated in this assay (Table 7.4). 
Fragment 
ΔH 
(kJ/mol) 
ΔS 
(kJ/(mol x K) 
ΔG 
(kJ/mol) 
KD (mM) 
LE 
(kJ/(mol x #)) 
A No competition. 
B -467.2 -1.61 12.8 5.8 ± 2.0 0.23 
C 8.3 -0.01 10.8 12.8 ± 2.7 0.21 
D -5.4 -0.07 16.0 1.6 ± 0.2 0.35 
E -1593.9 -5.40 16.1 1.5 ± 0.2 0.38 
F 15.8 0.02 10.2 16.6 ± 10.4 0.15 
G -292.7 -1.02 12.7 5.9 ± 1.5 0.28 
H -102.0 -0.38 11.2 11.1 ± 5.0 0.24 
I -260.8 -0.91 11.6 9.3 ± 3.8 0.23 
J -11.5 -0.08 11.1 11.5 ± 8.4 0.18 
K -64.4 -0.25 11.0 11.8 ± 9.6 0.22 
L No competition. 
M -47.0 -0.19 9.0 26.2 ± 31.8 0.20 
N -1753.2 -5.93 14.5 2.8 ± 1.6 0.27 
O -382.6 -1.33 12.5 6.5 ± 4.7 0.30 
 
Table 7.4 – Assessment of fragment hits by ITC competition assay 
ITC displacement experiments were analysed using the one-site fit model in ORIGIN together with the 
calculation outlined in section 7.3.2. Changes in entropy (ΔS) and enthalpy (ΔH) as well as the binding 
constant (KD) were determined. LE was calculated as the coefficient of ΔG per number of non-
hydrogen atoms (= #). 
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7.4.3 Identification of a more optimal protein construct for X-ray 
crystallography by limited proteolysis 
For the evaluation of the fragment hits, it was highly desirable to investigate their 
binding mode using X-ray crystallography. Therefore a protein construct was needed 
that resulted in robust diffraction-quality crystals and could be used for co-
crystallisation or fragment soaking. The sPHGDH construct used for crystallisation 
thus far was not ideal in this context, because it often formed plate-like, multiple 
layered crystals that diffracted to a rather low resolution of 2.7 Å. In addition, 
sPHGDH co-purified with its natural cofactors, which were shown to be difficult to 
remove from the cofactor-binding pocket (see section 6.3.1) that, together with the 
substrate-binding site, forms the active site on the protein that was the intended 
target of potential inhibitors. 
In this context, limited proteolysis was used to identify suitable protein constructs for 
crystallisation experiments by mixing the protein with catalytic amounts of protease. 
Proteases have been shown to remove primarily solvent accessible and flexible or 
unstructured domains of proteins such as disordered termini and loops. Through 
removal of those unstructured regions, the loss of conformational entropy associated 
with crystallisation should be reduced, resulting in a more stable protein core that 
should crystallise more easily, as well as resulting in well-diffracting crystals [191, 
192]. In principle, there are two different ways to perform limited proteolysis, either in 
situ, which is the direct use of the protease-protein mixture in crystallisation trials or 
by construct-directed proteolysis which involves identification of the proteolytic 
fragment and subsequent re-cloning, expression and purification prior to its use in 
crystallisation trials (Figure 7.8). 
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Figure 7.8 - Schematic representation of two different limited proteolysis strategies 
(A) In situ proteolysis of protein consisting of core (green) and flexible (black) regions mixed with 
protease (yellow) directly in the crystallisation drop. (B) Construct-directed proteolysis whereupon the 
protein core obtained is characterised by LC-MS and N-terminal sequencing before being re-cloned 
and expressed for use in crystallisation trials (Picture adapted from [193]). 
In situ proteolysis was attempted using 100 µg sPHGDH combined with different 
proteases (trypsin, α-chymotrypsin, thermolysin and endoproteinase GluC) at a molar 
ratio of 1:100 and/or 1:1000. Samples were used in crystallisation screens, prepared 
with malate- or citrate-containing buffers over a range of pH and various PEGs (400 
– 10000). Screens in citrate-containing buffer yielded only plate shaped crystals as 
seen before with the parental sPHGDH construct (Figure 7.9 A). Trypsin-treated 
sPHGDH resulted in one small crystal in MMT buffer, pH 7, 25 % w/v PEG 1000 
(Figure 7.9 B). 
 
Figure 7.9 - Crystals obtained through in situ proteolysis. 
(A) Crystallisation conditions: 0.1 M sodium citrate, pH 5.6, 30 % w/v PEG 3350, 1:1000 molar ratio of 
Chymotrypsin:Protein. (B) Crystallisation conditions: 0.1 M MMT buffer, pH 7, 25 % w/v PEG 1000, 
Trypsin: Protein in a molar ratio of 1:100. (C) Crystallisation conditions: 0.1 M HEPES, pH 7.5, 0.02 M 
MgCl2 hexahydrate, 22 % (w/v) Poly(acrylic acid sodium salt) 5100, Chymotrypsin: Protein in a molar 
ratio of 1:1000. 
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Crystal trials using chymotrypsin and sPHGDH at a molar ratio of 1:1000 were 
expanded to include a set of commercial screens with a subset of screens also 
including fragment E at 5 mM to test the hypothesis that a ligand binding to the 
protein might exert a stabilising effect and thus facilitate protein crystallisation. 
Crystals were obtained from different crystallisation conditions in the presence and 
absence of fragment E (for example Figure 7.9 C). The two best crystals were 
harvested and measured at DLS synchrotron (Table 7.5). 
 
Table 7.5 – Data collection statistics for crystals resulting from in-situ proteolysis of sPHGDH 
with chymotrypsin. 
Data were collected from single crystals at 100 K on beamline I04, DLS. The data were processed, 
scaled and merged using xia2 (3daii-run), aimless, pointless and programs from the ccp4i2 suite. The 
statistics are presented as averages with values for the highest resolution shell in parentheses. (A) 
Crystallisation of sPHGDH with chymotrypsin at 1:1000 molar ratio, (B) crystallisation of charcoal-
treated sPHGDH with chymotrypsin at molar ratio 1:1000 with 5 mM Fragment E. 
Analysis of the crystals obtained from in situ proteolysis of sPHGDH with 
chymotrypsin showed that the crystals still comprised sPHGDH. Although the 
electron density for the lid domain was very weak, this had been observed in 
previous crystals of untreated sPHGDH (Figure 7.10). In addition, the crystals 
measured were still of the same symmetry (space group P 1 21 1) as sPHGDH 
crystals, which might not change for crystals of a proteolysed sPHGDH, but would 
have been a strong indicator that the crystals were not due to template sPHGDH. 
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Figure 7.10 – Crystal structure of sPHGDH after in-situ proteolysis with chymotrypsin. 
(A) Crystal structure of sPHGDH after chymotrypsin treatment with the different chains coloured in 
grey and blue and the cofactor NAD
+
 coloured by atom type with carbon atoms in yellow. (B) Close up 
view of the region in the black rectangle of (A) with electron density map (2Fo-Fc) shown in blue at a 
contour level of 0.40 electrons/Ā
3
. 
In parallel, construct-directed proteolysis was performed, whereupon sPHGDH or 
PHGDH was mixed with five different proteases separately (papain, endoproteinase 
Glu-C, thermolysin, trypsin and chymotrypsin) in 1:100 and 1:1000 molar ratios. The 
protein-protease mixtures were incubated at RT or 37 °C for one hour and analysed 
by SDS-PAGE (Figure 7.11). In general, proteolysis at RT showed evidence of partial 
cleavage. Treatment of sPHGDH with catalytic amounts of endoproteinase Glu-C or 
thermolysin at 37 °C yielded a new fragment at about 26 kDa (Figure 7.11 B, lanes 2 
and 3). Thermolysin also cleaved PHGDH at 37 °C into two fragments, one at 36 
kDa, which is expected to correspond to sPHGDH and one at 26 kDa (Figure 7.11 D, 
lane 3). 
 
(A) (B) 
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Figure 7.11 - Limited proteolysis of sPHGDH (A and B) and PHGDH (C and D) at RT (A and C) or 
37 °C (B and D). 
100 µg or 50 µg sPHGDH (A and B) or PHGDH (C and D) respectively was mixed with five different 
proteases at molar ratios of 1:100 and 1:1000. The digestion was performed for 1 h at RT (A and C) or 
37 °C (B and D) and analysed by SDS-PAGE. 
In order to identify the new fragment obtained through thermolysin treatment, a fresh 
sample of sPHGDH was mixed with thermolysin at 1:100 molar weight ratio and the 
reaction left to proceed at 37 °C for 1 hour. As the sample contained only trace 
amounts of thermolysin it was directly subjected to ESI-MS (Biomolecular Mass 
Spectrometry Facility, Leeds University) (Figure 7.12 D). Through mass spectrometry 
analysis under denaturing conditions, a major protein fragment of 22116.93 Da was 
identified together with two minor species of 22301.00 and 22528.31 Da (Figure 
7.12A and B). The mass of the fragments together with the known cleavage sites of 
thermolysin, which cleaves before bulky and aromatic residues such as Ile, Leu, Val, 
Ala, Met and Val, but not after acidic amino acids such as Asp or Glu, allowed the 
potential amino acid sequences of the new PHGDH fragments to be narrowed down 
to five potential fragments (Table 7.6) [194]. 
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Figure 7.12 - Identification of new PHGDH fragment 93. 
(A) Positive ESI-MS m/z spectrum of new fragment 93, (B) Molecular mass profile of m/z spectrum 
shown in (A), (C) Amino acid sequence of sPHGDH (with His6-tag) with potential thermolysin cleavage 
sites after the amino acids highlighted in red. (D) SDS-PAGE analysis of thermolysin treated His6-
sPHGDH sample used for mass spectrometry. 
ID Residues (aa #) Corresponding mass (Da) Deviation from measured mass 
93 93-298 22116.60 -0.33 
22 22-227 22118.66 1.73 
92-2 92-299 22300.83 -0.17 
94 94-301 22301.78 0.78 
92-3 92-301 22528.10 -0.21 
Table 7.6 – Potential PHGDH fragments concordant with mass spectrometry data and 
thermolysin cleavage sites. 
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7.4.4 Crystallisation of construct 93 
Cloning, expression and purification 
Of the five potential PHGDH fragments, three, namely 93, 92-2 and 92-3 were 
chosen for construct design and expression, each of them being closely associated 
with one of the masses detected. 
In order to keep the expressed sequence in the pNIC28-BsaI vector, two rounds of 
PCR-based mutagenesis were performed with the first round generating the N-
terminal truncation and the second round the C-terminal truncation as described in 
section 7.3.4. The first construct used for transformation into E. coli Rosetta (DE3) 
was fragment 93 as this corresponded to the major species detected by mass 
spectrometry. 
Fragment 93 was purified by Ni-affinity chromatography and the His6-tag cleaved with 
TEV protease. Although the cleaved protein was further purified by size exclusion 
chromatography, two bands were evident on SDS-PAGE analysis. Therefore an 
additional anion exchange purification step was performed and this yielded pure 
protein (Figure 7.13). The measured OD260/OD280 ratio of 0.71 for purified protein 93 
indicated that protein 93 co-purified with the cofactors NAD+/NADH, but to a lesser 
extent than sPHGDH, which had an OD260/OD280 ratio of 0.8-0.9. Charcoal treatment 
of purified 93 performed as described for sPHGDH decreased the OD260/OD280 ratio 
to 0.6, very close to the predicted ratio of 0.57 for pure protein. 
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Figure 7.13 - Purification of protein 93. 
Protein construct 93 was purified from E. coli Rosetta (DE3) cells. After cell lysis, 93 was purified by 
Ni-affinity chromatography (A and B), followed by size exclusion chromatography (Superdex 75 26/60) 
(C and D) and anion exchange chromatography (E and F). A representative purification is shown with 
the UV chromatograms of the respective purification steps together with the SDS-PAGE analysis of 
the eluted fractions. 
Crystallisation of 93 
Crystallisation of charcoal-treated fragment 93 alone or in combination with fragment 
E or 3-indole-DL-aspartic acid (compound 3, section 4.4.2) was attempted using 
sparse matrix screens at 4 °C or 20 °C. Crystals were obtained from a variety of 
conditions and at both temperatures. Of nine crystals tested, diffraction data could be 
collected from five crystals and therefore those conditions were taken forward for 
optimisation trials at 20 °C (Figure 7.14). From the optimisation process, condition 
consisting of 0.1 M PCTP buffer, pH 7.0, 22-26 % (w/v) PEG 1500, gave the most 
robust crystals to use for soaking experiments or to set up co-crystallisation 
experiments. 
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Figure 7.14 – Crystallisation of construct 93 
(A) Reservoir compositions giving rise to crystals of 93. (B) Crystal 93-3. 
In general, crystals of construct 93 diffracted to high resolution of 1.2 Å, and after 
crystal optimisation the crystal quality was improved further, so that for nearly every 
crystal tested a dataset could be collected. Crystals of 93 belonged to spacegroup 
P1, whereas sPHGDH was mostly found to crystallise in spacegroup P 1 21 1. 
Among the first crystals of construct 93 to be measured was a co-crystal with 5 mM 
NAD+ (crystal 93-10) for which data collection, processing, refinement and model 
validation statistics are shown as a representative example (Table 7.7). 
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(A) Data collection and phasing  (B) Refinement  
 
Wavelength (Å) 0.92 
  
Rwork/Rfree 0.18/0.21 
 Space Group P 1   Mean B-value (Å2)  
 a, b, c (Å) 43.4, 50.3, 53.2      All atoms 37 
 α, β, γ (°) 98, 113, 104      Protein 32 
 Resolution (Å) 39.0-1.35 (1.37-      Water 46 
  1.35)      NAD+ 32 
 I/σI 6.5 (1.1)   No of atoms  
 CC(1/2) 0.992 (0.517)      Protein 5884 
 Rmerge 0.06 (0.73)      Water 242 
 Completeness (%) 87.4 (86.3)      NAD+ 66 
 Multiplicity 2.0 (2.0)   Rmsd  
        Bond lengths (Å) 0.02 
        Angles (°) 1.88 
 
(C) Molprobity Parameters Value 
 
Clashscore, all atoms 5.76a 
 Poor rotamers 0.94 % 
 Ramachandran outliers 0.0 % 
 Ramachandran favoured 97.5 % 
 No of Cβ deviations (> 0.25 Å) 1.1 % 
 Molprobity Score 1.42b 
 Residues with bad bonds 0.20 % 
 Residues with bad angles 0.02 % 
 
Table 7.7 – Data collection, processing, refinement and model validation statistics for the co-
crystal structure of 93 with NAD
+
 (93-10). 
(A) Data collection statistics for 93-10, collected on a single crystal at 100 K on beamline I04-1, DLS. 
The data were processed, scaled and merged using xia2, aimless, pointless and programs from the 
CCP4i2 suite. Values for high resolution shell in parentheses. (B) Refinement statistics generated with 
Refmac5 as part of CCP4i2 suite. (C) Validation statistics generated by MolProbity web server. The 
clashscore
a
 was 84
th
 percentile and the MolProbity score
b
 was 87
th
 percentile for a structure of 1.35 ± 
0.25 Å. 
The co-crystal structure of 93 and NAD+ was used to compare the overall structure of 
93 to that of sPHGDH as well as the NAD+ binding site (Figure 7.15). Despite the 
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missing lid domain, construct 93 folded properly and overlaid well onto sPHGDH. The 
binding site for NAD+ remained unchanged in 93 with NAD+ making the same 
interactions with the protein as with sPHGDH, apart from new hydrogen bonds 
between Arg235 and one ribose. This new hydrogen bond was possible, as the side 
chain of Arg235 adopted a different conformation in crystal 93, probably because 
amino acids from the lid domain, which formed interactions with Arg235 in crystal 
sPHGDH, were missing in 93. 
 
Figure 7.15 – Comparison of cofactor binding sites in crystals of sPHGDH and 93. 
(A) Ribbon diagram of 93 (purple) superposed on sPHGDH (grey). The surface of 93 is shown and 
coloured by electrostatic potential and outlines the domain common to 93 and sPHGDH. (B) 2D image 
of cofactor binding site of 93 showing the interactions of NAD
+
 and 93. 
7.4.5 Soaking of fragments into crystals of 93 
Although construct 93 lacks the lid domain that covers the substrate-binding site in 
sPHGDH, the good quality diffraction of the 93 crystals was ideal for use in soaking 
experiments. In addition, the crystals tolerated up to 20 % (v/v) DMSO, which allowed 
complete dissolution of the majority of the fragments investigated. Furthermore, 
structures of apo-crystals confirmed that the cofactor-binding site was free of cofactor 
and therefore accessible for binding of potential ligands. 
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Figure 7.16 – Crystal structure of apoenzyme 93. 
(A) Apo-structure of 93 coloured as rainbow model with the C-terminus in red and the N-terminus in 
blue. (B) Focus on cofactor-binding site of 93 showing the hypothetical position of NAD
+
 in grey and 
the actually positioned water molecules in red. Position of cofactor was estimated through overlay of 
crystal 93 with NAD
+
 bound onto apo-structure. 
Purchased fragments A-O were dissolved at 80 mM in soaking buffer, which 
contained 20 % DMSO to increase solubility of fragments and potentially function as 
a cryo-protectant. As 20 % (v/v) DMSO was found to be an insufficient amount of 
cryo-protectant, 15 % PEG 400 was added to the soaking buffer. The fragments were 
then soaked individually into crystals for 24 hours at 20 °C. Under these conditions, 7 
out of the 15 fragments investigated were found in the respective crystals (Figure 
7.17). All of the fragments bound to the adenine-pocket of the cofactor-binding site. A 
subset formed specific hydrogen bonds with the protein, such as fragment N that 
formed a hydrogen bond with a backbone amine of amino acid residue Gly151 
(Figure 7.17). 
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Figure 7.17 – Fragments detected after soaking into crystals of construct 93 
Chemical structure and position in the adenine-binding site of 93 are shown. The protein surface 
around the binding site is coloured by electrostatic potential: red is negatively charged and blue is 
positively charged. Ligands are coloured by atom type with green = carbon, red = oxygen, blue = 
nitrogen and halogen = grey. The electron density maps (2Fo-Fc) is shown in green at a contour level 
of 0.5-0.75 electrons/Ā
3
. 
7.4.6 Fragment optimisation 
Of the fragments that could be soaked into crystals of 93, a subset was taken forward 
for optimisation. Commercial suppliers were sought for analogues of the hit 
fragments that would allow further exploration of the binding pocket. Additionally, 
some initial structure-activity relationship (SAR) studies were initiated around a 
number of scaffolds as described in the following sections. 
Benzamide series 
Among the purchased fragments for which binding was observed in crystals of 93, 
three fragments (fragments D, M, N) were substituted benzene rings. Overlay of 
these three fragments showed that the benzene ring of fragments N and M bound in 
the same part of the adenine-site, whereas fragment D bound more deeply into the 
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pocket and thus filling a small hydrophobic pocket that was not accessed by 
fragments M and N (Figure 7.18 A). Of the three fragments with a substituted 
benzene ring, 3-chloro-4-fluorobenzamide (fragment D) and N-(3-chloro-4-
methoxyphenyl)acetamide (fragment N) had similar binding affinities for sPHGDH 
according to ITC experiments. Fragment N was chosen for further investigation, as 
the 4-methoxy-group was oriented favorably for growth in an additional direction, 
compared to fragment D. Fragment N formed one halogen and one hydrogen bond, 
the first one through its chloro-substituent with the protein backbone (Gly151) and the 
latter one through the NH of the amide group with a water molecule present in the 
pocket (Figure 7.18 B). 
 
Figure 7.18 – Evaluation of the binding mode of N-(3-chloro-4-methoxyphenyl)acetamide 
(fragment N) 
(A) Overlay of fragments N (magenta), D (green) and M (cyan) in the adenine-binding site of 93. (B) 
Binding mode of fragment N to the cofactor-binding site with the fragment coloured by atom type. The 
protein backbone is shown in grey with the protein surface coloured by electrostatic potential. 
Hydrogen and halogen bonds are shown as dashed lines. 
Starting from fragment N, three compounds were initially investigated: the N-
methylated form of N-(3-chloro-4-methoxyphenyl)acetamide (27) to evaluate the 
importance of the hydrogen bond, and two compounds with larger alkyl ether 
functions (Et and iPr) in the 4-position of the benzenecarboxamide (28, 29) to start 
growing further out of the pocket (Table 7.8). N-methylation resulted in a three-fold 
decrease in KD and the extended alkyl ether functional groups further decreased 
affinity for sPHGDH. However, in order to fully understand the influence of the 
ethoxy- and isopropoxy-groups, the respective matched pairs, i.e. the 3-chloro 
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analogues of 28 and 29 and/or the des-chloro analogue of N would need to be made 
and tested. 
ID N 27 28 29 
Structure 
    
KD 
(sPHGDH) 
2.8 ± 0.7 8.3 ± 4.4 18.8 ± 14.2 21.1 ± 21.8 
LE 0.27 0.20 0.18 0.16 
Table 7.8 – Analogues of N-(3-chloro-4-methoxyphenyl)acetamide (fragment N) 
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Isoxazole series 
The initial fragment hit, 3-hydroxybenzisoxazole (fragment O), was found to orient in 
the adenine-binding pocket in such a way that fragment growth in two directions 
could be initiated by either growing along the cofactor-binding pocket (2) or out of the 
pocket (1) (Figure 7.19). In addition, the fragment formed two hydrogen bonds with 
side chains of Ser211 and Asp174, which ideally should be retained during fragment 
growing. A small hydrophobic pocket (3) adjacent to the fragment was not occupied 
and could be filled with a small group by substitution on the 5-position of the 
benzisoxazole so as to increase interactions with the protein (Figure 7.19). 
 
Figure 7.19 – Evaluation of binding mode of 3-hydroxybenzisoxazole (fragment O). 
The alpha trace of the protein is shown in grey ribbons with amino acids involved in hydrogen bonds 
and the bound fragment shown as sticks and coloured by atom type. The protein surface is coloured 
by electrostatic potentials and hydrogen bonds are indicated by dashed lines. 
From an analogue by catalogue search, the 6-chloro (O2) and 7-methyl (O1) 
substituted 3-hydroxybenzisoxazoles were chosen to probe fragment growth in the 
direction of vector (1) (Figure 7.19). Both fragments were investigated by competitive 
ITC with fragment O1 showing weaker and O2 improved binding affinities for 
sPHGDH compared to the unsubstituted 3-hydroxybenzisoxazole (Table 7.9). Crystal 
structures of the fragments showed that fragment analogue O1 overlaid in principle 
with the original fragment O. However, small shifts in the binding mode resulted in 
the formation of different hydrogen bonds with the protein. The hydroxyl-group of 
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fragment O1 formed a hydrogen bond with Thr206 whereas in the parental fragment 
O the same group formed a hydrogen bond with Ser211 (Figure 7.20 A and B). In 
contrast, fragment O2 bound in a different orientation so that the chloro group in the 
5-position filled into a small hydrophobic pocket instead of providing a vector to grow 
out of the pocket (Figure 7.20 C). 
 
Figure 7.20 – Binding of 3-hydroxybenzisoxazole and analogues with substituents at positions 
5 and 7. 
Binding of fragments O (cyan), O1 (yellow) and O2 (light green) to the adenine-binding pocket of 93. 
(A) Fragment O, (B) Fragment O, O1 and O2, (C) Fragment O and O1, (D) Fragment O and O2. The 
protein is shown as ribbon diagram in grey together with the protein surface coloured by electrostatic 
potential. The compound surfaces are coloured according to the respective fragment. Hydrogen bonds 
are shown as dashed lines. Red circles in pictures (C) and (D) highlight the position of the introduced 
side chains compared to parental fragment O. 
Investigation of the two analogues showed that the additional methyl-group in the 7-
position decreased binding affinity resulting in a lower ligand efficiency (LE) as well. 
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On the other hand the chloro-group in the 6-position increased binding affinity by 
filling the adjacent hydrophobic pocket, and thereby improved LE (Table 7.9). 
ID O O1 O2 
Structure 
 
 
 
KD (sPHGDH) [mM] 6.5 ± 4.7 15.9 ± 7.4 2.4 ± 0.7 
LE 0.30 0.22 0.33 
Table 7.9 – Binding affinity of 3-hydroxybenzisoxazole analogues O1 and O2 as determined by 
displacement ITC. 
The previously mentioned small lipophilic pocket (3) in Figure 7.19, which was not 
occupied by the original fragment O, was occupied by fragment O2 by virtue of 
binding to the adenine-site in a different orientation from the unsubstituted parental 
compound. In order to fill the hydrophobic pocket, whilst retaining the binding mode 
of fragment O, a substituent in the 5-position would be needed. Therefore 5-fluoro-3-
hydroxybenzisoxazole (O5) was investigated. Although the binding affinity decreased 
compared to 3-hydroxybenzisoxazole the crystal structure showed that the fluoro-
group was binding in the expected hydrophobic pocket (Figure 7.21). Following on 
from this result, the 5-bromo-3-hydroxybenzisoxazole (O6) was also investigated to 
see if a bigger functional group would be equally well tolerated in the hydrophobic 
pocket. Indeed, O6 bound in the expected orientation, although due to the increased 
size of the bromo-group the compound was shifted compared to O5 (Figure 7.21 B). 
Through this shift, the hydroxyl-group of fragment O6 was brought in proximity to 
Asp174 and the backbone of His205 so that two additional hydrogen bonds were 
formed (Figure 7.21 C). 
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Figure 7.21 – Binding mode of 5-fluoro/bromo-3-hydroxybenzisoxazole to adenine-binding 
pocket. 
Binding of fragments O (cyan), O5 (magenta) and O6 (green) to the adenine pocket of 93. (A) 
Fragment O, (B) Fragment O and O5, (C) Fragment O5 and O6. The protein is shown as ribbon 
diagram in grey together with the protein surface coloured by electrostatic potential. The compound 
surfaces are coloured according to the respective fragment. (D) Hydrogen bond formation of fragment 
O5 and O6 with PHGDH 93. The protein is shown as ribbon diagram together with the amino acids 
around the adenine pocket as sticks (grey) and fragment O5 and O6 are coloured by atom type with 
carbons in cyan and green, respectively. Hydrogen bonds are shown as dashed lines. 
ID O O5 O6 
Structure 
   
KD (sPHGDH) [mM] 6.5 ± 4.7 15.4 ± 10.2 Precipitated 
LE 0.30 0.22 - 
Table 7.10 - Binding affinity of 3-hydroxybenzisoxazole analogues O5 and O6 as determined by 
displacement ITC. 
 217 
To probe for growth in the direction of vector (2), as well as the importance of the 
hydrogen bond to Ser211, 3-alkylated hydroxybenzisoxazoles were synthesised. 3-
Methoxy- (25) and 3-ethoxyisoxazole (26) were synthesised by etherification using 
alkyl iodide with a moderate yield of 43 and 51 %, respectively. The synthesis also 
yielded the alkylated amines as side products, and these were tested as control 
compounds. The alkoxy-compounds showed reduced or no binding affinity for 
sPHGDH and none of the alkylated compounds were seen to bind in the crystal 
structure, indicating that hydrogen bond formation with Asp174 is indeed important 
for the benzisoxazole binding (Table 7.11). Interestingly, of the alkylated amines only 
the ethylated amine 26-sp was able to bind to sPHGDH. 
ID O 25 26 25-sp 26-sp 
Structure 
 
  
  
KD 
(sPHGDH) 
[mM] 
 No 
competition. 
Precipitated. No 
competition. 
10.6 ± 8.2 
Table 7.11 – Binding affinities of alkylated 3-hydroxybenzisoxazole fragments. 
As the hydrogen bond donor and acceptor attributes of the hydroxyl function were 
important for binding of fragments with the benzisoxazole core, 3-
aminobenzo[d]isoxazole was investigated. The amine provided a potential starting 
point for growth in the direction of vector (2) allowing retention of the H-bond to 
Asp174, while growing from this position (compound O4). 3-Aminobenzo[d]isoxazole 
was an equally potent ligand for sPHGDH as the hydroxyl analogue (fragment O), 
and both compounds bound in the same orientation to the adenine-binding pocket 
(Figure 7.22). 
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Figure 7.22 – Binding mode of 3-aminobenzo[d]isoxazole 
(A) Overlay of 3-amino (purple) (O4) and 3-hydroxybenzo[d]isoxazole (cyan) (O) bound to the 
adenine-pocket of 93. (B) ITC competition experiment and derived thermodynamic parameters. 
The 3-amine function allowed for further growth of the fragment using different 
peptide-coupling methods. Unfortunately none of the compounds in this small amide 
library produced KD values in the ITC competition experiment due to poor solubility 
and likewise compounds were not observed in the crystals after soaking for 24 hours 
(Table 7.12). 
 
ID 17 18 19 
R 
 
  
Yield (%) 20 24 76 
Table 7.12 – Small amide library of 3-aminobenzisoxazole. 
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Indole series 
Indole, which is structurally similar to 1,2-benzisoxazole was also among the 
scaffolds identified in the fragment hits. 5-Amino-1-methyl-1H-indole was purchased 
and found to be significantly more effective in stabilizing sPHGDH (ΔTm = 1.2 ± 0.4 
°C) compared to all the other purchased fragments, but could not be investigated by 
competitive ITC due to poor solubility. Investigation of the binding mode in the crystal 
showed that 5-amino-1-methyl-1H-indole did not form any specific polar binding 
interactions with the protein. It was however in proximity to Ser211 such that the OH-
group could be a potential hydrogen bond donor to target (Figure 7.23). Interestingly, 
the position of the indole-fragment in the adenine-binding site was rotated 180° 
compared to the 3-hydroxybenzisoxazole (Figure 7.23). 
 
Figure 7.23 - Evaluation of binding of 5-amino-1-methyl-1H-indole (fragment H) to 93. 
The protein backbone is shown in grey as a ribbon diagram with amino acids involved in hydrogen 
bonds shown as sticks and coloured by atom type with carbons in green. The protein surface is 
coloured by electrostatic potential. 
To probe the importance of the N-methylation, the unmethylated 5-amino-indole was 
investigated. The orientation of the des-methyl analogue H5 could not be clearly 
determined as the electron density for the fragment observed in crystals of 93 was 
too weak. 
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ID H H5 
Structure 
  
KD (mM) 11.1 ± 5.5 No competition. 
LE 0.24 - 
Table 7.13 – Binding affinities of methylated and non-methylated 5-aminoindole. 
3- and 5-substituted indoles were investigated in order to probe the two vectors to 
grow out of the adenine-binding site. 3-Hydroxyindole (H1) and indole-3-acetic acid 
(H2) showed an orientation flipped by 180° along a vertical axis compared to 
fragment H (Figure 7.24 A). In this orientation, both compounds are able to form 
hydrogen bonds with side chains of the protein. 
 
Figure 7.24 – Binding mode of fragments H1 and H2 to 93. 
(A) Binding of fragments H1 (gold) and H2 (blue) to the adenine-binding pocket of 93 (shown in grey, 
protein surface coloured by electrostatic potential). Hydrogen bond interactions of (B) fragment H1 and 
(C) H2 with the protein. Hydrogen bonds are shown as dashed lines. 
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ID H1 H2 H3 
Structure 
 
 
 
KD (mM) 5.1 ± 2.3 8.6 ± 5.8 Precipitated (ITC). 
LE 0.28 0.22 - 
Table 7.14 – Binding affinities of 3- and 5- substituted indoles. 
Fragment H3 could not be investigated by ITC due to precipitation in the buffer 
conditions used. Soaking of H3 into crystals of 93 revealed a binding mode flipped by 
180° around a horizontal axis when compared to fragment H (Figure 7.25 A). 
Together with the binding mode seen for H1 and H2, this indicates that the electron-
rich hydrogen bond donor and acceptor groups within these compounds 
preferentially bind towards the region of the NAD-binding pocket normally occupied 
by the ribose moiety (Figure 7.25 B). 
 
Figure 7.25 – Binding mode of 5-acetamide-1H-indole (H3) to 93. 
(A) Binding of fragment H3 (orange) and H (green) to the adenine-binding pocket of 93 (shown in grey, 
protein surface coloured by electrostatic potential). (B) NAD
+
 (coloured by atom type with carbons in 
green) bound to the cofactor-binding site of 93. Water molecules are shown as red spheres and H-
bonds as dashed black lines. 
Apart from growing the initial fragment H further out of the pocket, an attempt was 
made to grow the fragment towards Ser211 and to provide a functional group for 
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hydrogen bond formation with the side chain of Ser211. Initially, 4-vinyl-1H-indole 
(21) was synthesised and soaked into crystals of 93 to see if the vinyl-group would 
orient towards the targeted amino acid. In addition, the carbon-carbon double bond 
allowed for derivatisation, such as oxidation to yield the diol (23). 4-Vinyl-1H-indole 
bound in the crystal with the vinyl group pointing towards Ser211, whereas the 
saturated analogue (22), which was prepared as a control compound, bound in a 
different orientation. The vinyl group was 2.7 Å from Ser211 so that oxidation of the 
alkene would place the terminal hydroxyl group approximately 1.4 Å closer to Ser211 
and hydrogen bonding distance. Unfortunately, compound 23 could not be observed 
to bind upon soaking into crystals of 93. 
 
Figure 7.26 – Binding of compounds 21 and 22 to 93. 
Binding of compounds 21 (blue) and 22 (purple) to the adenine-binding pocket of 93 (shown in grey 
and blue). Distance to Ser211 is indicated with a red line. 
Similar to compound 23, it was hypothesised that an indole with a carboxamide 
function in the 4-position would be able to form a hydrogen bond with Ser211 and 
additionally allow for further growth (Figure 7.27). Compound 24 was synthesised 
containing an aromatic ring bound to the carboxamide nitrogen. Due to the solubility 
issues previously observed with compounds synthesised in the benzisoxazole series 
containing a benzene ring, a pyrazine was investigated. However, compound 24 was 
not observed to bind into crystals of 93, despite prolonged soaking times of up to 7 
days. 
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Figure 7.27 – Potential binding mode of compound 24 to PHGDH construct 93. 
Compound 24 was modelled into the binding site of 93 through overlay onto the parent fragment, H. 
The preferred torsion angles of compound 24 were validated in Mogul [195] through comparison to 
similar compounds in small-molecule crystal structures. 
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Other heterocyclic ring systems 
Among the commercially sourced fragment hits were two unfused heterocyclic 
systems consisting of a benzene ring linked to a five-membered unsaturated ring 
(pyrazole and oxazole). Both compounds were equipotent in the ITC competition 
experiment, and bound in the same orientation to 93 (Figure 7.28, Table 7.15). For 
compound B, an amide group provided one potential vector for growth out of the 
binding pocket. 
 
Figure 7.28 – Evaluation of binding of 3-(1,3-oxazol-5-yl)aniline (I) and 1-methyl-3-phenyl-1H-
pyrazol-5-amine (B) to 93. 
(A) Overlay of 3-(1,3-oxazol-5-yl)aniline (fragment I, green) and 1-methyl-3-phenyl-1H-pyrazol-5-amine 
(fragment B, purple) bound to the adenine-pocket of 93. (B) Overlay of fragment B (purple) and the 
methyl-substituent containing analogue B1 (blue) bound to the adenine-pocket of 93. 
ID I B B1 
Structure 
 
  
Kd (sPHGDH) 
[mM] 
9.3 ± 3.8 5.8 ± 2.0 104.1 
LE 0.23 0.21 0.10 
Table 7.15 – Unfused heterocyclic fragments I, B and B1 investigated by ITC.  
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7.5 Discussion 
After having pursued a targeted approach for finding inhibitors of PHGDH by 
investigating with compounds designed to interact with the cofactor and substrate-
binding sites, a more general approach was undertaken by screening a fragment 
library. There are several advantages of fragment screens over the traditional 
screening of large libraries, and these have been outlined in section 7.1. One major 
advantage is that due to the smaller size and less functionality of fragments resulting 
in a higher probability of binding to targets a smaller library is screened so that the 
approach is more amenable for academic institutions that do not possess large HTS 
libraries or have the adequate screening facilities. 
In this study, the fragment library was screened by DSF, which is an established 
screening technique for measuring binding of larger ligands, but has also been 
successfully used for fragment screening [196-198]. However, false positives and 
negatives appear commonly in DSF screens, so that a thorough hit validation with a 
different biophysical technique is necessary [199, 200]. For the determination of hits 
in the DSF a certain shift in Tm of between 0.5 and 1 °C is often used as a cut-off. In 
this screen, the z-score was used for hit evaluation, which takes into account a 
random error distribution within the plate, but also relies on means and standard 
deviations of all measurements which are influenced by outliers (potential false 
negatives and/or positives) [201]. In order to minimise the effect of outliers the 
fragment screen was performed twice, and the average z-score of both experiments 
used to validate hits. Comparison of the two screens gave a Pearson’s correlation 
coefficient of 0.36, which is a moderate correlation, but was expected given that the 
changes in Tm due to ligand binding are very small. Validation of the performed DSF 
screens by comparison of the changes in Tm observed in the presence of 1 mM 
NADH gave intra- as well as inter-assay variations which were very low with a 
coefficient of variation (CV) of 1-8 % and 5 %, respectively. However, NADH bound 
very tightly to PHGDH resulting in large Tm shifts, so that small deviations in the 
detected Tm have less influence on standard error and CV. 
Of the original fragment hits from the DSF screen only a limited number of fragments 
(15 out of 42 hits) was commercially available. These were re-tested in the DSF 
screen, and a positive Tm-shift was reproduced with half of the compounds. In order 
to further validate the initial hits, an orthogonal assay was sought, such as ITC in 
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competition mode. This technique does not rely on fluorescence like DSF, and still 
allows investigation protein-ligand interactions in solution. In addition, competitive 
ITC has been successfully used with low-affinity ligands [189, 190]. As expected, the 
calculated KD values for the fragments spanned a range of affinities from 1.5 mM to 
no measurable affinity. The calculated errors in KD were relatively large for most 
fragments, which reflects the fact that errors from two ITC titrations have to be taken 
into account; the control experiment and the displacement experiment. Nevertheless, 
ITC displacement experiments have been shown to determine KD values as reliable 
as those obtained by direct ITC under low-c conditions [202]. However, the nature of 
the ITC competition experiment allows only the detection of ligands binding to the 
cofactor-binding site, whereas the DSF screen was performed with full-length 
PHGDH, which may present other potential ligand-binding sites.  
With the small size of the fragments compared to the large cofactor-binding pocket, 
structural information on how the fragments bind to the protein was crucial to allow 
for optimisation of the hits. Although crystallisation of sPHGDH had been 
successfully performed within this project, the poor diffraction quality of sPHGDH 
crystals rendered them unsuitable for co-crystallisation or soaking of low-affinity 
fragments. Ideally crystals diffracting to high resolution were desired in order to 
facilitate detection of weakly bound ligands expected to be represented by weak 
difference electron density. As many crystallisation conditions for sPHGDH had been 
investigated without finding a suitable high resolution system, a different protein 
construct was more likely to yield better crystals than further attempts of optimisation 
of sPHGDH crystals. Limited proteolysis uses proteases to remove floppy regions of 
the protein to yield a more stable construct with increased likelihood of crystallising. 
This approach has been successfully used and has increased the success rate of 
crystallisation for proteins of different organisms [191, 192]. In this study, the in-situ 
proteolysis approach where protein and protease are mixed and subjected together 
to crystallisation, resulted in only a few crystals. Analysis of these crystals revealed 
that most likely the protein still contained all domains, although the electron density 
for the lid domain was very weak and difficult to interpret. In parallel, construct-
directed proteolysis was performed and led to the identification of a new PHGDH 
fragment of 20-25 kDa in size. Mass-spectrometric analysis of the fragment together 
with the potential cleavage-sites in the protein sequence for the protease used, 
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narrowed down the sequence of the new fragment called ‘93’. This was then 
successfully cloned, expressed and crystallised. Comparison of the crystal structure 
of 93 to that of sPHGDH showed that the lid domain, which covers the substrate-
binding site was completely removed, thus construct 93 would allow investigation 
only of ligands that bind to the cofactor-binding site, and similarly to the ITC 
competition experiment, allow only validation of ligands binding to the cofactor-
binding site. Although protein construct 93 provided a very good crystal system that 
could be used for soaking experiments, one had to bear in mind that only part of the 
actual enzyme was present and as the ligands were optimised, they would ideally 
also be investigated in the structure of sPHGDH or even full-length PHGDH. 
Comparison of 93 to sPHGDH and full-length M. tuberculosis PHGDH highlights the 
large proportion of the enzyme which is missing (Figure 7.29). 
 
Figure 7.29 – Comparison of PHGDH structures. 
(A) Full-length PHGDH from M. tuberculosis (PDB 1YGY) [60], (B) human sPHGDH (PDB 2G76) and 
(C) human PHGDH construct 93. Structures are shown as ribbon diagrams with the equivalent 
domains highlighted in the same colours in all three structures. If ligands were present in the crystal 
structure they are shown in spheres and coloured by atom type with carbons in green. 
Of the soaked fragments, all fragments seen in the crystal bound to the adenine-
binding site. As the removal of the lid domain in construct 93 mainly affects the 
nicotinamide binding site, which is no longer covered by the substrate binding site, 
but is open to solvent, it is not surprising to see enriched binding of ligands at the 
adenine-site which has not undergone structural changes. Therefore, the missing lid 
domain in the crystal could have biased the results of fragment soaking and once 
fragments have been improved to greater potency, they should be investigated in at 
least sPHGDH until crystal structures of the full-length protein became available. 
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The adenine-binding site is often very conserved among different enzymes that bind 
to adenine-containing cofactors such as ATP, CoA or NAD. General structural 
recognition features for adenine are a polar interaction, often with the backbone of 
the protein and a majority of non-specific hydrophobic interactions [203]. In this 
context, some of the fragments for which binding was observed in the crystal of 93, 
did not form specific hydrogen bonds with the protein. Therefore, increasing the 
specific protein contacts as well as exploring possibilities for fragment growth were 
the main aims of the initiated SAR studies. 
Three of the fragments soaked into 93 were substituted benzene rings, namely 3-
chloro-4-fluorobenzamide (fragment D), N-(3-chloro-4-methoxyphenyl)acetamide 
(fragment N) and 5-fluoro-2-methylbenzoic acid (fragment M). Interestingly, the 
benzene ring of fragment D did not overlay with the two others, showing that the 
adenine-binding pocket provided sufficient space for two-ring systems, such as the 
subsequently investigated benzisoxazoles and indoles. The SAR performed around 
fragment N revealed that (a) the hydrogen bond formed between the nitrogen of the 
amide function and a water molecule was not critical for binding and affinity of the 
fragment and (b) that the chloro-group in the 3-position was a key element for 
binding. The chloro-group bound into a small hydrophobic pocket of the adenine-
binding site that, throughout the SAR studies, was seen to be successfully filled with 
small halogen atoms, such as chloro and fluoro as seen with 6-substituted 3-
hydroxybenzisoxazoles. 
In this series, 6-bromo-3-hydroxybenzisoxazole was shown to shift away from the 
position of the 6-fluoro-substituted compound due to the larger bromo-group. The 
importance of targeting this small hydrophobic pocket was further emphasized when 
investigating 5-chloro-3-hydroxybenzisoxazole (fragment O2). Although initially 
thought of as a starting point for further fragment growth from the 5-position, 
fragment O2 was found to change its binding orientation in order to allow for the 
chloro-group to fill the hydrophobic pocket. SAR studies of 3-hydroxybenzisoxazole 
further showed that the initial hit could be substituted with 3-aminebenzisoxazole 
(O4) without losing binding affinity and whilst retaining the same binding mode. The 
3-aminobenzisoxazole provided a starting point to grow the fragment further into the 
cofactor-binding pocket through peptide coupling. Unfortunately, the designed 
amides lacked sufficient solubility to determine KD values. 
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Although structurally similar to benzisoxazole, 5-amino-1-methyl-1H-indole (fragment 
H) bound in a different orientation, which could be due to the methyl-group binding to 
the before mentioned small hydrophobic pocket. This was supported by the fact that 
the desmethyl analogue (H5) did not adopt a specific orientation in the adenine-
binding site. Larger indole fragments containing charged functional groups were 
shown to improve binding affinity (H1 and H2) through binding to the ribose-binding 
site of the cofactor-binding pocket, thus providing a suitable replacement for the 
ribose moiety. The indole-series was also grown towards Ser211, which could 
provide for an additional specific hydrogen bond. 4-Vinyl-1H-indole showed that the 
vinyl-linker reduced the distance to Ser211 to 2.7 Å, however, the final diol analogue, 
which was predicted to form a hydrogen bond to Ser211, was not shown to bind to 
93, but could be confirmed to bind to PHGDH in an ITC displacement experiment. 
7.6 Conclusion 
The fragment-based approach provided some initial low-affinity ligands of PHGDH. 
Fragment hits were identified by DSF and competitive ITC experiments and binding 
further validated using crystals of PHGDH protein construct 93. Construct 93 was 
successfully engineered using limited proteolysis and was a key element in the 
validation and SAR studies of the fragment hits. The SAR studies conducted so far 
provide some insight into critical structural elements for compounds targeting the 
adenine-binding site of PHGDH: (a) hydrogen bond formation with Thr206, Ser211 
and Asp174 has been seen with a subset of fragments, (b) filling the small 
hydrophobic pocket with a small halogen atom, such as fluorine or chlorine and (c) 
vectors for growth of fragments in two directions with growth towards the ribose-
binding site of the cofactor pocket facilitated with charged groups (Figure 7.30). 
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Figure 7.30 – Structural features of the adenine-binding pocket. 
Residues around the adenine-binding site to target for hydrogen bond formation are indicated with 
orange squares. The small hydrophobic pocket in the adenine-binding site is highlighted with an 
orange circle. The two potential routes to grow the initial fragments out of the pocket are shown with 
orange arrows. 
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Chapter 8. Discussion, conclusions and future directions 
The early discovery of aerobic glycolysis in cancer by Otto Warburg in the 1920s [11, 
204] had been neglected until recently due to the focus on other drivers in cancer [5]. 
The importance of potential diagnostic and treatment opportunities that lie in cancer 
metabolism was only rediscovered in the last few years [12]. Whereas detection of 
early stage cancers through genetic screening is limited due to the somatic 
provenance of many cancers, screening methods based on the detection of 
oncometabolites, which are metabolites detected at significantly lower levels in 
healthy volunteers, might provide a better screening opportunity [205, 206]. In 
addition, inhibitors of certain metabolic pathways that show increased activity in 
cancer cells provide a new treatment opportunity. In this context, increased activity of 
PHGDH, the first enzyme in the serine synthesis pathway, has been reported [69, 
72]. PHGDH oxidises 3-PG to PHP and thus diverts glycolytic flux into serine 
synthesis, which itself is implicated in the synthesis of various biomolecules. In a first 
evaluation of the relevance of PHGDH in breast cancer and melanoma, gene 
knockdown experiments showed that, in cancers expressing high levels of PHGDH, 
knockdown reduced cell growth in vitro [69, 72]. The translation of the reduction in 
cell growth in certain breast cancer cell lines following PHGDH knockdown into in 
vivo mice models was, however, ambiguous as two studies showed contradictory 
results [72, 115]. With the recognition of the increased importance of altered 
metabolism in cancers, together with initial, though controversial, reported target 
validation of PHGDH, the aim of this study was to investigate PHGDH as a potential 
target for cancer therapy by undertaking various steps of the drug discovery process, 
from target validation to screening and development of PHGDH inhibitors. 
The initial observation that PHGDH was overexpressed in colon carcinoma [35], 
breast cancer [72] and melanoma [207] cell lines, has since been extended to 
cervical cancer [116, 208], lung squamous cell carcinoma [209] and astrocytoma 
[77]. In order to investigate if other cancer types could also be potential candidates 
for treatment with PHGDH inhibitors, a panel of various cancer cell lines spanning 15 
different cancer types was investigated for their PHGDH expression levels. Apart 
from those cell lines reported to have PHGDH amplification and/or overexpression, a 
gastric cancer, a medulloblastoma and a choriocarcinoma cell line were among the 
cell lines with the highest PHGDH expression, indicating that PHGDH inhibitors could 
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be a treatment option in those cancer types as well (Figure 3.5). Surprisingly, a 
negative correlation of PHGDH protein expression with c-Myc expression was 
determined in contrast to reports of c-Myc positively regulating enzymes of the serine 
synthesis pathway [127]. However, visual inspection of the correlation graph did not 
convincingly confirm the calculated correlation coefficient. Therefore, increasing the 
panel of investigated cell lines would help to increase confidence in the correlation 
analysis. Similar correlation analysis of protein expression was also performed with 
PARP1, a major NAD+-consuming enzyme that has also been linked to proliferation 
[210]. PARP1 expression did not correlate with PHGDH expression. 
In order to further understand the effects of PHGDH knockdown in cancer cells, and 
to determine to what extent the target validation could be confirmed, siRNA-mediated 
knockdown experiments were performed in breast cancer and melanoma cell lines 
(Chapter 3). In agreement with the literature, PHGDH knockdown resulted in 
significantly reduced cell growth in the PHGDH-amplified breast cancer cell line 
MDA-MB-468 whereas no effect was seen with non-amplified MDA-MB-231 cells as 
determined by colony formation assays and live cell imaging (Figure 3.12, Figure 
3.13) [72, 115]. On the other hand, Hs578T breast cancer cells, which have been 
reported to overexpress PHGDH and thus be susceptible to PHGDH knockdown 
despite not containing a PHGDH-amplification, and the PHGDH-amplified melanoma 
cell line, SKMel28 were not affected by PHGDH knockdown in our hands. However, 
the data presented in the literature were generated with stable transduced shRNA-
containing cell lines, which allows for longer periods of protein knockdown compared 
to the transient siRNA-mediated knockdown and this could have been the reason for 
the different results obtained in those cell lines. shPHGDH-containing cell lines of the 
three breast cancer cell lines were therefore generated with two different on-target 
PHGDH shRNAs and one non-target control shRNA. Determination of efficiency of 
knockdown in the respective puromycin-selected populations showed that protein 
levels were only reduced to 50 % whereas siRNA-mediated knockdown resulted in 
70-80 % protein reduction. Perhaps as a consequence of the less efficient 
knockdown, no reduction in cell growth was seen in Hs578T or MDA-MB-468 cells. 
The knockdown experiments would seem to indicate that levels of PHGDH have to 
be reduced to at least 70-80 %, as seen after siRNA treatment, to generate an 
observable response in cells. 
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Target validation is generally performed with knockdown models. These models may 
not, however, predict the effect that an inhibitor might have, as is seen in the case of 
PARP inhibitors where inhibition, but not depletion of the enzyme blocks DNA repair. 
These considerations highlight the importance of using chemical probes in target 
validation [211-213]. Because there is no inhibitor of PHGDH described to date, this 
work focused on developing such a small molecule. Due to the structural homology 
of NAD+-binding pockets among different enzymes, the specificity of designed 
inhibitors was predicted to be provided through targeting the adjacent substrate-
binding pocket. Because the natural substrate of PHGDH, 3-PG, being an acid, 
which is charged under physiological conditions, its binding-pocket on PHGDH is 
naturally complementary in character to a polar ligand. Polar ligands are likely to be 
challenging to transport across the cell membrane and might require administration 
as a prodrug, e.g. an ester instead of an acid. Combination of functional groups so as 
to simultaneously target the substrate- and cofactor-binding pockets in a single 
molecule may however help to increase the specificity and improve the PK/PD 
properties of a potential inhibitor. Previous studies have shown the effectiveness of 
these so-called bi-substrate inhibitors in targeting substrate- and cofactor-binding 
pockets of dehydrogenases in the case of IDH and LDHA [97, 140]. Malate-
containing fragments were used as a starting point (Chapter 4), as the substrate-
analogue D-malate had been observed to bind to PHGDH in a crystal structure of the 
catalytic subunit of human PHGDH (sPHGDH) (PDB 2G76), while human PHGDH 
has also been shown to catalyse the reduction of oxaloacetate to malate [65]. 
Compounds were tested in an established FP assay using NADH as fluorophore. 
Displacement of NADH accompanied by a decrease in polarised light could be 
detected with increasing concentrations of ADPR, thus validating the assay (Figure 
4.6). Of the malate-containing compounds tested, a significant concentration-
dependent displacement of NADH was measured with 3-indole-DL-aspartic acid 
when assessed with full-length PHGDH or the catalytic subunit only (sPHGDH). In 
the chiral environment of the protein, the stereochemistry of a chiral ligand can be an 
important determinant of the response to inhibitor binding, and the synthesis of the 
enantiopure compounds was undertaken following literature procedures [145, 146]. 
With the synthesis route to enantiopure 3-indole-aspartic acid in place, the procedure 
was extended to different heterocyclic cores, namely benzisoxazole and 
benzothiophene. Although the respective nitrophenylesters were synthesised to 
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same (benzisoxazole) or better (benzothiophene) yields, the subsequent amide 
coupling was remarkably lower in yield compared to the 3-indole-aspartic acid 
synthesis. All compounds within this small library were able to displace NADH in the 
FP assay, however the original 3-indole-aspartic acids were the most potent 
compounds in this assay (Figure 4.8). The original hit compound 3-indole-DL-aspartic 
acid was also investigated in the enzyme activity assay, however, the compound 
interfered with the fluorescent read-out, so that no conclusion could be drawn on how 
hits from the FP assay would translate into inhibition of PHGDH activity. 
In contrast to the previous assumption that human PHGDH uses only 3-PG as a 
substrate [57], more recent literature data has shown that human PHGDH could also 
reduce α-ketoglutarate and oxaloacetate to 2-hydroxyglutarate and malate, 
respectively [65]. Therefore further substrate (3-PG) and product (PHP) analogues 
were assessed for their potential to stabilise the Tm by human PHGDH. These 
experiments confirmed 3-PG as the most stabilising ligand among the panel, being 
the only compound to increase the Tm of more than 1 °C. Interestingly, combination 
of 3-PG and NAD+ stabilised the protein to a greater extent than each compound 
alone. This effect was even more prominent with DL-malate, which did not stabilise 
the protein unless in combination with NAD+ (Figure 4.11). These data point towards 
a Bi-Bi ordered mechanism. In the case of DL-malate as a substrate, NAD+ bound 
first, which would be the order of binding as seen with E. coli PHGDH and the 
opposite order to that of M. tuberculosis PHGDH [57]. This synergistic binding was 
only seen with NAD+ and not with NADH. In addition to DSF-based binding studies, 
human sPHGDH was co-crystallised with some of the substrate and product 
analogues, yielding a crystal structure with L-tartrate bound to one chain of the 
dimeric sPHGDH. Comparison of the two chains in the crystal asymmetric unit 
revealed a lid domain movement upon L-tartrate binding that had not been previously 
described, although a similar movement is reported to occur in a variety of other 
dehydrogenases [214, 215]. 
Having explored the substrate-binding pocket of PHGDH, the next step was to focus 
on the cofactor-binding pocket, which provides a larger potential binding site for 
inhibitors (Chapter 5). Although selectively targeting the cofactor-binding pocket is 
expected to be challenging due to its structural conservation among different 
enzymes, NAD+-requiring enzymes have been targeted through this site. Firstly, the 
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nicotinamide binding region was investigated using ADPR, which is essentially NAD+ 
without the nicotinamide group. ADPR was found to be a moderate inhibitor of 
PHGDH in an established enzyme activity assay that, compared to activity assays 
described in the literature for PHGDH, was performed in the physiological direction of 
3-PG oxidation and NAD+ reduction (Figure 5.3). In addition, the binding affinity of 
ADPR was further analysed by direct ITC revealing a KD for ADPR of 40.0 ± 5.4 μM, 
and an exothermic binding event with little contribution from entropic effects (Figure 
5.4). Although ADPR was likely to bind to the cofactor-binding site, confirmation was 
sought through co-crystallisation of sPHGDH with ADPR. Interestingly, in the crystal 
obtained, modelling of ADPR into the active site could not completely satisfy the 
observed electron density, revealing partial occupancy of the binding site with the 
natural cofactors NAD+ and/or NADH (Figure 5.5). Charcoal-treatment was 
undertaken with sPHGDH and full-length PHGDH, leading to the removal of the co-
purified cofactor. No quantification method was available to investigate if all bound 
cofactor could be removed by charcoal treatment. However, direct ITC titration of 
NADH into full length PHGDH showed that NADH had very high affinity for the 
enzyme (KD = 0.22 ± 0.03 μM) and this was 2000-fold higher than for NAD
+ (KD = 444 
± 18 μM) (Figure 6.6). In addition, NAD+ analogues TAD, PAD and APAD were 
investigated for their potential to function as cofactors for human PHGDH. In the 
enzyme activity assay, APAD and PAD showed significantly higher Vmax than NAD
+ 
and TAD, as expected due to their higher redox potentials. However, the Km values 
showed that NAD+ was the preferred cofactor for this reaction, and this was further 
confirmed in DSF screens, where only NAD+ stabilised PHGDH with an increase in 
Tm of 1 °C (Figure 5.7, Figure 5.8). Interestingly, except for NAD
+ and DL-malate, 
PAD in combination with α-ketoglutarate was the only NAD+ analogue to exert a 
synergistic effect on binding with a substrate other than 3-PG. A co-crystal structure 
of sPHGDH with TAD was obtained and although there was clear electron density for 
bound cofactor, it is not possible to determine if this was TAD or one of the natural 
ligands due to the afore mentioned co-purification issues. After having looked into 
variations around the nicotinamide group, the importance of the phosphate linker was 
investigated through comparison of ATP, ADP and AMP binding by DSF. 
Stabilisation of PHGDH was increased with increasing numbers of phosphate groups 
with 0.2 mM ATP raising the Tm by 4.7 ± 0.9 °C, whereas AMP was about as 
effective as NAD+ with an increase in Tm of 0.6 ± 0.4 °C. Addition of ADP resulted in 
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a significantly higher increase in the Tm of PHGDH compared to NAD
+, but slightly 
lower than with ADPR, thus showing that in the absence of the substrate, 3-PG, the 
additional nicotinamide function has rather a negative impact on cofactor binding 
(Figure 5.10). Finally, we focused on variations around the adenine moiety and 
showed by comparison of NAD+ with nicotinamide hypoxanthine dinucleotide (NHD) 
by DSF that the presence of the amine-group at the 4-position of the purine, and 
hence its hydrogen bond with Ser211, were important for binding to PHGDH. 
However, the effect of the 4-NH2 group seemed no longer relevant when comparing 
NAD+ and GDP, suggesting that the additional 6-NH2 group of GDP might 
compensate for the missing NH2-group in the 4-position or that a shift in GDP binding 
mode could bring the 4-carbonyl function within hydrogen bond distance to Ser211. 
In addition, a small library of 1- and 4-substituted purines was investigated due to 
availability of these compounds within the NICR compound library. Of the six 
compounds investigated, two compounds, both containing a triisopropylsilyl group in 
the 4-position, showed similar potency to ADPR in the enzyme activity assay using 
full-length PHGDH, but did not inhibit sPHGDH activity in the same assay format 
(Figure 5.16). Kinetic analysis of their mechanism of action confirmed this result, with 
the inhibitors showing up as non-competitive with NAD. This suggested that these 
compounds were more likely to bind outside the nucleotide- and substrate-binding 
regions. These two compounds were not considered good starting points for inhibitor 
development and in the absence of a crystal structure of full-length PHGDH to aid 
determination of the binding mode and thus rationally design more optimal 
analogues, these compounds were not pursued. 
The search for potential PHGDH inhibitors made clear that a major obstacle to the 
identification and optimisation of potential inhibitors lay in the co-purification of 
sPHGDH, and to a lesser extent PHGDH, with cofactor, especially as crystallisation 
experiments could only be performed with sPHGDH. Previously, E. coli PHGDH had 
been reported to co-purify with NADH due to its high affinity (estimated KD ~50 nM) 
[216, 217]. In the case of E. coli PHGDH, removal of NADH was achieved by mixing 
with PHP, which resulted in the formation of the less-tightly binding cofactor NAD+, 
which could then be separated from the protein through column chromatography 
[216]. However, as PHP was no longer commercially available, another strategy had 
to be employed. Therefore, charcoal-treatment of purified protein was attempted as 
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charcoal adsorbs nucleotides. The only means to monitor the effect of charcoal-
treatment was through monitoring the OD260/OD280 ratio. Despite extensive charcoal-
treatment this could not be decreased below 0.65, which is still greater than the ratio 
reported for pure protein (0.57). Charcoal-treatment was also performed on purified 
full-length PHGDH, but did not alter the OD260/OD280 ratio. Purified full-length PHGDH 
had an OD260/OD280 ratio of 0.65-0.67, which indicates that PHGDH either does not 
co-purify with its cofactors or co-purifies to a lesser extent. This is an important 
difference as the previously described experiments with malate-containing 
compounds, and NAD+ analogues and truncates were performed on full-length 
PHGDH and thus are more likely to provide a true readout of direct binding rather 
than of competition with prebound cofactor. 
Although it was not clear from the OD260/OD280 ratio if all binding sites were free of 
cofactor after charcoal treatment of sPHGDH, NADH-binding investigated by ITC 
showed that the estimate of binding sites on the protein increased from 0.3 to 0.8 
after charcoal-treatment. Similarly, the Tm of the charcoal treated protein was lower 
than for the untreated sPHGDH. However, the charcoal-treatment had limitations, not 
only because the success of NADH removal could not be quantified accurately and, 
at least according to ITC experiments was not complete, but also a batch-to-batch 
variation in the outcome of charcoal-treatment was observed making a comparison of 
experiments run with different protein batches difficult. In addition, activated charcoal 
also adsorbed protein to a certain extent, thus negatively impacting on the yield of 
purified protein. In search of a different strategy for the generation of cofactor-free 
protein, site-directed mutants were developed that had point-mutations in amino 
acids that were either directly involved in cofactor binding through hydrogen bonds or 
hydrophobic interactions, or were in close proximity to the cofactor-binding pocket 
(chapter 6). Since attempts to crystallise full-length PHGDH within this study failed, 
mutations were performed on sPHGDH, to enable protein crystallisation studies. Four 
adenine- and three nicotinamide-site mutants of sPHGDH were designed, expressed 
and purified with all purified mutants displaying OD260/OD280 ratio in the range 0.6-
0.7, indicating that all mutants co-purified with cofactor to a lesser degree than 
sPHGDH. The mutants were subsequently analysed for proper folding by DSF and 
CD and both techniques confirmed proper folding. CD spectra also showed that the 
introduced mutations had affected the secondary structure, as the amount of 
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unordered structure had increased in all the mutants, putting the likelihood of 
successful crystallisation in question. This decrease in secondary structure could 
also result from non-binding of the cofactor, thus confirming the initial design 
hypothesis. Depending on the introduced mutation, the proteins showed weak to no 
affinity for NADH as measured by ITC and DSF, with the adenine-site mutants 
reducing the affinity more than the nicotinamide-site mutants (Figure 6.14, Figure 
6.15). These results indicate that the protein-cofactor interactions around the 
nicotinamide-binding site are less relevant for cofactor binding. These findings are in 
agreement with the results obtained when investigating the binding affinities of 
fragments of NAD+ (Chapter 5). Independently of NADH-binding detected by ITC and 
DSF, none of the mutants were able to catalyse 3-PG oxidation (Figure 6.16). 
Whether this means that the observed NADH binding does not reflect NAD+ binding 
or that the cofactor might not be aligned correctly for catalysis, remains to be 
elucidated. Crystal structures of the mutants would provide further insight into the 
effects of the mutations on the active site of the protein, thus allowing full validation of 
their utility as surrogates in hit-finding strategies. Although crystals were obtained 
with one mutant (R154E), the diffraction pattern measured was not good enough to 
permit structure solution. Further optimisation of the initial crystallisation conditions 
might result in better crystals in this regard. However, due to the increasing 
unordered content within the protein as determined by CD, the mutations would 
appear to have introduced structural changes unfavourable to crystallisation. 
After having probed the cofactor and substrate-binding sites with compounds 
specifically designed to target these sites, a more general approach to the 
identification of inhibitors was undertaken by performing a fragment screen, kindly 
provided by CRT Cambridge (chapter 7). Due to the small size of the fragments, a 
higher hit-rate than with larger compounds was anticipated. These compounds could 
then be further improved to eventually yield high affinity PHGDH inhibitors. Of the 
assays developed for PHGDH, the DSF assay was the most amendable format for 
high throughput screening, although this format is prone to false positive and 
negative results that interfere with the measured fluorescence [218]. The fragment 
library was screened twice and, as expected for this assay format, the correlation 
between the two runs was rather low, with a Pearson correlation coefficient of 0.36. 
In order to decrease the likelihood of obtaining false positive results, the Z-score was 
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used as a way of defining hits. Thus 42 hits were obtained (hit rate of 6.4 %) of which 
15 were purchased and re-assessed by DSF. Binding to PHGDH was confirmed for a 
subset of these compounds. Looking for a second, orthogonal assay to validate 
these hits, an ITC-competition experiment was established, where NADH was titrated 
into a mixture of sPHGDH and the fragment. Although the competitive ITC could be 
validated by using ADPR, the accuracy of calculating KD values from these 
experiments with lower affinity ligands is questionable. This is due to having to 
account for the errors in two titration experiments, one in the presence and one in the 
absence of fragment leading to very large errors in the calculated Ka, KD, ΔH and ΔS 
values for the fragment. This is particularly significant in the case of fragments with 
very weak binding affinity. Nevertheless, the ITC competition experiment was useful 
in validating and (to a lesser extent) ranking the hits, as well as for comparing the 
initial fragment hits with further optimised fragment analogues. Fragment-based drug 
discovery requires information on how the fragments bind to the protein to properly 
guide fragment optimisation. Although sPHGDH had been successfully crystallised, 
co-purification with cofactors together with low resolution and unreliable diffraction 
quality of sPHGDH crystals made this construct unsuitable for use with low-affinity 
ligands at medium to high throughput. Seeking for an alternative construct, sPHGDH 
and PHGDH were subjected to limited proteolysis, which has been shown to be a 
successful strategy for obtaining more stable constructs for crystallisation due to 
removal of flexible or unstructured regions by proteases [191, 192]. By this means, 
the PHGDH truncate 93 was identified and shown to form crystals that diffracted to 
high resolution (1.1-1.7 Å) and that could be used for soaking experiments. Of the 15 
purchased fragments, 7 were found to bind in crystals of truncate 93 after soaking for 
24 hours, and were taken forward for fragment optimisation. For other fragments, 
longer soaking times of up to 1 week were used without resulting in crystals 
containing the ligand. All compounds seen in crystals of truncate 93 after soaking 
were found in the adenine-binding site. As construct 93, compared to sPHGDH, is 
missing the lid domain that contains the substrate-binding site and closes onto the 
nicotinamide-binding area of the cofactor-binding pocket, it might be that the 
fragments not seen to bind in crystals of 93 were actually binders to the nicotinamide-
site. 
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Of the fragments seen in the adenine-binding site, four general features for 
optimisation could be derived: (1) there was a potential vector for growth out of the 
cofactor-binding site opposite to (2) a second vector that pointed in the direction of 
the ribose-binding site of the cofactor pocket, (3) the adenine-binding site contained a 
small hydrophobic pocket that could be filled with small halogens, such as chlorine or 
fluorine and (4) Ser211 was a potential hydrogen donor in close proximity to the 
adenine pocket that could be targeted to increase the number of specific interactions 
between the ligand and the protein. 
In general, attempts to grow initial hits in the direction of vector (1) did not result in 
increased potency, and in the case of modified 3-hydroxybenzisoxazole, adding 
groups to grow out of the adenine-pocket resulted in reorientation of the fragments to 
fill the adjacent small lipophilic pocket instead. This lipophilic pocket was successfully 
targeted with chlorine and fluorine and also shown to be too small to accommodate 
bromine. Targeting of Ser211 was attempted in the indole series through adding 
groups in the 4-position and, although the 4-vinyl indole placed the vinyl group in the 
direction of Ser211, the respective diol was not observed to bind in the crystal 
structure and thus it could not be confirmed if an additional H-bond to Ser211 had 
been formed. Growth in the direction of the ribose pocket was possible, as shown 
with indoles with polar linkers (acidic groups, amide group, hydroxyl group). In this 
context, the malate analogue, 3-indole-aspartic acid, that had been investigated as 
potential binder to the substrate-site/nicotinamide-subsite, could also be envisaged to 
bind to the adenine-subsite of the cofactor-binding pocket. 
8.1 Conclusion 
The work presented here on PHGDH as a target in cancer therapy spans the early 
part of the drug discovery process from initial target validation to screening for 
potential inhibitors, including structural investigations of the target and the beginning 
of early SAR studies around initial hits. 
PHGDH as a target was validated in PHGDH-amplified breast cancer cells, and 
analysis of a panel of cancer cell lines revealed high PHGDH protein expression in 
other cancers, which could be potentially targetable with PHGDH inhibitors. 
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Cofactor and substrate binding to PHGDH were shown to be synergistic and a crystal 
structure of sPHGDH with the substrate analogue, L-tartrate, bound to one chain of 
the crystallographic dimer revealed a distinct domain movement upon substrate 
binding. 
For the inhibitor search, a variety of biochemical and biophysical assays were 
developed for human PHGDH and a truncated construct of the protein was 
generated that was particularly useful for obtaining protein crystals that diffracted to 
high resolution. 
In addition, novel fragment binders to PHGDH were identified and crystals further 
optimised based on structural information from crystal soaking experiments. 
8.2 Future directions 
The investigations presented herein provide many opportunities for further extension: 
1) Strengthening the target validation through the use of in vivo models as well 
as investigation of PHGDH knockdown in cells under different conditions, such as 
serine starvation and/or hypoxia. The target validation could also be extended into 
other cancers apart from melanoma and breast cancer, as well as investigated in 
relation to genetic alterations, such as mutations in p53 or c-Myc [117, 127]. 
2) Truncate 93 provides the possibility for a crystal-based high throughput 
fragment screen to allow identification of alternative scaffolds. 
3) Extension of testing hit compounds in all assay formats available to date to 
investigate if the results correlate and allow to rank the hits in the same order. 
3) Extension of the SAR studies around the obtained fragment hits. After 
increasing the potency of these compounds, their activity could be investigated in the 
in vitro enzyme activity assay, and subsequently cell-based assays could be 
developed and used for inhibitor validation. 
4) Ultimately, crystallisation of full-length PHGDH would allow observation of the 
potential ligands in a more relevant context as well as screening for allosteric binding 
sites as alternative targetable sites.  
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Chapter 9. Experimental Part – Chemistry 
9.1 Summary of Generic Reactions, Analytical and Chromatographic 
Conditions 
9.1.1 Chemicals and Solvents 
All commercial reagents were purchased from Sigma-Aldrich Chemical Company, 
Alfa Aesar, Apollo Scientific or Tokyo Chemical Industry UK Ltd. The chemicals were 
of the highest available purity. Unless otherwise stated, chemicals were used as 
supplied without further purification. Anhydrous solvents were obtained from 
AcroSealTM or Aldrich SureSeal™ bottles and were stored under nitrogen. Petrol 
refers to the fraction with a boiling point between 40 and 60 °C. 
9.1.2 Chromatography 
Thin layer chromatography performed to monitor reaction progress was conducted 
on plates pre-coated with silica gel (Merck 60F254). The eluent was as stated (where 
this consisted of more than one solvent, the ratio is stated as volume:volume) and 
visualisation was either by short wave (254 nm) ultraviolet light, or by treatment with 
the visualisation reagent potassium permanganate (KMnO4) followed by heating. 
‘Flash’ medium pressure liquid chromatography (MPLC) was carried out either on a 
Biotage SP4 automated purification system or a Varian 971-FP automated 
purification system, using pre-packed Varian or Grace silica cartridges. 
9.1.3 Microwave Reactions 
All reactions carried out in a microwave were performed in a Biotage Initiator with 
Sixty robot. 
9.1.4 Analytical Techniques 
Melting points were determined using a VWR Stuart SMP40 apparatus and are 
uncorrected. 
1H and 13C nuclear magnetic resonance (NMR) spectra were obtained as either 
CDCl3 or MeOD solutions and recorded at 500 MHz and 125 MHz respectively, on a 
Bruker Avance III 500 spectrometer. Where 13C NMR data are not quoted, insufficient 
material was available or problems obtaining high-resolution spectra were 
encountered. Chemical shifts are quoted in parts per million (δ) referenced to the 
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appropriate deuterated solvent employed. Multiplicities are given as s (singlet), 
d (doublet), t (triplet), q (quartet), m (multiplet) or combinations thereof. Coupling 
constant values are given in Hz. Homonuclear and heteronuclear two-dimensional 
NMR experiments were used where appropriate to facilitate assignment of chemical 
shifts. 
LC-MS was carried out on a Waters Acquity UPLC system with PDA and ELSD 
employing positive or negative electrospray modes as appropriate to the individual 
compound. Where LRMS data is not quoted, the mass was not recognised for that 
compound. High-resolution mass spectrometry was performed by the EPSRC UK 
National Mass Spectrometry Facility, University of Wales Swansea, Singleton Park, 
Swansea, SA2 8PP. 
FTIR spectra were recorded on either a Bio-Rad FTS 3000MX diamond ATR or an 
Agilent Cary 630 FTIR as a neat sample. 
UV spectra were obtained using a U-2001 Hitachi Spectrophotometer with the 
sample dissolved in ethanol. 
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9.2 Synthesis of PHGDH inhibitors – Experimental procedures 
9.2.1 General procedures 
General procedure A: The carboxylic acid (1 mol eq.) was dissolved in acetonitrile 
(15 mL/mmol acid) before 3-amino-1,2-benzoisoxazole (2.5 mol eq.) was added, 
followed by addition of PCl3 (1 mol eq.). The reaction mixture was subjected to 
microwave irradiation at 150 °C for 5 to 25 minutes. The reaction was quenched with 
a few drops of water and the solvent removed in vacuo. The crude product was 
redissolved in EtOAc (60 mL/mmoL carboxylic acid) and washed with saturated 
NaHCO3 (60 mL/mmoL carboxylic acid) solution. The aqueous layer was extracted 
with EtOAc (3 x 30 mL/mmoL carboxylic acid). The organic extracts were combined 
and dried over MgSO4. The crude product was purified by MPLC, thereby recovering 
also the excess of 3-amino-1,2-benzisoxazole. 
General procedure B: To the appropriate alcohol (1 mol eq.) in acetonitrile 
(6 mL/mmol of alcohol) were added Cs2CO3 (3 mol eq.) and the desired alkyl iodide 
(3 mol eq.). The reaction was heated to 80 °C and stirred for 6 h. The reaction 
mixture was cooled to RT and any insoluble precipitant filtered off. The solvent was 
removed in vacuo and the crude product purified by MPLC. 
General procedure C [146]: The appropriate acetic acid (1 mol eq.) and 4-
nitrophenol (1 mol eq.) were dissolved in EtOAc (4 mL/mmol acetic acid) and the 
mixture cooled to 0 °C. DCC (1 mol eq.) dissolved in EtOAc (1 mL/mmol of DCC) 
was added dropwise to the reaction mixture and left to stir at 0 °C for 1 h. The 
reaction mixture was warmed to RT and stirred for a further hour. The precipitated 
dicyclohexylurea was filtered off and the filtrate concentrated in vacuo. The crude 
product was purified by recrystallisation. 
General procedure D [146]: The appropriate aspartic acid enantiomer (1 mol eq.) 
and tetramethylguanidine (2 mol eq.) were dissolved in MeOH (50 % (v/v) in water) 
(4 mL/mmol aspartic acid). Finely grounded appropriate p-nitrophenyl ester (1 mol 
eq.) was added and the reaction mixture stirred at RT for 48 h. The reaction was 
quenched by addition of water (20 mL/mmol aspartic acid) and extracted with Et2O (2 
x 30 mL). The aqueous fraction was acidified to pH 5 and extracted again with Et2O 
(3 x 30 mL). The aqueous layer was further acidified to pH 1 and extracted with n-
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butanol (1 x 40 mL, 1 x 10 mL). The butanol fractions were combined, washed with 
water (2 x 15 mL, 2 x 10 mL) and concentrated in vacuo. The crude product was 
purified by recrystallisation if necessary. 
9.2.2 Synthetic procedures 
4-Nitrophenyl 2-(1H-indol-3-yl)acetate, (8) 
 
Compound 8 was synthesised according to general procedure C using the following 
reagents: 3-indole acetic acid (5.80 g, 33.1 mmol), 4-nitrophenol (4.60 g, 33.1 mmol), 
N’N-dicyclohexylcarbodiimide (6.82 g, 33.1 mmol) and EtOAc (125 mL). The pure 
product was obtained by crystallisation at 4 °C. The solid was filtered off and dried to 
yield the title compound as a yellow solid (5.41 g, 55 %); Rf = 0.6 (petrol:EtOAc, 3:2); 
m.p. 104-105 °C; λmax(EtOH)/nm 272.4, 218.0; IR (neat) νmax/cm
-1 3398, 3322, 2927, 
2849, 2114, 1769, 1624, 1571; 1H NMR (500 MHz, CDCl3) δ 4.1 (2H, s, CH2), 7.21 
(1H, dd, J = 7.5 Hz, H-5), 7.24 (1H, s, H-2), 7.31-7.24 (3H, m, H-2’, H-2’’, H-6), 7.40 
(1H, d, J = 8.1 Hz, H-7), 7.71 (1H, d, J = 8.1 Hz, H-4), 8.25-8.20 (2H, m, H-3’ and H-
3’’); 13C NMR (125 MHz, CDCl3) δ 31.6 (CH2), 107.2 (C-2), 111.5 (C-7), 118.7 (C-4), 
120.1 (C-5), 122.5 (C-2’ and C-2’’), 122.6 (C-6), 123.5 (C-1), 125.3 (C-3’ and C-3’’), 
127.1 (C-3), 136.3 (C-8), 145.4 (C-4’), 155.7 (C-1’), 169.6 (CO); LRMS (ES+) m/z 
297.3 [M+H]+; HRMS (ESI) calcd for C16H13N2O4 [M+H]
+ 297.0870, found 297.0868. 
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(2-(1H-Indol-3-yl)acetyl)-D-aspartic acid, (9) 
 
Compound 9 was synthesised according to general procedure D using the following 
reagents: D-aspartic acid (333 mg, 2.5 mmol), tetramethylguanidine (627 μL, 
5.0 mmol), 4-nitrophenyl 2-(1H-indol-3-yl)acetate (8) (740 mg, 2.5 mmol) and aq. 
MeOH (50 % (v/v), 10 mL). Removal of n-butanol in vacuo yielded the title compound 
as a pale rose solid (692 mg, 95 %); Rf = 0.2 (DCM:MeOH, 2:1); m.p. 180-182 °C; 
λmax(EtOH)/nm 280.6, 219.8; IR (neat) νmax/cm
-1 3382, 3056, 2931, 2553, 2085, 1896, 
1716, 1618, 1523; 1H NMR (500 MHz, MeOD) δ 2.77 (2H, d, J = 5.7 Hz, CH2COOH), 
3.69 (2H, d, J = 1.3 Hz, CH2CONH), 4.73 (1H, t, J = 5.7 Hz, CHCOOH), 6.98 (1H, dd, 
J = 7.5 Hz, H-5), 7.06 (1H, dd, J = 7.5 Hz, H-6), 7.17 (1H, s, H-2), 7.31 (1H, d, J = 8.1 
Hz, H-7), 7.50 (1H, d, J = 8.1 Hz, H-4), 10.40 (2H, s, COOH); 13C NMR (125 MHz, 
MeOD) δ 33.7 (CH2CO), 36.8 (CH2COOH), 50.2 (CHCOOH), 109.0 (C-3), 112.2 (C-
7), 119.4 (C-5), 120.0 (C-4), 122.6 (C-6), 125.0 (C-2), 128.5 (C-9), 138.1 (C-8), 173.9 
(CO), 174.0 (CO), 174.6 (CO); LRMS (ES+) m/z 291.3 [M+H]+; Compound degraded 
before HRMS (ESI) analysis could be performed. 
(2-(1H-Indol-3-yl)acetyl)-L-aspartic acid, (10) 
 
Compound 10 was synthesised according to general procedure D using the following 
reagents: L-aspartic acid (333 mg, 2.5 mmol), tetramethylguanidine (627 μL, 
5.0 mmol), 4-nitrophenyl 2-(1H-indol-3-yl)acetate (8) (740 mg, 2.5 mmol) and aq. 
MeOH (50 % v/v) (10 mL). Removal of n-butanol in vacuo yielded the title compound 
as a pale rose solid (372 mg, 51 %); Rf = 0.2 (DCM:MeOH, 2:1); m.p. 180-182 °C; 
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λmax(EtOH)/nm 280.4, 219.6; IR (neat) νmax/cm
-1 3382, 3054, 2930, 2530, 2114, 1896, 
1715, 1616, 1523; 1H NMR (500 MHz, MeOD) δ 2.77 (2H, d, J = 5.7 Hz, CH2COOH), 
3.69 (2H, d, J = 1.3 Hz, CH2CONH), 4.73 (1H, t, J = 5.7 Hz, CHCOOH), 6.98 (1H, dd, 
J = 7.5 Hz, H-5), 7.06 (1H, dd, J = 7.5 Hz, H-6), 7.17 (1H, s, H-2), 7.31 (1H, d, J = 8.1 
Hz, H-7), 7.50 (1H, d, J = 8.1 Hz, H-4); 13C NMR (125 MHz, MeOD) δ 33.7 (CH2CO), 
36.8 (CH2COOH), 50.2 (CHCOOH), 109.0 (C-3), 112.2 (C-7), 119.4 (C-5), 120.0 (C-
4), 122.6 (C-6), 125.0 (C-2), 128.5 (C-9), 138.1 (C-8), 173.9 (CO), 174.0 (CO), 174.6 
(CO); LRMS (ES+) m/z 291.3 [M+H]+; Compound degraded before HRMS (ESI) 
analysis could be performed. 
4-Nitrophenyl 2-(benzo[d]isoxazol-3-yl)acetate, (11) 
 
Compound 11 was synthesised according to general procedure C using the following 
reagents: 2-(1,2-benzisoxazol-3-yl) acetic acid (1.00 g, 5.6 mmol), 4-nitrophenol 
(785 mg, 5.6 mmol), N’N-dicyclohexylcarbodiimide (1.17 g, 5.6 mmol) and EtOAc 
(25 mL). The product was purified by recrystallisation from petrol:EtOAc (1:1) to yield 
the title compound as an orange solid (766 mg, 46 %); Rf = 0.4 (petrol:EtOAc, 4:1); 
m.p. 97-98 °C; λmax(EtOH)/nm 275.8, 237.0; IR (neat) νmax/cm
-1 3117, 3076, 2921, 
2851, 2078, 1912, 1751, 1612, 1521; 1H NMR (500 MHz, CDCl3) δ 4.35 (2H, s, CH2), 
7.34-7.28 (2H, m, H-2’ and H-2’’), 7.38 (1H, ddd, J = 8.0, 1.3 Hz, H-5), 7.70-7.57 (2H, 
m, H-6 and H-7), 7.76 (1H, d, J = 8.0 Hz, H-4), 8.21-8.13 (2H, m, H-3’ ad H-3’’); 13C 
NMR (125 MHz, CDCl3) δ 32.0 (CH2), 110.4 (C-7), 121.4 (C-9), 122.4 (C-2’ and C-
2’’), 124.2 (C-4), 125.5 (C-3’ and C-3’’), 126.3 (C-5), 130.5 (C-6), 145.7 (C-4’), 145.8 
(C-3), 151.7 (C-1’), 155.0 (C-8), 166.1 (CO); LRMS (ES+) m/z 299.2 [M+H]+; 
Compound degraded before HRMS (ESI) analysis could be performed. 
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(2-(1H-Benzo[d]isoxazol-3-yl)acetyl)-D-aspartic acid, (12) 
 
Compound 12 was synthesised according to general procedure D using the following 
reagents: D-aspartic acid (150 mg, 1.1 mmol), tetramethylguanidine (283 μL, 2.2 
mmol), 4-nitrophenyl 2-(benzo[d]isoxazol-3-yl)acetate (11) (336 mg, 1.1 mmol) and 
aq. MeOH (50 % v/v) (10 mL). Removal of n-butanol in vacuo yielded the title 
compound as a white solid (34 mg, 11 %); Rf = 0.2 (DCM:MeOH, 2:1); m.p. 147-149 
°C; λmax(EtOH)/nm 281.8, 236.6; IR (neat) νmax/cm
-1 3264, 3083, 2927, 2598, 2114, 
1726, 1609, 1561; 1H NMR (500 MHz, MeOD) δ 2.84 (1H, dd, J = 6.9, 16.8 Hz, 
CHHCOOH), 2.90 (1H, dd, J = 5.5, 16.8 Hz, CHHCOOH), 4.03 (2H, s, CH2CONH), 
4.79 (1H, dd, J = 5.5, 6.9 Hz, CHCOOH), 7.38-7.32 (1H, m, H-5), 7.62-7.58 (2H, m, 
H-6 and H-7), 7.86 (1H, d, J = 8.0 Hz, H-4), 8.80 (1H, s, NH); 13C NMR (125 MHz, 
MeOD) δ 33.2 (CH2CONH), 36.8 (CH2COOH), 50.6 (CHCOOH), 110.5 (C-7), 122.6 
(C-9), 123.4 (C-4), 124.7 (C-5), 131.3 (C-6), 155.0 (C-3), 164.6 (C-8), 170.0 (CO), 
173.7 (CO), 173.8 (CO); LRMS (ES+) m/z 293.2 [M+H]+; HRMS (ESI) calcd for 
C13H13N2O6 [M+H]
+ 293.0768, found 293.0774. 
(2-(1H-Benzo[d]isoxazol-3-yl)acetyl)-L-aspartic acid, (13) 
 
Compound 13 was synthesised according to general procedure D using the following 
reagents: L-aspartic acid (150 mg, 1.1 mmol), tetramethylguanidine (283 μL, 2.2 
mmol), 4-nitrophenyl 2-(benzo[d]isoxazol-3-yl)acetate (11) (336 mg, 1.1 mmol) and 
aq. MeOH (50 % v/v) (10 mL). Removal of n-butanol in vacuo yielded the title 
compound as a white solid (25 mg, 8 %); Rf = (DCM:MeOH, 2:1) 0.2; m.p. 147-149 
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°C; λmax(EtOH)/nm 281.8, 236.8; IR (neat) νmax/cm
-1 3261, 3093, 2934, 2600, 2111, 
1726, 1609, 1561; 1H NMR (500 MHz, MeOD) δ 2.84 (1H, dd, J = 6.9, 16.8 Hz, 
CHHCOOH), 2.90 (1H, dd, J = 5.5, 16.8 Hz, CHHCOOH), 4.03 (2H, s, CH2CONH), 
4.79 (1H, dd, J = 5.5, 6.9 Hz, CHCOOH), 7.38-7.32 (1H, m, H-5), 7.62-7.58 (2H, m, 
H-6 and H-7), 7.86 (1H, d, J = 8.0 Hz, H-4), 8.80 (1H, s, NH); 13C NMR (125 MHz, 
MeOD) δ 33.2 (CH2CONH), 36.8 (CH2COOH), 50.6 (CHCOOH), 110.5 (C-7), 122.6 
(C-9), 123.4 (C-4), 124.7 (C-5), 131.3 (C-6), 155.0 (C-3), 164.6 (C-8), 170.0 (CO), 
173.7 (CO), 173.8 (CO); LRMS (ES+) m/z 293.2 [M+H]+; HRMS (ESI) calcd for 
C13H13N2O6 [M+H]
+ 293.0768, found 293.0768. 
4-Nitrophenyl 2-(benzo[b]thiophen-3-yl)acetate, (14) 
 
Compound 14 was synthesised according to general procedure C using the following 
reagents: benzo[b]thiophene-3-acetic acid (400 mg, 2.1 mmol), 4-nitrophenol (289 
mg, 2.1 mmol), N’N-dicyclohexylcarbodiimide (429 mg, 2.1 mmol) and EtOAc 
(10 mL). The product was purified by recrystallization from petrol:EtOAc (1:1) to yield 
the title compound as a yellow solid (599 mg, 91 %); Rf = 0.5 (petrol:EtOAc, 4:1); 
m.p. 99-101 °C; λmax(EtOH)/nm 298.4, 266.6, 226.2; IR (neat) νmax/cm
-1 3318, 2925, 
2848, 2118, 2081, 1758, 1615, 1571; 1H NMR (500 MHz, CDCl3) δ 4.16 (2H, s, CH2), 
7.25 (2H, d, J = 9.1 Hz, H-2’ and H-2’’), 7.39-7.47 (2H, m, H-5 and H-6), 7.49 (1H, s, 
H-2), 7.85 (1H, d, J = 7.7 Hz, H-4), 7.91 (1H, d, J = 7.7 Hz, H-7), 8.24 (1H, d, J = 9.1 
Hz, H-3’ and H-3’’); 13C NMR (125 MHz, CDCl3) δ 34.7 (CH2), 121.6 (C-2), 122.5 (C-
2’ and C-2’’), 123.2 (C-4), 124.6 (C-7), 124.9 (C-5), 125.4 (C-3’ and C-3’’), 125.6 (C-
6), 126.9 (C-3), 130.6 (C-9), 138.4 (C-8), 140.4 (C-4’), 155.4 (C-1’), 168.3 (CO); 
Compound degraded before HRMS (ESI) analysis could be performed. 
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(2-(1H-Benzo[b]thiophen-3-yl)acetyl)-D-aspartic acid, (15) 
 
Compound 15 was synthesised according to general procedure D using the following 
reagents: D-aspartic acid (106 mg, 0.8 mmol), tetramethylguanidine (200 μL, 1.6 
mmol), 4-nitrophenyl 2-(benzo[b]thiophen-3-yl)acetate (14) (250 mg, 0.8 mmol) and 
aq. MeOH (50 % v/v) (10 mL). Removal of n-butanol in vacuo yielded the title 
compound as a white solid (38 mg, 15 %); Rf = 0.25 (DCM:MeOH, 2:1); m.p. 156-158 
°C; λmax(EtOH)/nm 298.6, 290.0, 260.0; IR (neat) νmax/cm
-1 3318, 3156, 2920, 2087, 
1722, 1649, 1603, 1562; 1H NMR (500 MHz, MeOD) δ 2.81 (1H, dd, J = 7.0, 16.8 Hz, 
CHHCOOH), 2.87 (1H, dd, J = 5.3, 16.8 Hz, CHHCOOH), 3.84 (2H, s, CH2CONH), 
4.75 (1H, dd, J = 5.3, 7.0 Hz, CHCOOH), 7.36 (2H, m, H-5 and H-6), 7.46 (1H, s, H-
2), 7.81 (1H, d, J = 7.8 Hz, H-4), 7.86 (1H, d, J = 7.8 Hz, H-7); 13C NMR (125 MHz, 
MeOD) δ 35.8 (CH2CONH), 36.8 (CH2COOH), 48.6 (CHCOOH), 122.9 (C-4), 123.6 
(C-7), 125.2 (C-5 or C-6), 125.4 (C-5 or C-6), 125.5 (C-2), 130.8 (C-3), 140.1 (C-8 or 
C-9), 141.6 (C-8 or C-9), 172.8 (CO), 172.9 (CO), 173.9 (CO); LRMS (ES+) m/z 308.2 
[M+H]+; HRMS (ESI) calcd for C14H14NO5S [M+H]
+ 308.0587, found 308.0585. 
(2-(1H-Benzo[b]thiophen-3-yl)acetyl)-L-aspartic acid, (16) 
 
Compound 16 was synthesised according to general procedure D using the following 
reagents: D-aspartic acid (106 mg, 0.8 mmol), tetramethylguanidine (200 μL, 1.6 
mmol), 4-nitrophenyl 2-(benzo[b]thiophen-3-yl)acetate (14) (250 mg, 0.8 mmol) and 
aq. MeOH (50 % v/v) (10 mL). Removal of n-butanol in vacuo yielded the title 
compound as a white solid (32 mg, 13 %); Rf = 0.25 (DCM:MeOH, 2:1); m.p. 156-168 
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°C; λmax(EtOH)/nm 298.6, 289.8, 261.2; IR (neat) νmax/cm
-1 3318, 3156, 2920, 2087, 
1722, 1649, 1603, 1562; 1H NMR (500 MHz, MeOD) δ 2.81 (1H, dd, J = 7.0, 16.8 Hz, 
CHHCOOH), 2.87 (1H, dd, J = 5.3, 16.8 Hz, CHHCOOH), 3.84 (2H, s, CH2CONH), 
4.75 (1H, dd, J = 5.3, 7.0 Hz, CHCOOH), 7.36 (2H, m, H-5 and H-6), 7.46 (1H, s, H-
2), 7.81 (1H, d, J = 7.8 Hz, H-4), 7.86 (1H, d, J = 7.8 Hz, H-7); 13C NMR (125 MHz, 
MeOD) δ 35.8 (CH2CONH), 36.8 (CH2COOH), 48.6 (CHCOOH), 122.9 (C-4), 123.6 
(C-7), 125.2 (C-5 or C-6), 125.4 (C-5 or C-6), 125.5 (C-2), 130.8 (C-3), 140.1 (C-8 or 
C-9), 141.6 (C-8 or C-9), 172.8 (CO), 172.9 (CO), 173.9 (CO); LRMS (ES+) m/z 308.2 
[M+H]+; HRMS (ESI) calcd for C14H14NO5S [M+H]
+ 308.0587, found 308.0584. 
N-(Benzo[d]isoxazol-3-yl)-2-phenylacetamide, (17) [219] 
 
3-Amino-1,2-benzisoxazole (125 mg, 0.93 mmol) was dissolved in DCM (4 mL) 
before subsequent addition of NEt3 (130 µL, 0.93 mmol) followed by dropwise 
addition of phenylacetylchloride (123 µL, 0.93 mmol). After stirring the reaction at RT 
for 18 h, the solvent was removed in vacuo. The crude product was purified by MPLC 
(silica gel, petrol:EtOAc, 95:5), followed by recrystallisation from isopropanol to yield 
the title compound as a white solid (47 mg, 20 %); Rf = 0.5 (petrol:EtOAc, 95:5, UV); 
m.p. 143 °C; λmax (EtOH)/nm 283.8; IR (neat) νmax/cm
-1 3253, 3212, 3153, 3032, 
2343, 2116, 1998, 1804, 1712, 1621, 1569; 1H NMR (500 MHz, MeOD) δ 3.85 (2H, s, 
H-12), 7.37 – 7.25 (4H, m, H-5, H-15 and H-15’, H-16), 7.40 (2H, d, J = 7.5 Hz, H-14 
and H-14’), 7.56 (1H, d, J = 8.2 Hz, H-7), 7.61 (1H, td, J = 1.1, 6.8 Hz, H-6), 7.97 (1H, 
d, J = 8.2 Hz, H-7); 13C NMR (125 MHz, CDCl3) δ 43.7 (C-12), 110.8 (C-7), 117.5 (C-
9), 124.4 (C-5), 124.7 (C-4), 128.2 (C-16), 129.7 (C-15 and C-15’), 130.3 (C-14 and 
C-14’), 131.8 (C-6), 136.1 (C-3), 154.6 (C-8), 164.9 (CO); LRMS (ES+) m/z 253.2 
[M+H]+; HRMS (ESI) calcd for C15H13N2O2 [M+H]
+ 253.0972, found 253.0965.  
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N-(Benzo[d]isoxazol-3-yl)benzamide, (18), [220] 
 
N-(Benzo[d]isoxazol-3-yl)benzamide was synthesised according to general 
procedure A, using benzoic acid (45 mg, 0.37 mmol), 3-amino-1,2-benzoisoxazole 
(125 mg, 0.93 mmol), PCl3 (32 µL, 0.37 mmol) and acetonitrile (5 mL). The crude 
product was purified by MPLC (silica gel, petrol:EtOAc, 1:0  80:20) to yield the title 
compound as a white solid (21 mg, 24 %); Rf = 0.8 (petrol:EtOAc, 4:1); m.p. 126 °C; 
λmax(EtOH)/nm 285.0, 234.8; νmax/cm
-1 3207, 3149, 3058, 2922, 2731, 2372, 2343, 
2109, 1908, 1828, 1669, 1606, 1557; 1H NMR (500 MHz, MeOD) δ 7.37 (1H, ddd, J 
= 1.2, 6.5, 8.3 Hz, H-5), 7.54-7.68 (5H, m, H-6, H-7, H-13 and H-13’, H-14), 8.04 (3H, 
m, H-4, H-12 and H-12’);13C NMR (125 MHz, MeOD) δ 110.8 (C-7), 117.9 (C-9), 
124.4 (C-5), 125.2 (C-4), 129.3 (C-12 and C-12’), 129.8 (C-13 and C-13’), 131.7 (C-
6), 133.8 (C-14), 134.5 (C-11), 155.1 (C-3), 165.2 (C-8), 168.7 (CO); LRMS (ES+) 
m/z 239.2 [M+H]+; HRMS (ESI) calcd for C14H11N2O2 [M+H]
+ 239.0815, found 
239.0808. 
N-(Benzo[d]isoxazol-3-yl)cyclohexanecarboxamide, (19) 
 
Compound 19 was synthesised according to general procedure A. The reaction 
mixture contained cyclohexane carboxylic acid (48 mg, 0.37 mmol), 3-amino-1,2-
benzisoxazole (125 mg, 0.93 mmol) and PCl3 (32 µL, 0.372 mmol) in acetonitrile (5 
mL). The crude product was purified by MPLC (silica gel, petrol:EtOAc, 1:0  90:10) 
to yield the title compound as a white solid (69 mg, 76 %); Rf = 0.7 (petrol:EtOAc, 
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4:1); m.p. 143-145 °C; λmax(EtOH)/nm 283.6; IR (neat) νmax/cm
-1 3270, 2921, 2852, 
2119, 1662, 1608, 1542; 1H NMR (500 MHz, CDCl3) δ 1.35-1.24 (1H, m, H-14), 1.47-
1.35 (2H, m, H-13, H-13’, H-15 and H-15’), 1.66-1.55 (2H, m, H-12/H-12’ and H-16/H-
16’), 1.78-1.71 (1H, m, H-14’), 1.84-1.92 (2H, m, H-13/H-13’ and H-15/H-15’), 2.08-
2.01 (2H, m, H-12/H-12’ and H-16/H-16’), 2.58-2.44 (1H, m, H-11), 7.30 (1H, ddd, J = 
0.9, 7.0, 8.5 Hz, H-5), 7.50 (1H, dd, J = 0.9, 8.5 Hz, H-7), 7.56 (1H, ddd, J = 0.9, 7.0, 
8.5 Hz, H-6), 8.28 (1H, d, J = 7.0 Hz, H-4), 8.85 (1H, s, NH); 13C NMR (125 MHz, 
CDCl3) δ 25.7 (C-13/13’ and C-15/15’), 25.8 (C-14/14’), 29.6 (C-12/12’ and C-16/16’), 
45.7 (C-11), 109.9 (C-7), 116.0 (C-9), 123.4 (C-5), 126.2 (C-4), 126.3 (C-3) 130.8 (C-
6), 154.2 (C-8), 164.5 (CO); LRMS (ES+) m/z 245.2 [M+H]+; HRMS (ESI) calcd for 
C14H17N2O2 [M+H]
+ 245.1271, found 245.1276. 
4-Vinyl-1H-indole, (20) 
 
4-Bromo-1H-indole (500 mg, 2.55 mmol), caesium carbonate (2.49 g, 7.65 mmol), 
XPhos (61 mg, 0.128 mmol) and potassium vinyltrifluoroborate (376 mg, 2.81 mmol) 
were partly dissolved in dry DMF (10 mL). The PdCl2 catalyst was added and the 
solution degased for 20 minutes. Water was added to the reaction mixture and the 
reaction subjected to microwave irradiation at 120 °C for 15 min. The reaction 
mixture was filtered through Celite and washed with methanol. The solvent was 
removed in vacuo and the crude product purified by silica-based MPCL (PE: EtOAc = 
95:5) to yield the title compound as an orange oil (207.5 mg, 1.45 mmol, 57 %); Rf = 
0.5 (petrol:EtOAc, 3:2); λmax(EtOH)/nm 220.4, 302.2; IR (neat) νmax/cm
-1 3400, 2095, 
1894, 1829, 1703, 1601; 1H NMR (500 MHz, CDCl3) δ 5.42 (1H, dd, J = 2.1, 11.0 Hz, 
H-11cis), 5.95 (1H, dd, J = 2.1, 17.6 Hz, H-11trans), 6.78-6.81 (1H, m, H-3), 7.17 (1H, 
dd, J = 11.0, 17.6 Hz, H-10), 7.21 (1H, dd, J = 7.4, 8.0 Hz, H-6), 7.24 (1H, t, J = 2.8 
Hz, H-2), 7.30 (1H, d, J = 7.4 Hz, H-5), 7.32 (1H, d, J = 8.0 Hz, H-7), 8.15 (1H, s, 
NH); 13C NMR (125 MHz, CDCl3) δ 101.2 (C-3), 110.7 (C-7), 114.7 (C-11), 117.5 (C-
5), 122.2 (C-6), 124.5 (C-2), 126.1 (C-9), 130.2 (C-4), 135.5 (C-10), 136.3 (C-8); 
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LRMS (ES+) m/z 144.1 [M+H]+; Compound degraded before HRMS (ESI) analysis 
could be performed. 
4-Ethyl-1H-indole, (21) 
 
4-Vinyl-1H-indole (21) (75 mg, 0.52 mmol) in EtOAc:MeOH (5:1, 10 mL) was 
subjected to palladium-catalysed hydrogenation using a balloon filled with H2 and a 
10 % Pd/C catalyst. The reaction was conducted at RT for 4 h. The reaction mixture 
was filtered through Celite and the filtrate concentrated in vacuo. The crude product 
was purified by MPLC (silica gel, petrol:EtOAc, 1:0  95:5) to yield the title 
compound as a pale rose oil (39 mg, 52 %). Rf = 0.7 (petrol:EtOAc, 4:1); 
λmax(EtOH)/nm 270.0, 218.8; IR (neat) νmax/cm
-1 3400, 3051, 2963, 2929, 2869, 2116, 
1890, 1717, 1582, 1500; 1H NMR (500 MHz, CDCl3) δ 1.37 (3H, t, J = 7.6 Hz, H-11), 
2.96 (2H, q, J = 7.6 Hz, H-10), 6.60-6.63 (1H, m, H-3), 6.97 (1H, d, J = 7.4 Hz, H-5), 
7.16 (1H, dd, J = 7.4, 8.2 Hz, H-6), 7.20 (1H, dd, J = 2.8, 3.2 Hz, H-2), 7.26 (1H, d, J 
= 8.2 Hz, H-7), 8.13 (1H, s, NH); 13C NMR (125 MHz, CDCl3) δ 14.9 (C-11), 26.5 (C-
10), 101.1 (C-3), 108.9 (C-7), 118.3 (C-5), 122.4 (C-6), 123.6 (C-2), 127.1 (C-9), 
135.8 (C-8), 136.7 (C-4); LRMS (ES+) m/z 146.2 [M+H]+; Compound degraded before 
HRMS (ESI) analysis could be performed. 
1-(1H-Indol-4-yl)ethane-1,2-diol, (22) 
 
4-Vinyl-1H-indole (30 mg, 0.21 mmol) was dissolved in 7 mL of a THF:water (3:1) 
mixture and cooled to 0 °C. N-methyl morpholine-N-oxide (33 mg, 0.29 mmol) and 
osmium tetroxide solution (2.5 % wt in t-BuOH) (70 μL, 0.007 mmol) were added and 
the reaction mixture warmed to RT and stirred for 48 h. The reaction was quenched 
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with sat. aq. Na2SO4 solution (15 mL) and stirred at RT for 30 min. The organic 
fractions were extracted with EtOAc (3 x 20 mL) and the combined fractions dried 
over MgSO4 and concentrated in vacuo. The crude product was purified by MPLC 
(silica gel, petrol:EtOAc, 1:0  80:20) to yield the title compound as a green oil (21 
mg, 57 %); Rf = 0.2 (petrol:EtOAc, 1:1); λmax(EtOH)/nm 278.6, 218.8; IR (neat) 
νmax/cm
-1 3306, 2924, 2874, 2487, 2114, 1900, 1684, 1612, 1501; 1H NMR (500 
MHz, MeOD) δ 3.72 (1H, dd, J = 11.4, 8.1 Hz, CH2OH), 3.80 (1H, dd, J = 11.4, 3.8 
Hz, CH2OH), 5.14 (1H, dd, J = 8.1, 3.8 Hz, CHOH), 6.58 (1H, dd, J = 3.2, 0.8 Hz, H-
3), 7.11-7.08 (2H, m, H-5 and H-6), 7.23 (1H, d, J = 3.2 Hz, H-2), 7.33-7.28 (1H, m, 
H-7); 13C NMR (125 MHz, MeOD) δ 68.2 (C-11), 75.0 (C-10), 100.5 (C-3), 111.6 (C-
7), 117.1 (C-5), 122.1 (C-6), 125.4 (C-2), 127.1 (C-9), 134.1 (C-4), 137.8 (C-8); 
HRMS (ESI) calcd for C10H10NO2 [M+H]
- 176.0717, found 176.0719. 
N-(Pyrimidin-4-yl)-1H-indole-4-carboxamide, (23) 
 
Compound 24 was synthesised according to general procedure A. The reaction 
mixture contained 1H-indole-4-carboxylic acid (50 mg, 0.31 mmol), 4-
aminopyrimidine (74 mg, 0.78 mmol) and PCl3 (27 µL, 0.31 mmol) in acetonitrile 
(5 mL). The crude product was purified by MPLC (silica gel, petrol:EtOAc, 1:0  
90:10) to yield the title compound as a pale brown solid (10 mg, 14 %); Rf = 0.1 
(petrol:EtOAc, 1:1); m.p. 180-182°C; λmax(EtOH)/nm 315.2, 266.2, 205.4; IR (neat) 
νmax/cm
-1 3319, 2920, 2851, 2474, 2113, 1667, 1571; 1H NMR (500 MHz, MeOD) δ 
6.96 (1H, d, J = 3.1 Hz, H-3), 7.25 (1H, pt, J = 7.8 Hz, H-6), 7.44 (1H, d, J = 3.1 Hz, 
H-2), 7.68-7.62 (2H, m, H-5 and H-7), 8.40 (1H, dd, J = 1.2, 5.5 Hz, H-17), 8.67 (1H, 
d, J = 5.5 Hz, H-16), 8.87 (s, 1H, H-14); 13C NMR (125 MHz, MeOD) δ 102.6 (C-3), 
111.8 (C-17), 117.0 (C-5), 121.1 (C-7), 121.6 (C-6), 126.1 (C-9), 127.8 (C-4), 128.2 
(C-2), 138.6 (C-8), 158.7 (C-16), 159.3 (C-14), 160.1 (C-12), 170.5 (CO); LRMS 
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(ES+) m/z 239.3 [M+H]+; HRMS (ESI) calcd for C13H11N4O [M+H]
+ 239.0927, found 
239.0926. 
3-Methoxybenzo[d]isoxazole, (24) 
 
Compound 25 was synthesised according to general procedure B, using the following 
reagents: 3-hydroxybenzisoxazole (50 mg, 0.37 mmol), caesium carbonate (362 mg, 
1.11 mmol), methyl iodide (69 μL, 1.11 mmol) and acetonitrile (2 mL). The crude 
product was purified by MPLC (silica gel, petrol:EtOAc, 1:0  0:1) to yield the title 
compound as a clear oil (24 mg, 43 %); Rf = 0.9 (petrol:EtOAc, 1:3); λmax(EtOH)/nm 
281.4, 236.6; IR (neat) νmax/cm
-1 2943, 1919, 1613, 1544; 1H NMR (500 MHz, CDCl3) 
δ 4.17 (3H, s, OCH3), 7.26 (1H, ddd, J = 0.8, 7.0, 8.5 Hz, H-5), 7.43 (1H, ddd, J = 0.8, 
1.0, 8.5 Hz, H-7), 7.52 (1H, ddd, J = 1.2, 7.0, 8.5 Hz, H-6), 7.62 (1H, ddd, J = 1.0, 
1.2, 8.5 Hz, H-4); Not sufficient material for 13C NMR; LRMS (ES+) m/z 150.1 [M+H]+; 
Compound degraded before HRMS (ESI) analysis could be performed. 
3-Ethoxybenzo[d]isoxazole, (25) 
 
Compound 26 was synthesised according to general procedure B, using the following 
reagents: 3-hydroxybenzisoxazole (50 mg, 0.37 mmol), caesium carbonate (362 mg, 
1.11 mmol), methyl iodide (83 μL, 1.11 mmol) and acetonitrile (2 mL). The crude 
product was purified by MPLC (silica gel, petrol:EtOAc, 1:0  0:1) to yield the title 
compound as a white solid (31 mg, 51 %); Rf = 0.8 (petrol:EtOAc, 1:3); m.p. 30-31 
°C; λmax(EtOH)/nm 281.8, 236.6; IR (neat) νmax/cm
-1 3058, 2978, 2278, 2111, 1915, 
1795, 1611, 1534; 1H NMR (500 MHz, CDCl3) δ 1.52 (3H, t, J = 7.1 Hz, CH3), 4.51 
(2H, q, J = 7.1 Hz, CH2), 7.26 (1H, td, J = 0.7, 7.5 Hz, H-5), 7.43 (1H, ddd, J = 0.7, 
1.0, 8.5 Hz, H-7), 7.52 (1H, ddd, J = 1.2, 7.0, 8.5 Hz, H-6), 7.62 (1H, ddd, J = 1.0, 
1.2, 8.5 Hz, H-4); 13C NMR (125 MHz, CDCl3) δ 14.8 (CH3), 66.4 (CH2), 110.3 (C-7), 
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114.6 (C-9), 121.0 (C-4), 123.0 (C-5), 130.5 (C-6), 164.0 (C-3), 166.6 (C-8); LRMS 
(ES+) m/z 164.1 [M+H]+; HRMS (ESI) calcd for C9H10NO2 [M+H]
+ 164.1434, found 
164.1431. 
N-(3-Chloro-4-methoxyphenyl)-N-methylacetamide, (26) 
 
To a solution of N-(3-chloro-4-methoxyphenyl) (50 mg, 0.25 mmol) in dry THF was 
added NaH (60 % dispersion in mineral oil, 15 mg, 0.375 mmol) at 0 °C. After stirring 
for 10 min, methyl iodide (0.12 mL, 1.875 mmol) was added and the reaction stirred 
at RT for 2 h. The mixture was concentrated in vacuo and the remaining residue 
dissolved in water and the mixture extracted with Et2O (3 x 10 mL). The organic 
fractions were combined, washed with brine, dried over MgSO4 and concentrated in 
vacuo. The crude product was purified by recrystallization from hexane to yield the 
title compound as white solid (23 mg, 43 %); Rf = 0.3 (petrol:EtOAc, 1:3); m.p. 76-78 
°C; λmax(EtOH)/nm 280.8, 232.4; IR (neat) νmax/cm
-1 3034, 2930, 2837, 2321, 2086, 
1982, 1890, 1646; 1H NMR (500 MHz, CDCl3) δ 1.89 (3H, s, COCH3), 3.24 (3H, s, 
NCH3), 3.95 (3H, s, OCH3), 6.96 (1H, d, J = 8.5 Hz, H-5), 7.09 (1H, dd, J = 2.6, 8.5 
Hz, H-6), 7.26 (1H, d, J = 2.6 Hz, H-2); 13C NMR (125 MHz, CDCl3) δ 22.4 (COCH3), 
37.3 (NCH3), 56.4 (OCH3), 112.4 (C-5), 123.1 (C-3), 126.5 (C-6), 129.1 (C-2), 137.8 
(C-1), 154.6 (C-4), 170.7 (CO); LRMS (ES+) m/z 214.2 [M+H]+; Compound degraded 
before HRMS (ESI) analysis could be performed. 
N-(4-Ethoxyphenyl)acetamide, (28) 
 
Compound 28 was synthesised according to general procedure B. The reaction 
mixture contained 4-acetamidophenol (100 mg, 0.66 mmol), caesium carbonate (645 
mg, 1.98 mmol), ethyl bromide (148 μL, 1.98 mmol) and acetonitrile (4 mL). The 
crude product was purified by MPLC (silica gel, petrol:EtOAc, 1:0  0:1) to yield the 
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title compound as a white solid (96 mg, 81 %); Rf = 0.4 (petrol:EtOAc, 1:3); m.p. 133-
134 °C; λmax(EtOH)/nm 249.2; IR (neat) νmax/cm
-1 3279, 3193, 3131, 3074, 2983, 
2928, 2886, 2809, 2118, 1882, 1657, 1605, 1553; 1H NMR (500 MHz, CDCl3) δ 1.39 
(3H, s, OCH2CH3), 2.18 (3H, s, COCH3), 4.00 (2H, q, J = 8.9 Hz, OCH2CH3), 6.84 
(2H, d, J = 8.9 Hz, H-3 and H-3’), 7.37 (2H, d, J = 8.9 Hz, H-2 and H-2’); 13C NMR 
(125 MHz, CDCl3) δ 15.0 (OCH2CH3), 24.3 (COCH3), 63.9 (OCH2CH3), 114.9 (C-3 
and C-3’), 122.2 (C-2 and C-2’), 130.7 (C-1), 156.2 (C-4), 168.6 (CO); LRMS (ES+) 
m/z 180.2 [M+H]+; HRMS (ESI) calcd for C10H14NO2 [M+H]
+ 180.1019, found 
180.1011. 
N-(4-Isopropoxyphenyl)acetamide, (29) 
 
Compound 29 was synthesised according to general procedure B. The reaction 
mixture contained 4-acetamidophenol (100 mg, 0.66 mmol), caesium carbonate (645 
mg, 1.98 mmol), ethyl bromide (148 μL, 1.98 mmol) and acetonitrile (4 mL). The 
crude product was purified by MPLC (silica gel, petrol:EtOAc, 1:0  1:1) to yield the 
title compound as a white solid (116 mg, 90 %); Rf = 0.5 (petrol:EtOAc, 1:3); m.p. 
130-131 °C; λmax(EtOH)/nm 250.2; IR (neat) νmax/cm
-1 3239, 3183, 3122, 3066, 2975, 
2929, 2866, 2099, 2005, 1645, 1607, 1557, 1503; 1H NMR (500 MHz, CDCl3) δ 1.31 
(6H, d, J = 6.1 Hz, 2 x CH3), 2.18 (3H, s, COCH3), 4.53-4.45 (1H, m, COCH), 6.84 
(2H, d, J = 8.9 Hz, H-3 and H-3’), 7.36 (2H, d, J = 8.9 Hz, H-2 and H-2’); 13C NMR 
(125 MHz, CDCl3) δ 22.2 (2 x CH3), 24.3 (COCH3), 70.5 (OCH), 116.5 (C-3 and C-3’), 
122.2 (C-2 and C-2’), 130.7 (C-1), 155.1 (C-4), 168.6 (CO); LRMS (ES+) m/z 194.2 
[M+H]+; HRMS (ESI) calcd for C11H16NO2 [M+H]
+ 194.1176, found 194.1169. 
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Chapter 10. Appendix 
10.1 Data collection and phasing statistics 
The following section shows the data collection and phasing statistics. The data were 
processed, scaled and merged using xia2, aimless, pointless and programs from the 
CCP4i2 suite. 
Benzamide series 
(1) Fragment D (Data collected on a single crystal at 100 K on beamline I03, DLS.) 
 
Overall Inner Outer 
Low resolution limit 39.11 39.11 1.53 
High resolution limit 1.5 8.22 1.5 
Rmerge(within I+/I-) 0.075 0.04 0.604 
Rmerge(all I+ and I-) 0.075 0.031 0.637 
Rmeas (within I+/I-) 0.105 0.056 0.855 
Rmeas (all I+ & I-) 0.102 0.041 0.88 
Rpim (within I+/I-) 0.075 0.04 0.604 
Rpim (all I+ & I-) 0.07 0.026 0.605 
Rmerge in top intensity bin 0.05   
Number of observations 114413 801 5577 
Number unique 52769 359 2565 
Mean((I)/sd(I)) 5.5 14.5 1.3 
Half-set correlation CC(1/2) 0.912 0.991 0.293 
Completeness 88.1 98.4 87.2 
Multiplicity 2.2 2.2 2.2 
Anomalous completeness 76 98.1 70.7 
Anomalous multiplicity 1 1.1 1.1 
DelAnom CC(1/2) -0.862 -0.586 0 
Mid-Slope of Anom Probability 0.405 
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(2) Fragment M (Data collected on a single crystal at 100 K on beamline I04, DLS.) 
 
Overall Inner Outer 
Low resolution limit 39.19 39.19 1.42 
High resolution limit 1.4 7.67 1.4 
Rmerge(within I+/I-) 0.168 0.05 1.807 
Rmerge(all I+ and I-) 0.117 0.028 1.091 
Rmeas (within I+/I-) 0.237 0.071 2.555 
Rmeas (all I+ & I-) 0.16 0.038 1.489 
Rpim (within I+/I-) 0.168 0.05 1.807 
Rpim (all I+ & I-) 0.108 0.025 1.008 
Rmerge in top intensity bin 0.096   
Number of observations 130615 842 4111 
Number unique 68698 431 2450 
Mean((I)/sd(I)) 2.6 7.1 0.2 
Half-set correlation CC(1/2) 0.927 0.993 0.554 
Completeness 93.5 96.4 67.8 
Multiplicity 1.9 2 1.7 
Anomalous completeness 61.7 75.8 31 
Anomalous multiplicity 0.7 1.1 1.1 
DelAnom CC(1/2) -0.818 -0.721 0 
Mid-Slope of Anom Probability 0.394 
  
 
(3) Fragment N (Data collected on a single crystal at 100 K on beamline I04-1, DLS.) 
 
Overall Inner Outer 
Low resolution limit 42 42 1.63 
High resolution limit 1.6 8.76 1.6 
Rmerge (within I+/I-) 0.06 0.04 0.488 
Rmerge (all I+ and I-) 0.073 0.04 0.483 
Rmeas (within I+/I-) 0.085 0.057 0.69 
Rmeas (all I+ & I-) 0.099 0.054 0.653 
Rpim (within I+/I-) 0.06 0.04 0.488 
Rpim (all I+ & I-) 0.067 0.036 0.437 
Rmerge in top intensity bin 0.043   
Number of observations 92858 627 4685 
Number unique 43080 283 2162 
Mean((I)/sd(I)) 8.1 19.1 1.8 
Half-set correlation CC(1/2) 0.975 0.987 0.714 
Completeness 89.1 97.3 90.6 
Multiplicity 2.2 2.2 2.2 
Anomalous completeness 77.5 96.6 74.6 
Anomalous multiplicity 1 1.1 1.1 
DelAnom CC(1/2) -0.601 -0.594 0 
Mid-Slope of Anom Probability 1.082 
  
 262 
Isoxazole series 
(4) Fragment O (Data collected on a single crystal at 100 K on beamline I04-1, DLS.) 
 
Overall Inner Outer 
Low resolution limit 38.78 38.78 1.32 
High resolution limit 1.3 7.12 1.3 
Rmerge(within I+/I-) 0.056 0.028 0.822 
Rmerge(all I+ and I-) 0.045 0.024 0.635 
Rmeas (within I+/I-) 0.079 0.04 1.163 
Rmeas (all I+ & I-) 0.063 0.034 0.899 
Rpim (within I+/I-) 0.056 0.028 0.822 
Rpim (all I+ & I-) 0.045 0.024 0.635 
Rmerge in top intensity bin 0.026   
Number of observations 153124 1088 7334 
Number unique 78176 545 3737 
Mean((I)/sd(I)) 9.2 25.7 1.3 
Half-set correlation CC(1/2) 0.997 0.996 0.56 
Completeness 86.3 98.6 83.9 
Multiplicity 2 2 2 
Anomalous completeness 63.9 94.6 57.4 
Anomalous multiplicity 0.7 1 1 
DelAnom CC(1/2) 0 0 0 
Mid-Slope of Anom 
Probability 
1.047 
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(5) Fragment O1 (Data collected on a single crystal at 100 K on beamline I04, DLS.) 
 
Overall Inner Outer 
Low resolution limit 42.51 42.51 1.6 
High resolution limit 1.57 8.6 1.57 
Rmerge(within I+/I-) 0.127 0.037 0.309 
Rmerge(all I+ and I-) 0.105 0.047 0.228 
Rmeas (within I+/I-) 0.179 0.053 0.437 
Rmeas (all I+ & I-) 0.143 0.064 0.311 
Rpim (within I+/I-) 0.127 0.037 0.309 
Rpim (all I+ & I-) 0.096 0.044 0.211 
Rmerge in top intensity bin 0.086   
Number of observations 97115 598 4537 
Number unique 50309 305 2468 
Mean((I)/sd(I)) 3.5 6.5 1 
Half-set correlation CC(1/2) 0.946 0.978 0.922 
Completeness 96.1 95.9 94.3 
Multiplicity 1.9 2 1.8 
Anomalous completeness 66.4 77.3 54.9 
Anomalous multiplicity 0.8 1.1 1.1 
DelAnom CC(1/2) -0.567 0.47 0 
Mid-Slope of Anom Probability 0.451 
  
 
(6) Fragment O2 (Data collected on a single crystal at 100 K on beamline I04, DLS.) 
 
Overall Inner Outer 
Low resolution limit 50.25 50.25 1.42 
High resolution limit 1.4 7.67 1.4 
Rmerge(within I+/I-) 0.067 0.027 1.183 
Rmerge(all I+ and I-) 0.051 0.02 0.817 
Rmeas (within I+/I-) 0.095 0.038 1.672 
Rmeas (all I+ & I-) 0.07 0.026 1.113 
Rpim (within I+/I-) 0.067 0.027 1.183 
Rpim (all I+ & I-) 0.047 0.017 0.751 
Rmerge in top intensity bin 0.03   
Number of observations 102892 831 1190 
Number unique 55928 425 763 
Mean((I)/sd(I)) 6 15.9 0.5 
Half-set correlation CC(1/2) 0.993 0.999 0.45 
Completeness 77 96.6 21.1 
Multiplicity 1.8 2 1.6 
Anomalous completeness 48.1 77.7 7.8 
Anomalous multiplicity 0.7 1.1 1.1 
DelAnom CC(1/2) -0.543 -0.608 0 
Mid-Slope of Anom Probability 0.612 
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(7) Fragment O4 (Data collected on a single crystal at 100 K on beamline I04, DLS.) 
 
Overall Inner Outer 
Low resolution limit 39.03 39.03 1.73 
High resolution limit 1.7 9 1.7 
Rmerge(within I+/I-) 0.108 0.047 0.242 
Rmerge(all I+ and I-) 0.073 0.031 0.272 
Rmeas (within I+/I-) 0.153 0.067 0.343 
Rmeas (all I+ & I-) 0.099 0.042 0.374 
Rpim (within I+/I-) 0.108 0.047 0.242 
Rpim (all I+ & I-) 0.067 0.028 0.255 
Rmerge in top intensity bin 0.045   
Number of observations 73697 503 3176 
Number unique 39410 264 1997 
Mean((I)/sd(I)) 4.2 9.7 0.9 
Half-set correlation CC(1/2) 0.985 0.994 0.404 
Completeness 96.2 95 89.8 
Multiplicity 1.9 1.9 1.6 
Anomalous completeness 63.7 71.8 38 
Anomalous multiplicity 0.7 1.1 1.1 
DelAnom CC(1/2) -0.674 -0.782 0 
Mid-Slope of Anom Probability 0.371 
  
 
(8) Fragment O5 (Data collected on a single crystal at 100 K on beamline I04, DLS.) 
 
Overall Inner Outer 
Low resolution limit 39.12 39.12 1.5 
High resolution limit 1.47 8.05 1.47 
Rmerge(within I+/I-) 0.055 0.035 0.527 
Rmerge(all I+ and I-) 0.039 0.041 0.348 
Rmeas (within I+/I-) 0.077 0.049 0.745 
Rmeas (all I+ & I-) 0.053 0.056 0.475 
Rpim (within I+/I-) 0.055 0.035 0.527 
Rpim (all I+ & I-) 0.036 0.038 0.321 
Rmerge in top intensity bin 0.031 
  Number of observations 118832 723 5212 
Number unique 60640 372 2896 
Mean((I)/sd(I)) 7.8 16.1 1.6 
Half-set correlation CC(1/2) 0.996 0.985 0.911 
Completeness 95.9 95.9 93.1 
Multiplicity 2 1.9 1.8 
Anomalous completeness 67.4 74.9 51 
Anomalous multiplicity 0.8 1.1 1.1 
DelAnom CC(1/2) -0.492 -0.322 0 
Mid-Slope of Anom Probability 0.746 
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(9) Fragment O6, (Data collected on a single crystal at 100 K on beamline I02, DLS.) 
 
Overall Inner Outer 
Low resolution limit 39.06 39.06 1.37 
High resolution limit 1.35 7.39 1.35 
Rmerge(within I+/I-) 0.077 0.095 0.436 
Rmerge(all I+ and I-) 0.057 0.055 0.641 
Rmeas (within I+/I-) 0.109 0.134 0.616 
Rmeas (all I+ & I-) 0.076 0.073 0.866 
Rpim (within I+/I-) 0.077 0.095 0.436 
Rpim (all I+ & I-) 0.05 0.047 0.579 
Rmerge in top intensity bin 0.044   
Number of observations 150732 1056 5614 
Number unique 76482 478 2975 
Mean((I)/sd(I)) 5.3 10.1 1.2 
Half-set correlation CC(1/2) 0.994 0.977 0.363 
Completeness 94.2 97 73.9 
Multiplicity 2 2.2 1.9 
Anomalous completeness 65.7 95.9 43.4 
Anomalous multiplicity 0.8 1.1 1.1 
DelAnom CC(1/2) -0.693 -0.61 0 
Mid-Slope of Anom Probability 0.731 
  
 
Indole series 
(10) Fragment H (Data collected on a single crystal at 100 K on beamline I03, DLS.) 
 
Overall Inner Outer 
Low resolution limit 39.04 39.04 1.53 
High resolution limit 1.5 8.22 1.5 
Rmerge(within I+/I-) 0.157 0.081 0.847 
Rmerge(all I+ and I-) 0.119 0.046 0.768 
Rmeas (within I+/I-) 0.222 0.114 1.197 
Rmeas (all I+ & I-) 0.162 0.062 1.046 
Rpim (within I+/I-) 0.157 0.081 0.847 
Rpim (all I+ & I-) 0.109 0.041 0.706 
Rmerge in top intensity bin 0.077   
Number of observations 113904 788 5685 
Number unique 52816 357 2640 
Mean((I)/sd(I)) 2.4 5.3 1 
Half-set correlation CC(1/2) 0.914 0.984 0.253 
Completeness 88.1 98.1 88.1 
Multiplicity 2.2 2.2 2.2 
Anomalous completeness 75.4 98.1 71 
Anomalous multiplicity 1 1.1 1.1 
DelAnom CC(1/2) -0.36 -0.472 0 
Mid-Slope of Anom Probability 0.187 
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(11) Fragment H1 (Data collected on single crystal at 100 K on beamline I04, DLS.) 
 
Overall Inner Outer 
Low resolution limit 42.45 42.45 1.53 
High resolution limit 1.5 8.22 1.5 
Rmerge(within I+/I-) 0.072 0.028 0.594 
Rmerge(all I+ and I-) 0.055 0.02 0.608 
Rmeas (within I+/I-) 0.102 0.039 0.84 
Rmeas (all I+ & I-) 0.075 0.026 0.829 
Rpim (within I+/I-) 0.072 0.028 0.594 
Rpim (all I+ & I-) 0.05 0.017 0.56 
Rmerge in top intensity bin 0.031   
Number of observations 110732 707 5229 
Number unique 56869 347 2749 
Mean((I)/sd(I)) 4.8 12.3 1.1 
Half-set correlation CC(1/2) 0.996 0.997 0.517 
Completeness 96 96.7 94 
Multiplicity 1.9 2 1.9 
Anomalous completeness 67.3 81.8 58.8 
Anomalous multiplicity 0.8 1.1 1.1 
DelAnom CC(1/2) -0.506 -0.461 0 
Mid-Slope of Anom Probability 0.642 
  
 
(12) Fragment H2 (Data collected on a single crystal at 100 K on beamline I04, DLS.) 
 
Overall Inner Outer 
Low resolution limit 50.41 50.41 1.32 
High resolution limit 1.3 7.12 1.3 
Rmerge(within I+/I-) 0.039 0.018 0.953 
Rmerge(all I+ and I-) 0.032 0.023 0.686 
Rmeas (within I+/I-) 0.055 0.025 1.348 
Rmeas (all I+ & I-) 0.043 0.032 0.932 
Rpim (within I+/I-) 0.039 0.018 0.953 
Rpim (all I+ & I-) 0.029 0.022 0.628 
Rmerge in top intensity bin 0.022   
Number of observations 162937 1067 4669 
Number unique 83440 539 2630 
Mean((I)/sd(I)) 9.8 31.4 0.8 
Half-set correlation CC(1/2) 0.996 0.994 0.638 
Completeness 92.1 97.6 59.1 
Multiplicity 2 2 1.8 
Anomalous completeness 62.7 79.5 29.4 
Anomalous multiplicity 0.8 1.1 1.1 
DelAnom CC(1/2) -0.331 0.088 0 
Mid-Slope of Anom Probability 0.78 
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(13) Fragment H3 (Data collected on single crystal at 100 K on beamline I04, DLS.) 
 
Overall Inner Outer 
Low resolution limit 39.07 39.07 1.37 
High resolution limit 1.35 7.39 1.35 
Rmerge(within I+/I-) 0.077 0.027 0.605 
Rmerge(all I+ and I-) 0.061 0.025 0.692 
Rmeas (within I+/I-) 0.11 0.039 0.855 
Rmeas (all I+ & I-) 0.082 0.034 0.949 
Rpim (within I+/I-) 0.077 0.027 0.605 
Rpim (all I+ & I-) 0.055 0.023 0.646 
Rmerge in top intensity bin 0.042   
Number of observations 147861 958 5805 
Number unique 77486 487 3474 
Mean((I)/sd(I)) 4.2 10.1 0.7 
Half-set correlation CC(1/2) 0.994 0.994 0.292 
Completeness 94.6 97.4 85.9 
Multiplicity 1.9 2 1.7 
Anomalous completeness 62.3 79.6 38 
Anomalous multiplicity 0.7 1.1 1.1 
DelAnom CC(1/2) -0.799 -0.665 0 
Mid-Slope of Anom Probability 0.626 
  
 
(14) Fragment 21 (Data collected on a single crystal at 100 K on beamline I04-1, 
DLS.) 
 
Overall Inner Outer 
Low resolution limit 38.92 38.92 1.32 
High resolution limit 1.3 7.12 1.3 
Rmerge(within I+/I-) 0.177 0.115 0.721 
Rmerge(all I+ and I-) 0.102 0.053 0.768 
Rmeas (within I+/I-) 0.251 0.162 1.019 
Rmeas (all I+ & I-) 0.134 0.068 1.032 
Rpim (within I+/I-) 0.177 0.115 0.721 
Rpim (all I+ & I-) 0.085 0.042 0.685 
Rmerge in top intensity bin 0.085   
Number of observations 172830 1120 8527 
Number unique 86485 547 4172 
Mean((I)/sd(I)) 2.6 4.2 0.7 
Half-set correlation CC(1/2) 0.983 0.988 0.495 
Completeness 95.6 99.3 93 
Multiplicity 2 2 2 
Anomalous completeness 68.6 85.1 64.8 
Anomalous multiplicity 0.8 1.1 1.1 
DelAnom CC(1/2) -0.716 -0.289 0 
Mid-Slope of Anom Probability 0.64 
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(15) Fragment 22 (Data collected on a single crystal at 100 K on beamline I04-1, 
DLS.) 
 
Overall Inner Outer 
Low resolution limit 49.92 49.92 1.37 
High resolution limit 1.35 7.14 1.35 
Rmerge(within I+/I-) 0.144 0.077 0.464 
Rmerge(all I+ and I-) 0.094 0.053 0.66 
Rmeas (within I+/I-) 0.203 0.108 0.656 
Rmeas (all I+ & I-) 0.126 0.07 0.897 
Rpim (within I+/I-) 0.144 0.077 0.464 
Rpim (all I+ & I-) 0.083 0.045 0.604 
Rmerge in top intensity bin 0.073   
Number of observations 152934 1095 7691 
Number unique 77017 542 3974 
Mean((I)/sd(I)) 3.1 5 0.9 
Half-set correlation CC(1/2) 0.982 0.983 0.531 
Completeness 95.8 99.6 93.1 
Multiplicity 2 2 1.9 
Anomalous completeness 68.6 84.2 58.8 
Anomalous multiplicity 0.8 1.1 1.1 
DelAnom CC(1/2) -0.56 -0.282 0 
Mid-Slope of Anom Probability 0.696 
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Other heterocyclic ring systems 
(16) Fragment I (Data collected on a single crystal at 100 K on beamline I03, DLS.) 
 
Overall Inner Outer 
Low resolution limit 42.57 42.57 1.44 
High resolution limit 1.42 7.78 1.42 
Rmerge(within I+/I-) 0.092 0.04 1.37 
Rmerge(all I+ and I-) 0.089 0.042 2.046 
Rmeas (within I+/I-) 0.13 0.057 1.937 
Rmeas (all I+ & I-) 0.122 0.057 2.793 
Rpim (within I+/I-) 0.092 0.04 1.37 
Rpim (all I+ & I-) 0.083 0.038 1.891 
Rmerge in top intensity bin 0.056   
Number of observations 133955 941 6107 
Number unique 62238 427 2968 
Mean((I)/sd(I)) 3.3 10 0.1 
Half-set correlation CC(1/2) 0.985 0.988 0.363 
Completeness 87.9 98.8 84.1 
Multiplicity 2.2 2.2 2.1 
Anomalous completeness 74.4 98.6 61.4 
Anomalous multiplicity 0.9 1.1 1.1 
DelAnom CC(1/2) -0.247 0.061 0 
Mid-Slope of Anom Probability 0.543 
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(17) Fragment B (Data collected on a single crystal at 100 K on beamline I04-1, 
DLS.) 
 
Overall Inner Outer 
Low resolution limit 42.52 42.52 1.4 
High resolution limit 1.38 7.56 1.38 
Rmerge(within I+/I-) 0.069 0.045 0.876 
Rmerge(all I+ and I-) 0.059 0.041 0.637 
Rmeas (within I+/I-) 0.097 0.063 1.239 
Rmeas (all I+ & I-) 0.083 0.058 0.9 
Rpim (within I+/I-) 0.069 0.045 0.876 
Rpim (all I+ & I-) 0.059 0.041 0.637 
Rmerge in top intensity bin 0.036   
Number of observations 125963 900 6164 
Number unique 64601 451 3149 
Mean((I)/sd(I)) 8.7 21.7 1.2 
Half-set correlation CC(1/2) 0.988 0.989 0.496 
Completeness 85.4 97.6 83.2 
Multiplicity 1.9 2 2 
Anomalous completeness 64.1 94.1 56.8 
Anomalous multiplicity 0.8 1 1 
DelAnom CC(1/2) 0 0 0 
Mid-Slope of Anom Probability 0.997 
  
 
(18) Fragment B1 (Data collected on a single crystal at 100 K on beamline I04, DLS.) 
 
Overall Inner Outer 
Low resolution limit 39.16 39.16 1.63 
High resolution limit 1.6 8.76 1.6 
Rmerge(within I+/I-) 0.054 0.036 0.328 
Rmerge(all I+ and I-) 0.057 0.021 0.547 
Rmeas (within I+/I-) 0.076 0.052 0.465 
Rmeas (all I+ & I-) 0.078 0.029 0.755 
Rpim (within I+/I-) 0.054 0.036 0.328 
Rpim (all I+ & I-) 0.053 0.019 0.517 
Rmerge in top intensity bin 0.03   
Number of observations 89064 542 3225 
Number unique 46883 283 2003 
Mean((I)/sd(I)) 8 22.8 1.2 
Half-set correlation CC(1/2) 0.992 0.998 0.571 
Completeness 95.6 96.3 82.9 
Multiplicity 1.9 1.9 1.6 
Anomalous completeness 64.6 73 36.1 
Anomalous multiplicity 0.7 1.1 1.1 
DelAnom CC(1/2) -0.577 -0.745 0 
Mid-Slope of Anom Probability 0.883 
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10.2 Data refinement statistics 
The following section contains the data refinement statistics. The refinement statistics 
were generated with Refmac5 as part of CCP4i2 suite. 
Benzamide series 
Refinement Fragment D Fragment M Fragment N 
Rwork/Rfree 0.27/0.29 0.35/0.37 0.19/0.24 
Mean B-value (Å2)    
   All atoms 24 10 29 
   Protein 19 8 27 
   Water 23 9 32 
   Ligand 29 12 28 
No of atoms    
   Protein 5830 5811 5830 
   Water 167 97 122 
   Ligand 16 17 23 
Rmsd    
   Bond lengths (Å) 0.02 0.02 0.02 
   Angles (°) 1.80 1.71 2.05 
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Isoxazole series 
Refinement Fragment O Fragment O1 Fragment O2 Fragment O4 
Rwork/Rfree 0.21/0.23 0.32/0.34 0.26/0.29 0.29/0.32 
Mean B-value (Å2)     
   All atoms 26 15 21 17 
   Protein 19 10 17 12 
   Water 20 14 19 14 
   Ligand 39 21 27 25 
No of atoms     
   Protein 5698 5812 5830 5830 
   Water 116 235 173 205 
   Ligand 15 18 16 16 
Rmsd     
   Bond lengths (Å) 0.02 0.02 0.02 0.02 
   Angles (°) 2.00 2.07 2.06 1.82 
 
Refinement Fragment O5 Fragment O6 
Rwork/Rfree 0.25/0.28 0.25/0.27 
Mean B-value (Å2)   
   All atoms 20 31 
   Protein 18 21 
   Water 21 26 
   Ligand 22 45 
No of atoms   
   Protein 5798 5840 
   Water 203 188 
   Ligand 14 14 
Rmsd   
   Bond lengths (Å) 0.03 0.02 
   Angles (°) 2.34 2.03 
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Indole series 
Refinement Fragment H Fragment H1 Fragment H2 Fragment H3 
Rwork/Rfree 0.31/0.33 0.26/0.29 0.23/0.27 0.25/0.28 
Mean B-value (Å2)     
   All atoms 17 26 27 23 
   Protein 13 19 20 18 
   Water 15 25 25 24 
   Ligand 23 33 35 26 
No of atoms     
   Protein 5844 5830 5818 5830 
   Water 144 224 199 203 
   Ligand 21 20 21 20 
Rmsd     
   Bond lengths (Å) 0.01 0.02 0.02 0.02 
   Angles (°) 1.49 1.72 2.13 1.96 
 
Refinement Fragment 21 Fragment 22 
Rwork/Rfree 0.24/0.26 0.24/0.27 
Mean B-value (Å2)   
   All atoms 30 27 
   Protein 22 21 
   Water 27 26 
   Ligand 40 33 
No of atoms   
   Protein 5847 5829 
   Water 177 168 
   Ligand 20 22 
Rmsd   
   Bond lengths (Å) 0.02 0.02 
   Angles (°) 1.89 1.92 
 
  
 274 
Other heterocyclic ring systems 
Refinement Fragment I Fragment B Fragment B1 
Rwork/Rfree 0.33/0.35 0.23/0.27 0.27/0.31 
Mean B-value (Å2)    
   All atoms 6 19 21 
   Protein 7 16 17 
   Water 2 17 18 
   Ligand 8 25 28 
No of atoms    
   Protein 5758 5698 5830 
   Water 153 113 151 
   Ligand 20 24 27 
Rmsd    
   Bond lengths (Å) 0.02 0.02 0.02 
   Angles (°) 1.81 1.93 2.10 
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